RankNCT NumberTitleAcronymStatusStudy ResultsConditionsInterventionsOutcome MeasuresSponsor/CollaboratorsGenderAgePhasesEnrollmentFunded BysStudy TypeStudy DesignsOther IDsStart DatePrimary Completion DateCompletion DateFirst PostedResults First PostedLast Update PostedLocationsStudy DocumentsURLCountry
1000NCT04643522Semen Parameters and COVID-19 in Infertile MenCompletedNo Results AvailableSperm Count, Low|Hormone Disturbance|Covid19Other: Clinical assessmentSemen analyses parameters including sperm motility (total, progressive, non-progressive and immotile|Semen analyses parameters including sperm concentration|Semen analyses parameters including sperm morphology|Semen analyses parameters including semen volume|Sex-related hormone levels including testosterone|Sex-related hormone levels including follicle stimulating hormone and luteinizing hormoneAnkara City Hospital BilkentMale18 Years to 40 Years Â  (Adult)21OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveE1-20-1237January 7, 2020October 5, 2020October 10, 2020November 25, 2020November 30, 2020Ankara City Hospital, Ankara, Turkeyhttps://ClinicalTrials.gov/show/NCT04643522 Turkey
1001NCT04341207Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer PatientsONCOVIDRecruitingNo Results AvailableCancer & COVID 19Drug: Hydroxychloroquine|Drug: AzithromycinPrevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycinGustave Roussy, Cancer Campus, Grand ParisAll18 Years and older Â  (Adult, Older Adult)Phase 21000OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment2020-001250-21|2020/3078April 3, 20202022-04-01 00:00:002022-04-01 00:00:00April 10, 2020April 10, 2020Gustave Roussy, Villejuif, Val De Marne, Francehttps://ClinicalTrials.gov/show/NCT04341207 France
1002NCT04651413PCR Cycle Threshold Values and COVID-19 OutcomesRecruitingNo Results AvailableCovid19Diagnostic Test: PCR ValueDetermine if there is an inverse correlation with risk of poor outcome including admission to intensive care; mechanical ventilation and 28-day mortality.|Differences in cycle threshold (Ct) levels amongst patients with community acquired SARS-CoV-2University Hospitals of North Midlands NHS TrustAllChild, Adult, Older Adult800OtherObservationalObservational Model: Other|Time Perspective: Retrospective286389November 24, 2020March 31, 2021March 31, 2021December 3, 2020December 4, 2020University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, Staffordshire, United Kingdomhttps://ClinicalTrials.gov/show/NCT04651413 United Kingdom
1003NCT04401254Recovery of Patients From COVID-19 After Critical IllnessCOVID-RecoveryRecruitingNo Results AvailableCOVID-19|Critical IllnessDisability-free survival|Physiotherapy intervention|Health status|Global function|Cognitive function|Anxiety and depression|Screening for post-traumatic distress|Work Status|Proportion of patients with COVID-19 who received physiotherapy in ICU|The reported barriers to delivering physiotherapy interventions|Adverse events during physiotherapy interventions|Phenomenological data of the patient and family experienceAustralian and New Zealand Intensive Care Research Centre|The AlfredAll18 Years and older Â  (Adult, Older Adult)300OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveCOVID-Recovery V1.0 01May2020July 1, 20202021-12-01 00:00:002022-04-01 00:00:00May 26, 2020October 23, 2020Canberra Hospital, Garran, Australian Capital Territory, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, Saint Leonards, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Ipswich Hospital, Ipswich, Queensland, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Gold Coast Hospital, Southport, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Launceston Hospital, Launceston, Tasmania, Australia|Casey Hospital, Berwick, Victoria, Australia|Box Hill Hospital (Eastern Health), Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Dandenong Hospital, Dandenong, Victoria, Australia|Northern Health, Epping, Victoria, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Footscray Hospital, Footscray, Victoria, Australia|Frankston Hospital, Frankston, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Cabrini Health, Malvern, Victoria, Australia|Australian New Zealand Intensive Care Research Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Alfred Hospital, Prahran, Victoria, Australia|Epworth Richmond, Richmond, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australiahttps://ClinicalTrials.gov/show/NCT04401254 Australia
1004NCT04553575CoViD-19 Patient in Reims University Hospital in March to April 2020COVID-ReimsRecruitingNo Results AvailableCoronavirus InfectionsBiological: serologyHealth status in the 2 years after CoViD-19 diagnosisCHU de ReimsAllChild, Adult, Older Adult499OtherObservationalObservational Model: Cohort|Time Perspective: ProspectivePO20124*September 25, 20202022-09-01 00:00:002022-09-01 00:00:00September 17, 2020October 5, 2020Chu Reims, Reims, Francehttps://ClinicalTrials.gov/show/NCT04553575 France
1005NCT04756128Impact of Colchicine and Low-dose Naltrexone on COVID-19COLTREXONEEnrolling by invitationNo Results AvailableCovid19Drug: Colchicine 0.6 mg|Drug: Naltrexone"Progression of COVID-19 from ""moderate"" classification to ""severe/critical""|Total duration of hospitalization|Total duration of hospitalization (from first dose of study drug to discharge)|Composite in-hospital mortality|Total duration of ICU Admission|Total duration of intubation|Total duration of time spent on HFNC or NIPPV from first dose of study drug to discharge|Total duration of time above baseline oxygen requirements from first dose of study drug to discharge|In hospital days with a fever >/= 38 degrees Celsius (00:00 to 23:59:59) from first dose of study drug to discharge (or anticipated first dose if in standard of care arm)|Incidence of adverse events associated with the study drug|Incidence of significant adverse outcomes associated with/attributable to COVID-19|Cumulative dose of corticosteroids received in ED/Hospital|Cumulative dose of remdesivir received in ED/Hospital|Discharge Anticoagulation Needs|Continuous lab results - B-Type Natriuretic Peptide|Continuous lab results - C-Reactive Protein|Continuous lab results - D-Dimer|Continuous lab results - Ferritin|Continuous lab results - Procalcitonin|Continuous lab results - Serum Creatinine|Continuous lab results - Troponin|Continuous lab results - Hepatic Function Panel (ALT/AST/Alkaline Phosphotase)|Continuous lab results - Hepatic Function Panel (Bilirubin)|Continuous lab results - Hepatic Function Panel (Protein/Albumin)|Continuous lab results - Complete Blood Count with Differential Part 1|Continuous lab results - Complete Blood Count with Differential Part 2|Continuous lab results - Complete Blood Count with Differential Part 3"HealthPartners Institute|Park Nicollet FoundationAll18 Years and older Â  (Adult, Older Adult)Phase 2164OtherInterventionalAllocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentX2103400January 25, 2021December 31, 2021December 31, 2021February 16, 2021February 18, 2021Park Nicollet Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United Stateshttps://ClinicalTrials.gov/show/NCT04756128 United States
1006NCT04405492Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19ERap-COVNot yet recruitingNo Results AvailableSARS-CoV 2|COVID-19Device: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|Device: Capillary and salivary samplingClinical performance of several diagnostic tests : tests based either on detection of the virus SARS-CoV-2 or detection of human antibodies generated in response to infection|Sensitivity and specificity of immunological, antigenic, molecular and proteomic tests according to symptom duration, stage of the disease: asymptomatic, ambulatory, hospitalized, ventilated|Description of the incidence of infection among hospital caregivers, time to seroconversion according to clinical form, medium-term antibody persistence|Sensitivity and specificity of immunodiagnostic tests according to the sample used (serum and capillary blood) and according to the duration of the symptoms|Sensitivity and specificity of antigenic rapid tests, molecular tests, proteomic tests according to the sample used (salivary samples or nasopharyngeal swabs) and according to the duration of the symptoms|Suitability of rapid tests in view of its intended purpose for self-testingAssistance Publique - HÃ´pitaux de ParisAll18 Years and older Â  (Adult, Older Adult)Not Applicable1210OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: DiagnosticAPHP200556May 25, 2020March 25, 2021March 25, 2021May 28, 2020May 28, 2020https://ClinicalTrials.gov/show/NCT04405492
1007NCT04374565Convalescent Plasma for Treatment of COVID-19 Patients With PneumoniaActive, not recruitingNo Results AvailableCorona Virus Infection|SARS-CoV 2|SARS Pneumonia|PneumoniaDrug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent PlasmaTransfer to ICU|28 day mortality|Cumulative incidence of serious adverse events|Rates and duration of SARS-CoV-2|Serum of plasma antibody titer to SARS-CoV-2|Cellular and humoral immune response|Supplemental oxygen free days|Ventilator free days|ICU free days|Sequential organ failure assessment score|Need for vasopressors|Need for renal replacement therapy|Need for extracorporeal membrane oxygenation (ECMO)|Hospital length of stay (LOS)|ICU LOS|Grade 3 or 4 Adverse Events (AEs)University of VirginiaAll18 Years and older Â  (Adult, Older Adult)Phase 229OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment200114May 5, 2020April 5, 2021April 5, 2021May 5, 2020August 21, 2020University of Virginia Medical Center, Charlottesville, Virginia, United States|University of Virginia, Charlottesville, Virginia, United Stateshttps://ClinicalTrials.gov/show/NCT04374565 United States
1008NCT04351529Austrian COVID-19 RegistryRecruitingNo Results AvailableInfectious Disease|COVID-19Documentation of natural course and the therapeutic landscape of patients with COVID-19.Arbeitsgemeinschaft medikamentoese TumortherapieAll18 Years and older Â  (Adult, Older Adult)1000OtherObservationalObservational Model: Other|Time Perspective: OtherAGMT_COVID-19April 1, 20202021-12-01 00:00:002021-12-01 00:00:00April 17, 2020November 30, 2020LKH Feldkirch: Innere Medizin II/ Interne E (HÃ¤matologie und Onkologie), Feldkirch, Austria|Kepler UniversitÃ¤tsklinikum Linz, Med. Campus III., Klinik fÃ¼r Lungenheilkunde / Pneumologie, Linz, Austria|IIIrd Medical Department, Private Medical University Hospital Salzburg, Salzburg, Austria|KH Zams: Innere Medizin Internistische Onkologie und HÃ¤matologie, Zams, Austriahttps://ClinicalTrials.gov/show/NCT04351529 Austria
1009NCT04510623Host Response Mediators in Coronavirus (COVID-19) InfectionARBS CORONA IRecruitingNo Results AvailableCOVID-19|SARS-CoV2Other: ARBs and/or ACE inhibitors|Other: Usual CareCOVID-19 WHO ordinal scale|Organ Dysfunction|28-day mortality|Hospital/ICU length of stay|ICU admissionUniversity of British Columbia|Canadian Institutes of Health Research (CIHR)|British Columbia Centre for Disease Control|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Toronto|University of Ottawa|University of Calgary|University of Alberta|University of Victoria|Wuhan University|Peking Union Medical College|University of PennsylvaniaAll18 Years and older Â  (Adult, Older Adult)500OtherObservationalObservational Model: Cohort|Time Perspective: OtherH20-00600March 17, 2020June 30, 2021June 30, 2022August 12, 2020August 12, 2020University of Calgary - Foothills, Calgary, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|St Pauls Hospital, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|William Osler Health System, Brampton, Ontario, Canada|Queens University, Kingston, Ontario, Canada|Humber River Hospital, North York, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|St Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|Jewish General Hospital, MontrÃ©al, Quebec, Canada|McGill University Health Center, MontrÃ©al, Quebec, Canada|UniversitÃ© de Sherbrooke, Sherbrooke, Quebec, Canadahttps://ClinicalTrials.gov/show/NCT04510623 Canada
1010NCT04450017Clinical Features of Severe Patients With COVID-19RecruitingNo Results AvailableSARS-CoV2Diagnostic Test: The demographic, clinical, laboratory, and instrumental dataMechanical ventilation duration|Non-invasive Mechanical ventilation duration|Mortality|Ð¡omplete blood count|Biochemistry analysis|Ð¡omplete blood count dynamics|Biochemistry analysis dynamics|Computer tomography|High-sensitive troponin Ð¢|High-sensitive troponin Ð¢ dynamics|Vitamin D level|Vitamin D level dynamics|Immunogram|Immunogram dynamicsFederal Research Clinical Center of Federal Medical & Biological Agency, RussiaAll18 Years to 90 Years Â  (Adult, Older Adult)150OtherObservationalObservational Model: Case-Only|Time Perspective: RetrospectiveCOVID-ICUApril 6, 20202020-07-01 00:00:002020-08-01 00:00:00June 29, 2020June 29, 2020Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federationhttps://ClinicalTrials.gov/show/NCT04450017 Russian Federation
1011NCT04769700Post-partum Depression, Breastfeeding Adherence and Fear in COVID-19RecruitingNo Results AvailableBreast Feeding, Exclusive|Post Partum Depression|Covid19Behavioral: Edinburgh Postnatal Depression Scale|Behavioral: Breast Feeding Adherence|Behavioral: Fear of Covid-19 ScalePost-Partum Depression Frequency|Breast Feeding Adherence and behavior.|Fear of Covid-19 severityInstituto Mexicano del Seguro SocialFemale18 Years and older Â  (Adult, Older Adult)250OtherObservationalObservational Model: Cohort|Time Perspective: Cross-SectionalLactancia1January 1, 2021June 1, 2021June 1, 2021February 24, 2021February 24, 2021Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexicohttps://ClinicalTrials.gov/show/NCT04769700 Mexico
1012NCT04649827A Clinical Trial for Hospitalized Patients With COVID-19 in CearÃ¡: ResCOVID StudyResCOVIDRecruitingNo Results AvailableCOVID-19Other: Clinical ObservationICU outcome|Hospital outcome|Mechanical ventilation|Hospital complicationsEscola de SaÃºde PÃºblica do CearÃ¡All18 Years and older Â  (Adult, Older Adult)3000OtherObservationalObservational Model: Case-Only|Time Perspective: Other3.948.100April 2, 2020June 30, 2020December 30, 2021December 2, 2020December 2, 2020Hospital Leonardo Da Vinci, Fortaleza, Ceara, Brazilhttps://ClinicalTrials.gov/show/NCT04649827 Brazil
1013NCT04252274Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19DC-COVID-19RecruitingNo Results AvailablePneumonia, Pneumocystis|CoronavirusDrug: Darunavir and CobicistatThe virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2|The mortality rate of subjects at weeks 2Shanghai Public Health Clinical CenterAllChild, Adult, Older AdultPhase 330OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentDC-COVID-19January 30, 2020August 31, 2020December 31, 2020February 5, 2020April 13, 2020Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, Chinahttps://ClinicalTrials.gov/show/NCT04252274 China
1014NCT04391829Detection of SARS-CoV-2 in Semen of COVID-19 Positive MalesCOVIDSPERMRecruitingNo Results AvailableCOVID-19|Sars-CoV2|Corona Virus Infection|SemenDiagnostic Test: Ejaculated semen sampledetection of SARS-CoV-2 in the semen|duration of SARS-CoV-2 presence in semen|semen viscosity|semen volume|semen pH|Sperm motility|Sperm morphology|Sperm densityUniversitair Ziekenhuis BrusselMale18 Years to 50 Years Â  (Adult)Not Applicable20OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: DiagnosticCOVIDSPERMAugust 31, 2020August 31, 2021August 31, 2021May 18, 2020October 28, 2020UZ Brussel, Brussels, Belgiumhttps://ClinicalTrials.gov/show/NCT04391829 Belgium
1015NCT04359459Nasal Epithelial Genetic and Single Cell RNA COVID-19 StudyCIPOLLININot yet recruitingNo Results AvailableCOVID-19Nasal epithelial transcriptional response to SARS-CoV2|ACE2-AngII systemUniversity Medical Center GroningenAll18 Years and older Â  (Adult, Older Adult)150OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveCIPOLLINI2020-06-01 00:00:002022-06-01 00:00:002022-06-01 00:00:00April 24, 2020April 27, 2020https://ClinicalTrials.gov/show/NCT04359459
1016NCT04352751Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020RecruitingNo Results AvailableCovid-19Other: convalescent plasmaChange in COVID-19 severity statusHilton PharmaAll18 Years to 55 Years Â  (Adult)Not Applicable2000IndustryInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: OtherPIPK- 0000 /NIBD-0000/2020May 1, 20202021-04-01 00:00:002021-04-01 00:00:00April 20, 2020September 29, 2020National Institute of Blood Diseases and Bone Marrow Transplantation (NIBD), Karachi, Sindh, Pakistanhttps://ClinicalTrials.gov/show/NCT04352751 Pakistan
1017NCT04367207African Covid-19 Critical Care Outcomes StudyRecruitingNo Results AvailableSevere Acute Respiratory Syndrome Coronavirus 2In-hospital mortality|Risk factors (resources, comorbidities and interventions) associated with mortalityUniversity of Cape Town|University of KwaZuluAll18 Years and older Â  (Adult, Older Adult)2000OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveACCCOSMay 1, 2020December 1, 2020December 31, 2020April 29, 2020September 10, 2020Groote Schuur Hospital, Cape Town, Western Cape, South Africa"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04367207/Prot_SAP_000.pdf"https://ClinicalTrials.gov/show/NCT04367207 South Africa
1018NCT04363450Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)HCQPrePRecruitingNo Results AvailableCOVID-19|Corona Virus Infection|Wuhan Coronavirus|Prophylaxis|Healthcare Worker|Sars-CoV2|HydroxychloroquineDrug: Hydroxychloroquine|Drug: PlaceboIncidence of symptomatic COVID-19 infection in healthcare workers|Absenteeism from work due to COVID-19|Severity of COVID-19 infectionLouisiana State University Health Sciences Center in New Orleans|Lafayette General Health|University of Louisiana at LafayetteAll18 Years and older Â  (Adult, Older Adult)Phase 31700OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionLSU NO HSC IRB 20-050April 27, 2020March 31, 2021June 1, 2021April 27, 2020September 2, 2020Lafayette General Medical Center, Lafayette, Louisiana, United States|University Hospital and Clinics, Lafayette, Louisiana, United Stateshttps://ClinicalTrials.gov/show/NCT04363450 United States
1019NCT04373486Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer LevelsCOVID-APECompletedNo Results AvailableCovid-19 With Positive RT-PCRRate of positivity for Acute Pulmonary EmbolismUniversity Hospital, Strasbourg, FranceAll18 Years and older Â  (Adult, Older Adult)160OtherObservationalObservational Model: Case-Only|Time Perspective: Other7840March 3, 2020April 30, 2020May 1, 2020May 4, 2020January 11, 2021Service de Radiologie B - NHC, Strasbourg, Francehttps://ClinicalTrials.gov/show/NCT04373486 France
1020NCT04715243Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS PatientsNIV COVID19RecruitingNo Results AvailableAcute Respiratory Distress Syndrome Caused by COVID-19Device: High flow nasal cannula (HFNC)|Device: Helmet NIV|Device: Face-mask NIVRate of endotracheal intubation|Hospital mortality|Hospital length of stay|Ventilator free daysSultan Qaboos UniversityAll18 Years and older Â  (Adult, Older Adult)Not Applicable360OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentSQU-EC/206/20202021-01-01 00:00:00April 30, 2021July 30, 2021January 20, 2021January 26, 2021Sultan Qaboos University Hospital, Muscat, Omanhttps://ClinicalTrials.gov/show/NCT04715243 Oman
1021NCT04474249Follow-up of Critical COVID-19 PatientsFUP-COVIDRecruitingNo Results AvailableCOVID19|ARDS|AKI|Circulatory Failure|Coagulation Disorder|Inflammatory ResponseMortality|Renal recovery|Respiratory recovery|Working capacity|Quality of life score|Cognitive recovery|Frailty|Activities of Daily Life|Anxiety|Depression|Neurological recoveryUppsala University|Uppsala University HospitalAll18 Years and older Â  (Adult, Older Adult)300OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveEPM-2020-02697June 25, 20202022-12-01 00:00:002022-12-01 00:00:00July 16, 2020July 20, 2020Uppsala University Hospital, Uppsala, Swedenhttps://ClinicalTrials.gov/show/NCT04474249 Sweden
1022NCT04539834Electrolyte State in Patients With COVID-19Active, not recruitingNo Results AvailableElectrolyte ImbalanceOther: electrolyteselectrolytes disturbances in patients with COVID-19|To asses the relation of the electrolyte disturbances with the severity of COVID-19 infection.Zagazig UniversityAll18 Years to 80 Years Â  (Adult, Older Adult)52OtherObservationalObservational Model: Case-Only|Time Perspective: Retrospective(ZU-IRB#: 6328-23-8-2020)May 1, 2020August 1, 2020October 1, 2020September 7, 2020September 7, 2020Zagazig University, Zagazig, Egypthttps://ClinicalTrials.gov/show/NCT04539834 Egypt
1023NCT04492371COVID-19 Infection and Multiple MyelomaEMN-COVIDRecruitingNo Results AvailableMultiple Myeloma|Covid19|Corona Virus InfectionNature of COVID19|Costs related to COVID-19|Systemic anti-cancer therapy subgroup|Laboratory values collected at hospitalization|COVID-19 infection in myeloma patient subgroups|Incidence of COVID-19 infection in frail patients|Infection outcome in different countriesEuropean Myeloma Network|Fondazione EMN Italy OnlusAll18 Years to 99 Years Â  (Adult, Older Adult)500OtherObservationalObservational Model: Cohort|Time Perspective: OtherEMN-COVIDJuly 1, 20202021-07-01 00:00:002021-07-01 00:00:00July 30, 2020July 30, 2020General Hopspital Vienna/Medical University, Vienna, Austria|UCL Saint-Luc, Brussels, Belgium|University Hospital Ostrava, Ostrava, Czechia|University Hospital WÃ¼rzburg, WÃ¼rzburg, Germany|Alexandra Clinical Terapeutics, Athens, Greece|AOU Consorziale Policlinico di Bari, Bari, Italy|Amsterdam UMC, Amsterdam, Netherlands|St James's University Hospital, Leeds, United Kingdomhttps://ClinicalTrials.gov/show/NCT04492371 United Kingdom
1024NCT04685512Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged HomeAR0-CORONARecruitingNo Results AvailableCovid19Drug: tenofovir disoproxil and emtricitabinePhase 2B: Reduction of SARS-CoV2 viral load assessed by Ct PCR at day-4 adjusted on Ct PCR SARS-CoV2 viral load at baseline (ANCOVA)|Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-4 with Ct > or = 28|Phase 2B/3: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Phase 3: Symptoms score|Phase 3: Proportion of secondary hospitalization|Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-7 with Ct > or = 28University Hospital, CaenAll18 Years and older Â  (Adult, Older Adult)Phase 2|Phase 3180OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment20-070November 18, 2020April 1, 2021April 1, 2021December 28, 2020December 28, 2020Caen University Hospital, Caen, Calvados, France|Regional Hospital, OrlÃ©ans, Francehttps://ClinicalTrials.gov/show/NCT04685512 France
1025NCT04812327Capturing Infectious COVID-19 Asymptomatic Cases in SingaporeNot yet recruitingNo Results AvailableCovid19|SARS CoV-2Diagnostic Test: BD Veritor Plus System for Rapid Detection of SARS CoV-2|Diagnostic Test: rt-PCR|Diagnostic Test: viral cultureAssess the performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 compared viral culture, over multiple collection time points|Assess the performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 compared to a commercially available RT-PCR asay, over multiple collection time points|Assess the performance a commercially available RT-PCR assay compared to viral culture, over multiple test time pointsBecton, Dickinson and CompanyAll21 Years and older Â  (Adult, Older Adult)150IndustryObservationalObservational Model: Case-Only|Time Perspective: ProspectiveSGP-21AsymVer-012021-06-01 00:00:002021-09-01 00:00:002021-11-01 00:00:00March 23, 2021March 23, 2021Changi General Hospital, Singapore, Singaporehttps://ClinicalTrials.gov/show/NCT04812327 Singapore
1026NCT04333225Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare WorkersCompletedNo Results AvailableCOVID-19Drug: HydroxychloroquineRate of COVID-19 positive conversion|Time-to-first clinical eventBaylor Research InstituteAll18 Years to 75 Years Â  (Adult, Older Adult)Phase 2228OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention020-132April 3, 2020June 30, 2020June 30, 2020April 3, 2020January 26, 2021Baylor University Medical Center, Dallas, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04333225 United States
1027NCT04603677Northern Colorado COVID-19 BiobankNoCo-CoBioEnrolling by invitationNo Results AvailableCovid19Evaluation of parameters for markers of SARS-CoV-2 infection and predictors for severe diseaseColorado State University|University of Colorado HealthAll18 Years and older Â  (Adult, Older Adult)200OtherObservationalObservational Model: Cohort|Time Perspective: Prospective20-10063HJuly 8, 2020July 30, 2022July 30, 2022October 27, 2020October 27, 2020Colorado State University, Fort Collins, Colorado, United States|Poudre Valley Hospital, UCHealth, Fort Collins, Colorado, United States|Greeley Hospital, UCHealth, Greeley, Colorado, United States|Medical Center of the Rockies, UCHealth, Loveland, Colorado, United Stateshttps://ClinicalTrials.gov/show/NCT04603677 United States
1028NCT04463849Effects of COVID-19 Infection on Beta-cell Function in Euglycemic PatientsCOBETOXRecruitingNo Results AvailableCOVID19|BETA-CELL FUNCTIONDiagnostic Test: Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infectionSerum Î² - cellular function index insulin levels|Serum Î² - cellular function index C-peptide levels|Serum Î² - cellular function HOMA-Î² index|Serum Î² - cellular function pro-insulin/insulin ratio|Evaluation of the secretory response of insulin to the arginine stimulation test|Percentage of patients with preserved Î² cells function|Glucose values|Values of continuous glucose monitoring|Changes in the inflammatory marker interleukin 1-Î²|Changes in the inflammatory marker interleukin IL-2|Changes in the inflammatory marker interleukin IL-6|Changes in the inflammatory marker interleukin IL-7|Changes in the inflammatory marker interleukin IL-10|Changes in the inflammatory marker tumor necrosis factor-Î±|Changes in the inflammatory marker interferon gamma|Changes in the inflammatory marker macrophage inflammatory protein-1Î²|Changes in the inflammatory marker monocyte chemoattractant protein-1|Changes in the inflammatory marker granulocyte-macrophage colony-stimulating factor|Changes in the inflammatory marker granulocyte colony-stimulating factorUniversity of Milan|Luigi Sacco University HospitalAll18 Years to 80 Years Â  (Adult, Older Adult)Not Applicable90OtherInterventionalAllocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic2020-06-01 00:00:00June 30, 2020June 30, 2021June 30, 2021July 9, 2020February 17, 2021Sacco University Hospital, Milan, MI, Italyhttps://ClinicalTrials.gov/show/NCT04463849 Italy
1029NCT04649320Perception of the COVID-19 Pandemic in Patients With Haematological or Solid NeoplasiasRecruitingNo Results AvailableCovid19Other: questionnaireInfluence of the COVID-19 pandemic on cancer patient's daily lifeMedical University InnsbruckAll18 Years and older Â  (Adult, Older Adult)300OtherObservationalObservational Model: Cohort|Time Perspective: Other1264/2020November 23, 2020December 31, 2020December 31, 2020December 2, 2020December 2, 2020Medical University of Innsbruck, Innsbruck, Tyrol, Austriahttps://ClinicalTrials.gov/show/NCT04649320 Austria
1030NCT04355533Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19PED-COVIDRecruitingNo Results AvailableCOVID-19 InfectionBiological: serology test|Biological: nasopharyngeal swab|Biological: rectal swab|Biological: saliva sampleSeroconversion against SARS-CoV2 in children|Measure of Ab antiN and Ab anti-S1/2|Neutralization activity|Positive qPCR in children|correlation between different Ab and qPCR and neutralization activity|Protective immunity|duration of viral carriage in stool, saliva and or nasopharynx|correlation between antibody profile and viral clearance|Ab profile and memory of immunity|saliva biofluid characteristics of COVID-19 infected|Presence of the virus|Reinfection|Transmission of the virus to the family|Immune response|Mucosal immunity|seroconversion against SARS-CoV2 in parents|Measure of Ab antiN and Ab anti-S1 and neutralization activity|Positive qPCR in parents|correlation between different Ab and qPCRAssistance Publique - HÃ´pitaux de Paris|Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France|Commissariat a l'energie atomique et aux energies alternatives|Institut PasteurAllChild, Adult, Older AdultNot Applicable1000Other|IndustryInterventionalAllocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: DiagnosticAPHP200467|2020-A00999-30July 29, 20202022-07-01 00:00:002022-12-01 00:00:00April 21, 2020March 26, 2021HÃ´pital necker Enfants-Malades, Â¨Paris, Francehttps://ClinicalTrials.gov/show/NCT04355533 France
1031NCT04431908Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 SubjectsRecruitingNo Results AvailableCOVID-19Device: olfactory devicesensitivity, specificity and accuracy|repeatability|validation|asymptomatic sensitivity, specificity and accuracyYale UniversityAll18 Years and older Â  (Adult, Older Adult)250OtherObservationalObservational Model: Cohort|Time Perspective: Prospective2000028259June 15, 2020September 1, 2020October 1, 2020June 16, 2020August 4, 2020Yale New Haven Hospital, New Haven, Connecticut, United Stateshttps://ClinicalTrials.gov/show/NCT04431908 United States
1032NCT04370249Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19VIRUSCompletedNo Results AvailableAcute Respiratory Distress Syndrome|COVID-19Other: pulmonary ultrasound"Construction of a composite clinical-echo score (VIRUScore) predictive of risk of worsening respiratory impairment in COVID-19 adult patients admitted to the Emergency Department|Evaluate the prognostic performance of the VIRUScore on the risk of pulmonary aggravation|Evaluate the prognostic performance of the VIRUScore on the risk of severe pulmonary aggravation defined by resuscitation admission and/or death at D14 (sensitivity, specificity, positive predictive value, negative predictive value).|Construction of a decisional algorithm for triage and management of COVID-19 patients.|Search for ""ultrasound signature"" (lung fields and/or severity of involvement) associated with mild (return home) vs. moderate (oxygen therapy) vs. severe (resuscitation/death) clinical forms.|Evaluate the analytical concordance between the pulmonary ultrasound (LUScore) and the Gold-standard CT-scan (CT score)|Construction of a score predictive of aggravation in the sub-population of patients returned home"Nantes University Hospital|WINFOCUS-FranceAll18 Years and older Â  (Adult, Older Adult)313OtherObservationalObservational Model: Case-Only|Time Perspective: RetrospectiveRC20_0164April 9, 2020August 31, 2020August 31, 2020April 30, 2020February 24, 2021Chu de Nantes, Nantes, Francehttps://ClinicalTrials.gov/show/NCT04370249 France
1033NCT04841759The Effects of a Multi-factorial Rehabilitation Program for Healthcare Workers Suffering From Post-COVID-19 Fatigue SyndromeRecruitingNo Results AvailableCOVID-19Other: ExerciseChange of maximum oxygen uptake (VO2max) over time-points (baseline - 4 weeks - 8 weeks) assessed during cardio-pulmonary exercise testing (CPET)|Change of walking distance during a six minutes walk test (6MWT) over time-points (baseline - 4 weeks - 8 weeks)|Change of numbers over time-points (baseline - 4 weeks - 8 weeks) how often someone can stand up and sit down on a chair within 30 seconds during a 30-seconds sit-to-stand test (30secSTS)|Change of absolute body fat over time-points (baseline - 4 weeks - 8 weeks) via Bioelectrical Impedance Analysis (BiA)|Change of body fat percentage over time-points (baseline - 4 weeks - 8 weeks) via Bioelectrical Impedance Analysis (BiA)|Change of absolute Lean Body Mass (LBM) over time-points (baseline - 4 weeks - 8 weeks) via Bioelectrical Impedance Analysis (BiA)|Change of realtive Lean Body Mass (LBM) over time-points (baseline - 4 weeks - 8 weeks) via Bioelectrical Impedance Analysis (BiA)|Change of generalized anxiety measured over time-points (baseline - 4 weeks - 8 weeks) via Generalized Anxiety Disorder Scale-7 (GAD-7)|Change of depression measured over time-points (baseline - 4 weeks - 8 weeks) via the Patient Health Questionnaire-9 (PHQ-9)|Change of mental stress measured over time-points (baseline - 4 weeks - 8 weeks) via Perceived Stress Scale (PSS-10)|Change of fatigue measured over time-points (baseline - 4 weeks - 8 weeks) via Brief Fatigue Inventory (BFI)|Change of resilience measured over time-points (baseline - 4 weeks - 8 weeks) via Brief Resilience Scale (BRS)|Change and time kinetics of handgrip strength (HGS) over time-points (baseline and before each exercise session) measured via handgrip Dynamometer.|Change and time kinetics of physical and functional limitations of COVID-19 survivors over time-points (baseline and before each exercise session) via Post-Covid-19-Functional Scale (PCFS)|Change of work ability over time-points (baseline, 4 weeks, 8 weeks) via Work Ability Index (WAI) questionnaire.|Change of troponin (TnT) over time-points (baseline - 4 weeks - 8 weeks) via blood sample.|Change of BNP over time-points (baseline - 4 weeks - 8 weeks) via blood sample.|Change of CK-MB over time-points (baseline - 4 weeks - 8 weeks) via blood sample.|Change of HS-CRP over time-points (baseline - 4 weeks - 8 weeks) via blood sample.|Change of IL-6 over time-points (baseline - 4 weeks - 8 weeks) via blood sample.|Change of cholesterol over time-points (baseline - 4 weeks - 8 weeks) via blood sample.|Change of triglycerides over time-points (baseline - 4 weeks - 8 weeks) via blood sample.Medical University of ViennaAll18 Years to 65 Years Â  (Adult, Older Adult)Not Applicable30OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care1181/2021April 1, 2021September 30, 2021October 31, 2021April 12, 2021April 12, 2021Medical University of Vienna, Vienna, Austriahttps://ClinicalTrials.gov/show/NCT04841759 Austria
1034NCT04364594COVID-19 Search in Conjunctival CellsCOVID-TCompletedNo Results AvailableCOVID 19|Pulmonary DiseaseDiagnostic Test: conjunctival swabConjunctival swab results based on RT-PCR|Conjunctival swab positivity in relation to Pulmonary and blood abnormalitiesFondazione Policlinico Universitario Agostino Gemelli IRCCSAll18 Years and older Â  (Adult, Older Adult)Not Applicable50OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic0013008/20March 26, 2020April 24, 2020May 30, 2020April 28, 2020July 23, 2020Maria Cristina Savastano, Roma, Italyhttps://ClinicalTrials.gov/show/NCT04364594 Italy
1035NCT04426344Core Warming of COVID-19 PatientsWithdrawnNo Results AvailableCOVID 19Device: ensoETM deviceViral load measured in tracheal aspirate 72 hours after initiation of core warming|PaO2/FiO2 ratio 72 hours after initiation of core warming|Duration of mechanical ventilationWashington University School of MedicineAll18 Years and older Â  (Adult, Older Adult)Not Applicable0OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment2020051502020-10-01 00:00:002020-12-01 00:00:002020-12-01 00:00:00June 11, 2020October 19, 2020Barnes-Jewish Hospital, Saint Louis, Missouri, United Stateshttps://ClinicalTrials.gov/show/NCT04426344 United States
1036NCT04590053Allocetra-OTS in COVID-19, Phase IIRecruitingNo Results AvailableCovid19Biological: Allocetra-OTSAssessment of safety by determining the number of participants with any Adverse Events (AE) and Serious Adverse Events (SAE)|Preliminary Efficacy: Recovery from COVID-19 as determined by negative PCR or asymptomatic by the NIH classification for the severity of illness|Mortality|Preliminary Efficacy: To assess prevention of respiratory deterioration associated with COVID-19 by measuring the PaO2/FiO2 ratio|Hospitalization|Life support|Clinical status by the new NIH Patient Classification for the severity of illness|Clinical status by NEWS2|Support measurements: percentage of subjects reporting each severity rating on a 7-point ordinal scale|Support measurements: improvement of severity rating on a 7-point ordinal scale|Virus Clearance|Exploratory: Serum cytokines/chemokines and immunomodulating factors|Exploratory: complete blood counts|Exploratory: Histone and cell-free DNA levelsHadassah Medical Organization|Barzilai Medical Center|Tel-Aviv Sourasky Medical CenterAll18 Years to 80 Years Â  (Adult, Older Adult)Phase 224OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: PreventionDM004October 20, 20202021-02-01 00:00:002021-03-01 00:00:00October 19, 2020October 22, 2020Barzilai Medical Center, Ashkelon, Israel|Hadassah Medical Center, Jerusalem, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israelhttps://ClinicalTrials.gov/show/NCT04590053 Israel
1037NCT04516512Assessment of SARS-CoV-2 Seroprevalence in DetentionCOVIDETNot yet recruitingNo Results AvailableCOVID-19Biological: Blood drawDetermination of the immunological parameters (Immunoglobins G) of the SARS-CoV-2 infection|Symptoms suggestive of COVID-19|Factors assumed to be related to infection with SARS-CoV-2 and the occurrence of moderate to severe forms of COVID-19Assistance Publique - HÃ´pitaux de ParisAll18 Years to 80 Years Â  (Adult, Older Adult)Not Applicable2500OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: ScreeningAPHP200667September 1, 2020January 1, 2021January 1, 2021August 18, 2020August 18, 2020https://ClinicalTrials.gov/show/NCT04516512
1038NCT04508556Performance Assessment of SARS-CoV-2 Detection Breath Biopsy - SARS-CoV-2 StudyCOVIDCompletedNo Results AvailableCovid19Device: Breath Biopsy face masks with removable filters and fitted PVA strip|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: oropharyngeal swabsPositive control for technical validation|Evaluation of test performanceOwlstone Ltd|OLVG|Maastricht UniversityAll18 Years and older Â  (Adult, Older Adult)40Industry|OtherObservationalObservational Model: Cohort|Time Perspective: Cross-SectionalSARS-CoV-2 studySeptember 30, 2020December 19, 2020December 19, 2020August 11, 2020April 1, 2021OLVG, Amsterdam, Netherlandshttps://ClinicalTrials.gov/show/NCT04508556 Netherlands
1039NCT04330586A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19RecruitingNo Results AvailableCOVID-19Drug: Ciclesonide Metered Dose Inhaler [Alvesco]Rate of SARS-CoV-2 eradication at day 14 from study enrollment|Rate of SARS-CoV-2 eradication at day 7 from study enrollment|Time to SARS-CoV-2 eradication (days)|Viral load area-under-the-curve (AUC) reduction versus control|Time to clinical improvement (days)|Proportion of clinical failureKorea University Guro HospitalAll18 Years to 80 Years Â  (Adult, Older Adult)Phase 266OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentKUMC-COVID-19April 1, 2020March 31, 2021March 31, 2021April 1, 2020February 5, 2021Korea University Guro Hospital, Seoul, Korea, Republic ofhttps://ClinicalTrials.gov/show/NCT04330586 Republic of
1040NCT04592055The Effect of COVID-19 on Diabetes MellitusCOVID-19-DMRecruitingNo Results AvailableDiabetes Mellitus|Covid19A1cUÅŸak UniversityAll18 Years to 80 Years Â  (Adult, Older Adult)500OtherObservationalObservational Model: Case-Only|Time Perspective: RetrospectiveUU-DM002March 20, 2020October 15, 2020November 1, 2020October 19, 2020October 19, 2020Usak University Training and Research Hospital, Usak, Turkeyhttps://ClinicalTrials.gov/show/NCT04592055 Turkey
1041NCT04654325Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 PatientsCOVIDEYENot yet recruitingNo Results AvailableSARS-CoV-2Diagnostic Test: conjunctival swabpresence of SARS-CoV-2 genome in tears|presence of systemic symptoms evaluated at the time of making an appointment by a systematic standardized interrogation|assessement of viral load levelsAssistance Publique - HÃ´pitaux de ParisAll18 Years and older Â  (Adult, Older Adult)Not Applicable1280OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: OtherAPHP201268|2020-A02996-332020-12-01 00:00:002021-12-01 00:00:002021-12-01 00:00:00December 4, 2020December 4, 2020https://ClinicalTrials.gov/show/NCT04654325
1042NCT04646655Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19EMOS-COVIDRecruitingNo Results AvailableCovid19|ThrombosisDrug: EnoxaparinMortality rate|Progression of respiratory failure|Number of major bleeding episodes|Respiratory function improvement|Number of major cardiovascular events|Deep Vein ThrombosisASST Fatebenefratelli Sacco|Massimo Arquati|Riccardo Colombo|Umberto Russo|Manuela Nebuloni|Spinello AntinoriAll18 Years to 80 Years Â  (Adult, Older Adult)Phase 3300OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentHLS-02COVID19/2020July 27, 2020May 31, 2021July 31, 2021November 30, 2020November 30, 2020ASST Fatebenefratelli Sacco, Milan, Italyhttps://ClinicalTrials.gov/show/NCT04646655 Italy
1043NCT04610567Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)Nano-COVID19RecruitingNo Results AvailableCoronavirus|Inflammation|Covid19Drug: Methotrexate-LDE phase 1|Drug: Methotrexate-LDE phase 2|Drug: Placebo-LDE phase 2Duration of hospital stay|Number of participants requiring mechanical ventilation|Number of participants requiring vasoactive drugs|Number of participants requiring renal replacement therapy|Incidence of secondary infection|Sequential Organ Failure Assessment (SOFA) score|World Health Organization (WHO) COVID-19 score|Interleukin 6 (IL-6)|Dimer-D|Chest CT scan|Incidence and severity of laboratory alterations|Clinical side effects|Other adverse eventsUniversity of Sao Paulo General Hospital|Hospital Santa MarcelinaAll18 Years to 85 Years Â  (Adult, Older Adult)Phase 1|Phase 2100OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment36746020.5.1001.0068October 27, 2020March 15, 2021July 15, 2021October 30, 2020January 14, 2021Heart Institute (InCor) - University of SÃ£o Paulo Medical School, SÃ£o Paulo, Brazil, SÃ£o Paulo, SP, Brazil|Hospital Santa Marcelina, SÃ£o Paulo, SP, Brazil|Institute Prevent Senior, SÃ£o Paulo, SP, Brazilhttps://ClinicalTrials.gov/show/NCT04610567 Brazil
1044NCT04433364COPE - COVID-19 in Pregnancy and Early ChildhoodCOPERecruitingNo Results AvailableSars-CoV2|Covid-19|Pregnancy Complications|Pregnancy Preterm|Pregnancy in Diabetic|Neonatal InfectionOther: biological samples, questionnaires and interviewsBiobank with linkage to registers|Experiences of pregnancy during a pandemicSahlgrenska University Hospital, SwedenFemale18 Years and older Â  (Adult, Older Adult)1200OtherObservationalObservational Model: Cohort|Time Perspective: Prospective2020-02848 0604June 2, 2020June 2, 2021June 2, 2041June 16, 2020June 16, 2020Falu Hospital, Falun, Dalarna, Sweden|Halmstad lasarett, Halmstad, Halland, Sweden|Varbergs sjukhus, Varberg, Halland, Sweden|Helsingborgs lasarett, Helsingborg, SkÃ¥ne, Sweden|SkÃ¥ne Universitetssjukhus, Lund, SkÃ¥ne, Sweden|Eskiltuna hospital, Eskilstuna, SÃ¶dermanland, Sweden|Boras hospital, Boras, VGR, Sweden|Sahlgrenska Univeristy Hospital, Gothenburg, VGR, Sweden|Ryhovs sjukhus, JÃ¶nkÃ¶ping, Sweden|Kalmar Lasarett, Kalmar, Sweden|Karlstad lasarett, Karlstad, Sweden|Kristiandstad lÃ¤nssjukhus, Kristianstad, Sweden|Skaraborgs sjukhus SkÃ¶vde, SkÃ¶vde, Sweden|BB Stockholm, Stockholm, Sweden|Danderyd, Stockholm, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden|Karolinska University Hospital- Huddinge, Stockholm, Sweden|SÃ¶dersjukhuset, Stockholm, Sweden|SÃ¶dertÃ¤lje, Stockholm, Sweden|Sundsvall, Sundsvall, Sweden|UmeÃ¥ University Hospital, UmeÃ¥, Sweden|Uppsala University Hospital, Uppsala, Sweden|VÃ¤sterÃ¥s, VÃ¤sterÃ¥s, Sweden|Ystad, Ystad, Sweden|Ã–rebro University Hospital, Ã–rebro, Sweden|LinkÃ¶ping University Hospital, LinkÃ¶ping, Ã–stergÃ¶tland, Sweden|Vrinnevisjukhuset, NorrkÃ¶ping, Ã–stergÃ¶tland, Swedenhttps://ClinicalTrials.gov/show/NCT04433364 Sweden
1045NCT04505709Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19Enrolling by invitationNo Results AvailableCovid19Identification of host genetic markers associated with the evolution of COVID-19|Analysis of bioethical aspects related to in-hospital management of the health crisis|Analysis of the spectrum of mutants of SARS-CoV-2 and its possible association with the clinical evolution of COVID-19Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az|Hospital Universitario 12 de Octubre|Fundacion Investigacion Biomedica Hospital 12 de Octubre|Hospital Universitario Fundacion Jimenez Diaz|Hospital Universitario Infanta Elena|Hospital Universitario Virgen de la Arrixaca|Instituto Murciano de InvestigaciÃ³n Biosanitaria Virgen de la ArrixacaAll18 Months and older Â  (Child, Adult, Older Adult)1000OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveSTOP-Coronavirus|COV20/00181August 1, 2020August 1, 2021August 1, 2021August 10, 2020August 10, 2020Fundacion Jimenez Diaz, Madrid, Spainhttps://ClinicalTrials.gov/show/NCT04505709 Spain
1046NCT04428008Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis PatientsTa1RecruitingNo Results AvailableCOVID-19Drug: ThymalfasinReduction in documented infection with COVID-19 Reduction in infection with COVID-19|Need for hospitalization|Hospital length of stay|Need for ICU admission|ICU length of stay|Need for mechanical ventilation|Duration of mechanical ventilation|Recovery time from COVID-19|Change in any existing comorbidities or occurrence of newly diagnosed disease|Incidence of non-COVID-19 infections|Change in lymphocyte subsets (CD4, CD8)|Mortality|Treatment-emergent adverse events|Treatment-emergent changes in vital signs|Treatment-emergent laboratory parametersInova Health System|Davita Clinical Research|Clinical Research Consultants, LLCAll60 Years and older Â  (Adult, Older Adult)Phase 2240Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: PreventionACW-1221958-1January 12, 20212021-04-01 00:00:002022-01-01 00:00:00June 11, 2020January 13, 2021Clinical Research Consultants, Kansas City, Kansas, United Stateshttps://ClinicalTrials.gov/show/NCT04428008 United States
1047NCT04514302Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19Not yet recruitingNo Results AvailableCOVID-19Drug: Placebo|Drug: Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS)Proportion of patients with improvement in clinical status|Time to clinical improvement|Proportion of patients that reach a score of 6, 7 or 8 in the NIAID 8-point ordinal scale|Duration of hospitalization|SARS-CoV-2 PCR negativization rate|Proportion of patients with clinical improvement at day 7|Proportion of patients with immediate adverse events (< 24 hours)|Proportion of patients with late adverse events (1 - 28 days)Hospital San Jose Tec de MonterreyAll18 Years and older Â  (Adult, Older Adult)Phase 1|Phase 251OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentINOSARS-CoV-2 TecSaludOctober 20, 2020February 20, 2021June 20, 2021August 14, 2020August 14, 2020Hospital San JosÃ©, Monterrey, Nuevo Leon, Mexicohttps://ClinicalTrials.gov/show/NCT04514302 Mexico
1048NCT04341415Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients OutcomeSOS-COVID19TerminatedNo Results AvailableCovid19|SARS-CoV InfectionProcedure: Auricular neuromodulation|Procedure: ControlComparison of the percentage of clinically improved inpatients between D0 and D14Fondation Ophtalmologique Adolphe de RothschildAll18 Years and older Â  (Adult, Older Adult)Not Applicable31OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: TreatmentCRN_2020_8April 9, 2020November 20, 2020January 15, 2021April 10, 2020April 13, 2021Centre Hospitalier Simone Veil, Beauvais, France|Fondation Adolphe de Rothschild, Paris, Francehttps://ClinicalTrials.gov/show/NCT04341415 France
1049NCT04447131Effect of COVID-19 on Platelet AggregationRecruitingNo Results AvailableCOVID-19|SARS-CoV-2Other: venipuncture in peripheral veinPlatelet aggregation analyzed by Multiplate-ADP|Platelet aggregation by Multiplate-ASPI and Multiplate-TRAP in patients hospitalized for COVID-19 versus healthy controls.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus healthy controls.|Platelet aggregation for COVID-19 versus patients hospitalized for respiratory symptoms but negative for Influenza and COVID-19 research.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for respiratory symptoms but negative for influenza or COVID-19 research.|Platelet aggregation in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.|Reticulated platelet fraction in patients hospitalized for COVID-19 versus patients hospitalized for Influenza.|Platelete aggreggation versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization|Reticulated platelet fraction versus composite outcome of death from any cause, thrombotic events, need for ICU, need for intubation during hospitalization|Platelet aggregation versus time (days) of total hospitalization and in the ICU|Reticulated platelet fraction versus time (days) of total hospitalization and in the ICU|Platelet aggregation versus WHO ordinal scale of outcomes for COVID-19University of Sao Paulo|FundaÃ§Ã£o de Amparo Ã  Pesquisa do Estado de SÃ£o PauloAll18 Years and older Â  (Adult, Older Adult)200OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveSDC 5089/20/118April 29, 2020June 30, 2021July 30, 2021June 25, 2020November 5, 2020Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazilhttps://ClinicalTrials.gov/show/NCT04447131 Brazil
1050NCT04329611ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 DiseaseTerminatedNo Results AvailableCOVID-19Drug: HydroxychloroquineComposite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality|Symptom duration|Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased (categorical)Dr. Michael Hill|Alberta Health Services|University of Alberta|University of Calgary|Calgary Health Trust|Alberta Innovates Health Solutions|Government of AlbertaAll18 Years and older Â  (Adult, Older Adult)Phase 3148OtherInterventionalAllocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentABCOV-01 version 1.5April 13, 2020July 20, 2020July 20, 2020April 1, 2020July 31, 2020University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canadahttps://ClinicalTrials.gov/show/NCT04329611 Canada
1051NCT04407390Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the ElderlyNR-COVID19RecruitingNo Results AvailableCOVIDDietary Supplement: Nicotinamide riboside|Dietary Supplement: PlaceboHypoxic respiratory failure|Mortality|Sepsis|Circulatory failure|Days in hospital|NAD levelsUniversity of Copenhagen|Bispebjerg Hospital|Elysium HealthAll70 Years and older Â  (Older Adult)Phase 2100Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentH-20026601June 1, 2020May 1, 2021May 1, 2022May 29, 2020June 2, 2020Bispebjerg Hospital, Copenhagen NV, Denmarkhttps://ClinicalTrials.gov/show/NCT04407390 Denmark
1052NCT04313023The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2RecruitingNo Results AvailableCOVID-19Drug: PUL-042 Inhalation Solution|Drug: PlaceboSeverity of COVID-19|Incidence of SARS-CoV-2 infection|ICU admission|Mechanical ventilation|MortalityPulmotect, Inc.|United States Department of DefenseAll18 Years and older Â  (Adult, Older Adult)Phase 2200Industry|U.S. FedInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionPUL-042-501June 9, 20202021-05-01 00:00:002021-06-01 00:00:00March 18, 2020March 17, 2021University of California Irvine, Orange, California, United States|Premier Urgent Care of California, San Bernardino, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|Invesclinic US LLC, Fort Lauderdale, Florida, United States|Luminous Cinical Research- South Florida Urgent Care, Miami, Florida, United States|DBC Research, Tamarac, Florida, United States|Affinity Clinical Research, LLC, Tampa, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Willis-Knighton Physcian Network, Bossier City, Louisiana, United States|Englewood Health, Englewood, New Jersey, United States|Ascension St John, Bartlesville, Oklahoma, United States|Ascension St. John, Tulsa, Oklahoma, United States|Invesclinic US LLC, Edinburg, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04313023 United States
1053NCT04753762Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 InfectionIMACovidRecruitingNo Results AvailableCOVID-19 Virus Disease|Cardiac ComplicationTo Characterize cardiac involvement by cardiac TTE imaging during 4 months after confirmed COVID-19 infection|To Characterize cardiac involvement by cardiac MRI during 4 months after confirmed COVID-19 infection|To characterize cardiac evolution at 12 +/-2 months from COVID-19 infection|To evaluate Cardiac events at 12 +/-2 months from COVID-19 infection|To evaluate all cause deaths at 12 +/-2 months from COVID-19 infectionCentral Hospital, Nancy, FranceAll18 Years to 79 Years Â  (Adult, Older Adult)50OtherObservationalObservational Model: Other|Time Perspective: Retrospective2020PI086March 1, 2020January 1, 2022November 1, 2022February 15, 2021February 15, 2021Laura FILIPPETTI, VandÅ“uvre-lÃ¨s-Nancy, Francehttps://ClinicalTrials.gov/show/NCT04753762 France
1054NCT04347876Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?RecruitingNo Results AvailableCOVID-19|BCG VaccinationDiagnostic Test: Tuberculin testPneumonia severity index|Need for ICU admission|COVID -19 test conversion|MortalityAssiut UniversityAll12 Years to 80 Years Â  (Child, Adult, Older Adult)100OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveAssiutU12April 11, 2020June 16, 2020June 30, 2020April 15, 2020April 15, 2020AssiutU, Assiut, Egypthttps://ClinicalTrials.gov/show/NCT04347876 Egypt
1055NCT04689672Predictivity of Hemogasanalysis and Lung UltraSound in Determining COVID-19 SeverityCOVID-PEGALUSRecruitingNo Results AvailableCovid19Diagnostic Test: Lung ultrasoundPatients' short-term outcome|Patients' long-term outcome|Intensity of careIRCCS San RaffaeleAll18 Years and older Â  (Adult, Older Adult)600OtherObservationalObservational Model: Cohort|Time Perspective: OtherCOVID-PEGALUSDecember 16, 2020May 10, 2021May 10, 2021December 30, 2020December 30, 2020IRCCS San Raffaele, Milan, MI, Italyhttps://ClinicalTrials.gov/show/NCT04689672 Italy
1056NCT04549376Virucidal Effect of Povidone Iodine on COVID-19 In-VivoVEP-COVRecruitingNo Results AvailableCOVID19Drug: Povidone-Iodine 0.4% NI|Drug: Povidone-Iodine 0.5% NI|Drug: Povidone-Iodine 0.6% NI|Drug: Povidone-Iodine 0.5% NS|Drug: Povidone-Iodine 0.6% NS|Other: Placebo comparator: DW-NI|Other: Placebo comparator: DW-NSProportion of COVID-19 positive cases following intervention|Adverse eventsPi Research Consultancy Center, Bangladesh|Dhaka Medical CollegeAll15 Years to 90 Years Â  (Child, Adult, Older Adult)Phase 2200OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: PreventionPiRCC-1131-2020July 1, 2020October 20, 2020October 30, 2020September 16, 2020September 16, 2020Dhaka Medical College, Dhaka, Bangladeshhttps://ClinicalTrials.gov/show/NCT04549376 Bangladesh
1057NCT04568044Evaluation of Humoral Immunity Following COVID-19 in PregnancyImmunoCOVIDRecruitingNo Results AvailableCOVID-19|Pregnancy Related|Influenza, HumanProcedure: Blood samplePhenotyping antibody secreting cells (ASCs) and memory B cells during COVID-19 infection, and post recovery.|Quantification of SARS-CoV-2 specific IgG production by memory B cells to measure long-lasting immune protection against re-infection.|Quantification of SARS-COV-2 viral load using PCR.|Immuno-phenotype circulatory T follicular helper cells (cTFH) cells post SARS-CoV-2 infection.|Investigating T cell mediated immune function post COVID-19|In pregnancy, comparing antibody production, and immune phenotype and function (as outlined above) between COVID-19 infection, and influenza infected or vaccinated.Imperial College LondonAll18 Years to 60 Years Â  (Adult)128OtherObservationalObservational Model: Cohort|Time Perspective: Prospective20SM6089September 16, 2020December 31, 2022July 3, 2023September 29, 2020March 17, 2021Chelsea and Westminster NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdomhttps://ClinicalTrials.gov/show/NCT04568044 United Kingdom
1058NCT04689724Covid-19 Airway ManagementRecruitingNo Results AvailableCovid-19_airways ManagementSerious adverse events at intubation|Signs, symptoms or confirmed COVID19 infection in healthcare providersUniversity Health Network, TorontoAll18 Years and older Â  (Adult, Older Adult)250OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective20-5620August 10, 20202021-02-01 00:00:002022-05-01 00:00:00December 30, 2020December 30, 2020University Health Network, Toronto, Ontario, Canadahttps://ClinicalTrials.gov/show/NCT04689724 Canada
1059NCT04534725COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;C-SMARTRecruitingNo Results AvailableCancer|Covid19|Respiratory Viral InfectionDrug: Interferon alfa|Drug: Selinexor|Drug: LenzilumabIncidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)|incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing|incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .|incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records|time to clinical improvement or discharge from hospital assessed using medical records|ARM 1: Duration of acute respiratory/ILI symptoms in case of confirmed respiratory infection during the study period. Assessed using patient symptom Diary PRO tool|ARM 1: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). Assessed using patient medical records|ARM 1: Time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records|ARM 1: Illness severity in case of confirmed COVID-19 diagnosed during the study period using WHO clinical progression scale|ARM 1: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records|ARM 1: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records|ARM 1: Incidence of sero-conversion of SARS-CoV-2 at the end of the study period. assessed using qPCR|ARM 1: Incidence of death from any cause during the study period. assessed using patient medical records|ARM 1: Incidence of testing for COVID-19 during the study period. assessed using medical records|ARM 2 Duration of acute respiratory symptoms in case of confirmed COVID-19 diagnosed during the study period. assessed with PRO and medical records.|ARM 2: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). assessed using medical records|ARM 2: Illness severity in case of confirmed COVID-19 diagnosed during the study period. assessed using WHO clinical progression scale.|ARM 2: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records.|ARM 2: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records|ARM 2: Incidence of seroconversion of SARS-CoV-2 at the end of the study period. assessed using qPCR.|ARM 2: Incidence of testing for COVID-19 during the study period assessed using medical records|ARM 3: Time to clinical improvement assessed using medical records.|ARM 3: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale|ARM 3: change to clinical condition assessed with Karnofsky Performance score|ARM 3: Time to progression to severe COVID-19, defined by WHO ordinal scale|ARM 3: Time to all-cause mortality|ARM 3:Duration of hospitalisation assessed using medical records|ARM 3: Duration of COVID-19 symptoms assessed using patient reported symptom diary.|ARM 3: Duration of oxygen supplementation (days). assessed using medical records.|ARM 3: change in nasopharyngeal SARS-CoV-2 viral load shedding (assessed via qPCR)|ARM 3: Safety and tolerability of selinexor using relevant medical records|ARM 3: incidence of changes in blood results relevant to clinical improvement assessed using medical records|ARM 4: Incidence of all cause death by day 28 and 60|ARM 4: Time to all-cause mortality|ARM 4: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale|ARM 4: Incidence of ARDS assessed using medical records|ARM 4: incidence of HLH. assessed using medical records|ARM 4: Duration of hospitalisation. assessed using hospital medical records.|ARM 4: Proportion discharged from hospital. assessed using medical records|ARM 4: Incidence of mechanical ventilation up to day 28. assessed using medical records|ARM 4: Ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records|ARM 4: Organ failure free days and proportion who did not develop organ failure. assessed using medical records.|ARM 4: Incidence and duration of ICU admission. assessed using medical records|ARM 4: incidence and duration of supplemental oxygen use. assessed using medical records|ARM 4: Time to clinical improvement defined as National Early Warning Score 2 (NEWS2) of <2 maintained for 24 hours.|ARM 4: incidence of non-invasive ventilation. assessed using medical records|ARM 4: number of participants alive and off oxygen at day 60. assessed using medical records.|ARM 4: proportion of participants who had improved oxygenation for >48 hours. assessed using medical records|ARM 4: Incidence of adverse events based on the national cancer institute CTCAE v5. Assessed using medical records|ARM 4: incidence of SAEs based on NCI CTCAE v5 assessed using medical records|ARM 4: change in nasopharyngeal SARS-CoV-2 viral load shedding. assessed using qPCR.Peter MacCallum Cancer Centre, AustraliaAll18 Years and older Â  (Adult, Older Adult)Phase 32282OtherInterventionalAllocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentPeter Mac ID 20/135December 17, 20202021-12-01 00:00:002021-12-01 00:00:00September 1, 2020January 5, 2021Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiahttps://ClinicalTrials.gov/show/NCT04534725 Australia
1060NCT04401410Anti-SARS Cov-2 T Cell Infusions for COVID 19BATITRecruitingNo Results AvailableSARS-CoV 2|Viral Infection|COVID 19Biological: Dose Finding Phase (MTD)|Biological: Partially HLA-matched SARS-CoVSTs|Other: Routine care (no SARS-CoVSTs)Dose Escalation Phase: Rate of Dose Limiting Toxicities by CTCAE 5.0 [14 days post infusion]|Randomized Trial: Rate of Clinical Response as assessed by the World Health Organization (WHO) Ordinal Scale [7 days post-randomization or hospital discharge]|Randomized Trial: Rate of Treatment-related adverse events (tAE) by CTCAE 5.0 [14 days post-randomization]Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System|AlloVirAll18 Years and older Â  (Adult, Older Adult)Phase 158Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentH-47739 BAT ITNovember 4, 2020August 15, 2021August 15, 2021May 26, 2020April 1, 2021Houston Methodist Hospital, Houston, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04401410 United States
1061NCT04422444Post Intensive Care Syndrome in COVID19 PatientsPICS-COVID19RecruitingNo Results AvailableCOVID19|Post Intensive Care Unit SyndromeDiagnostic Test: QuestionnairesChange from baseline Short Form 12 Health Survey (SF12) at 12 month|Change from baseline Lawton & Brody Instrumental activities of daily living scale at 12 months|Change from baseline Perceived Deficits Questionnaire (PDQ) at 12 months|Change from baseline Hospital Anxiety and Depression Scale (HADS) at 12 months|Change from baseline Davidson Trauma Scale (DTS) at 12 monthsCorporacion Parc TauliAll18 Years to 90 Years Â  (Adult, Older Adult)100OtherObservationalObservational Model: Cohort|Time Perspective: Prospective2020/577June 1, 2020May 1, 2021June 1, 2022June 9, 2020June 12, 2020CorporaciÃ³ Parc TaulÃ­, Sabadell, Barcelona, Spainhttps://ClinicalTrials.gov/show/NCT04422444 Spain
1062NCT04471636Telemedicine in Outpatient Covid-19 PatientsCOVID-SMARTRecruitingNo Results AvailableCovid-19|Cardiovascular Risk FactorDevice: Withings ScanWatchRate of participants with a combination of hospitalization and unplanned use of hospital emergency department or emergency medical service|Rate of participants hospitalized|Rate of participants with unplanned use of hospital emergency department or emergency medical service|Rate of participants experiencing death of any cause|Rate of participants experiencing death of Covid-19Ludwig-Maximilians - University of Munich|Gesundheitsreferat (GSR), Landeshauptstadt MÃ¼nchen|Deutsches Zentrum fÃ¼r Herz-Kreislauf-Forschung (DZHK)All18 Years and older Â  (Adult, Older Adult)Not Applicable600OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment20-448September 18, 20202021-11-01 00:00:002021-12-01 00:00:00July 15, 2020April 14, 2021LMU Klinikum, Munich, BY, Germanyhttps://ClinicalTrials.gov/show/NCT04471636 Germany
1063NCT04422977Serological Study of the Exposure of Personnel to Sars-cov-2SEROPHUGACNot yet recruitingNo Results AvailableSars-CoV2Diagnostic Test: Sars-Cov-2 serologyMeasurement of overall seroprevalence of SARS-Cov-2 in an hospital staffCentre Hospitalier Saint Joseph Saint Luc de LyonAll18 Years to 70 Years Â  (Adult, Older Adult)Not Applicable900OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: DiagnosticSEROPHUGACJune 8, 2020June 30, 2020June 30, 2020June 9, 2020June 9, 2020https://ClinicalTrials.gov/show/NCT04422977
1064NCT04515108Perinatal Outcomes and Hematologic Parameters in COVID-19 PregnanciesCompletedNo Results AvailablePregnancy, Infections in|Covid19Other: Clinical assessmentcomplete blood count parameters (including the number of lymphocytes, Leukocytes, monocytes, platelets and red blood cells).|APGAR score|maternal and newborn length|maternal and newborn weight|body temperatureAnkara City Hospital BilkentFemale18 Years to 42 Years Â  (Adult)108OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveE1-20-672March 10, 2020August 5, 2020August 10, 2020August 17, 2020August 17, 2020Ankara City Hospital, Ankara, Turkeyhttps://ClinicalTrials.gov/show/NCT04515108 Turkey
1065NCT04376658Quality of Life and Long-term Outcomes After Hospitalization for COVID-19RecruitingNo Results AvailableQuality of Life|Long-term Outcomes|Coronavirus InfectionOther: COVID-19One-year utility score of health-related quality of life|Incidence of all-cause mortality|Incidence of rehospitalizations|Percentage of return to work or study|Score of Instrumental Activities of Daily Living|Score of dyspnea|Percentage of long-term ventilatory support need|Symptoms of anxiety and depression|Symptoms of posttraumatic stress disorder|Utility score of health-related quality of life at 3, 6, and 9 months|Score of self-rated healthHospital Moinhos de Vento|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital do Coracao|Hospital AlemÃ£o Oswaldo Cruz|BeneficÃªncia Portuguesa de SÃ£o Paulo|Brazilian Clinical Research Institute|Brazilian Research In Intensive Care NetworkAll18 Years and older Â  (Adult, Older Adult)1000OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveCoalition COVID-19: Long-termJuly 15, 2020April 15, 2022July 15, 2022May 6, 2020February 2, 2021Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazilhttps://ClinicalTrials.gov/show/NCT04376658 Brazil
1066NCT04323878Early CPAP in COVID-19 Patients With Respiratory Failure. A Prospective Cohort Study.EC-COVID-PCSRecruitingNo Results AvailableEarly CPAP Ventilation in COVID-19 PatientsDeath or need of intubation|30-day mortalityMario Negri Institute for Pharmacological ResearchAll18 Years and older Â  (Adult, Older Adult)3000OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveEC-COVID-PCS-FeniceJune 1, 20202021-03-01 00:00:002021-12-01 00:00:00March 27, 2020December 17, 2020Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italyhttps://ClinicalTrials.gov/show/NCT04323878 Italy
1067NCT04405973Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMOCompletedNo Results AvailableCOVID-19|SARS-CoV 2|Extracorporeal Membrane Oxygenation|ARDSDevice: vv-ECMOoverall survival|duration of ECMO treatment|duration of ventilation treatment|duration of initiation of ECMO treatment to ICU dischargeDr. Alexander Supady|University Hospital FreiburgAll18 Years to 100 Years Â  (Adult, Older Adult)133OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveEK-FR 329/20May 19, 2020September 30, 2020September 30, 2020May 28, 2020November 4, 2020University Clinic Freiburg, Freiburg, Germanyhttps://ClinicalTrials.gov/show/NCT04405973 Germany
1068NCT04635592Serological Diagnostics of COVID-19 in Health Care WorkersKORANITNot yet recruitingNo Results AvailableSARS-CoV InfectionDiagnostic Test: SARS-CoV2 nasal swabpositive nasal swab and serological test|Relation of positive SARS-CoV2 tests to risky contact historyUniversity Medical Centre LjubljanaAll18 Years to 70 Years Â  (Adult, Older Adult)300OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveKOAIT-1-20202020-11-01 00:00:00December 31, 2020January 31, 2021November 19, 2020November 20, 2020University Medical Centre Ljubljana, Ljubljana, Sloveniahttps://ClinicalTrials.gov/show/NCT04635592 Slovenia
1069NCT04379089Neurologic Manifestations of COVID 19 in ChildrenRecruitingNo Results AvailableCOVID|Neurologic ManifestationsOther: Observational study onlyPrevalence|Child and family health functionsUniversity of Pittsburgh|University of Utah|Johns Hopkins UniversityAllup to 17 Years Â  (Child)1000OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveSTUDY20060012|STUDY20040154|STUDY20040278April 29, 2020December 31, 2021December 31, 2022May 7, 2020March 4, 2021UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United Stateshttps://ClinicalTrials.gov/show/NCT04379089 United States
1070NCT04438837Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care WorkersNot yet recruitingNo Results AvailableCoronavirus Disease 2019 (COVID-19)|Post-Exposure ProphylaxisDrug: HydroxychloroquineClinical COVID-19|Confirmed COVID-19|Time to virological recovery|Time to symptoms onset|Development of pneumonia|Development of severe disease|Need for hospitalization or ICU|Adverse events|Mortality|Time to de-isolationRambam Health Care CampusAll18 Years and older Â  (Adult, Older Adult)Not Applicable582OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention0193-20-RMB CTIL2020-07-01 00:00:002022-06-01 00:00:002022-06-01 00:00:00June 19, 2020July 23, 2020Rambam Health Care Campus, Haifa, Israelhttps://ClinicalTrials.gov/show/NCT04438837 Israel
1071NCT04649515Efficacy and Safety of TY027, a Treatment for COVID-19, in HumansRecruitingNo Results AvailableCoronavirus Disease-2019 (COVID-19)Biological: TY027|Other: 0.9% salineTo evaluate the efficacy of a single dose intravenous (IV) infusion of TY027 in reducing disease progression, defined as progression to score 4 and below on COVID scale|Rate of AEs (grade 3 and above) and SAEs in COVID-19 patients|All cause mortality rate|Proportion of subjects in categories 4, 3, 2 and 1 of the COVID scale|Number of days COVID-19 patients require supplemental oxygen, high flow oxygen, non-invasive and invasive mechanical ventilation (if applicable)|Proportion of COVID-19 patients tested negative for SARS-CoV-2 via reverse transcriptase-polymerase chain reaction (RT-PCR)|Proportion of COVID-19 patients with a minimum of 0.5 log time-weighted viral load reduction from saliva samples, via sub-genomic qRT-PCRTychan Pte Ltd.All21 Years to 100 Years Â  (Adult, Older Adult)Phase 31305IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentSCT-301December 4, 2020August 31, 2021December 30, 2021December 2, 2020December 14, 2020Singapore General Hospital, Singapore, Singaporehttps://ClinicalTrials.gov/show/NCT04649515 Singapore
1072NCT04477213Risk Profiling of the Occupational Exposure of COVID-19 to Healthcare Workers.Not yet recruitingNo Results AvailableCOVID19|Healthcare WorkersRate of COVID-19 in healthcare workers (HCWs)|clinical severity of infection in HCWsNMC Specialty HospitalAll18 Years to 70 Years Â  (Adult, Older Adult)600OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveNMCHCW-COVIDJanuary 15, 2021February 15, 2021February 15, 2021July 20, 2020December 10, 2020https://ClinicalTrials.gov/show/NCT04477213
1073NCT04493307The Evaluation of Hemostasis in Hospitalized COVID-19 PatientsTARGET-COVIDRecruitingNo Results AvailableCOVID-19Diagnostic Test: PhlebotomyFrequency of Hypercoagulability as measured by thromboelastography measured by TEG and platelet aggregation.|Frequency of High Platelet Reactivity (HPR)|Frequency of thrombo-inflammatory syndrome|Correlation between TEG6s parameters and clinical outcomes|Correlation between HPR and clinical outcomes|Determine response to anticoagulation therapy|Determine level of platelet aggregation|Determine platelet thrombi and fibrin rich platelet thrombus Area Under the Curve|Determine short and long IgG, IgM and IgG antibody levelsLifeBridge Health|Haemonetics Corporation|Inflammatory Markers Laboratory|Chronolog Corporation|Precision Biologics, IncAll3 Years and older Â  (Child, Adult, Older Adult)100Other|IndustryObservationalObservational Model: Other|Time Perspective: Prospective1602903June 30, 20202021-02-01 00:00:002021-06-01 00:00:00July 30, 2020October 22, 2020Sinai Center for Thrombosis Research, Baltimore, Maryland, United Stateshttps://ClinicalTrials.gov/show/NCT04493307 United States
1074NCT04493294Low Dose Whole Lung Radiotherapy for Older Patients With COVID-19 PneumonitisNot yet recruitingNo Results AvailableCOVID-19 PneumonitisRadiation: Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitisMortality rate|Duration of hospitalization|Time to recovery|Oxygen saturation rate|Patient inflammatory statusInternational Geriatric Radiotherapy Group|Brigitta G. BaumertAll65 Years and older Â  (Older Adult)Phase 1|Phase 2500OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentIGRG012020-11-01 00:00:002021-12-01 00:00:002021-12-01 00:00:00July 30, 2020July 30, 2020https://ClinicalTrials.gov/show/NCT04493294
1075NCT04656613A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAESPUTNIK-UAENot yet recruitingNo Results AvailableCovid19|SARS-CoV InfectionBiological: Gam-COVID-Vac|Other: placeboSARS-CoV-2 glycoprotein-specific antibodies titer|Seroconversion rate|IFN-gamma antigen-specific release|CD4+/CD8+ proliferating cells|Virus-neutralizing antibodies titer|Incidence and severity of adverse eventsGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|PDC-CROAll18 Years and older Â  (Adult, Older Adult)Phase 31000OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention06-Gam-COVID-Vac-20202020-12-01 00:00:002021-08-01 00:00:002021-12-01 00:00:00December 7, 2020December 7, 2020https://ClinicalTrials.gov/show/NCT04656613
1076NCT04625036NO-mediated Vascular Function in Covid-19 PatientRecruitingNo Results AvailableCOVID-19 PneumoniaDiagnostic Test: Single passive leg movementLeg Blood Flow|Clinical evaluations|Clinical characteristics|Presence of device|Therapy|Biochemical evaluations - ProBNP|Biochemical evaluations - D-dimer|Biochemical evaluations - PCR|Functional evaluations - 1-Minute Sit To Stand|Functional evaluations - 6-Minute Walking Test|Functional evaluations - Biceps' muscle strength with dynamometer|Functional evaluations - Quadriceps' muscle strength with dynamometerIstituti Clinici Scientifici Maugeri SpA|Universita di VeronaAll30 Years to 80 Years Â  (Adult, Older Adult)30OtherObservationalObservational Model: Case-Only|Time Perspective: Cross-SectionalICS Maugeri 2437 CEMay 30, 20202021-04-01 00:00:002021-06-01 00:00:00November 12, 2020March 1, 2021ICS Maugeri IRCCS, U.O. Emergenza Coronavirus di Lumezzane, Lumezzane, Brescia, Italyhttps://ClinicalTrials.gov/show/NCT04625036 Italy
1077NCT04654442Feasibility and Analytic Performance of TestNPass (IVDMD) for CoViD-19 Diagnosis on Saliva SampleGraphealNpasRecruitingNo Results AvailableCovid19|SARS-CoV-2Diagnostic Test: TestNPassFeasibility of TestNPass IVDMD for CoViD19 diagnosis on saliva samples.|TestNPass IVDMD swiftness|TestNPass IVDMD ease of use|Analytics performance (sensibility) of TestNPass IVDMD|Analytics performance (specificity) of TestNPass IVDMD|Correlation of TestNPass electric signal intensity with RT-PCR Cycle thresholdUniversity Hospital, Grenoble|GraphealAll18 Years and older Â  (Adult, Older Adult)60OtherObservationalObservational Model: Case-Control|Time Perspective: Cross-Sectional38RC20.378|2020-A03087-32March 4, 20212021-05-01 00:00:00May 15, 2021December 4, 2020March 10, 2021Grenoble University Hospital, Grenoble cedex 9, Francehttps://ClinicalTrials.gov/show/NCT04654442 France
1078NCT04492358Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care CenterRecruitingNo Results AvailableCovid19Drug: Colchicine|Drug: Prednisone tablet|Drug: standard of careNumber of patients that a short cycle of steroids administered together with colchicine reduces mortality from COVID-19|Number and grade of adverse events at group of colchicine and glucocorticoids throughout the treatment and in the two weeks following treatment|Percentage of patients who stop medication due to adverse events.|Severity of symptoms by COVID-19 in the two treatment armsMaria Joyera RodrÃ­guez|Fundacion Clinic per a la Recerca BiomÃ©dicaAll65 Years and older Â  (Older Adult)Phase 2|Phase 3144OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment2020-002462-14October 22, 20202021-10-01 00:00:002021-10-01 00:00:00July 30, 2020November 9, 2020Centre BlauclÃ­nic Dolors Aleu, Barcelona, Spain|Hospital Clinic, Department of Internal Medicine, Barcelona, Spain|Clinica Sant Antoni, Barcelona, Spainhttps://ClinicalTrials.gov/show/NCT04492358 Spain
1079NCT04408456Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19PEP-CQCompletedNo Results AvailableCoVID-19Drug: HCQ|Other: Standard therapyIncidence confirmed case of COVID-19|Incidence of probable case of COVID-19|Incidence of adverse drug reaction (ADR)Postgraduate Institute of Medical Education and ResearchAll18 Years and older Â  (Adult, Older Adult)Phase 3325OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: PreventionIEC-04/2020-1624March 1, 2020July 31, 2020July 31, 2020May 29, 2020August 4, 2020Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Post Graduate Institute of Medical Education and Research, Chandigarh, Indiahttps://ClinicalTrials.gov/show/NCT04408456 India
1080NCT04345406Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19Not yet recruitingNo Results AvailableCOVIDDrug: ACEIs|Drug: Conventional treatmentnumber of patients with virological cureTanta UniversityAllChild, Adult, Older AdultPhase 360OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentACEIS COVID 19April 15, 2020December 1, 2029December 1, 2029April 14, 2020April 14, 2020Tanta University, Tanta, Egypthttps://ClinicalTrials.gov/show/NCT04345406 Egypt
1081NCT04706143Immunologic Responses to Single and Double Doses of COVID-19 Vaccines in EgyptiansNot yet recruitingNo Results AvailableCOVID-19 VaccinesBiological: COVID-19 Vaccinesmeasure immune cell activation induced by the vaccine|measure antibody response to vaccines|measure the cytokine response to different vaccinesAssiut UniversityAll25 Years to 65 Years Â  (Adult, Older Adult)100OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveAssiutU21January 15, 2021June 1, 2021August 1, 2021January 12, 2021January 14, 2021https://ClinicalTrials.gov/show/NCT04706143
1082NCT04344977Collection of Anti-SARS-CoV-2 Immune PlasmaNIAIDCompletedNo Results AvailableCoronavirus Disease 2019 (COVID-19)Identification of eligible donors and collection of anti-SARS-CoV-2 immune plasmaNational Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)All18 Years to 70 Years Â  (Adult, Older Adult)151NIHObservationalObservational Model: Case-Only|Time Perspective: Prospective200081|20-I-0081June 1, 2020November 20, 2020March 3, 2021April 14, 2020March 5, 2021Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center, Torrance, California, United States|University of Miami Infectious Diseases Research Unit, Miami, Florida, United States|Bloodworks Northwest, Seattle, Washington, United Stateshttps://ClinicalTrials.gov/show/NCT04344977 United States
1083NCT04659356NOSOcomial COVID-19 in ICU (NOSOCOVID)NOSOCOVIDRecruitingNo Results AvailableCoronavirus Infectious Disease (COVID-19)|Nosocomial Infection|Nosocomial COVID-19Other: Patients admitted in Intensive Care UnitsIncidence of nosocomial COVID-19|Occurrence of a nosocomial COVID-19 that is certain and Occurrence of a nosocomial COVID-19 that is probable.|evaluate the occurenceNantes University HospitalAll18 Years and older Â  (Adult, Older Adult)600OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveMR_NOSOCOVIDSeptember 1, 2020July 1, 2021July 14, 2021December 9, 2020March 23, 2021Nantes University Hospital, Nantes, Francehttps://ClinicalTrials.gov/show/NCT04659356 France
1084NCT04542941Assessment of Safety and Efficacy of CCPCOVIDITCompletedNo Results AvailableCovid19Biological: COVID Convalescent PlasmaTime to viral clearance (RT-PCR negativity)|Time to symptom resolution|Time to severe/critical disease|Number of participants reporting an adverse event as evidenced by clinical manifestationsMakerere University|Uganda Blood Transfusion Services|Joint Clinical Research Center|Uganda Peoples Defence Forces Medical Services|Mulago Hospital, UgandaAll18 Years to 100 Years Â  (Adult, Older Adult)Not Applicable136OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentCCPJune 16, 2020December 31, 2020December 31, 2020September 9, 2020January 15, 2021Mulago Specialised Hospital, Kampala, Ugandahttps://ClinicalTrials.gov/show/NCT04542941 Uganda
1085NCT04456413Convalescent Plasma as Treatment for Subjects With Early COVID-19 InfectionRecruitingNo Results AvailableCOVID-19Biological: Convalescent Plasma|Other: Best Supportive CareHospitalization Rate|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at 2 and 4 weeks|Rate of nasopharyngeal swab positivity in donors|Rate of donor titers level|Impact of donor titers level on efficacy|Patients' anti-SARS-CoV2 titer assessment pre-infusion for the Treatment group, at 2 weeks , 4 weeks and 2 months.Hackensack Meridian Health|United States Department of DefenseAll18 Years and older Â  (Adult, Older Adult)Phase 2306Other|U.S. FedInterventionalAllocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentPro2020-0542November 6, 20202021-11-01 00:00:002021-11-01 00:00:00July 2, 2020March 1, 2021Hackensack University Medical Center, Hackensack, New Jersey, United States"""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT04456413/ICF_000.pdf"https://ClinicalTrials.gov/show/NCT04456413 United States
1086NCT04830774Natural History of COVID-19-Related Atrial FibrillationunCOVer-AFNot yet recruitingNo Results AvailableCOVID-19|Atrial Fibrillation New OnsetDevice: ILR, PMK, ICDAF Burden|AF Progression|Time to adjudicated ischemic stroke/transient ischemic attack (TIA)/systemic arterial embolism|Composite of all-cause mortality, stroke and bleeding|Time to adjudicated cardiovascular deathTexas Cardiac Arrhythmia Research FoundationAll18 Years and older Â  (Adult, Older Adult)Not Applicable200OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: ScreeningTCAI-unCOVer1April 15, 2021December 31, 2021December 31, 2023April 5, 2021April 6, 2021Department of Cardiovascular/Respiratory Diseases, Nephrology, Anesthesiology, and Geriatric Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Lazio, Italy|Cardiology Unit, ASST-Fatebenefratelli Sacco, Luigi Sacco University Hospital, Milan, Italy, Milan, Lombardia, Italyhttps://ClinicalTrials.gov/show/NCT04830774 Italy
1087NCT04569877GM-CSF Inhalation to Prevent ARDS in COVID-19 PneumoniaGI-COVIDRecruitingNo Results AvailableSevere Acute Respiratory Syndrome (SARS) Pneumonia|COVID-19 PneumoniaDrug: Molgramostim nebuliser solution|Other: Placebo nebuliser solutionMechanical ventilation|Clinical status of subject at day 15 and day 29 (on a 7-point ordinal scale):|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Oxygen supply|Clinical parameter: temperature|Clinical parameter: blood pressure|Clinical parameter: heart beat|Clinical parameter: respiratory rate|Severe acute respiratory syndrome coronavirus 2 polymerase chain reaction (PCR)|Laboratory: C-reactive protein test|Laboratory: ferritin|Laboratory: Interleukin-6|Laboratory: procalcitonin|Bacterial pneumonia|Vaso-active drugs|Mortality|GM-CSFUniversity of GiessenAll18 Years and older Â  (Adult, Older Adult)Phase 2238OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentKKS-279|2020-001654-21September 24, 2020December 25, 2022December 25, 2022September 30, 2020October 5, 2020Prof. Dr. Susanne Herold, PhD, GieÃŸen, Germanyhttps://ClinicalTrials.gov/show/NCT04569877 Germany
1088NCT04536285Hospitalized Children and Adolescent Patients With Type 1 Diabetes During the COVID-19 Pandemic in EgyptCompletedNo Results AvailableType 1 Diabetes|Covid19Clinical characteristic of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.|Laboratory characteristic of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.|Prognosis of pediatric and adolescent patients with type 1 diabetes hospitalized with COVID -19.|Incidence of new onset type 1 diabetes among confirmed cases of Covid-19 infection among children and adolescents|Presentation of diabetes and its acute complications among pediatric and adolescent patients with type 1 diabetes during COVID-19 Pandemic in EgyptAin Shams UniversityAll1 Year to 18 Years Â  (Child, Adult)36OtherObservationalObservational Model: Case-Only|Time Perspective: Cross-SectionalFMASU P59/2020May 1, 2020August 31, 2020August 31, 2020September 2, 2020September 2, 2020Pediatrics and Adolescents Diabetes Unit (PADU), Pediatrics Hospital, Faculty of Medicine, Ain Shams University, Cairo, Egypthttps://ClinicalTrials.gov/show/NCT04536285 Egypt
1089NCT04381338Rehabilitation for People With COVID-19 in ICUCOVID_REHABNot yet recruitingNo Results AvailableCorona Virus Disease 19 (COVID-19)|COVID|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Critical IllnessOther: Pulmonary and Motor RehabilitationLength of ICU stay|Length of hospital stayUniversity of Padova|Prof. S Masiero, University of Padova, Italy|Dr. A. Venturin, General Hosipital, Padova, Italy|Dr. I. Tiberio, General Hospital, Padova, Italy|Dr. D. Zampieri, University of Padova, Italy|Dr.ssa M Cattelan, University of Padova, Italy|Prof. P. Zanatta, University Hosiptal, Verona, Italy|Dr.ssa C. Carollo, General Hospital, Padova, Italy|Prof. E. Polati, University Hospital, Verona, Italy|Prof. K. Donadello, University Hospital, Verona, ItalyAll18 Years and older Â  (Adult, Older Adult)Not Applicable92OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentUPadova_1May 10, 2020September 30, 2020September 30, 2020May 8, 2020May 8, 2020Teaching Hospital, University of Padova, Padova, Italy|Teaching Hospital, University of Verona, Verona, Italyhttps://ClinicalTrials.gov/show/NCT04381338 Italy
1090NCT04343742Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19RecruitingNo Results AvailableCOVID-19Drug: chlorine dioxide 3000 ppmnegative testing of covid19Genesis FoundationAllChild, Adult, Older Adult20OtherObservationalObservational Model: Case-Only|Time Perspective: ProspectiveGenesis AKCOVID- FG-1April 1, 2020April 7, 2020June 1, 2020April 13, 2020May 27, 2020Hospital Fhsj, Bogota, Cundinamarca, Colombia|San Carlos Hospital, Bogota, Cundinamarca, Colombiahttps://ClinicalTrials.gov/show/NCT04343742 Colombia
1091NCT04729153Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and SeverityNot yet recruitingNo Results AvailableCovid19Drug: DAAD CompoundEvaluate the effect of DAADs on covid -19Assiut UniversityAll18 Years to 70 Years Â  (Adult, Older Adult)100OtherObservationalObservational Model: Case-Control|Time Perspective: RetrospectiveDAADs and covid-192021-02-01 00:00:002022-02-01 00:00:002022-03-01 00:00:00January 28, 2021February 3, 2021https://ClinicalTrials.gov/show/NCT04729153
1092NCT04531345Cytokine Status of Covid-19 PatientsCompletedNo Results AvailableCovid19Diagnostic Test: Flow cytometric analysisCytokine levels of patientsIstanbul Training and Research HospitalAll18 Years to 80 Years Â  (Adult, Older Adult)60OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveCovid CytokineOctober 1, 2020November 1, 2020November 15, 2020August 28, 2020January 12, 2021Istanbul Training and Reseach Hospital, Istanbul, Turkeyhttps://ClinicalTrials.gov/show/NCT04531345 Turkey
1093NCT04457349Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19RecruitingNo Results AvailableCOVID 19Procedure: Therapeutic Plasma Exchange (TPE)mortality|the mean time with oxygen therapy|the mean time with Non-invasive mechanical ventilation|the mean time of intubation|respiratory function parameters|radiological lung extension|mean duration of hospitalization and ICU use|the requirement of additional organ support|the levels of IL-6|Incidence of adverse events|time to reverse-transcriptase polymerase chain reaction (RT-PCR) virus negativity|the levels of CRP|the levels of procalcitonin (PCT)|levels of D-dimer|levels of ferritinAlexandria UniversityAll18 Years and older Â  (Adult, Older Adult)Not Applicable10OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatmentplasma exchange in COVID 19July 25, 2020December 29, 2020January 20, 2021July 7, 2020January 5, 2021Faculty of Medicine, Alexandria university, Egypt, Alexandria, Egypthttps://ClinicalTrials.gov/show/NCT04457349 Egypt
1094NCT04363008COVID 19 BiomarkersRecruitingNo Results AvailableCOVID 19Diagnostic Test: serum inflammatory biomarkersInflammation|Oxygenation|Chronic Pulmonary outcomes|Pulmonary artery pressure using transthoracic echocardiography|Exertion|Quality of life assessmentUniversity of British ColumbiaAllChild, Adult, Older Adult150OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveH20-00971March 30, 2020April 30, 2020September 30, 2021April 27, 2020May 8, 2020Vancouver General Hospital, Vancouver, British Columbia, Canadahttps://ClinicalTrials.gov/show/NCT04363008 Canada
1095NCT04346602A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019RecruitingNo Results AvailableCOVID-2019Other: all treatment about COVID-2019fever|cough|diarrhea|anxiety|insomnia|depressionJilin UniversityAll1 Year to 80 Years Â  (Child, Adult, Older Adult)132OtherObservationalObservational Model: Cohort|Time Perspective: Prospective130004February 1, 2020June 1, 2020December 1, 2020April 15, 2020April 15, 2020the First Hospital of Jilin University, Chang chun, Jilin, Chinahttps://ClinicalTrials.gov/show/NCT04346602 China
1096NCT04327531Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey StudyCompletedNo Results AvailableCOVID-19|Physician-Patient RelationsBehavioral: turkish physiciansEvaluation of covid-19 knowledge level of turkish physicians|what they think about the futureKanuni Sultan Suleyman Training and Research HospitalAll25 Years to 55 Years Â  (Adult)200OtherObservationalObservational Model: Ecologic or Community|Time Perspective: Prospectiveturkishcovid19March 26, 2020May 22, 2020May 28, 2020March 31, 2020June 5, 2020Pinar Yalcin Bahat, Istanbul, Ä°Ì‡stanbul, Turkeyhttps://ClinicalTrials.gov/show/NCT04327531 Turkey
1097NCT04366141COVID-19 (Coronavirus Disease 2019) Intubation Barrier BoxCompletedNo Results AvailableCOVID-19Device: COVID-19 barrier boxTime to tracheal intubation (TTI)|First pass success rate|Total time of airway manipulation|Number of intubation attempts|Number of Operators needed for intubation|Number of alternative techniques used for intubation|Cormack-Lehane Grade for the first attempt of intubation|Lifting force applied on laryngoscope blade|Laryngeal pressure application|Vocal cord position|Anesthesiologist perception of intubation difficulty|Anesthesiologist perception of contributors to difficulty in intubation, if any|Patient acceptability of the COVID Barrier Box|Patient comfort with the COVID Barrier Box|Patient comments on the COVID Barrier BoxUniversity of British ColumbiaAll18 Years and older Â  (Adult, Older Adult)Not Applicable100OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: PreventionH20-01270May 1, 2020February 1, 2021February 1, 2021April 28, 2020February 24, 2021Providence Health Care, Vancouver, British Columbia, Canadahttps://ClinicalTrials.gov/show/NCT04366141 Canada
1098NCT04542343COVID-19 Risk Reduction Among African American ParishionersRecruitingNo Results AvailableCoronavirusBehavioral: Change in knowledge, motivation, skills, resourcesPercentage of Participants Achieving Improvement of Health Conditions Using the Severity of Medical Chronic Conditions Surveys|Percentage of Participants Achieving Target Levels of Knowledge, Attitude, and Behaviors with NIH Toolbox Surveys|Prevalence of COVID-19 testing using Participant COVID-19 Test History Survey|Prevalence of pneumococcal and influenza vaccinations using Participant Immunization History SurveyCharles Drew University of Medicine and ScienceAll65 Years and older Â  (Older Adult)Not Applicable265OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive CareCOVID19ChurchNovember 1, 2020September 30, 2021September 30, 2021September 9, 2020January 26, 2021Charles R. Drew University of Medicine & Science, Los Angeles, California, United Stateshttps://ClinicalTrials.gov/show/NCT04542343 United States
1099NCT04510454Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19ONCOVID-21RecruitingNo Results AvailableCancer|COVIDDiagnostic Test: Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCRTo determine the ddPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection|To determine the RT-qPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection|To determine the ddPCR and RT-qPCR abilities to detect the SARS-CoV-2 in oropharyngeal samples of symptomatic patients with suspected COVID-19 infection|To determine the ability of a clinical diagnosis based both on patients' symptoms and chest CT-scan to detect the SARS-CoV-2 in symptomatic patients with suspected COVID-19 infection|To determine the agreements between nasopharyngeal samples and oropharyngeal samples|To determine the agreements between a clinical diagnosis and ddPCR and RT-qPCR assays|To assess the 28-day mortality rate|To determine potential predictive factors of death among patients' characteristics|To evaluate the over risk of death of patients COVID+ versus COVID-Centre Leon BerardAll18 Years and older Â  (Adult, Older Adult)Not Applicable200OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: DiagnosticONCOVID-21 - ET20-118November 2, 20202021-05-01 00:00:002021-05-01 00:00:00August 12, 2020February 9, 2021Centre Leon Berard, Lyon, Francehttps://ClinicalTrials.gov/show/NCT04510454 France
1100NCT04329507Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)RecruitingNo Results AvailableCOVID-19|Respiratory DiseaseDiagnostic Test: Breath testTo perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.|Detection of markers of Covid-19 pneumonia in non-invasive breath samples.|Relationship of this biomarker signature to the presence of SARS-CoV-2 in nasal and throat swabs.|Subsequently, the signature's relationship to other biomarkers of SARS-CoV-2 infection which are currently being explored|In a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between SARS-CoV-2 positive patients and those that are negative until hospital discharge or undue participant burden .NHS LothianAll18 Years and older Â  (Adult, Older Adult)200OtherObservationalObservational Model: Cohort|Time Perspective: Prospective282014March 25, 2020March 25, 2021March 25, 2021April 1, 2020September 14, 2020NHS Lothian, Edinburgh, United Kingdomhttps://ClinicalTrials.gov/show/NCT04329507 United Kingdom
1101NCT04668469Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 PandemicCompletedNo Results AvailableCovid19Drug: Ivermectin|Drug: Hydroxychloroquine|Behavioral: personal protective Measuresnumber of participants with improvement of clinical condition (symptoms and signs)|Reduction of recovery time, hospital stay days and mortality rate|improvement of laboratory investigations and 2 consecutive negative PCR tests taken at least 48 hours apart.Benha UniversityAll18 Years to 80 Years Â  (Adult, Older Adult)Not Applicable600OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentRe96.2020June 8, 2020September 15, 2020October 30, 2020December 16, 2020December 16, 2020Benha Faculty of Medicine, Benha University, BanhÄ, Qaluopia, Egypthttps://ClinicalTrials.gov/show/NCT04668469 Egypt
1102NCT04353596Stopping ACE-inhibitors in COVID-19ACEI-COVIDCompletedNo Results AvailableSARS-CoV-2|COVID-19Drug: ACE inhibitor, angiotensin receptor blockerCombination of maximum Sequential Organ Failure Assessment (SOFA) Score and death|Composite of admission to an intensive care unit (ICU), the use of mechanical ventilation, or all-cause death|Mean and area under the curve of Sequential Organ Failure Assessment (SOFA) Score|Rates of non-invasive ventilation|Rates of renal replacement therapies|Change of viral burden|Change of C-reactive protein (CRP), interleukin 6 (IL-6), D-Dimer, IL-6, hochsensitives Troponin (hsTN), NT-pro-brain natriuretic peptide (NT-pro BNP)|Number of patients with systolic/diastolic blood pressure > 180/120 mmHg|Hospitalisation due to cardiac decompensation|Rates of mechanical ventilation|Rates of clonal hematopoiesis of indeterminate potential (CHIP)Medical University Innsbruck|Ludwig-Maximilians - University of Munich|Deutsches Zentrum fÃ¼r Herz-Kreislauf-Forschung (DZHK)All18 Years and older Â  (Adult, Older Adult)Phase 4216OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: TreatmentEudraCT 2020-001206-35April 20, 2020February 16, 2021February 24, 2021April 20, 2020March 2, 2021Medical University Innsbruck, University Hospital of Internal Medicine III, Innsbruck, Tyrol, Austria|Medical University of Graz, Graz, Austria|Landeskrankenhaus Hall, Hall In Tirol, Austria|Medical University Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine II, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine IV, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine I, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine V, Innsbruck, Austria|Klinikum Klagenfurt, Klagenfurt, Austria|Bezirkskrankenhaus Kufstein, Kufstein, Austria|Klinikum Lienz, Lienz, Austria|Bezirkskrankenhaus St. Johann, Sankt Johann In Tirol, Austria|Bezirkskrankenhaus Schwaz, Schwaz, Austria|Krankenhaus St. Vinzenz Zams, Zams, Austria|LMU Klinikum, Medizinische Klinik I, Munich, Bavaria, Germany|University Hospital Aachen, Aachen, Germany|University Hospital Augsburg, Augsburg, Germany|Asklepios Stadtklinik Bad TÃ¶lz, Bad TÃ¶lz, Germany|Klinikum Dachau, Dachau, Germany|University Hospital Erlangen, Erlangen, Germany|University Hospital Essen, Essen, Germany|University of Freiburg, Freiburg, Germany|Klinikum Memmingen, Memmingen, Germany|LMU Klinikum, Medizinische Klinik III, Munich, Germany|LMU Klinikum, Medizinische Klinik II, Munich, Germany|LMU Klinikum, Medizinische Klinik IV, Munich, Germany|MÃ¼nchen Klinik Bogenhausen und Schwabing, Munich, Germany|Rotkreuzklinikum Munich, Munich, Germany|Krankenhaus MÃ¼hldorf, MÃ¼hldorf, Germany|Klinikum Rosenheim, Rosenheim, Germany|Krankenhaus Weiden, Weiden, Germanyhttps://ClinicalTrials.gov/show/NCT04353596 Germany
1103NCT04408209Convalescent Plasma for the Treatment of Patients With Severe COVID-19 InfectionRecruitingNo Results AvailableCOVID-19 InfectionProcedure: Convalescent PlasmaSurvival|Clinical improvement ie percentage of patients not fulfilling the criteria for severe diseaseNational and Kapodistrian University of Athens|Hellenic Society of HematologyAll18 Years and older Â  (Adult, Older Adult)Not Applicable60OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment245-14-4-20April 23, 2020August 30, 2021September 15, 2021May 29, 2020November 4, 2020"""Evangelismos"" General Hospital, Athens, Attiki, Greece|""Agios Savas"" Oncology Hospital, Athens, Attiki, Greece|""Alexandra"" General Hospital, Athens, Attiki, Greece|""Sotiria"" General Hospital, Athens, Attiki, Greece|Attikon"" University General Hospital, Athens, Chaidari, Greece|University General Hospital of Patras, Patra, Rio, Greece"https://ClinicalTrials.gov/show/NCT04408209 Greece
1104NCT04816656An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 PandemicCOVID-ONCOCompletedNo Results AvailableCovid19|Oncology|PROMs|Chemotherapeutic ToxicityOther: ePROMs assessmentPatient-Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE)|5-level EQ-5D version (EQ5D5L)|Covid-19 triage questionnaire|COVID-19 questionnaire|COVID-19 Peritraumatic Distress Index (CPDI)|Patient satisfactionJessa Hospital|Hasselt UniversityAll18 Years and older Â  (Adult, Older Adult)Not Applicable43OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care20.60-onco20.07August 3, 2020February 1, 2021March 22, 2021March 25, 2021March 26, 2021Hasselt University, Hasselt, Limburg, Belgium|Jessa Ziekenhuis, Hasselt, Limburg, Belgiumhttps://ClinicalTrials.gov/show/NCT04816656 Belgium
1105NCT04392141Colchicine Plus Phenolic Monoterpenes to Treat COVID-19RecruitingNo Results AvailableCOVID-19Drug: Standard Treatment|Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene FractionsMortality rate|Change in patients clinical manifestation|Length of hospitalization|C-reactive protein|Lymphocyte count|Serum lactate dehydrogenase|Serum Interleukin-6|Erythrocyte sedimentation rateKermanshah University of Medical SciencesAll10 Years and older Â  (Child, Adult, Older Adult)Phase 1|Phase 2200OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment1399.062April 1, 2020November 1, 2020November 1, 2020May 18, 2020November 3, 2020Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic ofhttps://ClinicalTrials.gov/show/NCT04392141 Islamic Republic of
1106NCT04355234Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and NewbornsCOVIPREGActive, not recruitingNo Results AvailablePregnancyDiagnostic Test: identify SARS-CoV-2 infection by serology|Biological: collection of biological samplesSeroprevalence or Number of women who are positive for SARS-CoV-2 in parturient woman|Consequences of SARS-CoV-2 infection in pregnant women and their newborns : Pregnancy outcome, maternal or neonatal complications|Assessment of the vertical transmission of SARS-CoV-2 and the possible routes of this transmission in women who are positive for SARS-CoV-2 during pregnancy|Assessment of susceptibility to infection during the 3 trimesters of pregnancy|Evaluation of the confinement on the risk of exposure to the virus during pregnancy .|collection of biological samples for new investigations in women who are positive for SARS-CoV-2 during pregnancy.|Assessment of the rate of SARS-CoV-2 infection in pregnant women the risk factors for the disease.|Assessment of the rate of SARS-CoV-2 infection in newborns and the risk factors for the disease.Assistance Publique - HÃ´pitaux de ParisFemale18 Years and older Â  (Adult, Older Adult)Not Applicable2500OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: ScreeningAPHP 200448May 4, 2020August 31, 2021August 31, 2021April 21, 2020April 5, 2021Tsastaris Vassillis, Paris, Francehttps://ClinicalTrials.gov/show/NCT04355234 France
1107NCT04695457Correlation Between the Incidence of COVID-19 in Nursing-homes and the Profile of Nursing Homes in the French AlpsPROCOPADCompletedNo Results AvailableCovid19|Nursing HomeIdentification of factors associated with the occurrence of COVID-19 outbreak in French Alps' nursing homesCentre Hospitalier Annecy GenevoisAllChild, Adult, Older Adult74OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective20-13July 15, 2020November 16, 2020November 16, 2020January 5, 2021January 5, 2021Ch Annecy Genevois, Pringy, Francehttps://ClinicalTrials.gov/show/NCT04695457 France
1108NCT04703452poSt Covid-19 Infection centraL sENsitisaTionSILENT 1RecruitingNo Results AvailableCovid19Other: Indicators of central sensitisationSymptoms of Central Sensitisation|Pressure pain thresholds|Temporal summation|Descending nociceptive inhibition|Functionality and disabilityUniversitair Ziekenhuis BrusselAll18 Years and older Â  (Adult, Older Adult)100OtherObservationalObservational Model: Case-Only|Time Perspective: Cross-SectionalSILENT 1January 19, 20212022-01-01 00:00:002022-01-01 00:00:00January 11, 2021January 22, 2021Universitair Ziekenhuis Brussel, Jette, Brussel, Belgiumhttps://ClinicalTrials.gov/show/NCT04703452 Belgium
1109NCT04391127Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 InfectionCompletedNo Results AvailableCOVID-19Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: PlaceboMean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativizationCentenario Hospital Miguel HidalgoAll16 Years to 90 Years Â  (Child, Adult, Older Adult)Phase 3108OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment2020-A-09May 4, 2020November 6, 2020November 6, 2020May 18, 2020November 9, 2020Jose Manuel Arreola Guerra, Aguascalientes, Mexicohttps://ClinicalTrials.gov/show/NCT04391127 Mexico
1110NCT04525443Endothelial Function and COVID-19CompletedNo Results AvailableCOVID-19Reactive hyperemia index (RHI)|Percentage of COVID-19 patients with impaired endothelial vasodilator function.|Percentage of non-COVID-19 patients with impaired endothelial vasodilator function.Hospital San Carlos, Madrid|Mayo ClinicAllChild, Adult, Older Adult110OtherObservationalObservational Model: Case-Control|Time Perspective: Prospective20/451June 3, 2020November 11, 2020February 11, 2021August 25, 2020February 26, 2021Mayo Clinic, Rochester, Minnesota, United States|Hospital ClÃ­nico San Carlos, Madrid, Spainhttps://ClinicalTrials.gov/show/NCT04525443 Spain
1111NCT04562246SARS-CoV-2 IgG and IgM Serologic AssaysRecruitingNo Results AvailableCovid19Diagnostic Test: Serologic assays for antibodies to SARS-CoV-2Prevalence of antibodies to SARS-CoV-2Henry Ford Health SystemAll18 Years and older Â  (Adult, Older Adult)500OtherObservationalObservational Model: Cohort|Time Perspective: Prospective13839August 14, 20202021-08-01 00:00:002021-08-01 00:00:00September 24, 2020September 24, 2020Henry Ford Health System, Detroit, Michigan, United Stateshttps://ClinicalTrials.gov/show/NCT04562246 United States
1112NCT04796584Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating MedicationNot yet recruitingNo Results AvailableMultiple SclerosisOther: Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virusTiter of antibody against SARS-CoV-2 spike protein|Quantity of IFN-g secreted in response to stimulation with SARS-CoV-2 spike protein|Quantity of TNF-a secreted in response to stimulation with SARS-CoV-2 spike proteinProvidence Health & ServicesAll18 Years to 55 Years Â  (Adult)40OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveSARSmRNA_MSMarch 17, 2021March 17, 2022June 17, 2022March 15, 2021March 15, 2021Providence Neurological Specialties West, Portland, Oregon, United Stateshttps://ClinicalTrials.gov/show/NCT04796584 United States
1113NCT04659187CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From GermanyCORONA GermanyRecruitingNo Results AvailableCOVID-19Composite of death and/or need for mechanical ventilation and/or admission to ICU|Occurrence of a clinical manifest cardiovascular event|Overall mortality and mortality rate|Risk stratification score to predict the primary endpointsAsklepios proresearch|Asklepios Kliniken GmbH & Co. KGaAAllChild, Adult, Older Adult4000Industry|OtherObservationalObservational Model: Cohort|Time Perspective: Prospective#3871March 26, 2020May 30, 2021July 1, 2021December 9, 2020December 17, 2020Asklepios Fachkliniken MÃ¼nchen-Gauting, Gauting, Bavaria, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Asklepios Klinik Wandsbek, Hamburg, Germany|Asklepios Klinik Barmbek, Hamburg, Germany|Asklepios Kliniken GmbH & Co. KGaA, Hamburg, Germany|Asklepios Klinik Nord, Hamburg, Germany|Asklepios Westklinikum Hamburg, Hamburg, Germany|Asklepios Klinik Altona, Hamburg, Germanyhttps://ClinicalTrials.gov/show/NCT04659187 Germany
1114NCT04555187Cardiovascular Risk Stratification in Covid-19CaVaR-Co19Active, not recruitingNo Results AvailableCovid19|Cardiovascular Risk FactorNumber and rate of persons with cardiovascular composite outcome|Rate of all-cause death outcome|Rate of cardiac arrhythmiaOregon Health and Science UniversityAll18 Years and older Â  (Adult, Older Adult)60000OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveSTUDY00021368June 8, 20202021-12-01 00:00:002021-12-01 00:00:00September 18, 2020September 21, 2020Oregon Health and Science University, Portland, Oregon, United Stateshttps://ClinicalTrials.gov/show/NCT04555187 United States
1115NCT04474067COVID-19 - Cytokine StormRecruitingNo Results AvailableCOVID-19Other: No interventionClinical Outcomes of Patients with COVID-19 using the National Early Warning Score 2 (NEWS2) system|Clinical Outcomes of Patients with COVID-19 using the new NIH Patient Classification of severity of illness|Mortality|Cytokine/Chemokine/Hematopoietic Growth Factors/ Complement and Other Immune Modulators in Patients with COVID-19Hadassah Medical Organization|Barzilai Medical Center|The Chaim Sheba Medical CenterAll18 Years and older Â  (Adult, Older Adult)300OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveDM002June 28, 20202021-03-01 00:00:002021-03-01 00:00:00July 16, 2020December 22, 2020Hadassah Medical Center, Jerusalem, Israelhttps://ClinicalTrials.gov/show/NCT04474067 Israel
1116NCT04433013A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19Not yet recruitingNo Results AvailableCOVID-19Drug: Lianhua Qingwen|Drug: PlaceboProportion of participants who test negative for COVID-19|Time taken in days for relief of clinical symptoms|Proportion of participants with mild symptoms of COVID-19 progressing to moderate or severe illness|Proportion of participants who test positive for COVID-19 with Ct value>30Nanyang Technological University|Ministry of Health, SingaporeAll21 Years and older Â  (Adult, Older Adult)Phase 3300OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: TreatmentIRB-2020-05-0292020-07-01 00:00:002020-12-01 00:00:002021-02-01 00:00:00June 16, 2020June 17, 2020https://ClinicalTrials.gov/show/NCT04433013
1117NCT04318314COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2COVID19-HCWRecruitingNo Results AvailableHealth Care Worker Patient Transmission|Coronavirus|Coronavirus Infections|Immunological AbnormalityDiagnostic Test: COPAN swabbing and blood sample collectionSeroconversion to SARS-CoV-2 positivityUniversity College, London|St. Bartholomew's Hospital|Royal Free Hospital NHS Foundation Trust|UCLHAll18 Years and older Â  (Adult, Older Adult)400OtherObservationalObservational Model: Cohort|Time Perspective: Prospective130852March 18, 2020December 31, 2020December 31, 2021March 23, 2020May 21, 2020Barts Heart Center, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdomhttps://ClinicalTrials.gov/show/NCT04318314 United Kingdom
1118NCT04366180Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare WorkersRecruitingNo Results AvailableCovid-19Dietary Supplement: Probiotic|Dietary Supplement: ControlIncidence of SARS CoV-2 infection in healthcare workers|Incidence of hospital admissions caused by SARS-CoV-2 infection|Incidence of ICU admissions caused by SARS-CoV-2 infection|Incidence of pneumonia caused by SARS-CoV-2 infection|Incidence of oxygen support requirement caused by SARS-CoV-2 infection|Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection|Days with body's temperature > 37.5 ÂºC|Days with cough|Days with fatigue|Medical treatmentBiosearch S.A.All20 Years and older Â  (Adult, Older Adult)Not Applicable314IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionP054April 24, 20202020-06-01 00:00:002020-10-01 00:00:00April 28, 2020April 30, 2020Raquel Rodriguez Blanque, Granada, Spainhttps://ClinicalTrials.gov/show/NCT04366180 Spain
1119NCT04701892poSt Covid-19 Infection centraL Sensitisation 2SILENT 2RecruitingNo Results AvailableCovid19Other: Indicators of central sensitisationSymptoms of Central Sensitisation|Pressure pain thresholds|Temporal summation|Descending nociceptive inhibition|Functionality and disabilityUniversitair Ziekenhuis BrusselAll18 Years and older Â  (Adult, Older Adult)200OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveSILENT 2January 19, 20212023-01-01 00:00:002023-01-01 00:00:00January 8, 2021January 22, 2021Universitair Ziekenhuis Brussel, Jette, Brussel, Belgiumhttps://ClinicalTrials.gov/show/NCT04701892 Belgium
1120NCT04544033IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian PatientsRecruitingNo Results AvailableCovid19Diagnostic Test: interleuken 6 level measurment|Diagnostic Test: Interleukin-6 Gene-174C detectioninterleuken- 6 gene (174G/C) single nucleotide polymorphism|interleukin 6 levelTanta UniversityAllChild, Adult, Older Adult120OtherObservationalObservational Model: Case-Only|Time Perspective: ProspectiveIL6 in egyptian COVID patientsSeptember 15, 20202021-04-01 00:00:002021-05-01 00:00:00September 10, 2020March 30, 2021Bsant Safwat Kasem, Tanta, El Gharbyia, Egypthttps://ClinicalTrials.gov/show/NCT04544033 Egypt
1121NCT04356534Convalescent Plasma Trial in COVID -19 PatientsCompletedNo Results AvailableSARS-CoV 2|COVID-19Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2|Other: Routine care for COVID-19 patientsRequirement for invasive ventilation|Change in viral clearance|Radiological change|Change in white cell count|C reactive protein measurement|lactate dehydrogenase measurement|Procalcitonin measurement|D Dimer measurement|Ferritin measurement|Troponin T measurement|Brain naturetic peptide measurement|Mortality rateRoyal College of Surgeons in Ireland - Medical University of Bahrain|Salmaniya Medical Complex|Bahrain Defence Force Hospital|Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, AwaliAll21 Years and older Â  (Adult, Older Adult)Not Applicable40OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentBDF/R&REC/2020-423April 19, 2020June 15, 2020July 9, 2020April 22, 2020July 28, 2020Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrainhttps://ClinicalTrials.gov/show/NCT04356534 Bahrain
1122NCT04765839Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority PopulationsCERCActive, not recruitingNo Results AvailableVaccine Preventable DiseaseOther: Educational, culturally appropriate COVID-19 messagesCOVID-19 attitudesMayo ClinicAll18 Years to 101 Years Â  (Adult, Older Adult)Not Applicable90OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care21-000205February 12, 2021March 22, 2021March 22, 2021February 23, 2021February 23, 2021Mayo Clinic, Rochester, Minnesota, United Stateshttps://ClinicalTrials.gov/show/NCT04765839 United States
1123NCT04349618Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 PneumoniaVT4COVIDRecruitingNo Results AvailableAcute Respiratory Distress Syndrome|COVID19|Sars-CoV2|PneumoniaOther: PROTECTIVE VENTILATION|Other: ULTRAPROTECTIVE VENTILATIONA composite score based on all-cause mortality and the number of ventilator free-days (VFD)|All-cause mortality (intention to treat)|Ventilator-free days (VFD)|All-cause mortality with per protocol analysis|Time to successful extubation|Length of hospital stay|Respiratory parameters assessed daily from inclusion to weaning of deep sedation or 14 days whichever comes first|Daily sedation dose during the first 14 days of the study|Rate of use of rescue therapies|Incidence density rate of severe mixed acidosis|Incidence density rate of ventilator associated pneumonia|Incidence density rate of acute cor pulmonale|Incidence density rate of barotrauma|Incidence density rate of any serious adverse events|Cognitive impairment assessed by phone call using the Telephone Montreal Cognitive Assessment (T-MoCA) test|Quality of life assessed by the RAND 36-Item Health Survey (SF-36) score|Post-traumatic stress disorder assessed by the Impact of Event Scale - revised (IES-R) score by phone call|Cost-efficacy ratio of the innovative strategy compared to the reference strategyHospices Civils de LyonAll18 Years and older Â  (Adult, Older Adult)Not Applicable200OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment69HCL20_0322April 15, 2020April 15, 2023April 15, 2023April 16, 2020February 15, 2021Service de MÃ©decine Intensive RÃ©animation CHU Gabriel Montpied, Clermont-Ferrand, France|Service de MÃ©decine Intensive RÃ©animation HÃ´pital Michallon - CHU Grenoble Alpes, La Tronche, France|Service de MÃ©decine Intensive RÃ©animation HÃ´pital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de RÃ©animation Chirurgicale HÃ´pital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de MÃ©decine Intensive RÃ©animation HÃ´pital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de RÃ©animation Chirurgicale HÃ´pital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de rÃ©animation Polyvalente Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France|Service de RÃ©animation Clinique de la Sauvegarde, Lyon, France|Service de RÃ©animation Polyvalente Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-BÃ©nite, France|Service de RÃ©animation Centre hospitalier Annecy Genevois, Pringy, France|Service de MÃ©decine Intensive RÃ©animation HÃ´pital Nord - CHU Saint-Etienne, Saint-Priest-en-Jarez, Francehttps://ClinicalTrials.gov/show/NCT04349618 France
1124NCT04389489Postpartum Sexual Function in Pregnant Women With COVID-19RecruitingNo Results AvailableCOVID-19|Dyspareunia|Postpartum PeriodEvaluation of pregnant women diagnosed with COVID-19 using Carol Postpartum Sexual Function and Dyspareunia ScaleKanuni Sultan Suleyman Training and Research HospitalFemale18 Years to 45 Years Â  (Adult)140OtherObservationalObservational Model: Ecologic or Community|Time Perspective: ProspectiveMTalmacCarolMay 14, 2020September 25, 2020September 30, 2020May 15, 2020September 2, 2020Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Halkali, Turkeyhttps://ClinicalTrials.gov/show/NCT04389489 Turkey
1125NCT04371692Prevalence of COVID-19 Infection Among HCW in a French University HospitalEXPOCOVIANot yet recruitingNo Results AvailableSars-CoV2Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testingthe prevalence of SARS- Cov2 infection Health Care Worker with or without symptoms suggestive of a COVID-19 infection|Occupational exposures associated with the SARS-Cov2 infection|Environmental exposures associated with the SARS-Cov2 infection|immunologic status of health Care Worker|inflammatory biomarkers status of Health Care WorkerUniversity Hospital, Lille|Fondation SantÃ© RoquetteAll18 Years and older Â  (Adult, Older Adult)100OtherObservationalObservational Model: Cohort|Time Perspective: Prospective2020_35|2020-A00951-382020-04-01 00:00:002020-09-01 00:00:002020-09-01 00:00:00May 1, 2020May 1, 2020https://ClinicalTrials.gov/show/NCT04371692
1126NCT04449042The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) RegistryRecruitingNo Results AvailableAirway Management|COVID19Procedure: airway management during sedation or general anesthesiaairway complications|airway device|PPE|First pass success|induction techniques|failed intubation|complication risk factorsBoston Children's Hospital|Children's Hospital of Philadelphia|Children's Hospital Colorado|Istituto Giannina Gaslini|The Hospital for Sick Children|Perth Children's Hospital of Western Austrailia|Lurie Children's Hospital of ChicagoAllup to 18 Years Â  (Child, Adult)15000OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveIRB-P00035427April 1, 20202025-12-01 00:00:002025-12-01 00:00:00June 26, 2020June 26, 2020Boston Children's Hopsital, Boston, Massachusetts, United Stateshttps://ClinicalTrials.gov/show/NCT04449042 United States
1127NCT04716465Dysautonomia in Patients Post COVID-19 InfectionDYSCORecruitingNo Results AvailableCovid19Other: DysautonomiaHeart rate variability|Electrodermal activity|Respiration rate|Blood volume pulse|Functionality and disabilityMoens Maarten|Universitair Ziekenhuis BrusselAll18 Years and older Â  (Adult, Older Adult)200OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveDYSCOJanuary 19, 20212023-01-01 00:00:002023-01-01 00:00:00January 20, 2021January 22, 2021Universitair Ziekenhuis Brussel, Jette, Brussel, Belgiumhttps://ClinicalTrials.gov/show/NCT04716465 Belgium
1128NCT04622826plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU PatientsRecruitingNo Results AvailableCovid-19 PneumoniaBiological: immune plasmaITU admission|administration of O2|hospital mortality|immune plasma infusion adverse reactionAzienda USL Toscana Nord OvestAll18 Years and older Â  (Adult, Older Adult)Phase 250OtherInterventionalAllocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: PreventionATNONordOvestMay 15, 2020December 31, 2020December 31, 2020November 10, 2020November 10, 2020Ospedale delle Apuane, Massa, Toscana, Italyhttps://ClinicalTrials.gov/show/NCT04622826 Italy
1129NCT04367857ARMOR Study: COVID-19 Seroprevalence Among Healthcare WorkersRecruitingNo Results AvailableCovid-19|Coronavirus Infection|CoronavirusOther: COVID-19 Serology|Behavioral: Health Care Worker SurveyProportion seropositiveColumbia UniversityAll18 Years and older Â  (Adult, Older Adult)1000OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveAAAS9998April 18, 20202021-10-01 00:00:002021-10-01 00:00:00April 29, 2020April 30, 2020NewYork-Presbyterian Hosptial/Columbia University Irving Medical Center, New York, New York, United Stateshttps://ClinicalTrials.gov/show/NCT04367857 United States
1130NCT04565080Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD)RecruitingNo Results AvailableParkinson's Disease|Functional Movement Disorders|COVID-19Change in neurological symptoms domain of the survey between pre and post COVID 19 in FMD and PD patients.National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)All18 Years and older Â  (Adult, Older Adult)150NIHObservationalObservational Model: Ecologic or Community|Time Perspective: Cross-Sectional10000159|000159-NApril 19, 2021December 31, 2021December 31, 2021September 25, 2020April 14, 2021National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United Stateshttps://ClinicalTrials.gov/show/NCT04565080 United States
1131NCT04379479Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T)FUTURE-TNot yet recruitingNo Results AvailableCOVID-19|SARS-CoV-2 InfectionDrug: Dialyzable Leukocyte Extract|Drug: Placebo oral"Change in the score of the ""Contingency scale to assess the severity of acute respiratory disease in cases suspected/confirmed by COVID-19""|Clinical deterioration|Duration of the clinical status"National Polytechnic Institute, MexicoAll18 Years and older Â  (Adult, Older Adult)Phase 2562OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentIC-20-001|SH-001-20202020-05-01 00:00:002020-08-01 00:00:002020-12-01 00:00:00May 7, 2020May 7, 2020Escuela Nacional de Ciencias BiolÃ³gicas, Instituto PolitÃ©cnico Nacional, Mexico City, Mexicohttps://ClinicalTrials.gov/show/NCT04379479 Mexico
1132NCT04583306The Salivary Raman COVID-19 FingerprintDISCOVERRecruitingNo Results AvailableCovid19Other: Raman analysis of saliva, characterization of the Raman database and building of the classification modelIdentification and characterization of a new COVID-19 salivary signature through Raman spectroscopy|Evaluation of the spectral differences between the experimental groups|Determination of the classification model through multivariate analysis|Correlation with the clinical data|Test of the methodology|Portable Raman as point of careFondazione Don Carlo Gnocchi OnlusAll18 Years to 90 Years Â  (Adult, Older Adult)120OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveFDG_SalivaCOVID01June 1, 2020December 15, 2020June 1, 2021October 12, 2020October 12, 2020, IRCCS Fondazione Don Carlo Gnocchi, Centro Spalenza, Rovato, BS, Italy|IRCCS Fondazione Don Carlo Gnocchi, Santa Maria Nascente Hospital (Milano), Milano, MI, Italyhttps://ClinicalTrials.gov/show/NCT04583306 Italy
1133NCT04397822COVID-19 : Study of INFLAmmasome and PLAtelets FunctionsCO-QUETTESRecruitingNo Results AvailableCOVID-19Biological: Blood samplesActivation of platelet NLRP3 inflammasomeUniversity Hospital, ToulouseAll18 Years and older Â  (Adult, Older Adult)110OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveRC31/20/0142April 16, 20202021-10-01 00:00:002022-04-01 00:00:00May 21, 2020November 30, 2020CHU Toulouse, Toulouse, Francehttps://ClinicalTrials.gov/show/NCT04397822 France
1134NCT04376853CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatchCoronaWatchRecruitingNo Results AvailableCOVID-19Device: Apple Watch Series 5Biomarker|Protective factors|SmartWatch compliance|Arrhythmias|QT time changes|Longitudinal risk modelsUniversity Hospital Heidelberg|The German Heart Foundation|Klaus Tschira Stiftung|Freunde und FÃ¶rderer der Kardiologie HeidelbergAll18 Years and older Â  (Adult, Older Adult)50OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveCoronaWatchApril 15, 20202020-06-01 00:00:002020-07-01 00:00:00May 6, 2020May 6, 2020Department III of Internal Medicine, University Hospital Heidelberg, Heidelberg, Baden-WÃ¼rttemberg, Germanyhttps://ClinicalTrials.gov/show/NCT04376853 Germany
1135NCT04537559Impact of COVID-19 Outbreak on Non-COVID-19 PatientsNoCOVImpactEnrolling by invitationNo Results AvailableCOVID-19Intra-hospital mortality|composite outcome (worsening during hospitalization)|Pathologies leading to hospitalization|overall mortality at 3 months (90 days)|Potentially avoidable readmission rate|mortality rate by pathology at 3 months|length of stay|rate of transfer to intermediate or intensive care|rate of transfer to rehabilitation care|specific gravity outcomes for patients with pneumonia : CURB 65 scale (Confusion, Urea, Respiratory rate, Blood pressure, Age [>65])|specific gravity outcomes for patients with cardiac Failure : KILLIP class|specific gravity outcomes for patients with cardiac Failure : Weight variation|specific gravity outcomes for patients with cardiac Failure or lung disease|Leukocytes serum level|Polynuclear neutrophils serum level|Lymphocytes serum level|Hemoglobin serum level|Thrombocytes serum level|Quick serum level|INR (International Normalized Ratio)|fibrinogen serum level|PTT serum level (partial Thromboplastin time)|D-Dimers serum level|glucose serum level|glycated hemoglobin serum level (HbA1C)|C-reactive protein serum level (CRP)|sodium serum level|potassium serum level|chlorides serum level|calculated osmolality serum level|Phosphates serum level|corrected calcium serum level|urea serum level|creatinine serum level|eGFR (CKD-EPI) serum level|albumin serum level|prealbumin serum level|cyanocobalamin serum level|folate serum level|25-hydroxy vitamin D (D2 + D3) serum level|proBNP (Brain Natriuretic Peptid) serum level|Ultra sensitive Troponin T serum level|ASAT (aspartate transaminase) serum level|ALAT (alanine aminotransferase) serum level|Alkaline phosphatases serum level|Gamma glutamyl transpeptidase. serum level|Total bilirubin serum level|ferritin serum level|TSH serum level|Arterial pH|Arterial pCO2 (carbon dioxide partial pressure)|Arterial pO2 (oxygen partial pressure)|Arterial lactate|Arterial HCO3 (bicarbonate)|protein serum level|Arterial pressure|cardiac rates|respiratory rates|temperature|oxygen saturation|peak flow|specific scales : VAS of pain|specific scales : FIM|specific scales : SOFA score|specific scales : MNA|specific scales : NRS|serum or urine positive bacteriologic sample|Patient questionnaireUniversity Hospital, Geneva|Thomas Agoritsas|Sebastian Carballo|Pauline Darbellay|Olivier Grosgurin|Christophe Marti|Mathieu Nendaz|Jean-Luc Reny|Jacques Serratrice|Aimad Ourahmoune|Delphine Courvoisier|Virginie Prendki|Christine Serratrice|Dina Zekry|Omar Kherad|Eric GerstelAll16 Years and older Â  (Child, Adult, Older Adult)40000OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective2020-01017March 1, 2020July 31, 2020October 31, 2020September 3, 2020September 7, 2020Geneva University Hospital, Geneva, Canton De GenÃ¨ve, Switzerlandhttps://ClinicalTrials.gov/show/NCT04537559 Switzerland
1136NCT04387760Favipiravir vs Hydroxychloroquine vs Control in COVID -19RecruitingNo Results AvailableSARS-CoV 2|COVID-19Drug: Hydroxychloroquine|Drug: Favipiravir|Other: Routine care for COVID-19 patientsPrimary outcome is the Medial clinical scale at end of study follow up|Requirement of Escalation of Respiratory Support|Adverse effects(cardiac, renal, hepatic, hypoglycaemia (defined as RBS <3.9 mmol/L))|Requirement of ICU Admission|Mortality rate|Readmission rate|Daily National Early Warning (NEWS) 2 Score|Daily Sequential Organ Failure Assessment (SOFA) score|Change in Laboratory indices|Discharge and Length of Hospital Stay|QT prolongation|Cardiac arrythmia (fatal and non fatal)|Viral clearanceRoyal College of Surgeons in Ireland - Medical University of Bahrain|Ebrahim Khalil Kanoo Community Medical Center|Hereditary blood Disorder Centre - Salmaniya Medical Complex|Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali|Jidhafs COVID-19 Centre|Sitra FICU|Salmaniya Medical Complex- 6th Floor|Salmaniya Medical Complex- HelipadAll21 Years and older Â  (Adult, Older Adult)Phase 2150OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment40 / 07-May-2020August 11, 2020April 14, 2021May 14, 2021May 14, 2020March 9, 2021Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrainhttps://ClinicalTrials.gov/show/NCT04387760 Bahrain
1137NCT04381845Immunity and Infections in the Psychiatric PopulationCOVIDIMMUNOPSYNot yet recruitingNo Results AvailableCOVID|Psychiatric DisordersDiagnostic Test: COVID19 immunization testingNumber of COVID-positive patientsAssistance Publique - HÃ´pitaux de Paris|Institut National de la SantÃ© Et de la Recherche MÃ©dicale, FranceAll18 Years and older Â  (Adult, Older Adult)Not Applicable200OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: DiagnosticAPHP200553December 10, 2020March 10, 2021March 10, 2021May 11, 2020October 26, 2020https://ClinicalTrials.gov/show/NCT04381845
1138NCT04379466Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19CovRepRecruitingNo Results AvailableCOVID-19A list of COVID-19 specific TCR sequences|One or more measures from peripheral blood immunophenotyping that is/are associated with COVID-19 outcome|Group of COVID-19 specific TCR sequences that is associated with COVID-19 outcomeAssistance Publique - HÃ´pitaux de ParisAll18 Years to 75 Years Â  (Adult, Older Adult)60OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveAPHP200544|2020-A01245-34May 5, 2020October 11, 20202021-04-01 00:00:00May 7, 2020August 18, 2020HÃ´pital Pitie SalpÃ©trÃ¨re, Paris, Francehttps://ClinicalTrials.gov/show/NCT04379466 France
1139NCT04345510Testing for COVID-19 Infection in Asymptomatic PersonsRecruitingNo Results AvailableCOVID-19 InfectionCOVID-19 infectionGerman Cancer Research CenterAll18 Years and older Â  (Adult, Older Adult)500OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveCOVID-19-1.0-DKFZApril 20, 2020September 30, 2021September 30, 2021April 14, 2020March 10, 2021German Cancer Research Center, Heidelberg, Baden-WÃ¼rttemberg, Germanyhttps://ClinicalTrials.gov/show/NCT04345510 Germany
1140NCT04469153Interest of the Dosage of Ferritin / Glycosylated Ferritin in COVID-19RecruitingNo Results Availablethe Prognostic Value of Ferritin|Glycosylated Ferritin in SARS-CoV-2 Infection in Hospitalized COVID-19 PatientsOther: No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological testsassessment of the prognostic value of ferritin in sars-cov2 positiv patientsHospices Civils de LyonAll18 Years and older Â  (Adult, Older Adult)57OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective2020_FerriGly COVIDJune 29, 2020September 1, 2020December 31, 2020July 13, 2020July 13, 2020hopital de la Croix Rousse, Lyon 4, Rhone Alpes, Francehttps://ClinicalTrials.gov/show/NCT04469153 France
1141NCT04725097A Study to Evaluate Rapid Throughput Screening for Human COVID-19 InfectionRecruitingNo Results AvailableCovid19COVID 19 DetectionMayo ClinicAll18 Years to 89 Years Â  (Adult, Older Adult)10000OtherObservationalObservational Model: Cohort|Time Perspective: Prospective20-011415December 10, 2020July 31, 2021August 30, 2021January 26, 2021January 26, 2021Mayo Clinic, Rochester, Minnesota, United States|Sri Jayadeva, Bengaluru, Karnataka, India|Gregorio MaraÃ±on Hospital, Madrid, Spain|Imperial College, London, England, United Kingdomhttps://ClinicalTrials.gov/show/NCT04725097 United Kingdom
1142NCT04414098Ruxolitinib in the Treatment of Covid-19Not yet recruitingNo Results AvailableCOVID-19Drug: INC424 / RuxolitinibEvaluate the efficacy of ruxolitinib in the treatment of COVID-19 severe acute respiratory syndrome|Evaluate the median duration of hospitalization.|Evaluate the evolution of systemic inflammation parameters.|Evaluate COVID-19 mortality rate|Evaluate the proportion of the requirement of mechanical ventilation.|Evaluate ruxolitinib adverse reactions|Evaluate the proportion of secondary infections during the treatment with ruxolitinibMarcelo Iastrebner|Novartis|Clinica ZabalaAll18 Years and older Â  (Adult, Older Adult)Phase 2100Other|IndustryInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentCZabalaJune 1, 2020August 15, 2020September 15, 2020June 4, 2020June 4, 2020https://ClinicalTrials.gov/show/NCT04414098
1143NCT04550338Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 ExposureTXACOVIDPREVNot yet recruitingNo Results AvailableCOVID-19Drug: Tranexamic acid|Drug: PlaceboConversion from negative to positive COVID-19 testUniversity of Alabama at BirminghamAll18 Years to 80 Years Â  (Adult, Older Adult)Phase 3100OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionTXA.COVID.3August 1, 2021December 31, 2022March 31, 2023September 16, 2020February 16, 2021https://ClinicalTrials.gov/show/NCT04550338
1144NCT04377464COVID-19 - Quality of Life After InfectionNot yet recruitingNo Results AvailableCOVID-19|Quality of LifeOther: SF12, EQ-5D-5L and work status standardized quantitative assessmentsSix-month SF-12v2(HK) Scores|Six-month EQ-5D-5L Scores|One-month SF-12v2(HK)|One-month EQ-5D-5L Scores|Three-month SF-12v2(HK) Scores|Three-month EQ-5D-5L Scores|One, Three and Six-month Return to Work StatusChinese University of Hong KongAll18 Years and older Â  (Adult, Older Adult)200OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveNTEC-2020-0227May 5, 2020April 30, 2021April 30, 2022May 6, 2020May 6, 2020"""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04377464/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04377464/Prot_SAP_001.pdf"https://ClinicalTrials.gov/show/NCT04377464
1145NCT04431466A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19IFORSRecruitingNo Results AvailableCoronavirus InfectionDrug: Ivermectin|Other: Standard treatment for COVID-19Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.|Viral load variation in the nasopharyngeal swab.|Proportion of patients with undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.|Proportion of patients with clinical improvement.Universidade Federal de Sao CarlosAll18 Years and older Â  (Adult, Older Adult)Phase 264OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentIFORSJuly 1, 2020December 1, 2020July 1, 2021June 16, 2020September 2, 2020Hospital UniveristÃ¡rio da Universidade Federal de SÃ£o Carlos (HU-UFSCar), SÃ£o Carlos, SÃ£o Paulo, Brazil|Hospital UniversitÃ¡rio da Universidade Federal de SÃ£o Carlos (HU-UFSCar), SÃ£o Carlos, SÃ£o Paulo, Brazilhttps://ClinicalTrials.gov/show/NCT04431466 Brazil
1146NCT04393974COVID-19 and Cancer PatientsOnCovidRecruitingNo Results AvailableCancer|Sars-CoV2Describe presenting characteristics and severity or SARS-CoV-2 infection in patients with cancer|Assessing what factors are involved in prognosis of cancer patients with COVID-19Imperial College LondonAll18 Years and older Â  (Adult, Older Adult)1000OtherObservationalObservational Model: Case-Only|Time Perspective: Retrospective282140March 24, 2020March 24, 2022March 24, 2022May 19, 2020May 21, 2020Imperial College Healthcare NHS Trust, London, United Kingdomhttps://ClinicalTrials.gov/show/NCT04393974 United Kingdom
1147NCT04492904Singapore COVID-19 Chemosensory Tracking (SCCT) StudyRecruitingNo Results AvailableCovid19Other: Home-use Test and Follow-up QuestionnaireTaste and smell acuity|Experienced symptoms, changes in appetite and food-related quality of lifeClinical Nutrition Research Centre, Singapore|National University Hospital, SingaporeAll21 Years to 70 Years Â  (Adult, Older Adult)5000OtherObservationalObservational Model: Case-Control|Time Perspective: Other2020/00810July 23, 2020March 31, 2021March 31, 2021July 30, 2020July 30, 2020Clinical Nutrition Research Centre, Singapore, Singapore, Singaporehttps://ClinicalTrials.gov/show/NCT04492904 Singapore
1148NCT04816942Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in EgyptCompletedNo Results AvailableConvalescent Plasma|Covid19|Immunoglobulins|Plasma|EgyptBiological: Convalescent PlasmaCOVID-19 Cure rateMinistry of Health and Population, EgyptAll18 Years and older Â  (Adult, Older Adult)Phase 3102OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment10-2020/13April 23, 2020July 21, 2020October 12, 2020March 25, 2021March 25, 2021Ministry of Health, Cairo, Giza, Egypthttps://ClinicalTrials.gov/show/NCT04816942 Egypt
1149NCT04364802COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and InpatientsPIIPPIRecruitingNo Results AvailableCOVID-19|SARS-CoV 2Drug: Povidone-Iodine Nasal Spray and GarglePercent of healthcare workers testing positive for COVID-19.|Percent of patients testing positive for COVID-9.|Percent of community participants testing positive for COVID-9.|PVP-I Ease of Use|PVP-I ComfortAlexandra Kejner|University of KentuckyAll18 Years to 99 Years Â  (Adult, Older Adult)Phase 2300OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention58748April 29, 20202021-05-01 00:00:002021-05-01 00:00:00April 28, 2020November 24, 2020University of Kentucky, Lexington, Kentucky, United Stateshttps://ClinicalTrials.gov/show/NCT04364802 United States
1150NCT04704466Impact of Covid-19 Pandemic on Management of Head and Neck CancersVADS-CovidRecruitingNo Results AvailableHead and Neck Cancer|Covid19|Patient CareVariation of delay (in days) between the first cancer consultation and the beginning of the first line of treatmentCentre Hospitalier Universitaire, AmiensAll18 Years and older Â  (Adult, Older Adult)150OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectivePI2021_843_0003January 7, 20212021-06-01 00:00:002021-07-01 00:00:00January 11, 2021February 1, 2021CHU Amiens, Amiens, Francehttps://ClinicalTrials.gov/show/NCT04704466 France
1151NCT04690816Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune DiseasesRecruitingNo Results AvailableSystemic Autoimmune DiseasesPrimary Objective: Characterize how COVID-19 modulates systemic inflammation, autoimmunity features, organ damage and vasculopathy in adult and pediatric patients with a previous diagnosis of systemic autoimmunity. Assess how subjects with syste...|Understand prevalence and severity of COVID-19 in individuals with autoimmune diseases, and the variables that associate/predict these responses.National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institutes of Health Clinical Center (CC)All15 Years and older Â  (Child, Adult, Older Adult)350NIHObservationalObservational Model: Case-Control|Time Perspective: Prospective10000207|000207-ARFebruary 11, 2021December 31, 2024December 31, 2024December 31, 2020March 19, 2021National Institutes of Health Clinical Center, Bethesda, Maryland, United Stateshttps://ClinicalTrials.gov/show/NCT04690816 United States
1152NCT04528368Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory SupportRecruitingNo Results AvailableCOVID-19Biological: Convalescent plasmaArea under the curve of SARS-COV-2 viral load obtained from nasopharyngeal and /or oropharyngeal swabs.|Assessment of clinical improvement using an Ordinal Severity Scale|Evaluate oxygen saturation|Evaluate oxygen supplementation|Assess respiratory rate|Evaluate the PaO2 / FiO2 ratio (for patients on mechanical mechanisms)|Length of hospital stay|Length of stay in intensive care|Assess the rate of orotracheal intubation|Change in the profile of cytokines/chemokines in both groups|Presence of antibodies against SARS-CoV-2 in serum after convalescent plasma administration|Death rate|Rate of transfusion reactions to convalescent plasma infusionD'Or Institute for Research and Education|Hospital do CoracaoAllChild, Adult, Older AdultPhase 260OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment34651120.8.0000.5249December 11, 2020April 30, 2021May 30, 2021August 27, 2020February 1, 2021D'Or Institute for Research and Education, Rio de Janeiro, Brazilhttps://ClinicalTrials.gov/show/NCT04528368 Brazil
1153NCT04712175Diagnostic Validation of Rapid Detection of the COVID-19 Causative Virus (SARS-CoV-2) in Saliva Samples by Mass SpectrometrySALICOVNot yet recruitingNo Results AvailableCovid19Diagnostic Test: Nasopharyngeal sampling|Diagnostic Test: Saliva samplingDetection of SARS-CoV-2 on nasopharyngeal samples (gold standard)|Detection of SARS-CoV-2 on a saliva samples by mass spectrometry|Detection of SARS-CoV-2 on saliva samples via RT-PCRCentre Hospitalier Universitaire de NÄ«mes|Technological Innovations for Detection and Diagnosis LaboratoryAll18 Years and older Â  (Adult, Older Adult)250OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveLOCAL-COVID/2020/AS-012021-01-01 00:00:002021-07-01 00:00:002021-07-01 00:00:00January 15, 2021January 15, 2021CHU de NÃ®mes, NÃ®mes, Francehttps://ClinicalTrials.gov/show/NCT04712175 France
1154NCT04531111Glycemic Control Among Children and Adolescents With Type 1 Diabetes During COVID-19 Pandemic in EgyptRecruitingNo Results AvailableType 1 Diabetes|Covid19Impact of COVID-19 pandemic and lockdown on glycemic control among a sample of Egyptian children and adolescents with type 1 diabetes|Impact of COVID-19 pandemic and lockdown on insulin dosage among a sample of Egyptian children and adolescents with type 1 diabetesAin Shams UniversityAll2 Years to 18 Years Â  (Child, Adult)150OtherObservationalObservational Model: Case-Only|Time Perspective: Cross-SectionalFMASU P66/2020July 7, 20202020-08-01 00:00:002020-08-01 00:00:00August 28, 2020August 28, 2020Pediatrics and Adolescents Diabetes Unit (PADU), Pediatrics Hospital, Faculty of Medicine, Ain Shams University, Cairo, Egypthttps://ClinicalTrials.gov/show/NCT04531111 Egypt
1155NCT04462393Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19CompletedNo Results AvailableCOVID-19|Critical IllnessOther: Admission to ICU for COVID-1930-day mortality|ICU mortalityLinkoeping University|Region Ã–stergÃ¶tlandAll18 Years and older Â  (Adult, Older Adult)1563OtherObservationalObservational Model: Cohort|Time Perspective: OtherSweCOVIDMarch 6, 2020May 6, 2020May 6, 2020July 8, 2020July 9, 2020Department of Anaesthesia and Intensive Care, Linkoeping University Hospital, Region Ã–stergÃ¶tland, LinkÃ¶ping, Ã–stergÃ¶tland, Swedenhttps://ClinicalTrials.gov/show/NCT04462393 Sweden
1156NCT04359615Favipiravir in Hospitalized COVID-19 PatientsFICNot yet recruitingNo Results AvailableCOVID-19Drug: Favipiravir|Drug: HydroxychloroquineTime to clinical improvement|Mortality|oxygen saturation by pulse oximetry (SpO2) Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse eventsShahid Beheshti University of Medical SciencesAll18 Years and older Â  (Adult, Older Adult)Phase 440OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentFavipiravir in COVID-19April 20, 2020May 3, 2020May 5, 2020April 24, 2020April 28, 2020Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic ofhttps://ClinicalTrials.gov/show/NCT04359615 Islamic Republic of
1157NCT04381819Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19RecruitingNo Results AvailableSARS Virus|Severe Acute Respiratory SyndromeDiagnostic Test: SARS-CoV-2 PCRDeath|Recovery from COVID-19|Progression to ICU care or ventilation|Clearance of SARS-CoV-2 from respiratory specimen|Immune response to COVID-19Oslo University Hospital|University Hospital, Akershus|Vestre Viken Hospital Trust|Ã˜stfold Hospital Trust|Haukeland University Hospital|University Hospital of North Norway|St. Olavs HospitalAll18 Years and older Â  (Adult, Older Adult)1000OtherObservationalObservational Model: Cohort|Time Perspective: Prospective20-04072March 2, 2020February 28, 2022December 31, 2023May 11, 2020May 11, 2020Vestre Viken Drammen Hospital, Drammen, Viken, Norway|Haukeland University Hospital, Bergen, Norway|Ã˜stfold Hospital Trust, Fredrikstad, Norway|Akershus University Hospital, LÃ¸renskog, Norway|Oslo University Hospital, Oslo, Norway|University Hospital North Norway, TromsÃ¸, Norway|St Olavs Hospital, Trondheim, Norwayhttps://ClinicalTrials.gov/show/NCT04381819 Norway
1158NCT04685213Electrical Stimulation for Critically Ill Covid-19 PatientsCOVID-19RecruitingNo Results AvailableCovid19|Pain|Muscle AtrophyDevice: Electrical Stimulation|Device: Electrical Stimulation - ShamChange in muscle function|muscle fatigue|Change in tissue oxygen saturation|Ankle circumference|Thigh circumference|Foot circumference|Venous Return Flow|Frailty|Length of stay|Major adverse events|instrumental activities of daily living scale|Community engagement Scale|Depression scale|Weight loss|Neuropathy|Change in muscle strengthBaylor College of Medicine|Avazzia, IncAll18 Years to 100 Years Â  (Adult, Older Adult)Phase 120Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive CareH-47781August 18, 2020August 18, 2021August 18, 2021December 28, 2020December 28, 2020Baylor College of Medicine, Houston, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04685213 United States
1159NCT04380766Covid-19 Pandemic and Pancreatic Surgery in ItalyPanCOVIDCompletedNo Results AvailablePancreatic CancerProcedure: Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancerChanges in pancreatic cancer management during the COVID-19 pandemicFondazione Policlinico Universitario Agostino Gemelli IRCCSAll18 Years and older Â  (Adult, Older Adult)730OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveFPGemelliIRCCSJanuary 1, 2019July 31, 2020July 31, 2020May 8, 2020August 3, 2020Fondazione Policlinico Universitario Agostino Gemelli IRCCS di Roma, Roma, Lazio, Italyhttps://ClinicalTrials.gov/show/NCT04380766 Italy
1160NCT04312243NO Prevention of COVID-19 for Healthcare ProvidersNOpreventCOVIDActive, not recruitingNo Results AvailableCoronavirus Infections|Healthcare Associated InfectionDrug: Inhaled nitric oxide gasCOVID-19 diagnosis|Positive SARS-CoV-2 rt-PCR testMassachusetts General HospitalAll18 Years to 99 Years Â  (Adult, Older Adult)Phase 224OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: PreventionNOpreCOVID-19April 7, 2020April 7, 2021April 7, 2022March 18, 2020March 10, 2021Massachusetts General Hospital, Boston, Massachusetts, United Stateshttps://ClinicalTrials.gov/show/NCT04312243 United States
1161NCT04842435Clinical Study in the Treatment of Patients With Moderate Course of COVID-19Not yet recruitingNo Results AvailableCOVID-19Drug: COVID-globulin|Drug: PlaceboThe proportion of subjects in the study groups in whom, during the first 7 days after drug administration, one of the following events developed according to the laboratory-instrumental methods or on the basis of a clinical presentation|All-cause mortality|The elimination time of the SARS-CoV-2 virus|The median time to clinical improvement on the WHO Ordinal Scale for Clinical Improvement|The incidence of severe and extremely severe COVID-19 disease|The need for respiratory support|The need for invasive mechanical ventilation of the lungs, ECMO|Time to cancellation of oxygen support|The need to stay at the intensive care unit|Duration of fever (â‰¥ 380C), days|The dynamics of the decrease in points on the NEWS scale|Dynamical CRP, ferritin, D-dimer values|Changes in the degree of lung lesion determined by the CTMicrogen Scientific Industrial Company for Immunobiological MedicinesAll18 Years to 65 Years Â  (Adult, Older Adult)Phase 2|Phase 3376OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentIGK-P-II/III-00-003/2020April 9, 2021September 30, 2021October 5, 2021April 13, 2021April 13, 2021https://ClinicalTrials.gov/show/NCT04842435
1162NCT04355624Kidney Involvement in COVID-19 Disease (COVKID)COVKIDRecruitingNo Results AvailableCOVID|Kidney InjuryKidney involvement in COVID-19 disease|Physiopathologic mechanism of kidney involvement in SARS-CoV-2 infection|To identify risk factors for kidney involvement in in SARS-CoV-2 infection|To evaluate the impact of kidney involvement in SARS-CoV-2 infection|To assess the long-term health effect of kidney injury on survivors of SARS-CoV-2 infection in case of AKI KDIGO 2 or 3Centre Hospitalier Universitaire de NiceAll18 Years and older Â  (Adult, Older Adult)80OtherObservationalObservational Model: Cohort|Time Perspective: Prospective20reamedcovid02April 15, 2020April 30, 2020July 30, 2020April 21, 2020May 13, 2020Centre hospitalier d'Antibes Juan les pins, Antibes, France|Centre hospitalier de Cannes, Cannes, France|Centre hospitalier de Grasse, Grasse, France|CHU de Nice, Nice, Francehttps://ClinicalTrials.gov/show/NCT04355624 France
1163NCT04371510Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis PatientsPredictCovid-DRecruitingNo Results AvailableCOVID-19 by SARS-CoV-2 InfectionOther: blood samplePredictive value of IL-6 contents of whole blood samples after ex vivo stimulationCentre Hospitalier Universitaire de NiceAll18 Years to 85 Years Â  (Adult, Older Adult)Not Applicable115OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other20-PP-08April 22, 2020October 22, 2020February 22, 2021May 1, 2020May 1, 2020CHU de nice, Nice, Alpes-Maritimes, Francehttps://ClinicalTrials.gov/show/NCT04371510 France
1164NCT04359316Azithromycin in Hospitalized COVID-19 PatientsAICNot yet recruitingNo Results AvailableCOVID-19Drug: Hydroxychloroquine|Drug: AzithromycinTime to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse eventsShahid Beheshti University of Medical SciencesAll18 Years and older Â  (Adult, Older Adult)Phase 440OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentAzithromycin in COVID-19April 20, 2020May 3, 2020May 5, 2020April 24, 2020April 24, 2020Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic ofhttps://ClinicalTrials.gov/show/NCT04359316 Islamic Republic of
1165NCT04827160Prediction of Thrombosis Using D-dimer Trends in COVID-19TRENDSCompletedNo Results AvailableCovid19D-dimer trends|Thrombosis|All-cause mortality|Orotracheal intubationCentral Hospital, Nancy, FranceAll18 Years and older Â  (Adult, Older Adult)280OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective2020308March 2, 2020August 11, 2020August 11, 2020April 1, 2021April 1, 2021CHRU Nancy, Nancy, Francehttps://ClinicalTrials.gov/show/NCT04827160 France
1166NCT04731051The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer PatientsNot yet recruitingNo Results Available2019 Novel CoronavirusDrug: HCQ01|Drug: standard of care (SOC) for COVID-19Proportion of participants who improve by at least one level lower on the 11-point World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI), where patients are scored on a scale of 0-10 with 0 being uninfected and 10 being dead .|Proportion of participants who improve by at least one level lower on the 11-point WHO-OSCI|Change in condition measured using the 11-point WHO-OSCI|All-cause mortality|Hydroxychloroquine (HCQ) concentration in plasma versus time profiles|Change from Baseline Oxygenation as determined by the SpO2 / FiO2 ratio|Treatment-related adverse events of HCQ|Rate of Transfer to the Intensive Care Unit|Time to Clinical Improvement|Duration of hospitalization|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of â‰¤ 2 maintained for 24 hrs|Status of discharged or not requiring supplemental oxygen|Rates of Intensive Care Unit mortality|Intensive Care length of stay|Oxygenation free days|Ventilator free days|Incidence & duration of new oxygen use|Incidence and duration of new mechanical ventilation use|Cardiac Arrhythmia - Polymorphic Ventricular Tachycardia|Cardiac Arrhythmia - Ventricular Tachycardia|Cardiac Arrhythmia - Lengthening QTcKing Hussein Cancer Center|Amman Pharmaceutical Industries (API)|Sana Pharmaceutical Industry|ACDIMA Center for Bioequivalence and Pharmaceutical Studies (ACDIMA BioCenter)All18 Years and older Â  (Adult, Older Adult)Phase 1|Phase 228OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentHYDR0121/CCO2021-03-01 00:00:002021-09-01 00:00:002021-09-01 00:00:00January 29, 2021February 1, 2021King Hussein Cancer Center, Amman, Jordanhttps://ClinicalTrials.gov/show/NCT04731051 Jordan
1167NCT04789460The Relationship Between Laboratory Features of Covid-19 Patients in the Hospital With PrognosisNot yet recruitingNo Results AvailableCovid19mortality rate|need for intensive care unit rate|length stay in hospitalSultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyAll18 Years and older Â  (Adult, Older Adult)1200OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveCOLAMORMarch 5, 2021March 28, 2021March 28, 2021March 9, 2021March 9, 2021https://ClinicalTrials.gov/show/NCT04789460
1168NCT04560608Elucidating the Symptomatic, Explanatory and Prognostic Characteristics of GERIAtric Patients Hospitalized for COVID-19GERIA-COVIDRecruitingNo Results AvailableCovid19Medical history and co-morbidities|The physical examination data, and reports of relevant investigations data provided by the physician and the family during hospitalization|Electrocardiography QT Interval|Number of different therapeutic classes|Comprehensive Geriatric Assessment (CGA)|Biological parameters|Medical imaging results|Diagnosis of COVID-19|Length of hospitalization|Number of death from any cause|Reports of relevant investigations data provided by the physician and the family during the two-month telephone follow-upUniversity Hospital, AngersAll70 Years and older Â  (Older Adult)255OtherObservationalObservational Model: Cohort|Time Perspective: Other2020/100|ar20-0087v0March 15, 2020January 31, 2021January 31, 2021September 23, 2020December 2, 2020Angers University Hospital, Angers, Francehttps://ClinicalTrials.gov/show/NCT04560608 France
1169NCT04402814IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.RecruitingNo Results AvailableSARS-CoV 2Diagnostic Test: Clungene rapid test cassetteIgG/IgM antibodiesFadi Haddad, M.D.|Sharp HealthCareAll18 Years and older Â  (Adult, Older Adult)90OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveIgG/IgM COVID19|2005801May 5, 2020October 1, 2020December 1, 2020May 27, 2020July 27, 2020Fadi A. Haddad MD Inc., La Mesa, California, United States|Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Memorial Hosptial, San Diego, California, United Stateshttps://ClinicalTrials.gov/show/NCT04402814 United States
1170NCT04354519The United Kingdom Multiple Sclerosis Register Covid-19 SubstudyUKMSRCV19RecruitingNo Results AvailableMultiple Sclerosis|COVID-19Incidence of COVID-19 Infections within an MS Cohort in the UK|Hospitalisations in MS Patients with COVID-19|Mortality|Patient Reported Expanded Disability Status Score|Hospital Anxiety and Depression Scale|Multiple Sclerosis Impact Scale 29 V2|Multiple Sclerosis Walking Scale 12 V2|Fatigue Severity Scale|EuroQol 5D (3l)Swansea UniversityAll18 Years and older Â  (Adult, Older Adult)3000OtherObservationalObservational Model: Cohort|Time Perspective: Prospective16SW0194March 14, 2020July 14, 2021July 14, 2022April 21, 2020June 22, 2020Swansea Univeristy, Swansea, United Kingdom"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT04354519/Prot_000.pdf"https://ClinicalTrials.gov/show/NCT04354519 United Kingdom
1171NCT04537117Knowledge, Attitudes and Clinical Practices of Pediatric Dentists Regarding Covid-19CompletedNo Results AvailableCOVID-19Other: QuestionaireResponsesFayoum UniversityAllChild, Adult, Older Adult202OtherObservationalObservational Model: Other|Time Perspective: Cross-Sectionalpedodontists during Covid-19April 20, 2020May 5, 2020May 5, 2020September 3, 2020September 3, 2020Fayoum University, Fayoum, Egypthttps://ClinicalTrials.gov/show/NCT04537117 Egypt
1172NCT04345536Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University HospitalCovidRegOUHRecruitingNo Results AvailableCOVID-19Mortality|Severe diseaseOslo University HospitalAllChild, Adult, Older Adult400OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveCovidRegOUHMarch 15, 2020January 1, 2022May 1, 2022April 14, 2020February 25, 2021Oslo University Hospital, Oslo, Norwayhttps://ClinicalTrials.gov/show/NCT04345536 Norway
1173NCT04490486Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19COVID-19Not yet recruitingNo Results AvailableCOVID-19|Acute Respiratory Distress Syndrome|Corona Virus InfectionBiological: UCMSCs|Other: PlaceboPercent of participants with treatment related Serious Adverse Events (SAE)|Change in inflammatory marker levels|Change in systemic inflammatory marker levels|COVID-19 Viral Load|Change in SOFA score|Change in electrolytes levels|Change in LDH levels|Number of subjects discharged from the ICU|Percentage of participants with less requirement for vasoactive agents|Rate of Mortality|Percentage of participants with changes in immune marker expression|Percentage of participants with changes in radiologic findings|Percentage of participants with less pneumonia symptomsJoshua M Hare|University of MiamiAll18 Years and older Â  (Adult, Older Adult)Phase 121OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment20200575September 1, 2021June 1, 2024June 1, 2024July 29, 2020February 5, 2021University of Miami, Miami, Florida, United Stateshttps://ClinicalTrials.gov/show/NCT04490486 United States
1174NCT04473261Efficacy of Iodine Complex Against COVID-19 PatientsI-COVID-PKRecruitingNo Results AvailableCovid19|SARS-CoV-2|Corona Virus InfectionDrug: Iodine Complex|Drug: Placebo|Drug: Idoine ComplexqRT-PCR|HRCT chest|Severity of SymptomsSohaib Ashraf|Sheikh Zayed Federal Postgraduate Medical InstituteAll18 Years and older Â  (Adult, Older Adult)Phase 1|Phase 2200OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentSZMC/IRB/Internal/216/2020July 14, 2020July 15, 2021August 15, 2021July 16, 2020January 11, 2021Shaikh Zayed Hospital, Lahore, Pakistanhttps://ClinicalTrials.gov/show/NCT04473261 Pakistan
1175NCT04334928Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare PersonnelEPICOSRecruitingNo Results AvailableCoronavirus InfectionDrug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: HydroxychloroquineNumber of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)|Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)|Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in daysPlan Nacional sobre el Sida (PNS)|Effice Servicios Para la Investigacion S.L.All18 Years to 70 Years Â  (Adult, Older Adult)Phase 34000Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: PreventionPrEP COVID-19April 15, 2020December 31, 2020December 31, 2020April 6, 2020August 25, 2020Hospital Universitario de Ferrol, Ferrol, A CoruÃ±a, Spain|Hospital ClÃ­nico Universitario de Santiago, Santiago De Compostela, A CoruÃ±a, Spain|Hospital General de Elche, Elche, Alicante, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan de Deu de Esplugues, Esplugues De Llobregat, Barcelona, Spain|Parc Sanitari Sant Joan de DÃ©u de Sant Boi, Sant Boi De Llobregat, Barcelona, Spain|Hospital MoisÃ¨s Broggi, Sant Joan DespÃ­, Barcelona, Spain|Hospital Infanta Margarita, Cabra, CÃ³rdoba, Spain|Hospital Insular de Las Palmas, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Canarias, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital de Donostia, San SebastiÃ¡n, Guipuzcoa, Spain|Hospital San Pedro, LogroÃ±o, La Rioja, Spain|Hospital Principe de Asturias, AlcalÃ¡ De Henares, Madrid, Spain|Hospital FundaciÃ³n de AlcorcÃ³n, AlcorcÃ³n, Madrid, Spain|Hospital Colllado Villalba, Collado-Villalba, Madrid, Spain|Hospital de Getafe, Getafe, Madrid, Spain|Hospital Severo Ochoa, LeganÃ©s, Madrid, Spain|Hospital de MÃ³stoles, MÃ³stoles, Madrid, Spain|Hospital Rey Juan Carlos, MÃ³stoles, Madrid, Spain|Hospital QuirÃ³n Pozuelo, Pozuelo De AlarcÃ³n, Madrid, Spain|Hospital de TorrejÃ³n, TorrejÃ³n De Ardoz, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital Virgen del Castillo, Yecla, Murcia, Spain|Hospital Costa del Sol, Marbella, MÃ¡laga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Reina SofÃ­a, Tudela, Navarra, Spain|Hospital Arnau de Vilanova, LlÃ­ria, Valencia, Spain|Hospital de Araba, Alava, Vitoria, Spain|Hospital General Universitario de Albacete, Albacete, Spain|Centro MÃ©dico Teknon, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Dexeus, Barcelona, Spain|Hospital QuirÃ³n Barcelona, Barcelona, Spain|Hospital Universitario Sagrat Cor, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital ClÃ­nico San Cecilio, Granada, Spain|Hospital Universitario de LeÃ³n, LeÃ³n, Spain|Hospital Universitario RamÃ³n y Cajal, Madrid, Spain|FundaciÃ³n JimÃ©nez DÃ­az, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Gregorio MaraÃ±on, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Reina SofÃ­a, Murcia, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Virgen de la Victoria, MÃ¡laga, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Clinico Universitario, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain|Hospital Rio Hortega, Valladolid, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Hospital Nuestra SeÃ±ora de Sonsoles, Ãvila, Spainhttps://ClinicalTrials.gov/show/NCT04334928 Spain
1176NCT04550403Clinical Phenotype and Outcomes of Inpatients With COVID-19 and DiabetesRecruitingNo Results AvailableDiabetes Mellitus|Covid19prevalence of intensive care unit admission and/or in-hospital mortality among COVID-19 inpatients|prevalence of death among COVID-19 inpatients with and without diabetes|prevalence of intensive care unit admission among COVID-19 inpatients with and without diabetes|demographic and clinical characteristics (age,gender, comorbidity status) and death and/or intensive care unit admission during hospitalization|laboratory parameters (glycated hemoglobin, glucose at admission, renal and liver function markers, blood count, inflammatory markers, hemostasis) and death and/or intensive care unit admission during hospitalization|pharmacological therapies and death and/or intensive care unit admission during hospitalization|number of days of hospitalization in patients with and without diabetesAzienda Ospedaliero-Universitaria di ParmaAllChild, Adult, Older Adult700OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective27557July 30, 2020May 30, 2021December 31, 2021September 16, 2020January 13, 2021Endocrinology and metabolic diseases Unit, Parma, Italyhttps://ClinicalTrials.gov/show/NCT04550403 Italy
1177NCT04349228Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health ProfessionalsCOVID_2ProWithdrawnNo Results AvailableCOVID19|Sars-CoV2|Hydroxychloroquine|Prophylaxis|Healthcare WorkerDrug: Hydroxychloroquine (HCQ)|Drug: Placebo oral tabletSymptomatic COVID(+) infection rateAbderrahmane Mami Hospital|Eshmoun Clinical Research Centre|DatametrixAll18 Years to 65 Years Â  (Adult, Older Adult)Phase 30OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: PreventionECC2020-03April 28, 2020July 15, 2020July 15, 2020April 16, 2020August 28, 2020Eshmoun Clinical Research Centre/ HÃ´pital Abderrahmane Mami-Ariana, Tunis, Tunisiahttps://ClinicalTrials.gov/show/NCT04349228 Tunisia
1178NCT04328272Effectiveness of Hydroxychloroquine in Covid-19 PatientsCovidNot yet recruitingNo Results AvailableCOVID19Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tabletsNational Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimersProf. Dr. Umar Farooq|Ayub Medical College, AbbottabadAll18 Years to 50 Years Â  (Adult)Phase 375OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: TreatmentAth/ct101/22/3March 28, 2020May 28, 2020June 28, 2020March 31, 2020April 2, 2020Ayub Teaching Institution, AbbottÄbÄd, K.p.k, Pakistanhttps://ClinicalTrials.gov/show/NCT04328272 Pakistan
1179NCT04429620Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF MethodIIFRecruitingNo Results AvailableSars-CoV2Diagnostic Test: ImmunfluorescenceSensitivity of the method by SARS-CoV2 ELISA compared|Detectability of the antibodies IgA type against SARS-CoV2 virusSzeged University|Bilogical Research Centre, SzegedAll18 Years and older Â  (Adult, Older Adult)100OtherObservationalObservational Model: Case-Control|Time Perspective: OtherSARS-CoV-2-IIF-002May 30, 2020December 31, 2020December 31, 2020June 12, 2020June 25, 2020University of Szeged, Albert Szent-GyÃ¶rgyi Health Center, Szeged, Hungaryhttps://ClinicalTrials.gov/show/NCT04429620 Hungary
1180NCT04640402A Phase â…¡ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)RecruitingNo Results AvailableCOVID-19Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|Biological: Low-dose placebo (18-59 years) & Two dose regimen|Biological: Low-dose placebo (18-59 years) & Three dose regimen|Biological: High-dose placebo (18-59 years) & Two dose regimen|Biological: High-dose placebo (18-59 years) & Three dose regimen|Biological: Low-dose placebo (60-85 years) & Two dose regimen|Biological: Low-dose placebo (60-85 years) & Three dose regimen|Biological: High-dose placebo (60-85 years) & Two dose regimen|Biological: High-dose placebo (60-85 years) & Three dose regimenGeometric mean (GMT) of specific antibody|The incidence of adverse reaction (AR)|The incidence of adverse events (AE)|The incidence of severe adverse events (SAE)|The incidence of serious adverse events|Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies|The positive conversion rate of S-RBD protein-specific antibody|Geometric mean fold increase (GMI) of S-RBD protein-specific antibody|The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody|Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodiesJiangsu Province Centers for Disease Control and Prevention|West China HospitalAll18 Years to 85 Years Â  (Adult, Older Adult)Phase 2960OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: PreventionJSVCT099November 17, 2020February 18, 2021November 18, 2021November 23, 2020March 30, 2021Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, Chinahttps://ClinicalTrials.gov/show/NCT04640402 China
1181NCT04459455Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 PandemicCompletedNo Results AvailableAnxietyBehavioral: Contain COVID Anxiety SSI|Behavioral: Remain COVID Free SSIChange in Anxiety Control Questionnaire (ACQ) from Baseline to Immediately Post-Intervention|Change in Generalized Anxiety Disorder-7 (GAD-7) from Baseline to 2-week follow-up|Change in Activity Social Distancing Intentions - 3 item version (SOC-D) from Baseline to immediately post-intervention|COVID-19 Related Questions|Inventory of Depression and Anxiety Symptoms (IDAS)|Self Hate Scale (SHS)|Comprehension Questions|Everyday Discrimination Scale-Short version|Perceived Changes in generalized anxiety symptoms|Activity Hand Washing Intentions - 3 item version (WASH-I)Stony Brook UniversityAll18 Years and older Â  (Adult, Older Adult)Not Applicable500OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentIRB2020-00204August 19, 2020October 15, 2020October 15, 2020July 7, 2020October 20, 2020Stony Brook University, Stony Brook, New York, United Stateshttps://ClinicalTrials.gov/show/NCT04459455 United States
1182NCT04426084Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control StudyActive, not recruitingNo Results AvailableCOVID-19Other: Hypertension|Other: Diabetes type 2|Other: Obesity|Drug: Antihypertensive Agents|Drug: Statins (Cardiovascular Agents)Severe Covid-19|Severe Covid-19 with pulmonary embolism|CRRT(Continuous Renal Replacement Therapy)|ECMO (Extracorporeal Membrane Oxygenation )|ICU MortalityKarolinska InstitutetAll18 Years and older Â  (Adult, Older Adult)22784OtherObservationalObservational Model: Case-Control|Time Perspective: Other4March 1, 2020May 11, 2020December 31, 2022June 11, 2020June 11, 2020SÃ¶dersjukhuset, Stockholm, Swedenhttps://ClinicalTrials.gov/show/NCT04426084 Sweden
1183NCT04694716Determination of Serum Trace Element and Physical Activity Levels in COVID-19RecruitingNo Results AvailableCovid19Other: No interventionLevels of serum trace elements parameters|Physical Activity Level|Levels of Routine Blood SamplesIzmir Bakircay University|Cigli Regional Training Hospital|MuÄŸla SÄ±tkÄ± KoÃ§man UniversityAll35 Years to 65 Years Â  (Adult, Older Adult)40OtherObservationalObservational Model: Cohort|Time Perspective: Prospective2020-12-141January 6, 20212021-02-01 00:00:002021-03-01 00:00:00January 5, 2021February 11, 2021Kadirhan Ozdemir, Ä°zmir, Turkeyhttps://ClinicalTrials.gov/show/NCT04694716 Turkey
1184NCT04476602Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) ProtocolCROWNRecruitingNo Results AvailableCovid-19 (SARS-CoV-2)Hospital AdmissionNorthwell HealthAll18 Years and older Â  (Adult, Older Adult)500OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective20-0618April 27, 2020December 31, 2020December 31, 2020July 20, 2020September 16, 2020410 Lakeville Road, Suite 107, New Hyde Park, New York, United Stateshttps://ClinicalTrials.gov/show/NCT04476602 United States
1185NCT04366245Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 InfectionRecruitingNo Results AvailableSARS-CoV 2Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infectionSafety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale â‰¥ 3 after 72 hours of randomization or an increase of 2 points or more from the basal level|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients requiring treatment.|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.Andalusian Network for Design and Translation of Advanced TherapiesAll18 Years to 80 Years Â  (Adult, Older Adult)Phase 1|Phase 272OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentPC/COVID-19April 23, 20202021-12-01 00:00:002021-12-01 00:00:00April 28, 2020June 11, 2020Hospital U. Jerez de la Frontera, Jerez de la Frontera, CÃ¡diz, Spain|Hospital U. Puerto Real, Puerto Real, CÃ¡diz, Spain|Hospital Costa del Sol, Marbella, MÃ¡laga, Spain|Hospital U. TorrecÃ¡rdenas, AlmerÃ­a, Spain|Hospital U. Puerta del Mar, CÃ¡diz, Spain|Hospital U. Virgen de las Nieves, Granada, Spain|Hospital U. San Cecilio, Granada, Spain|Hospital Juan RamÃ³n JimÃ©nez, Huelva, Spain|Hospital Regional U. de MÃ¡laga, MÃ¡laga, Spain|Hospital U. Virgen de la Victoria, MÃ¡laga, Spain|Hospital Unversitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del RocÃ­o, Sevilla, Spain|Hospital U. Nuestra SeÃ±ora de Valme, Sevilla, Spain|Hospital San Juan de Dios, Sevilla, Spainhttps://ClinicalTrials.gov/show/NCT04366245 Spain
1186NCT04508712Long-term Outcomes in Patients With COVID-19RecruitingNo Results AvailableCOVID-19Physical functions|Respiratory function|Cognitive function|Depression status|Sensory functions|Heart functionRenJi HospitalAll18 Years and older Â  (Adult, Older Adult)900OtherObservationalObservational Model: Case-Only|Time Perspective: ProspectiveCOVID-19 PrognosisAugust 10, 2020August 31, 2021August 31, 2021August 11, 2020October 23, 2020Renji Hospital, Shanghai Jiaotong University School of Medicine, Pudong, Shanghai, Chinahttps://ClinicalTrials.gov/show/NCT04508712 China
1187NCT04665193An Approach to Screening for COVID-19 at Vancouver AirportRecruitingNo Results AvailableAsymptomatic Condition|HealthyDiagnostic Test: Rapid Antigen TestCOVID-19 statusUniversity of British Columbia|Vancouver Airport Authority|WestJet Airlines|Providence Health & ServicesAll19 Years to 80 Years Â  (Adult, Older Adult)Not Applicable900OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: ScreeningH20-03225November 23, 2020April 30, 2021April 30, 2021December 11, 2020December 11, 2020Vancouver International Airport, WestJet Domestic Terminal, Level 3, Richmond, British Columbia, Canada"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04665193/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04665193/ICF_001.pdf"https://ClinicalTrials.gov/show/NCT04665193 Canada
1188NCT04407169Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory DiseaseCRITICoVidCompletedNo Results AvailableCOVIDOther: no interventionPercentage of patients who reached, during their hospitalization, a value greater than or equal to 6 on the WHO CoVid-19 infection progression scale|Determined potential predictive factors of critic form in patients with chronic lung diseases|Determined percentage of death|Determined duration of oxygen therapy|Determined duration of hospitalization|Determine mean values of the WHO CoVid-19 infection progression scale measuredCentral Hospital, Nancy, FranceAll18 Years and older Â  (Adult, Older Adult)617OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective2020PI081June 1, 2020November 17, 2020November 17, 2020May 29, 2020November 20, 2020Valentin Simon, Vandoeuvre Les Nancy, Francehttps://ClinicalTrials.gov/show/NCT04407169 France
1189NCT04770467A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19Not yet recruitingNo Results AvailableCOVID-19Drug: BRII-196 and BRII-198|Drug: PlaceboIncidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Change from pre-dose baseline in RBC count|Change from pre-dose baseline in WBC count|Change from pre-dose baseline in Platelets count|Change from pre-dose baseline in Hemoglobin result|Change from pre-dose baseline in Creatine kinase result|Change from pre-dose baseline in Alanine aminotransferase (ALT) result|Time-weighted average changes in SARSCoV-2 RNA levels in nasopharyngeal swabs from baseline to Day 8|Duration of COVID-19 related symptoms through Day 29 among subjects with mild-moderate COVID-19|Proportion of subjects who have mild-moderate COVID-19 and develop severe COVID-19 after randomization|Assessment of PK parameters: maximum serum concentration observed (Cmax)Brii Biosciences, Inc.|Brii Biosciences LimitedAll18 Years and older Â  (Adult, Older Adult)Phase 256IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: TreatmentBRII-196-198-0022021-03-01 00:00:002022-10-01 00:00:002022-10-01 00:00:00February 25, 2021March 12, 2021Investigative Site 1, Hong Kong, Chinahttps://ClinicalTrials.gov/show/NCT04770467 China
1190NCT04677283Study of Symptoms Linked to Covid-19 in Residents and Professionals in EHPAD, Associated With a Dual Diagnostic Approach by PCR and Serology: a Cohort in ÃŽle-de-France.COVID - EHPADRecruitingNo Results AvailableSymptoms Related to Covid-19"To define positive cases of coronavirus by ""Polymerase Chain Reaction"" results and symptomatologies|Assessment of commorbidity risk according Charlson score|Assessment of patient's level of dependence through an appreciation of instrumental activities of daily living according Lawton scale|Assessment of teh degree of autonomy according AGGIR score|Measuring cognitive impairment according Mini-Mental State Examination (MMSE) scores|Screening for a nutritional disorder according Body Mass Index (BMI) score"GÃ©rond'ifAll18 Years and older Â  (Adult, Older Adult)2020OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective2020-A01027-32April 5, 20202020-12-01 00:00:002021-03-01 00:00:00December 21, 2020December 21, 2020Autonomy Department; ARS ÃŽle-de-France, Paris, ARS ÃŽle-de-France, Francehttps://ClinicalTrials.gov/show/NCT04677283 France
1191NCT04618861Surfactant Protein D Levels in Covid-19 Infection: Case-Control StudyCompletedNo Results AvailableCovid19|Pneumonia|Surfactant Protein DeficiencyMeassuring the serum surfactant protein D levels in patient who have Covid-19 infection or pneumonia.|Analyzing the correlations between serum surfactant protein D levels and demographic,laboratory, clinical and radiological datas.Kafkas University18 Years and older Â  (Adult, Older Adult)127OtherObservationalObservational Model: Case-Control|Time Perspective: Cross-SectionalClinical-1October 13, 2020November 2, 2020November 2, 2020November 6, 2020November 6, 2020Aylin Koseler, Denizli, Outside Of The US, Turkeyhttps://ClinicalTrials.gov/show/NCT04618861 Turkey
1192NCT04344288Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 InfectionCORTI-CovidTerminatedNo Results AvailableViral Pneumonia Human Coronavirus|COVID-19Drug: Prednisone|Other: Control groupNumber of patients with a theoretical respiratory indication for transfer to intensive care unit evaluated by a SpO2 <90% stabilized at rest and under not more than 5 L / min of supplemental oxygen using medium concentration mask.|disease severity assessed on a 7-level ordinal scale|number of patients with a supplemental oxygen use|radiological signs on chest imaging|number of patients transferred to intensive care unit|number of patients requiring invasive ventilation|Duration of oxygen therapy|number of adverse events induced by corticosteroid treatment|number of patients with infections other than SARS-CoV-2|number of deathsHospices Civils de LyonAll18 Years and older Â  (Adult, Older Adult)Phase 211OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment69HCL20_0321|2020-001553-48April 21, 2020August 18, 2020August 18, 2020April 14, 2020October 26, 2020HÃ´pital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France|Groupement Hospitalier Nord, Lyon, France|HÃ´pital Edouard Herriot, Lyon, France|HÃ´pital St Joseph Saint Luc, Lyon, France|HÃ´pital St Joseph, Marseille, France|Centre hospitalier Lyon Sud, Pierre-BÃ©nite, France|CHU St Etienne, Saint-Ã‰tienne, France|Clinique Charcot, Sainte-Foy-lÃ¨s-Lyon, France|CHG Vienne, Vienne, France|MÃ©dipÃ´le, Villeurbanne, France|Clinique des Portes du Sud, VÃ©nissieux, France|CH Annecy-Genevois, Ã‰pagny, Francehttps://ClinicalTrials.gov/show/NCT04344288 France
1193NCT04403906Somerset and South Essex Coronavirus Antigen TestingSOCRATESNot yet recruitingNo Results AvailableCOVID|SARS-CoV 2Diagnostic Test: PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test)To compare the result of SARS-COV2 PCR test to PCL rapid antigen test|Number of technically failed samples due to test issues.|Time taken for PCL Antigen test resultSomerset NHS Foundation TrustAll18 Years and older Â  (Adult, Older Adult)Not Applicable200OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: DiagnosticIRAS2831372020-06-01 00:00:002021-06-01 00:00:002021-08-01 00:00:00May 27, 2020May 27, 2020Musgrove Park Hospital, Taunton, Somerset, United Kingdomhttps://ClinicalTrials.gov/show/NCT04403906 United Kingdom
1194NCT04346355Efficacy of Early Administration of Tocilizumab in COVID-19 PatientsTerminatedNo Results AvailableCOVID-19 PneumoniaDrug: TocilizumabEntry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte countAzienda UnitÃ  Sanitaria Locale Reggio EmiliaAll18 Years and older Â  (Adult, Older Adult)Phase 2126OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentRCT-TCZ-COVID-19|2020-001386-37March 31, 2020June 6, 2020June 6, 2020April 15, 2020June 22, 2020"Ospedale di Guastalla, Guastalla, RE, Italy|Azienda UnitÃ  Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|ASST Cremona, Cremona, Italy|Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Ospedale Evangelico Internazionale di Genova, Genova, Italy|Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy|Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|IRCCS Istituto Auxologico Italiano Milano, Milano, Italy|Azienda Ospedaliero-Universitaria ""Maggiore della CaritÃ "" di Novara, Novara, Italy|Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy|Azienda Ospedaliero-Universitaria Parma, Parma, Italy|Azienda UnitÃ  Sanitaria Locale di Piacenza, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|AO Ordine Mauriziano di Torino, Torino, Italy|ASST Bergamo Ovest -Treviglio, Treviglio, Italy|AULSS 2 Marca Trevigiana, Treviso, Italy|AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy|AULSS 3 Serenissima Ospedale ""Dell'Angelo"", Venezia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|IRCCS Sacro Cuore Don Calabria, Verona, Italy"https://ClinicalTrials.gov/show/NCT04346355 Italy
1195NCT04644146Genetic Predisposition to Severe Forms of COVID-19 (SARS-CoV2 Infection)COVIDGENRecruitingNo Results AvailableCovid19Genetic: GENETICPrimary criteria of data evaluationHospices Civils de LyonAll18 Years to 70 Years Â  (Adult, Older Adult)40OtherObservationalObservational Model: Case-Control|Time Perspective: Retrospective69HCL20_1072December 1, 2020June 1, 2021December 1, 2021November 25, 2020November 25, 2020University Hospital LYON (Hospices Civils de LYON), Lyon, Francehttps://ClinicalTrials.gov/show/NCT04644146 France
1196NCT04765254COVID-19 Infection in Diabetic PatientsRecruitingNo Results AvailableCovid19|Diabete Type 2|Non Diabetic Patients|Chest CT ScanOther: no intervention as it is an observational studyInvestigation of bad prognosis cause for covid-19 diabetic patientsCairo UniversityAll30 Years and older Â  (Adult, Older Adult)300OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveITH00131February 20, 2021March 20, 2021April 10, 2021February 21, 2021February 21, 2021Cairo University teaching hospitals, Cairo, Kasr Al Ainy, Egypthttps://ClinicalTrials.gov/show/NCT04765254 Egypt
1197NCT04366778Thrombosis and Covid-19COVBIOCompletedNo Results AvailableThrombosis|Covid-19|SARS-CoV 2Diagnostic Test: TEM-tPACoagulability|Venous thrombotic event (VTE) or arterial thrombosisHospices Civils de LyonAll18 Years and older Â  (Adult, Older Adult)341OtherObservationalObservational Model: Cohort|Time Perspective: Prospective69HCL20_0401 - COVBIO|ID-RCBMay 1, 2020January 1, 2021January 1, 2021April 29, 2020January 25, 2021HÃ´pital Louis Pradel, Bron, Francehttps://ClinicalTrials.gov/show/NCT04366778 France
1198NCT04353154The RAPID COVID TRIAGE AlgorithmActive, not recruitingNo Results AvailableCOVID-19Diagnostic Test: Spartan Cube Point-of Care Covid-19 testSensitivityOttawa Heart Institute Research CorporationAll18 Years and older Â  (Adult, Older Adult)66OtherObservationalObservational Model: Cohort|Time Perspective: Prospective20200228-01HApril 15, 2020January 31, 2021February 28, 2021April 20, 2020February 15, 2021University of Ottawa Heart Institute, Ottawa, Ontario, Canadahttps://ClinicalTrials.gov/show/NCT04353154 Canada
1199NCT04838093COVID-19 Testing in Patients With Vascular DisordersCompletedNo Results AvailableCovid19Diagnostic Test: PCRprevalence of SARS-CoV-2 infectionMedical University of ViennaAllChild, Adult, Older Adult2243OtherObservationalObservational Model: Cohort|Time Perspective: Prospective2049/2020March 1, 2020December 1, 2020January 1, 2021April 8, 2021April 8, 2021Medical University of Vienna, Vienna, Austriahttps://ClinicalTrials.gov/show/NCT04838093 Austria
1200NCT04340479The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma EvaluationRecruitingNo Results AvailableCOVID|Trauma|UltrasoundDiagnostic Test: Ultrasound lung imaging as part of FAST+ evaluationCorrelation of FAST+ pulmonary findings with active COVID infection|Description of additional ancillary findings of the FAST+ examination among infected and non-infected patientsUniversity of Colorado, DenverAllChild, Adult, Older Adult20OtherObservationalObservational Model: Cohort|Time Perspective: Prospective20-0751July 30, 20202022-05-01 00:00:002022-05-01 00:00:00April 9, 2020August 24, 2020Children's Hospital Colorado, Aurora, Colorado, United Stateshttps://ClinicalTrials.gov/show/NCT04340479 United States
1201NCT04828460Monitoring of COVID-19 Vaccine Response in Organ Transplant PatientsCOVATRANSRecruitingNo Results AvailableCovid19|Kidney TransplantationPercentage of patients who develop a seroconversion for SARS Cov-2 anti Spike antibodies|Compare the seroconversion between different vaccines|Describe the patients characteristics associated with seroconversionUniversity Hospital, Strasbourg, FranceAllChild, Adult, Older Adult3500OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective8133February 9, 20212021-06-01 00:00:002023-02-01 00:00:00April 2, 2021April 2, 2021HÃ´pitaux Universitaires de Strasbourg, Strasbourg, Francehttps://ClinicalTrials.gov/show/NCT04828460 France
1202NCT04377672Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)RecruitingNo Results AvailableCorona Virus InfectionBiological: Anti-SARS-CoV-2 Human Convalescent PlasmaSafety of treatment with high-titer anti-SARS-CoV-2 plasma as assessed by adverse events|Proportion of subjects with disease worsening event|Pharmacokinetics of anti-SARS-CoV-2 antibodies as defined by changes in antibody titers|Proportion of subjects with a natural antibody response to SARS-CoV-2 infectionJohns Hopkins UniversityAll1 Month to 18 Years Â  (Child, Adult)Phase 130OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentIRB00247557May 28, 2020May 28, 2021May 28, 2022May 6, 2020June 2, 2020Johns Hopkins Hospitals, Baltimore, Maryland, United Stateshttps://ClinicalTrials.gov/show/NCT04377672 United States
1203NCT04399252Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19RecruitingNo Results AvailableMicrobiomeDietary Supplement: Lactobaciltus rhamnosus GG|Dietary Supplement: Lactobaciltus rhamnosus GG PlaceboIncidence of one or more symptoms of COVID-19 during the study period|Incidence of laboratory-confirmed COVID-19 during the study period|Complications of COVID-19|Types of symptoms of COVID-19|Duration of symptoms of COVID-19Duke UniversityAll1 Year and older Â  (Child, Adult, Older Adult)Not Applicable1132OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic SciencePro00105674June 24, 2020May 25, 2022May 25, 2022May 22, 2020April 1, 2021Duke University, Durham, North Carolina, United Stateshttps://ClinicalTrials.gov/show/NCT04399252 United States
1204NCT04587323VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 DiseaseRecruitingNo Results AvailableCOVID-19 DiseaseLaboratory Assays|VEGF-A|VEGF-C|VEGF-D|Tie-2|Flt-1|PlGF|FGFUniversity of Alabama at BirminghamAll18 Years and older Â  (Adult, Older Adult)100OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveIRB-300005378May 22, 2020March 20, 2023May 20, 2023October 14, 2020October 14, 2020University of Alabama at Birmingham, Birmingham, Alabama, United Stateshttps://ClinicalTrials.gov/show/NCT04587323 United States
1205NCT04590274Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Not yet recruitingNo Results AvailableCovid19|SARS (Severe Acute Respiratory Syndrome)Drug: Hydroxychloroquine|Dietary Supplement: Vitamins and Minerals|Drug: AzithromycinPercentage of individuals who develop COVID-19 symptomsInternational Brain Research FoundationAllChild, Adult, Older AdultPhase 15000OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: PreventionCTP-HCQ-COVID192020-11-01 00:00:002021-12-01 00:00:002021-12-01 00:00:00October 19, 2020October 19, 2020https://ClinicalTrials.gov/show/NCT04590274
1206NCT04534712Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19Not yet recruitingNo Results AvailableCovid19Diagnostic Test: LYMPHOCYTE MONOCYTE RATIOprogression|mortalityPostgraduate Institute of Medical Education and Research|Sir Ganga Ram HospitalAll18 Years to 80 Years Â  (Adult, Older Adult)100OtherObservationalObservational Model: Cohort|Time Perspective: Prospectiveyet to be assignedSeptember 1, 2020December 1, 2020February 1, 2021September 1, 2020September 1, 2020Sir Ganga Ram Hospital, New delhi, Delhi, Indiahttps://ClinicalTrials.gov/show/NCT04534712 India
1207NCT04292327Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus2019-nCoVActive, not recruitingNo Results AvailablePneumonia Caused by Human CoronavirusMortality|The time interval of Nucleic acid detection become negativeFujian Provincial HospitalAll18 Years to 75 Years Â  (Adult, Older Adult)400OtherObservationalObservational Model: Other|Time Perspective: RetrospectiveKY-2020-24.01January 1, 2020April 30, 2020July 31, 2020March 3, 2020March 3, 2020Fujian Provincial Hospital, Fuzhou, Fujian, Chinahttps://ClinicalTrials.gov/show/NCT04292327 China
1208NCT04669938Role of the Microbiota in the Evolution of the SARS-CoV-2 Disease,COVID-19, in Hospitalized PatientsMicrobioCOVIDRecruitingNo Results AvailableCovid19Other: oropharyngeal and intestinal microbiota|Other: host genotype|Other: host immune factors|Other: viral sequenceidentify risk factors associated with severe forms of COVID-19|link between the composition of the gut microbiota and admission to intensive care|predictive performance of semi-quantitative culture and rapid metagenomic evaluationAssistance Publique - HÃ´pitaux de ParisAll18 Years and older Â  (Adult, Older Adult)200OtherObservationalObservational Model: Case-Only|Time Perspective: ProspectiveAPHP201083December 4, 2020March 31, 2022March 31, 2022December 17, 2020December 17, 2020LESCURE, Paris, Francehttps://ClinicalTrials.gov/show/NCT04669938 France
1209NCT04780321JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection SubectsRecruitingNo Results AvailableCOVID-19Biological: Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)|Drug: PlaceboEfficacy Measurs(Time to negative conversion in viral nucleic acid test(by RT-PCR) for diagnostic samples)|Safety Measurements : 90 of participants with treatment-related adverse events as assessed byCTCAE v5.0|PK Measures:AUC0-tau|PK Measuresï¼šCmax|PK Measuresï¼šTmax|PK Measuresï¼št1/2|PK Measuresï¼šCL|PK Measuresï¼šVd|Proportions of participants with negative conversion in viral nucleic acid test|Viral load change from baseline|Pulmonary CTï¼ˆobserve by imaging reports to degree of pulmonary inflammation, degree of vitreous fibrosis)Shanghai Junshi Bioscience Co., Ltd.All18 Years to 65 Years Â  (Adult, Older Adult)Phase 1|Phase 290OtherInterventionalAllocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentJS016-002-Ib/IIOctober 30, 2020March 31, 2021June 30, 2021March 3, 2021March 3, 2021Beijing Ditan Hospital affiliated to Capital Medical University, Beijing, China|Huashan Hospital affiliated to Fudan University, Shanghai, Chinahttps://ClinicalTrials.gov/show/NCT04780321 China
1210NCT04633980Hydrogen Therapy in Patients With Moderate Covid-19H2CovidNot yet recruitingNo Results AvailableCovid-19Drug: Mixture 3,6% H2 in N2 (96.4%)adverse events|biomarkers of inflammation and oxidative stress.University Hospital, GrenobleAll18 Years and older Â  (Adult, Older Adult)Phase 110OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment38RC20.277December 1, 2020August 30, 2021September 30, 2021November 18, 2020November 18, 2020https://ClinicalTrials.gov/show/NCT04633980
1211NCT04422613Characterization of Persistent Pulmonary Abnormalities Following COVID-19 PneumoniaPULCO-19Active, not recruitingNo Results AvailablePneumonia, ViralDiagnostic Test: pulmonary anomalies 4 months after documented COVID-19 pneumoniaAlteration of the DLCO|Mechanism of the alteration of gas exchanges|Measurement on lung volumes|mechanism of the alteration of gas exchanges by chest scan|mechanism of the alteration of gas exchanges by scintigraphy|Respiratory symptom|Bronchial or ventilatory anomalies|Persistent respiratory anomaliesUniversity Hospital, ToulouseAll18 Years and older Â  (Adult, Older Adult)Not Applicable73OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: DiagnosticRC31/20/0181May 28, 20202021-05-01 00:00:002022-05-01 00:00:00June 9, 2020November 5, 2020University Hospital of Toulouse, Toulouse, Francehttps://ClinicalTrials.gov/show/NCT04422613 France
1212NCT04354389DAS181 for STOP COVID-19WithdrawnNo Results AvailableCOVID-19Drug: DAS181|Drug: PlaceboPercent of subjects return to room air (RTRA)|Percent of subjects who have recovered|Improved COVID-19 Clinical Classification|Return To Room Air (RTRA)|Percent of subjects who achieve clinical stability|SARS-CoV-2 RNA undetectable|Clinical Deterioration|Percent of subjects discharged|Death (all cause)Ansun Biopharma, Inc.All18 Years and older Â  (Adult, Older Adult)Phase 2|Phase 30IndustryInterventionalAllocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentDAS181-2-08|2020-003192-17July 25, 2020September 30, 2020November 30, 2020April 21, 2020August 11, 2020Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy|A.O.U Policlinico Di Modena, Modena, Italyhttps://ClinicalTrials.gov/show/NCT04354389 Italy
1213NCT04373824Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot StudyRecruitingNo Results AvailableCOVIDDrug: Ivermectineffect of Ivermectin on eradication of virus.Max Healthcare Insititute LimitedAll18 Years to 75 Years Â  (Adult, Older Adult)Not Applicable50OtherInterventionalAllocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentMHC-COVID-19- INV- ACT-BHRApril 25, 2020July 25, 2020July 25, 2020May 4, 2020May 4, 2020Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, Indiahttps://ClinicalTrials.gov/show/NCT04373824 India
1214NCT04407156Epidemiology of Acute Kidney Injury in COVID19 Disease in United KingdomCompletedNo Results AvailableCOVID|AKIOther: acute kidney injuryIncidence of Acute kidney injury in COVID-19|All-cause mortality in AKI patientsUniversity Hospitals of Derby and Burton NHS Foundation TrustAll18 Years to 110 Years Â  (Adult, Older Adult)724OtherObservationalObservational Model: Case-Control|Time Perspective: RetrospectiveUHDB/2020/050June 1, 2020June 7, 2020July 20, 2020May 29, 2020September 9, 2020Derby Hospital NHS Foundation Trust, Derby, Derbyshire, United Kingdomhttps://ClinicalTrials.gov/show/NCT04407156 United Kingdom
1215NCT04534803BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)Not yet recruitingNo Results AvailableCovid19Drug: BCG Vaccine|Other: PlaceboTo assess the efficacy of BCG vaccination compared to placebo in reducing severe Covid-19 disease among elderly residents of skilled nursing facilities.|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of cases)|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of cases), continued|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of episodes)|To assess the efficacy of BCG vaccination compared to placebo in reducing the following among elderly residents of skilled nursing facilities (by number of days)Harvard Medical School|Texas Medical Research Associates, L.L.C.All70 Years and older Â  (Older Adult)Phase 32100OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: PreventionIRB20-1243September 1, 2021October 30, 2022November 30, 2022September 1, 2020February 18, 2021https://ClinicalTrials.gov/show/NCT04534803
1216NCT04365231Hydroxychloroquine Azithromycin COVID-19 Pregnancy TrialHASCOPTWithdrawnNo Results AvailableCOVID19Drug: Hydroxychloroquine and azithromycin treatment|Other: conventional management of patientsPercentage of patients with a negative RT-PCR test result to COVID-19|Maternal outcomes: Percentage of severe forms of the disease|Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unitHospital St. Joseph, Marseille, FranceFemale18 Years and older Â  (Adult, Older Adult)Phase 30OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentHASCOPT2020April 1, 2020June 1, 2020April 1, 2021April 28, 2020November 20, 2020https://ClinicalTrials.gov/show/NCT04365231
1217NCT04806867Selection of Patients With Chronic Inflammatory Rheumatism Requiring Management During the COVID-19 PandemiaSePaRICCompletedNo Results AvailableCovid19|Inflammatory Rheumatism|Rheumatoid Arthritis|Spondyloarthritis|Inflammatory ArthritisOther: SePaRIC-Covid19 cohortProportion of patients requiring an advice from the referring rheumatologist following the telephone survey.|Evaluate the association between rheumatologist advice asked by student and/or patient and the factors studied|COVID-19 infection evaluation in the monitored patient population|Proportion of patients informed about COVID-19|Evaluate the association between the increase in rheumatic activity perceived by patients and the factors studied|Evaluate the association between pain increase perceived by patients and the factors studied|Evaluate the association between rheumatologist advice asked by student and the factors studied|Evaluate the association between rheumatologist advice asked by patient and the factors studied|To evaluate the satisfaction of the telephone call with patients and students. Time Frame: phone call dayUniversity Hospital, LimogesAll18 Years and older Â  (Adult, Older Adult)918OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective87RI20_0044 (SePaRIC)May 1, 2020July 1, 2020July 31, 2020March 19, 2021April 1, 2021Service de Rhumatologie, CHu de Limoges, Limoges, Francehttps://ClinicalTrials.gov/show/NCT04806867 France
1218NCT04416464Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19RecruitingNo Results AvailableQuality of Life|Long-term Outcomes|Coronavirus Infection|Morality|RehospitalizationOther: COVID-19 PneumoniaHealth-related quality of life.|Length of stay at the ICU.|Incidence of all-cause mortality|Rehospitalization.|Percentage of long-term ventilatory support need.|Percentage of renal replacement therapy need.|Symptoms of anxiety and depression.|Score of functional independence.|Score of cognitive function.|Percentage of major cardiac events.|Score of Chronic obstructive pulmonary disease (COPD)|Symptoms of posttraumatic stress disorder|Utility score of health-related quality of life at 3, 6, and 9 months.|Score of self-rated health.Universidade do Porto|Centro Hospitalar De SÃ£o JoÃ£o, E.P.E.|Centro Hospitalar do Porto|Universidade do Algarve|Centro Hospitalar Lisboa OcidentalAll18 Years and older Â  (Adult, Older Adult)230OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveQoL_ICU_COVIDJune 15, 2020July 31, 2022October 1, 2022June 4, 2020March 30, 2021Centro Hospitalar UniversitÃ¡rio do Algarve, Faro, Algarve, Portugal|Hospital de SÃ£o Francisco Xavier, Lisbon, Portugal|Centro Hospitalar UniversitÃ¡rio de SÃ£o JoÃ£o, Porto, Portugal|Centro Hospitalar UniversitÃ¡rio do Porto - Hospital de Santo AntÃ³nio, Porto, Portugalhttps://ClinicalTrials.gov/show/NCT04416464 Portugal
1219NCT04841707Total-Body Parametric 18F-FDG PET of COVID-19RecruitingNo Results AvailableCovid19Device: uEXPLORER/mCTBAB permeability assessed|4 month follow-up PET/CT scanUniversity of California, DavisAll18 Years and older Â  (Adult, Older Adult)Not Applicable15OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science1697954April 22, 2021February 22, 2022February 22, 2023April 12, 2021April 14, 2021University of California, Davis, Sacramento, California, United Stateshttps://ClinicalTrials.gov/show/NCT04841707 United States
1220NCT04710199Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)COVIMARRecruitingNo Results AvailableVirus DiseasesDrug: Maraviroc experimental group|Other: Standard treatmentEvaluate the efficacy of Maraviroc in SARS-CoV-2 infected patients hospitalized for COVID-19 using the Ordinal scale.|Analyze changes in analytical variables: changes in ambient air oxygen saturation (SatO2),related to the progression of COVID-19.|Study the variation in the number of biomarkers of inflammation.|Analyze changes in the number of innate immune activation (monocytes and dendritic cells) and adaptive (T lymphocytes).|Quantify the number of immunomodulatory treatments added to therapy|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Analyze changes in analytical variables:changes in neutrophils, related to the progression of COVID-19.|Analyze changes in analytical variables: changes in platelets, related to the progression of COVID-19.|Analytical variables related to the progression of COVID-19: changes in lactate dehydrogenase (LDH).|Analyze changes in analytical variables: changes in C-reactive protein, related to the progression of COVID-19.FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en SevillaAll18 Years and older Â  (Adult, Older Adult)Phase 240OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentCOVIMARFebruary 8, 20212021-08-01 00:00:002021-10-01 00:00:00January 14, 2021April 6, 2021Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitario Virgen del RocÃ­o, Sevilla, Spainhttps://ClinicalTrials.gov/show/NCT04710199 Spain
1221NCT04416308COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB)AntiCoV-HBCompletedNo Results AvailableCoronavirusDiagnostic Test: NG test|Diagnostic Test: Blood test|Behavioral: Self-questionnaryrate of presence of anti-SARS-CoV-2 antibodies (Ig G _ Ig M) among employees working in a GHT Haute Bretagne health establishment.|a) Validation of the Biotech NG test:|a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgG|a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgM.|b) Risk of presence of anti SARS-CoV-2 antibodies in function:|c) Risk of presence of anti SARS-CoV-2 antibodies in function:|d) Description of the experience and behavioral changes related to the epidemic,|e) Evolution of seroprevalence over time:Rennes University Hospital|Fonds NOMINOEAll18 Years and older Â  (Adult, Older Adult)Not Applicable9453OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic35RC20_9716May 29, 2020July 10, 2020October 12, 2020June 4, 2020April 14, 2021CENTRE HOSPITALIER de VITRE_ Saint Jean (La Guerche), La Guerche de Bretagne, La Guerche-de-Bretagne, France|Centre Hospitalier de Fougeres, FougÃ¨res, France|Centre Hospitalier Grand Fougeray, Grand-Fougeray, France|Centre Hospitalier de La Roche Aux Fees, JanzÃ©, France|Centre Hospitalier Montfort-Sur-Meu, Montfort sur Meu, France|Centre Hospitalier de Redon Carentoir, Redon, France|Chu Rennes, Rennes, France|Centre Hospitalier St Meen Le Grand, Saint-MÃ©en-le-Grand, France|CENTRE HOSPITALIER VITRE_Simone Veil, VitrÃ©, Francehttps://ClinicalTrials.gov/show/NCT04416308 France
1222NCT04542850Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19RecruitingNo Results AvailableSARS-CoV 2|COVID-19Dietary Supplement: 5-ALA-Phosphate + SFC (5-ALA + SFC)The incidence of treatment emergent Adverse Events (safety and tolerability) of 5-ALA-Phospate + SFC in patients with acute moderate or severe respiratory illness secondary to infection with SARS-CoV-2 virus (COVID-19).|Sum COVID-19 Modified Ordinal Scale for Clinical Improvement maximum daily score over 28 days of dosing for Moderate group and for Severe group|Rate of change in COVID-19 Modified Ordinal Scale for Clinical Improvement maximum daily score over 28 days of dosing for individual subjects in Moderate group and in Severe group|Patient and subgroup profile of COVID-19 Modified Ordinal Scale for Clinical Improvement score vs. days hospitalized|Overall survival|Results of investigatorÂ´s assessment of patientÂ´s oxygen therapy|Results of mechanical ventilation settings|Results of duration of ventilation|The time to resolution of patientÂ´s symptoms|Results of patientÂ´s oxygen saturation (respiratory parameters)|Length of hospitalization|The total time in ICU|Results of investigatorÂ´s assessment of patientÂ´s condition using (q)SOFA score|Results of patientÂ´s PT parameter|Results of patientÂ´s D-Dimer parameter|Results of patientÂ´s PTT parameter|Results of patientÂ´s SARS-CoV-2 viral load status (efficacy)|Results of patientÂ´s Procalcitonin level.|Results of patientÂ´s IL-6 level|Results of patientÂ´s Serum Ferritin level|Results of patientÂ´s C-Reactive protein (CRP) level|Results of patientÂ´s T helper cells (CD4/CD8) level.|Results of patientÂ´s Bilirubin level.|Results on patientÂ´s Leucocytes|Results on patientÂ´s Neutrophils|Results on patientÂ´s Lymphocyte|Results on patientÂ´s Platelets|Results on patientÂ´s Hemoglobin|Results on patientÂ´s Albumin|Results on patientÂ´s AST|Results on patientÂ´s ALT|Results on patientÂ´s Total bilirubin|Results on patientÂ´s Blood urea nitrogen|Results on patientÂ´s Serum creatinine|Results on patientÂ´s Creatinine kinase|Results on patientÂ´s LDH|Results on patientÂ´s Myoglobin glucose|Results on patientÂ´s aPTT|Results on patientÂ´s urine|Results on hepatic function|Results on patientÂ´s renal function|Results on patientÂ´s iron parameters|Results on patientÂ´s physical examination|Results on patientÂ´s Co-infections|Results on patientÂ´s Care Level|Results on patientÂ´s Mean arterial pressure(MAP)|Results on patientÂ´s heart rate (HR)|Results on patientÂ´s respiratory rate (RR)|Results on patientÂ´s 12-lead ECG|Organ damageRoyal College of Surgeons in Ireland - Medical University of Bahrain|Bahrain Defence Force Hospital|Salmaniya Medical ComplexAll21 Years to 70 Years Â  (Adult, Older Adult)Not Applicable40OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment68 / 02-Aug-2020November 15, 2020June 15, 2021September 15, 2021September 9, 2020February 26, 2021Bahrain Defense Force Royal Medical Services, Military Hospital, Manama, Bahrain|Salmaniya Medical Complex, Manama, Bahrainhttps://ClinicalTrials.gov/show/NCT04542850 Bahrain
1223NCT04381988A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving RadiotherapyRecruitingNo Results AvailableCOVID-19|CancerDrug: Hydroxychloroquine|Other: Placebo|Radiation: Radiation therapycumulative incidence of SARS-CoV-2 infection|cumulative incidence of severe COVID-19 or deathMemorial Sloan Kettering Cancer CenterAll18 Years and older Â  (Adult, Older Adult)Phase 2132OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention20-176May 7, 20202021-05-01 00:00:002021-05-01 00:00:00May 11, 2020May 13, 2020Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United Stateshttps://ClinicalTrials.gov/show/NCT04381988 United States
1224NCT04790994COVID-19 Prevalence in UNIVI Geriatric Institutions: Epidemiological Study of Immunological Status With Rapid Serological TestsActive, not recruitingNo Results AvailableCOVID-19Among asymptomatic residents and caregivers in French nursing homes and geriatric healthcare institutions belonging to the UNIVI Group: prevalence of covid 19|Exposure to SARS Cov-2 Among asymptomatic residents and caregivers in French nursing homes and geriatric healthcare institutions belonging to the UNIVI Group|Recurrence of Covid-19 at 1, 3 and 6 months among residents and caregivers who had at least on positive test at inclusion (RT-PCR test or NB Biotech rapid serological test)|Risk factors for Covid-19 infection in caregivers|Covid-19 symptoms among residents|Prevalence of Covid-19 at 3 monthsCentre MÃ©dical Porte VerteAllChild, Adult, Older Adult1145OtherObservationalObservational Model: Cohort|Time Perspective: Prospective2020-A01838-31July 24, 2020October 16, 2020April 16, 2021March 10, 2021March 10, 2021CentreMÃ©dicalPorteVerte, Versailles, Francehttps://ClinicalTrials.gov/show/NCT04790994 France
1225NCT04585945COVID-19 on Placental Gene Expression and PathologyPROSPERRecruitingNo Results AvailableCOVID-19|SARS-CoV-2 InfectionDiagnostic Test: Positive for SARS-CoV-2 infectionInflammatory biomarkers in umbilical cord blood between women with COVID-19 disease in the first, second and third trimester of pregnancy and determine if differences are mediated by severity of the illness.|Differences in placental pathology (inflammatory processes, vasculopathy, and villous maturity) for women with COVID-19 disease and determine of differences are mediated by gestational age at infection or severity of illness.|Differences in gene expression analysis for women with COVID-19 disease and determine if differences are medicated by gestational age at infection or severity of illness.Prisma Health-UpstateFemale18 Years and older Â  (Adult, Older Adult)100OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectivePro00101090August 4, 2020March 31, 2021September 30, 2021October 14, 2020February 3, 2021Prisma Health Upstate, Greenville, South Carolina, United Stateshttps://ClinicalTrials.gov/show/NCT04585945 United States
1226NCT04681430Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk IndividualsRES-Q-HRRecruitingNo Results AvailableCorona Virus Infection|SARS-CoV-2 Infection|SARS-CoV-2 PCR Test Positive|SARS-CoV-2 Acute Respiratory DiseaseBiological: Convalescent plasma|Drug: Camostat Mesilate|Drug: Placebo for Camostat Mesilate|Other: Standard of Care (SoC)WHO ordinal Covid-19 scale up to day 28|Cumulative number WHO categories 4b-8|Cumulative number WHO categories 3-4a|Not hospitalized|All-cause mortality|Reinfection|Secondary sclerosing cholangitis (SSC)|chronic pulmonary disease as sequelae from COVID-19|patients with remdesivir treatment|COVID-19 WHO status of patients at start of remdesivir treatment|patients with dexamethasone treatment|COVID-19 WHO status of patients at start of dexamethasone treatment|resolution of COVID-19 symptoms|negative SARS-CoV-2-PCR test|Oxygen therapy|COVID-19 pneumonia|Percentage of participants requiring mechanical ventilation|Number of ventilation days per participant up to day 90|hospital stay and intensive care|Mortality|SAEs|Grade 3/4 AEs|SARS-CoV-2 antibody IgA concentrations|SARS-CoV-2 antibody IgG concentrations|SARS-CoV-2 neutralizing antibody titers|Plasma treatment screening failuresHeinrich-Heine University, Duesseldorf|The Federal Ministry of Health, Germany (Bundesministerium fÃ¼r Gesundheit, BMG)All18 Years and older Â  (Adult, Older Adult)Phase 21094OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentRES-Q-HR|2020-004695-18January 8, 20212021-05-01 00:00:002021-11-01 00:00:00December 23, 2020February 1, 2021Abteilung Infektiologie Klinik fÃ¼r Innere Medizin II Department Innere Medizin UniversitÃ¤tsklinikum Freiburg, Freiburg im Breisgau, Baden-WÃ¼rttemberg, Germany|Klinik und Poliklinik fÃ¼r Innere Medizin II Klinikum rechts der Isar Technische UniversitÃ¤t MÃ¼nchen, MÃ¼nchen, Bavaria, Germany|UniversitÃ¤tsklinikum Frankfurt Medizinische Klinik 2: HÃ¤matologie, Onkologie, HÃ¤mostaseologie, Rheumatologie, Infektiologie/HIV, Frankfurt am Main, Hessen, Germany|UniversitÃ¤tsklinikum DÃ¼sseldorf Klinik fÃ¼r Hepatologie und Infektiologie, Duesseldorf, Germanyhttps://ClinicalTrials.gov/show/NCT04681430 Germany
1227NCT04446065PrevifenonÂ® as Chemoprophylaxis of COVID-19 in Health WorkersHERDNot yet recruitingNo Results AvailableCOVID-19|SARS-CoV2Drug: PrevifenonÂ®|Drug: PlaceboEvent of clinical acute respiratory disease with a diagnosis of COVID-19 confirmed with rtPCR|Rate of positive cases for IgM and IgG anti-SARS-CoV-2|Composite outcome considering symptomatic and asymptomatic cases with positive rtPCR test|Hospitalization due to any acute respiratory infection|Event of upper and lower airway respiratory infectionMELISA Institute Genomics & Proteomics Research SpA|Universidad AustralAll25 Years and older Â  (Adult, Older Adult)Phase 2|Phase 3524Industry|OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionMEL109042020September 30, 2020September 30, 2021October 30, 2021June 24, 2020September 9, 2020https://ClinicalTrials.gov/show/NCT04446065
1228NCT04667923Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndromeCOVID-NIVRecruitingNo Results AvailableCovid19|ARDSDiagnostic Test: Respiratory monitoring|Diagnostic Test: Respiratory muscles ultrasound|Diagnostic Test: Electro impedance tomography|Diagnostic Test: Capnography|Diagnostic Test: Arterial blood gas|Diagnostic Test: Quasistatic pressure-volume curveIntubation rate|Mortality|Change in arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio|Change in ventilatory ratio|Change in alveolar dead space|Change in tidal volume|Change in accessory respiratory muscles workloadI.M. Sechenov First Moscow State Medical UniversityAll18 Years to 80 Years Â  (Adult, Older Adult)50OtherObservationalObservational Model: Case-Only|Time Perspective: Prospective002-NIV-COVIDOctober 1, 20202021-06-01 00:00:002021-08-01 00:00:00December 16, 2020April 8, 2021Sechenov University clinic #4, Moscow, Russian Federationhttps://ClinicalTrials.gov/show/NCT04667923 Russian Federation
1229NCT04483635PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare TeamsPROTECTRecruitingNo Results AvailableCOVID-19Dietary Supplement: Placebo|Dietary Supplement: Vitamin DChange in incidence of laboratory-confirmed COVID-19 infection|Distribution of disease severity|Duration of symptoms in COVID-19 positive participants|Number of participants with COVID-19 positive IgG serology|Number of workday absences due to COVID-19 suspected/confirmed infection|Number of workday absences for any reason|Adverse health eventsSt. Justine's Hospital|Canadian Institutes of Health Research (CIHR)|Laboratoire RIVAAll18 Years to 69 Years Â  (Adult, Older Adult)Phase 32414OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionMP-21-2021-3044February 8, 2021September 30, 2021December 31, 2021July 23, 2020February 21, 2021CHUM, Montreal, Quebec, Canada|CHU Sainte-Justine (CHUSJ), Montreal, Quebec, Canadahttps://ClinicalTrials.gov/show/NCT04483635 Canada
1230NCT04331106Survey of the Anxiety Associated With the COVID-19 PandemicCORARecruitingNo Results AvailableAnxiety Related to the COVID-19 PandemicDiagnostic Test: Online QuestionnaireCharacteristics of COVID-19-related anxiety|COVID-19-related anxiety symptoms|Self-efficacy and coping with COVID-19|Consequences of COVID-19 in the last three weeks.|General Illness Attitude|Media reporting|Ultra-brief screening scale for anxiety and depression|Change in characteristics of COVID-19-related anxiety|Change in COVID-19-related anxiety symptomsCharite University, Berlin, GermanyAll18 Years and older Â  (Adult, Older Adult)7500OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveEA1/071/20March 27, 20202022-04-01 00:00:002022-04-01 00:00:00April 2, 2020January 27, 2021CharitÃ©-UniversitÃ¤tsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germanyhttps://ClinicalTrials.gov/show/NCT04331106 Germany
1231NCT04516811Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19RecruitingNo Results AvailableCOVID-19|SARS-CoV-2 Infection|Severe Acute Respiratory Syndrome Coronavirus 2Biological: COVID-19 convalescent plasma (CCP) plus standard of care (SOC)|Biological: Standard of care (SOC) plus placeboClinical Improvement|Adverse Events of special interest|Serious Adverse Events|Survival|Invasive mechanical ventilation|Disease severity|Time to outcomes of interest|Length of stay meausures|SARS-CoV PCR|Inflammatory markers|Radiography|Fever & Hypoxia|patients with HIV infection and other comorbidities|Timing of IP & Efficacy Outcome|Neutralising Ab|SARS CoV Antibody titreSouth African National Blood ServiceAll18 Years and older Â  (Adult, Older Adult)Phase 3600OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentPROTECT-Patient trialSeptember 21, 2020December 30, 2021July 31, 2022August 18, 2020September 25, 2020Universitas Hospital, Bloemfontein, Free State, South Africa|Mitchells Plain Hospital, Cape Town, Western Cape, South Africahttps://ClinicalTrials.gov/show/NCT04516811 South Africa
1232NCT04838834Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in ChildrenRECONNActive, not recruitingNo Results AvailableCOVID-19|SARS-CoV-2|Inflammatory Bowel DiseasesPresence of anti-SARS-CoV-2 Immunoglobulin G (IgG)|Presence of anti-SARS-CoV-2 IgG neutralizing antibodiesConnecticut Children's Medical Center|The Jackson LaboratoryAll2 Years to 27 Years Â  (Child, Adult)472OtherObservationalObservational Model: Cohort|Time Perspective: Prospective20-073May 15, 2020December 31, 2024December 31, 2024April 9, 2021April 9, 2021Connecticut Children's Medical Center, Hartford, Connecticut, United Stateshttps://ClinicalTrials.gov/show/NCT04838834 United States
1233NCT04561063COVID-19 Prophylaxis South Africa (COVER HCW)COVERRecruitingNo Results AvailableCovid19|SARS-CoV InfectionDrug: Nitazoxanide|Drug: Sofosbuvir/DaclatasvirNumber of SARS-CoV-2 infections|Duration of symptoms|Maximum score on WHO Ordinal Scale|Time to onset of SARS-CoV-2 infection|Number of symptomatic SARS-CoV-2 infections|Number of asymptomatic SARS-CoV-2 infections|Peak score on modified Flu PROUniversity of Witwatersrand, South AfricaAll18 Years to 99 Years Â  (Adult, Older Adult)Phase 21950OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: PreventionEZ-SS-025December 8, 20202021-07-01 00:00:002021-07-01 00:00:00September 23, 2020December 16, 2020Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa|Sunnyside Office Park, Johannesburg, Gauteng, South Africahttps://ClinicalTrials.gov/show/NCT04561063 South Africa
1234NCT04463264Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)RecruitingNo Results AvailableCOVID-19Drug: Nitazoxanide|Drug: PlaceboEradication of SARS COV-2 from patients' respiratory tract secretions by treatment day 7th.|Comparative decrease of the viral load|Clinical improvement|Pneumonia patients meeting severity criteria.|Number of days with feverLaboratorios Roemmers S.A.I.C.F.All18 Years to 59 Years Â  (Adult)Phase 2|Phase 3135IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: TreatmentNTZ-COVID ARG1June 26, 2020November 15, 2020December 26, 2020July 9, 2020October 8, 2020Hospital Universitario Austral, Presidente Derqui, Buenos Aires, Argentina, Argentinahttps://ClinicalTrials.gov/show/NCT04463264 Argentina
1235NCT04793984Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 PatientsRecruitingNo Results AvailableCovid19Device: Carragelose|Device: NaClClinical status of subjects as expressed on the WHO-8-Category ordinal scale:|Cycle threshold of SARS-CoV-2 PCRÂ·|multiplex viral examination|supplemental oxygen requirement|modified 10 point BORG scaleMarinomed Biotech AG|Austian Research Promotion AgencyAll18 Years and older Â  (Adult, Older Adult)Not Applicable228Industry|OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentCOVID-19/TCP_20_05March 8, 2021June 30, 2021October 30, 2021March 11, 2021March 11, 2021Gesundheitsverbund, Klinik Floridsdorf, Vienna, Austriahttps://ClinicalTrials.gov/show/NCT04793984 Austria
1236NCT04576351The Norwegian Study of Nervous System Manifestations and Sequelae After COVID-19NeuroCovidRecruitingNo Results AvailableCovid19Other: ObservationRate of peripheral and central nervous affection|Rate of psychiatric disorders at 6-months follow-up|Rate of psychiatric disorders at 12-months follow-up|Neuropsychological function at 6-months follow up|Neuropsychological function at 12-months follow up and change in function from 6 to 12 months.|Rate of stroke at 6-months follow up|Rate of stroke at 12-months follow up|Rate of death at 6-months follow-up|Rate of death at 12-months follow-up|Rate of peripheral nervous affection assessed by clinical neurological examination and/or EMG/neurography at 6-months follow-up|Rate of peripheral nervous affection assessed by clinical neurological examination and/or EMG/neurography at 12-months follow-up|Rate of myopathy at 6-months follow-up|Rate of myopathy at 12-months follow-up|Rate of brain MRI pathology at 6-months follow-up|Rate of brain MRI pathology at 12-months follow-up|Levels of serum neurofilaments at 6-months follow-up|Levels of serum neurofilaments at 12-months follow-up|Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms at 6-months follow-up|Rate of post-COVID neurological, cognitive or neuropsychiatric manifestations in the treatment arms at 12-months follow-up|Duration of hospital and rehabilitation stayOslo University Hospital|University Hospital, Akershus|Haukeland University Hospital|Helse Stavanger HF|St. Olavs Hospital|University Hospital of North Norway|Vestre Viken Hospital Trust|Sykehuset Telemark|Sykehuset Innlandet HF|Ostfold Hospital Trust|The Hospital of Vestfold|Sorlandet Hospital HF|Nordlandssykehuset HF|MÃ¸re og Romsdal Hospital TrustAll18 Years and older Â  (Adult, Older Adult)150OtherObservationalObservational Model: Cohort|Time Perspective: Prospective152727September 1, 2020December 31, 2023December 31, 2023October 6, 2020March 3, 2021SÃ¸rlandet Hospital Trust, Arendal, Norway|Haukeland University Hospital, Bergen, Norway|Nordlandssykehuset, Bodo, Norway|Vestre Viken Hospital Trust Drammen, Drammen, Norway|Ã˜stfold Hospital Trust Kalnes, GrÃ¥lum, Norway|SÃ¸rlandet Hospital Trust, Kristiansand, Kristiansand, Norway|Innlandet Hospital Trust, Lillehammer, Norway|Akershus University Hospital, LÃ¸renskog, Norway|MÃ¸re og Romsdal Hospital Trust, Molde, Norway|Oslo University Hospital, Oslo, Norway|Ostfold Hospital Trust, Sarpsborg, Norway|Skien Hospital, Skien, Norway|Stavanger University Hospital, Stavanger, Norway|University Hospital of North Norway, TromsÃ¸, Norway|St. Olav Hospital, Trondheim, Norwayhttps://ClinicalTrials.gov/show/NCT04576351 Norway
1237NCT04431856CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for TreatmentCo-PARENTCompletedNo Results AvailableAnxiety|Depression|Traumatic Stress DisorderBehavioral: Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|Behavioral: SHGMeasure of Anxiety as assessed by the OASIS|Measure of Depression as assessed by the ODSIS|Measure of PTSD as assessed by the PCL-5|Measure of Parenting Overprotection/Overcontrol as assessed by the S-EMBU|Measure of Parenting Rejection as assessed by the S-EMBU|Measure of Parenting Emotional Warmth as assessed by the S-EMBU|Measure of Parent Accommodation for Child Anxiety as assessed by the FASAUniversity of MiamiAll18 Years and older Â  (Adult, Older Adult)Not Applicable80OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention20200484May 15, 2020November 17, 2020November 17, 2020June 16, 2020December 1, 2020University of Miami, Miami, Florida, United Stateshttps://ClinicalTrials.gov/show/NCT04431856 United States
1238NCT04643860Differential Leucocyte Count and Covid-19 DiagnosisNot yet recruitingNo Results AvailableSARS-CoV-2 Infection Covid19Diagnostic Test: Differential Leucocyte Count (CLDC) device and algorithmvalidation|test sensitivityNeuromed IRCCSAll18 Years and older Â  (Adult, Older Adult)1000OtherObservationalObservational Model: Cohort|Time Perspective: Cross-SectionalDEP_0420202020-12-01 00:00:002021-02-01 00:00:002021-05-01 00:00:00November 25, 2020November 30, 2020IRCCS INM Neuromed, Department of Epidemiology and Prevention, Pozzilli, IS, Italyhttps://ClinicalTrials.gov/show/NCT04643860 Italy
1239NCT04632615Sleep Behaviour in Athletes During Home Confinement Due to the Covid-19 OutbreakSleep&Covid19Active, not recruitingNo Results AvailableSleep|Athlete|Training|Exercise|Covid19|Isolation, SocialChange in Subjective sleep quality|Change in Subjective sleep quantity|Change in Training volumeIstituto Ortopedico GaleazziAll18 Years to 40 Years Â  (Adult)84OtherObservationalObservational Model: Cohort|Time Perspective: Cross-SectionalSleep&Covid19May 22, 2020March 31, 2021March 31, 2021November 17, 2020March 5, 2021IRCCS Istituto Ortopedico Galeazzi, Milan, Italyhttps://ClinicalTrials.gov/show/NCT04632615 Italy
1240NCT04584697Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMGâ„¢) in Outpatients With COVID-19WithdrawnNo Results AvailableCovid19Biological: COVI-AMG|Drug: PlaceboIncidence of adverse events by type, frequency, severity, and causality (safety)|Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety)|Incidence of serious adverse events by type, frequency, severity, and causality (safety)|Incidence of dose-limiting toxicities (safety)|Incidence of clinically meaningful laboratory abnormalities (safety)|Viral load as assessed using plasma and salivary samples at various timepoints|Time from onset of COVID-19 symptoms to treatment (Day 1)|Presence and levels of anti-drug antibodies directed to COVI-AMG|Cytokine levels post-treatment|AUC of COVI-AMG (PK)|Cmax of COVI-AMG (PK)|Tmax of COVI-AMG (PK)|tÂ½ of COVI-AMG (PK)Sorrento Therapeutics, Inc.All18 Years and older Â  (Adult, Older Adult)Phase 1|Phase 20IndustryInterventionalAllocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentAMG-COV-1022020-12-01 00:00:002021-04-01 00:00:002021-04-01 00:00:00October 14, 2020February 12, 2021https://ClinicalTrials.gov/show/NCT04584697
1241NCT04337918Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 InfectionNOCOVIDCompletedNo Results AvailableCorona Virus InfectionDrug: NORS (Nitric Oxide Releasing Solution)Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19|Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19|Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19|Prevention Study: Measure the tolerability of NORS treatments|Treatment Sub Study: Measure the virucidal effect of NORS Treatments|Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery|Treatment Sub Study: Determine the reduction in clinical symptoms|Treatment & Sub Study: Determine positive sero-conversion for SARS-CoV-2Sanotize Research and Development corp.|The Emmes Company, LLC|Keyrus Life ScienceAll19 Years and older Â  (Adult, Older Adult)Phase 2143Industry|OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: PreventionCOVID-CTP-01May 8, 2020January 31, 2021February 2, 2021April 8, 2020February 10, 2021BC Diabetes, Vancouver, British Columbia, Canada|LMC Manna, Pointe-Claire, Quebec, Canada|Diex Recherche QuÃ©bec, QuÃ©bec, Quebec, Canada|Diex Recherche Joliette, Saint-Charles-BorromÃ©e, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canadahttps://ClinicalTrials.gov/show/NCT04337918 Canada
1242NCT04715607COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal SpecimensRecruitingNo Results AvailableSARS-CoV Infection|Covid19|CoronavirusDiagnostic Test: Sequence of testing.SARS-CoV-2 detection rates for oropharyngeal swabs (OPS) compared with nasopharyngeal swabs and saliva collection.|SARS-CoV-2 RT-PCR cycle threshold (Ct) values|OPS, NPS and saliva test discomfort and likelihood to get retested|Ratio of mutations in SARS-CoV-2Rigshospitalet, Denmark|Hvidovre University Hospital|Region HovedstadenAll16 Years to 120 Years Â  (Child, Adult, Older Adult)Not Applicable22000OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic2021-01January 22, 2021May 5, 2021May 30, 2021January 20, 2021March 10, 2021Valby COVID-19 teststed, Copenhagen, Valby, Denmarkhttps://ClinicalTrials.gov/show/NCT04715607 Denmark
1243NCT04331600Chloroquine as Antiviral Treatment in Coronavirus Infection 2020CompletedNo Results AvailableCOVID-19Drug: Chloroquine phosphate|Other: TelemedicineCOVID-19-related hospitalization or all-cause death|Decrease in COVID-19 symptoms|Development of pneumonia|Development of coronavirus infection-related complicationsWroclaw Medical UniversityAll18 Years and older Â  (Adult, Older Adult)Phase 416OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentWROCLAW CORONA STUDY 2020April 16, 2020December 17, 2020December 17, 2020April 2, 2020February 11, 2021Uniwersytecki Szpital Kliniczny, WrocÅ‚aw, Ul. Borowska 213, Poland|Wielospecjalistyczny Szpital Miejski, PoznaÅ„, Ul. Szwajcarska 3, Polandhttps://ClinicalTrials.gov/show/NCT04331600 Poland
1244NCT04559100Long-term Characterization of Patients With Severe/Critical Infection by COVID-19 VirusEnrolling by invitationNo Results AvailableCovid19Radiation: chest radiography|Radiation: thoracic computed tomography scan|Diagnostic Test: spirometry|Diagnostic Test: Diffusing capacity of carbon monoxide|Diagnostic Test: 6 minute walk test|Diagnostic Test: saint george respiratory questionnaireLung function|Radiological alterations|Quality of life alterationsFundacion Clinica Valle del LiliAll18 Years to 100 Years Â  (Adult, Older Adult)112OtherObservationalObservational Model: Other|Time Perspective: Prospective1631 COVID-LFTNovember 15, 2020October 1, 2021October 1, 2021September 22, 2020February 11, 2021Fundacion Valle del Lili, Cali, Valle Del Cauca, Colombiahttps://ClinicalTrials.gov/show/NCT04559100 Colombia
1245NCT04547127A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)CompletedNo Results AvailableCOVID-19Biological: Convalescent anti-SARS-CoV-2 MBT Plasma|Drug: Standard Medical TreatmentAll-Cause Mortality Rate|Change from Baseline in National Early Warning Score (NEWS)|Time to Clinical Response as Assessed by NEWS â‰¤ 2 Maintained for 24 hours|Time to Hospital Discharge|Time to ICU Discharge|Duration of All Oxygen Use|Duration of Mechanical Ventilation|Absolute Value Change from Baseline in Ordinal Scale|Mean Change from Baseline in Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-Point Ordinal ScaleInstituto Grifols, S.A.|Grifols Therapeutics LLCAll18 Years and older Â  (Adult, Older Adult)Phase 2200IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentGC2003|2020-001299-14April 29, 2020February 4, 2021February 4, 2021September 14, 2020March 3, 2021Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|FundaciÃ³n Jimenez Diaz, Madrid, Spain|Hospital ClÃ­nico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Complejo Hospitalario Universitario de Canarias, Santa Cruz De Tenerife, Spain|Hospital ClÃ­nico Universitario de Santiago -CHUS, Santiago, Spain|Hospital Universitari Joan XXIII, Tarragona, Spainhttps://ClinicalTrials.gov/show/NCT04547127 Spain
1246NCT04582266PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the USRecruitingNo Results AvailableCOVID-19Drug: RemdesivirPK Outcome: Area under the plasma concentration-time curve (AUC) of RDV|PK Outcome: Half-life (t1/2) of RDV|PK Outcome: Trough concentration (Ctrough) of GS-441524|Safety Outcome: Maternal renal adverse event (AE) of any grade|Safety Outcome: Maternal hepatic AE of any grade|Safety Outcome: Maternal hematologic AE of any grade|Safety Outcome: Maternal Grade 3 or higher AE|Safety Outcome: Serious AE|Safety Outcome: Maternal Grade 3 or higher AE assessed as related to RDV by the Clinical Management Committee (CMC)|Safety Outcome: Pregnancy loss|Safety Outcome: Congenital anomalies|Safety Outcome: Preterm birth, defined as < 37 weeks|Safety Outcome: Preterm birth, defined as < 34 weeks|Safety Outcome: Small for gestational age, defined as < 10th percentile|Safety Outcome: Newborn birth weight|Safety Outcome: Newborn length|Safety Outcome: Newborn head circumference|PK Outcome: AUC of RDV|PK Outcome: t1/2 of RDV|PK Outcome: Ctrough of GS-441524|Safety Outcome: Renal AE of any grade|Safety Outcome: Hepatic AE of any grade|Safety Outcome: Hematologic AE of any grade|Safety Outcome: Grade 3 or higher AE|Safety Outcome: Grade 3 or higher AE assessed as related to RDV by the CMCNational Institute of Allergy and Infectious Diseases (NIAID)FemaleChild, Adult, Older Adult40NIHObservationalObservational Model: Cohort|Time Perspective: ProspectiveIMPAACT 2032|DAIDS Study ID 38746February 12, 2021January 15, 2022January 15, 2022October 9, 2020March 25, 2021USC/Los Angeles County Medical Center NICHD CRS (5048), Los Angeles, California, United States|David Geffen School of Medicine at UCLA (CRS 5112), Los Angeles, California, United States|University California, San Diego (CRS 4601), San Diego, California, United States|Childrens Hospital (U. Colorado, Denver) NICHD CRS (5052), Denver, Colorado, United States|University of Florida (5051), Jacksonville, Florida, United States|Univ of Miami Pediatric/Perinatal HIV/AIDS (4201), Miami, Florida, United States|Emory University School of Medicine (CRS 5030), Atlanta, Georgia, United States|Ann & Robert H Lurie Children's Hospital of Chicago (4001), Chicago, Illinois, United States|Rush University Cook County Hospital NICHD CRS (5083), Chicago, Illinois, United States|Johns Hopkins University NICHD CRS (5092), Baltimore, Maryland, United States|Boston Medical Center Ped. HIV Program NICHD CRS (5011), Boston, Massachusetts, United States|Bronx-Lebanon Hospital Center (CRS 5114), Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS (5013), Bronx, New York, United States|Stony Brook University Medical Center (CRS 5040), Stony Brook, New York, United States|St. Jude Childrens Research Hosp, Memphis (6501), Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|University of Puerto Rico Pediatric HIV/AIDS CRS (6601), San Juan, Puerto Ricohttps://ClinicalTrials.gov/show/NCT04582266 Puerto Rico
1247NCT04552340Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV.RecruitingNo Results AvailableCovid19Other: Patient with SAR-CoV-2 infectionMortality predictors in patients with Respiratory Failure who require oxygen therapy in the Intensive Care Unit or ventilatory support.|Molecular profile of cell populations present in the BAL at early timepoint during SARS-CoV2 infection to predict severity of disease progression.|Type of possible complications such as AKI (Acute Kidney Injury) , infection, shock|SARS-CoV2 mechanisms of infection in alveolar macrophages|SARS-CoV2 genotypes in a cohort of patients representative of the Lombardy population|Number of successful respiratory weaningIstituto Clinico HumanitasAll18 Years and older Â  (Adult, Older Adult)1500OtherObservationalObservational Model: Cohort|Time Perspective: Prospective2485March 16, 20202023-03-01 00:00:002023-07-01 00:00:00September 17, 2020September 17, 2020Humanitas Research Hospital, Rozzano, Milan, Italyhttps://ClinicalTrials.gov/show/NCT04552340 Italy
1248NCT04324489DAS181 for Severe COVID-19: Compassionate UseCompletedNo Results AvailableCOVID-19Drug: DAS181Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|DeathRenmin Hospital of Wuhan University|Ansun Biopharma, Inc.All18 Years to 70 Years Â  (Adult, Older Adult)Not Applicable4Other|IndustryInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentDAS181-SARS-CoV-2March 6, 2020April 16, 2020April 30, 2020March 27, 2020May 5, 2020Renmin Hospital of Wuhan University, Wuhan, Hubei, Chinahttps://ClinicalTrials.gov/show/NCT04324489 China
1249NCT04691947Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VACERUCOV-VACRecruitingNo Results AvailableCOVID-19 VaccineBiological: ERUCOV-VAC|Other: Placebo VaccineTo assess the safety and tolerability of the COVID-19 vaccine|Serum IgG antibody Levels|Neutralizing Antibodies Levels|TNF-alpha Levels|Interferon Levels|Interleukine LevelsHealth Institutes of Turkey|TC Erciyes UniversityAll18 Years to 55 Years Â  (Adult)Phase 144OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: PreventionIDEAL00420-EU01-PK537-1November 5, 2020March 1, 2021March 15, 2022December 31, 2020January 5, 2021Erciyes University Hakan Ã‡etinsaya Iyi Klinik Uygulama ve Arastirma Merkezi, IKUM (Center for GCP), Kayseri, Turkeyhttps://ClinicalTrials.gov/show/NCT04691947 Turkey
1250NCT04834739Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19RecruitingNo Results AvailableCovid19|Functional CapacityOther: 6 minute walk test|Other: 1 minute Sit to Stand Test|Other: Fatigue Severity Scale|Other: Medical Research Council (MRC) dyspnea scale|Other: SF-12|Other: Beck Depression Inventory|Other: Beck Anxiety Inventory|Other: 5 times sit to stand test|Other: 6 point Likert Scale1 minute sit to stand test|5 times sit to stand test|6 minute walk test|Medical Research Council (MRC) dyspnea scale|6 point Likert Scale|Fatigue Severity Scale|Beck Depression Inventory|Beck Anxiety Scale|Short form 12Gaziosmanpasa Research and Education HospitalAll18 Years and older Â  (Adult, Older Adult)Not Applicable60OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research208January 4, 2021March 28, 2021April 30, 2021April 8, 2021April 8, 2021Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey|Gaziosmanpasa Training and Research Hospital, Istanbul, Turkeyhttps://ClinicalTrials.gov/show/NCT04834739 Turkey
1251NCT04473053Rapid Experimental Medicine for COVID-19DEFINERecruitingNo Results AvailableCOVID-19Drug: Nafamostat Mesilate|Drug: TD139|Other: Standard careThe safety of the candidate therapies in COVID-19 patients by measuring physiological changes in the circulatory and respiratory system.|The safety of the candidate therapies in COVID-19 patients by recording the number of treatment related adverse events.|Measuring the PK of the proposed trial treatments in COVID-19 patients.|Measure a change in the expression of key coagulation biomarkers in the blood of COVID-19 patients during and after treatment period.|Measure a change in the expression of key cytokines in the blood of COVID-19 patients during and after treatment period.|To evaluate the improvement or deteroriation of patients in each treatment arm.|To evaluate the number of oxygen-free days.|To evaluate incidence of any form of new ventilation use.|To evaluate ventilator-free days|Change in the ratio of the oxygen saturation to fraction of inspired oxygen concentration (SpO2/FiO2)|To evaluate SARS-CoV-2 viral load.|To evaluate time to discharge|To evaluate the use of renal dialysis or haemofiltration for each treatment arm.University of Edinburgh|University of Oxford|Latus TherapeuticsAll16 Years and older Â  (Child, Adult, Older Adult)Phase 2|Phase 360OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: TreatmentAC20063July 3, 2020July 3, 2021December 3, 2021July 16, 2020August 21, 2020NHS Lothian, Edinburgh, United Kingdomhttps://ClinicalTrials.gov/show/NCT04473053 United Kingdom
1252NCT04429724Health Professional Exposure Assessment to Covid-19SERODRONActive, not recruitingNo Results AvailableCOVID-19Diagnostic Test: Diagnostic test Covid-19Number of contaminated personnel|Number of symptomatic staff by occupational category and service|Number of contaminated personnel with effective protection|comparison of socio-demographic characteristics and co-morbidities between patients losing their antibodies and those maintaining their antibodiesTourcoing HospitalAll18 Years and older Â  (Adult, Older Adult)Not Applicable2129OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: PreventionRIPH_2020_8July 6, 20202021-04-01 00:00:002021-12-01 00:00:00June 12, 2020January 26, 2021CH Roubaix, Roubaix, France|CH Tourcoing, Tourcoing, France|CH Wasquehal, Wasquehal, France|CH Wattrelos, Wattrelos, Francehttps://ClinicalTrials.gov/show/NCT04429724 France
1253NCT04320017Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19JOCOVIDRecruitingNo Results AvailableCOVID-19|Myocardial Injury|MyocarditisDiagnostic Test: Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine careIncidence of acute myocardial events in COVID-19 population at baseline and during hospital stay|Description of cardiovascular outcomes in the cohort|Prognosis role of baseline cardio-vascular caracteristics on patients survival|Prediction of cardio-vascular events with baseline characteristics|Characterization of inflammation on cardio-vascular outcomes|Prognosis role of baseline clinico-biological caracteristics on patients transfer to ICU and survivalGroupe Hospitalier Pitie-SalpetriereAll16 Years and older Â  (Child, Adult, Older Adult)500OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveCIC1421-20-05March 20, 2020May 20, 2020May 20, 2020March 24, 2020April 22, 2020Clinical Investigation Center PitiÃ©-SalpÃªtriÃ¨re, Paris, Francehttps://ClinicalTrials.gov/show/NCT04320017 France
1254NCT04498286COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis PatientsCOMS-19RecruitingNo Results AvailableMultiple SclerosisDiagnostic Test: Testing of SARS-CoV-2 antibodiesThe correlation of COVID-19 disease course with MS immunomodulatory treatmentZoÃ© van Kempen|VU University Medical CenterAll18 Years and older Â  (Adult, Older Adult)800OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveNL74243.029.20August 6, 2020November 1, 2021December 1, 2021August 4, 2020August 4, 2020VU medical center, Amsterdam, Netherlandshttps://ClinicalTrials.gov/show/NCT04498286 Netherlands
1255NCT04558437"COVID-Impact ""Psychological IMPACT of Covid-19 on AP-HP Staff"""Covid-ImpactRecruitingNo Results AvailablePost Traumatic Stress Disorder (PTSD)|Anxiety|Depression|Epidemic Disease|COVID19Other: QuestionnairePrevalence of PTSD among APHP staff during the COVID-19 epidemic and at a distance (inclusion, 3 months or 6 months).|Prevalence of Anxiety Disorder among APHP staff during the COVID-19 epidemic and at a distance (inclusion, 3 months and 6 months).|Prevalence of Depressive Disorder among APHP staff during the COVID-19 epidemic and at a distance (inclusion, M3 and M6).Assistance Publique - HÃ´pitaux de ParisAll18 Years and older Â  (Adult, Older Adult)20000OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveAPHP200555June 12, 2020December 31, 2020December 31, 2020September 22, 2020September 22, 2020Assistance Publique - HÃ´pitaux de Paris, Paris, Ile De France, Francehttps://ClinicalTrials.gov/show/NCT04558437 France
1256NCT04544150Gastrointestinal Manifestations Among Patients With COVID19CompletedNo Results AvailableCovid19frequency of GIT symptoms among patients with COVID-19 infectionAssiut UniversityAllChild, Adult, Older Adult220OtherObservationalObservational Model: Case-Only|Time Perspective: ProspectiveCOVID19 and GUTJune 1, 2020September 1, 2020September 1, 2020September 10, 2020September 10, 2020Ahmed, Al MinyÄ, Alminya, Egypthttps://ClinicalTrials.gov/show/NCT04544150 Egypt
1257NCT04364984ARB, ACEi, DRi in COVID-19BIRCOVRecruitingNo Results AvailableHypertension|COVID-19Drug: Angiotensin converting enzyme inhibitorBP (hypertensive efficacy)|COVID-19 course|Cough in COVID-19 course|Throat pain in COVID-19 course|Diarrhea inf COVID-19 course|Need to apply to hospital in COVID-19 courseMedical Practice Prof D. IvanovAll18 Years to 90 Years Â  (Adult, Older Adult)10OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveCOVID20April 1, 2020May 1, 2021August 1, 2021April 28, 2020March 19, 2021Medical Practice Prof D.Ivanov, Kiev, Please Select, Ukrainehttps://ClinicalTrials.gov/show/NCT04364984 Ukraine
1258NCT04707534Dexamethasone for COVID-19RecruitingNo Results AvailableCovid19Drug: DexamethasoneWorld Health Organization ordinal scale at day 28|Ventilator-free days|28-day mortalityUniversity of OklahomaAll18 Years and older Â  (Adult, Older Adult)Phase 4300OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment12927January 21, 2021May 21, 2021June 21, 2021January 13, 2021January 28, 2021University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United Stateshttps://ClinicalTrials.gov/show/NCT04707534 United States
1259NCT04813562Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)RecruitingNo Results AvailableCOVID-19Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|Biological: a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56|Biological: a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56|Biological: a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56|Biological: a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (eucivirus neutralization assays)|The incidence of adverse reaction (AR)|The incidence of adverse events (AE)|The incidence of severe adverse events (SAE)|The Geometric mean titer (GMT) of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization assays)|The Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization assays)|The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (pseudovirus neutralization assays)|The positive conversion rate of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody|The GMT of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody|The GMI of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibodyJiangsu Province Centers for Disease Control and Prevention|Academy of Military Medical Sciencesï¼ŒAcademy of Military Sciencesï¼ŒPLA ZHONGYIANKE Biotech Co, Ltd. LIAONINGMAOKANGYUAN Biotech Co, LtdAll18 Years to 85 Years Â  (Adult, Older Adult)Phase 2480OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: PreventionJSVCT097March 23, 2021July 30, 2021June 30, 2022March 24, 2021March 24, 2021Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, Chinahttps://ClinicalTrials.gov/show/NCT04813562 China
1260NCT04433910A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19CAPSIDCompletedNo Results AvailableCOVID-19Drug: Convalesscent PlasmaComposite endpoint of survival and no longer fulfilling criteria of severe COVID-19.|Time to clinical improvement|Frequency and severity of adverse events by CTCAE v5.0, (Key secondary endpoint)|Case fatality rate|Length of hospital stay Length of hospital stay (if applicable)|Length of stay in ICU|Duration of ventilation support / ECMO|Time until negative SARS-CoV-2 PCR (nasopharyngeal sample)|Predictive value of comorbidities|Predictive value of coagulation markers|Predictive value of inflamation|Percentage of former COVID-19 patients willing to donate qualifying for plasma donation.|Amount of Plasma Units that could be collected for the clinical trial|Titer of anti-SARS-CoV-2 in transfused plasma units|Impact of donor characteristics on anti-SARS-CoV-2 humoral response|Course of anti-SARS-CoV-2 titer in both patient groups at different time points related to transfusion of convalescent plasma|Correlation of anti-SARS-CoV-2 titer in transfused plasma units and primary and key secondary outcomes.|Effect of timing of plasma transfusionsDeutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-HessenAll18 Years to 75 Years Â  (Adult, Older Adult)Phase 2106OtherInterventionalAllocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentCAPSID2020-DRK-BSD|2020-001310-38August 30, 2020January 21, 2021February 22, 2021June 16, 2020March 17, 2021University Hospital Ulm, Ulm, Baden-WÃ¼rttmberg, Germany|University Hopsital Frankfurt, Frankfurt, Hessia, Germany|Saarland University Hospital, Homburg, Saarland, Germany|University Hospital Berlin, Charite, Berlin, Germany|Universitiy Hospital Dresden, Dresden, Germany|University DÃ¼sseldorf, DÃ¼sseldorf, Germany|University Hospital Freiburg, Freiburg, Germany|University Hospital GieÃŸen, GieÃŸen, Germany|University Hopsital Greifswald, Greifswald, Germany|StÃ¤dtisches Klinikum Karslruhe, Karlsruhe, Germany|Universtity Hospital Schleswig-Holstein, Kiel, Germany|Universtity Hospital Schleswig-Holstein, LÃ¼beck, Germany|University Hospital Mannheim, Mannheim, Germany|University Hospital Marburg, Marburg, Germany|Klinikum Stuttgart, Stuttgart, Germany|University Hospital TÃ¼bingen, TÃ¼bingen, Germanyhttps://ClinicalTrials.gov/show/NCT04433910 Germany
1261NCT04389710Convalescent Plasma for the Treatment of COVID-19RecruitingNo Results AvailableCOVID-19Drug: Convalescent PlasmaNumber of patients who receive COVID-19 convalescent plasma transfusions in acute care facilities infected with SARS-CoV-2|Number and type of adverse events associated with COVID-19 convalescent plasma in patients with COVID-19|Length of hospital stay|Length of Intensive Care Unit stay|Length of intubation|Survival to discharge|Changes in complete blood count in patients after receiving convalescent plasma|Abnormal changes in Basic Metabolic Panel (BMP) measures in patients after receiving convalescent plasma|Changes in C-Reactive Protein (CRP) in patients after receiving convalescent plasma|Changes in d-dimer in patients after receiving convalescent plasma|Changes in fibrinogen in patients after receiving convalescent plasma|Changes in prothrombin time (PT) in patients after receiving convalescent plasma|Changes in partial thromboplastin time (PTT) in patients after receiving convalescent plasmaThomas Jefferson UniversityAll18 Years and older Â  (Adult, Older Adult)Phase 2100OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment20D.379April 15, 2020April 14, 2021April 14, 2021May 15, 2020June 25, 2020Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United Stateshttps://ClinicalTrials.gov/show/NCT04389710 United States
1262NCT04362267Longitudinal Study of Covid-19 Infection Among HCW in a French University HospitalPRECOVIARecruitingNo Results AvailableSars-CoV2Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testingthe incidence of SARS- Cov2 infection Heath Care Worker diagnosed by the positivity of SARS-Cov2 RT-PCT and serological testing|Occupational exposures associated with the SARS-Cov2 infection|Environmental exposures associated with the SARS-Cov2 infectionUniversity Hospital, Lille|Fondation SantÃ© RoquetteAll18 Years and older Â  (Adult, Older Adult)150OtherObservationalObservational Model: Cohort|Time Perspective: Cross-Sectional2020_34|2020-A00950-39June 15, 20202020-09-01 00:00:002020-09-01 00:00:00April 24, 2020August 6, 2020HÃ´pital Claude Huriez, CHU, Lille, Francehttps://ClinicalTrials.gov/show/NCT04362267 France
1263NCT04587219"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older"Active, not recruitingNo Results AvailableCoronavirus InfectionBiological: Gam-COVID-VacChanging of antibody levels against the SARS-CoV-2 glycoprotein S in 42 days|Number of Participants With Adverse Events|Changing of of virus neutralizing antibody titer|Changing of antigen-specific cellular immunity levelGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian FederationAll60 Years to 111 Years Â  (Adult, Older Adult)Phase 2110OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention05-Gam-COVID-Vac-2020October 22, 2020March 30, 2021April 30, 2021October 14, 2020January 22, 2021"Federal state budgetary institution ""Central clinical hospital with polyclinic"" Of the office Of the President of the Russian Federation, Moscow, Russian Federation"https://ClinicalTrials.gov/show/NCT04587219 Russian Federation
1264NCT04480411Use of Technology and Telemedicine to Improve Quality of Care in COVID 19 PatientsNot yet recruitingNo Results AvailableDiagnoses Disease|Covid19Behavioral: Doctorgram Patient KitPatient provider experience survey score|Provider experience survey score|Use of personal protective improvement|Number of in-patient encounters with COVID patients as a measure of provider exposure to high risk illnessStanford UniversityAll18 Years and older Â  (Adult, Older Adult)Not Applicable50OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other564722021-03-01 00:00:002022-02-01 00:00:002022-02-01 00:00:00July 21, 2020March 1, 2021Stanford University, Stanford, California, United Stateshttps://ClinicalTrials.gov/show/NCT04480411 United States
1265NCT04581746Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)coVIHd-19RecruitingNo Results AvailableVirus-HIV|Covid19Other: questionnairePrevalence of SARS CoV2 infection in PVVIH in Hauts de France|Determine the incidence rate of COVID 19 among PVVIH antiretroviral treatment|Determine the incidence rate of COVID 19 among PVVIH discontinuing antiretroviral treatment|Determine the incidence rate of COVID 19 among PVVIH who stopped all follow-up|Psychological consequences of this epidemic among PVVIH : HAD|Psychological consequences of this epidemic among PVVIH : PROQOL-HIVTourcoing HospitalAll18 Years and older Â  (Adult, Older Adult)Not Applicable1800OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: PreventionRIPH_2020_7November 25, 20202021-12-01 00:00:002021-12-01 00:00:00October 9, 2020January 26, 2021CHU Amiens Picardie, Amiens, France|CH Lens, Lens, France|CH Tourcoing, Tourcoing, Francehttps://ClinicalTrials.gov/show/NCT04581746 France
1266NCT04379336BCG Vaccination for Healthcare Workers in COVID-19 PandemicRecruitingNo Results AvailableCOVID-19|Sars-CoV2Biological: Bacille Calmette-GuÃ©rin (BCG)|Other: Placebo ComparatorIncidence of HCWs hospitalized due to COVID-19 per arm|Incidence of SARS-CoV-2 infection per arm|Incidence of upper respiratory tract infections per arm|Days of unplanned absenteeism due to COVID-19 or any reason per arm|Incidence of hospitalization for any reason per arm|Incidence of intensive care unit admission per arm|Incidence of death per arm|Prevalence of latent TB infection|Incidence of active TB per arm|Compare the effect of latent TB on morbidity and mortality due to COVID-19 per arm|Incidence of treatment related adverse eventsTASK Applied ScienceAll18 Years and older Â  (Adult, Older Adult)Phase 3500OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionTASK-008 BCG-CORONAMay 4, 2020April 28, 2021April 28, 2021May 7, 2020May 7, 2020TASK Foundation, Cape Town, Western Cape, South Africahttps://ClinicalTrials.gov/show/NCT04379336 South Africa
1267NCT04716985Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory CareHYDRO COVIDRecruitingNo Results AvailableSARS-CoV-2|Covid19|AMBULATORY CAREDietary Supplement: MOLECULAR HYDROGEN|Dietary Supplement: PLACEBO MAGNESIUMChange in the incidence rate of the onset of clinical worsening|Assessment of tolerance|Assessment of compliance|Assessment of medium-long term dyspnea symptoms|Assessment of medium-long term fatigue symptoms|Assessment of oximetry symptoms|Assessment of quality of life|Assesment of sleep quality|Assessment of care consumption|Assessment of blind treatment|Assessment of COVID-19 contact cases|Assessment of risk factors|Analysis of older patients|Assessment of painAGIR Ã  Dom|Laboratoire TIMC-IMAG|DrinkHRW, British Columbia, CanadaAll60 Years and older Â  (Adult, Older Adult)Not Applicable450OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention2020-A03137-32January 22, 2021July 22, 2021December 22, 2022January 20, 2021January 26, 2021Timc-Imag (Umr5525 Uga-Cnrs), Grenoble, Francehttps://ClinicalTrials.gov/show/NCT04716985 France
1268NCT04542213Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19Covid19DPP4iCompletedNo Results AvailableHyperglycemia|Covid19Drug: Linagliptin tablet|Drug: InsulinGlucose levels|Number of patients who achieve metabolic control|Number of patients who die or need mechanical ventilation|C reactive protein levelsHospital Regional de Alta Especialidad del BajioAll18 Years to 75 Years Â  (Adult, Older Adult)Phase 370OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentCEI-22-2020August 1, 2020February 28, 2021February 28, 2021September 9, 2020March 23, 2021Hospital Regional de Alta Especialidad del BajÃ¬o, LeÃ²n, Guanajuato, Mexico"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT04542213/Prot_SAP_000.pdf"https://ClinicalTrials.gov/show/NCT04542213 Mexico
1269NCT04689399Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR TestCompletedNo Results AvailableCovid19|Rapid Antigen Test|SARS-CoV-2Diagnostic Test: Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.Sensitivity and specificity of the rapid antigen test of COVID-19|Economic analyses|PCR analysis on nasopharyngeal swabsRigshospitalet, Denmark|Testcenter Danmark, Statens Serum Institut|Copenhagen Emergency Medical ServicesAll18 Years and older Â  (Adult, Older Adult)Not Applicable4697OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: DiagnosticCOVID-19December 26, 2020March 25, 2021March 25, 2021December 30, 2020March 30, 2021Christian von Buchwald, MD, DMSc, Professor, Copenhagen, Denmarkhttps://ClinicalTrials.gov/show/NCT04689399 Denmark
1270NCT04780594Impact of the COVID-19 Pandemic on the Surgical Activity of Bellvitge University HospitalCompletedNo Results AvailableCovid19|Surgery--Complications|Nosocomial InfectionProcedure: The study evaluates all surgical patients operated, both elective scheduled and emergent casesRegister the post-surgical complications|Register the rate of surgical reintervention|Register the ICU admission|Register the Hospital stay|Register the MortalityHospital Universitari de BellvitgeAll18 Years and older Â  (Adult, Older Adult)2530OtherObservationalObservational Model: Case-Crossover|Time Perspective: RetrospectiveCOVID19 surgical impactFebruary 13, 2020May 15, 2020December 9, 2020March 3, 2021March 3, 2021Marta Caballero, Hospitalet de Llobregat, Barcelona, Spain"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04780594/Prot_SAP_000.pdf"https://ClinicalTrials.gov/show/NCT04780594 Spain
1271NCT04844541Prophylaxis and Treatment of COVID-19PROTECT-APTNot yet recruitingNo Results AvailableCOVID-19Time-weighted average change in symptom score|Number of days with symptoms|Proportion of SARS-CoV-2 infected adults seeking non-scheduled care for COVID-19|Time to clearance of SARS-CoV-2 in upper respiratory specimens|Rate of change from the maximal viral load|Proportion of laboratory confirmed infections in SARS-CoV-2 uninfected adult contacts|Time-weighted average change from baseline viral load in SARS-CoV-2 uninfected contacts who become infected|Change in modified ordinal outcome scale|Change in IgM, IgG and neutralizing antibodies from baselineHenry M. Jackson Foundation for the Advancement of Military Medicine|Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)All18 Years and older Â  (Adult, Older Adult)500OtherObservationalObservational Model: Cohort|Time Perspective: ProspectivePC022021-04-01 00:00:002022-09-01 00:00:002022-12-01 00:00:00April 14, 2021April 14, 2021Johns Hopkins University, Baltimore, Maryland, United States|Duke Global Health Institute, Durham, North Carolina, United Stateshttps://ClinicalTrials.gov/show/NCT04844541 United States
1272NCT04469179Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19Active, not recruitingNo Results AvailableCOVID-19|SARS-CoV2Biological: SAB-185|Other: Normal SalineNumber of Participants Having Adverse Events|Number of Participants Having Transfusion-Related Adverse Events|Assesment of the PD of SAB-185 administered intravenously|Immune response elicited by SAB-185|Concentration of subject anti-SAB-185 antibodies elicited by SAB-185|Incidence of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens|Level of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimensSAb Biotherapeutics, Inc.|Biomedical Advanced Research and Development Authority|Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)All18 Years to 60 Years Â  (Adult)Phase 121Industry|U.S. Fed|OtherInterventionalAllocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentSAB-185-102August 20, 20202021-03-01 00:00:002021-04-01 00:00:00July 13, 2020March 4, 2021Quantum Clinical Trials, Miami Beach, Florida, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Sanford Health, Sioux Falls, South Dakota, United Stateshttps://ClinicalTrials.gov/show/NCT04469179 United States
1273NCT04828148Incidence of Infection and Mortality by COVID-19 in SpecialistsRecruitingNo Results AvailableCovid19|Health Care Associated Infection|Infection, Coronavirus|DeathBehavioral: SurveyIncidence of mortality in physicians due to COVID-19|Incidence of infection in physicians due to COVID-19|PhysicianÂ´s Risk factors of contagion such as age, gender, medical degree, and comorbiditiesInstituto Mexicano del Seguro SocialAll18 Years and older Â  (Adult, Older Adult)400OtherObservationalObservational Model: Cohort|Time Perspective: Cross-SectionalMortality PhysiciansMarch 1, 2021May 30, 2021June 1, 2021April 1, 2021April 5, 2021Centro MÃ©dico Nacional de Occidente, Guadalajara, Jalisco, Mexicohttps://ClinicalTrials.gov/show/NCT04828148 Mexico
1274NCT04485130DISulfiram for COvid-19 (DISCO) TrialDISCONot yet recruitingNo Results AvailableCovid19Drug: Disulfiram|Drug: PlaceboImmunologic impact of 5 days of disulfiram, as measured by the fold-change in plasma levels of pro-inflammatory cytokines (e.g, interleukin 6, interleukin 1-beta, etc.).|Virologic impact of 5 days of disulfiram, as measured by the fold-change in copies of SARS-CoV-2 virus per million cells between Baseline and Day 31.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Change in COVID-19 symptom severity score as assessed by a 5-point adapted somatic symptom severity score (SSS-8)University of California, San FranciscoAll18 Years and older Â  (Adult, Older Adult)Phase 260OtherInterventionalAllocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentDSF151837April 15, 2021October 30, 2021March 15, 2022July 24, 2020March 17, 2021University of California San Francisco, Fresno, Fresno, California, United States|San Francisco General Hospital, San Francisco, California, United Stateshttps://ClinicalTrials.gov/show/NCT04485130 United States
1275NCT04357574Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19CORONA-SHIELDEnrolling by invitationNo Results AvailableCOVID-19|CancerOther: TelehealthRadiation Oncology providers perception of of telehealth for on treatment patients in lieu of in person on treatment visits during COVID-19|Number of missed telehealth clinical evaluation visits during COVID-19|Number of unplanned emergency department visits or hospital admissions during COVID-19|Number of acute care visits with listed reason as anemia, nutrition (including dehydration), diarrhea, emesis, infectious (including fever, pneumonia, and sepsis), nausea, neutropenia, pain category during COVID-19Duke UniversityAll18 Years and older Â  (Adult, Older Adult)1000OtherObservationalObservational Model: Other|Time Perspective: ProspectivePro00105266April 14, 20202021-04-01 00:00:002021-04-01 00:00:00April 22, 2020April 2, 2021Duke Cancer Center, Durham, North Carolina, United Stateshttps://ClinicalTrials.gov/show/NCT04357574 United States
1276NCT04581161Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 PatientsRecruitingNo Results AvailableAcute Respiratory Failure|Covid19Device: Life2000Â® VentilatorLife2000Â® Compared to HFNC (AIRVO)|PEEP levelHill-RomAll18 Years and older Â  (Adult, Older Adult)Not Applicable10IndustryInterventionalAllocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentCR-RR-2020-004August 28, 20202020-10-01 00:00:002020-10-01 00:00:00October 9, 2020October 9, 2020Park Nicolette, Bloomington, Minnesota, United Stateshttps://ClinicalTrials.gov/show/NCT04581161 United States
1277NCT04600440Convalescent Plasma in the Treatment of Covid-19COP20RecruitingNo Results AvailableCovid-19|Respiratory InsufficiencyBiological: Convalescent plasmaNumber of days in need of oxygen|Number of days before discharge from hospital|Mortality within 3 months|Number of days before need of assisted ventilationSkane University HospitalAll18 Years and older Â  (Adult, Older Adult)Not Applicable100OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentCovid convalescent plasmaApril 25, 2020December 31, 2021February 28, 2022October 23, 2020October 23, 2020SkÃ¥ne University Hospital, Lund, Swedenhttps://ClinicalTrials.gov/show/NCT04600440 Sweden
1278NCT04715360Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma TherapyRecruitingNo Results AvailableCovid19|Sars-CoV-2 Infection|ARDS, Human|Severe covid19Combination Product: autologous activated platelet-rich plasma|Drug: AviganEffect of aaPRP on pro-inflammatory cytokines plasma level (IL-6, IL-1B, TNFa, IFN gamma, MCP-1) before and after intervention compared to control.|to evaluate the change of Effect of aaPRP on anti-inflammatory cytokines plasma level (IL-1RA, IL-4, IL-10) before and after intervention compared to control.|Effect of aaPRP on overall adverse event related to the treatment.|Effect of aaPRP on CRP level before and after intervention compared to control.|Effect of aaPRP on Thorax X-ray image pre and post intervention between control and aaPRP-treated group|Effect of aaPRP on duration of hospitality of patient compared to controlHayandra Peduli Foundation|Koja Regional Public HospitalAll18 Years to 65 Years Â  (Adult, Older Adult)Phase 1|Phase 230OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment20-12-1526December 29, 2020November 29, 2021December 27, 2021January 20, 2021January 20, 2021Koja Regional Public Hospital, Jakarta, DKI Jakarta, Indonesiahttps://ClinicalTrials.gov/show/NCT04715360 Indonesia
1279NCT04608266CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult PatientsCAMOVIDRecruitingNo Results AvailableCovid19Drug: Camostat Mesylate|Drug: PlaceboHospitalization for COVID-19 deterioration or death without hospitalization|Adverse events|Serious adverse events|Investigational medication discontinuation|Hospitalization for COVID-19 deterioration or death without hospitalization, evaluated by independent adjudication comittee|Clinical improvement using the Word Health Organization (WHO) COVID-19 scale|Need for intensive care|Duration of hospitalization|Need for invasive mechanical ventilation for severe COVID-19|Need for oxygen therapy for COVID-19|Overall survival|Duration of symptoms|SARS-CoV-2 virological assessment|SARS-CoV-2 serological assessment|Peripheral blood lymphocyte phenotyping|Acute kidney failure|Renal function|Concentration of urea in blood|Concentration of potassium in blood|Liver function|Liver function (2)Assistance Publique - HÃ´pitaux de ParisAll18 Years and older Â  (Adult, Older Adult)Phase 3596OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentAPHP200702December 3, 20202022-01-01 00:00:002022-03-01 00:00:00October 29, 2020April 5, 2021Centre Hospitalier Victor Dupouy, Argenteuil, France|AP-HP HÃ´pital Henri Mondor, CrÃ©teil, France|Centre Hospitalier Sud Ile de France - Melun, Melun, France|AP-HP HÃ´pital Bichat, Paris, France|APHP - Saint Louis, Paris, France|Centre de SantÃ© Richerand, Paris, Francehttps://ClinicalTrials.gov/show/NCT04608266 France
1280NCT04630054Face Masks to Reduce COVID-19 in BangladeshRecruitingNo Results AvailableCovid19Device: Face mask|Behavioral: Face mask awarenessSymptomatic SARS-CoV2 infection|SARS-CoV2 infection|Observed prevalence of proper mask wearing|Respiratory infection prevalenceYale University|Stanford University|Innovations for Poverty Action|North South UniversityAll18 Years and older Â  (Adult, Older Adult)Not Applicable450000OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention2000028482November 15, 2020February 15, 2021February 15, 2021November 16, 2020January 22, 2021Innovations for Poverty Action, Dhaka, Bangladesh"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT04630054/SAP_000.pdf"https://ClinicalTrials.gov/show/NCT04630054 Bangladesh
1281NCT04583969ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19RecruitingNo Results AvailableCOVID-19Biological: Lenzilumab|Other: Placebo|Drug: RemdesivirClinical efficacy in adults hospitalized with COVID-19 according to clinical status on an 8-point ordinal scale.|Change from baseline in C-reactive protein (CRP) concentration|Change from baseline in d-dimer concentration|Change from baseline in ferritin concentration|Change from baseline in fibrinogen concentration|Change from baseline in lactate dehydrogenase (LDH) concentration|Change from baseline in troponin concentration|Change in alanine aminotransferase (ALT) over time|Change in aspartate aminotransferase (AST) over time|Change in creatinine over time|Change in hemoglobin over time|Change in international normalized ratio (INR) over time|Change in platelets over time|Change in total bilirubin over time|Change in white blood cell (WBC) count with differential over time|Clinical efficacy, as assessed by time to recovery|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of study product administration|Duration of hospitalization|Duration of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Duration of new non-invasive ventilation or high flow oxygen use during the study|Duration of new oxygen use|Duration of non-invasive ventilation/high flow oxygen use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of ventilator/ extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Oxygenation use|Proportion of subjects alive and without respiratory failure|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to death|Ventilator/ extracorporeal membrane oxygenation (ECMO) useNational Institute of Allergy and Infectious Diseases (NIAID)|Gritstone Oncology, Inc.All18 Years to 99 Years Â  (Adult, Older Adult)Phase 2200NIH|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment20-0013BOctober 19, 2020December 31, 2021December 31, 2021October 12, 2020April 12, 2021St Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Mayo Clinic, Phoenix - Infectious Diseases, Phoenix, Arizona, United States|The University of Arizona - Banner University Medical Center Tucson Campus - Tucson, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kern Medical Center, Bakersfield, California, United States|UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States|Hoag Hospital Newport Beach, Newport Beach, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States|Penrose Hospital - Emergency Medicine, Colorado Springs, Colorado, United States|St. Francis Medical Center, Colorado Springs, Colorado, United States|St. Anthony Hospital, Lakewood, Colorado, United States|St. Anthony Hospital North Health Campus, Westminster, Colorado, United States|Nuvance Health Danbury Hospital - Infectious Disease, Danbury, Connecticut, United States|Yale School of Medicine - The Anlyan Center for Medical Research & Education - Immunobiology, New Haven, Connecticut, United States|Nuvance Health - Norwalk Hospital - Asthma Pulmonary and Critical Care Medicine, Norwalk, Connecticut, United States|MedStar Washington Hospital Center - Infectious Diseases, Washington, District of Columbia, United States|Advent Health Orlando - Critical Care, Orlando, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Cook County Health and Hospitals System - Ruth M Rothstein CORE Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|Northwestern Medicine - Central DuPage Hospital - Infectious Disease, Winfield, Illinois, United States|University of Louisville - Division of Infectious Diseases, Louisville, Kentucky, United States|Pikeville Medical Center - Department of Infectious Disease, Pikeville, Kentucky, United States|Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts, United States|Boston Medical Center - Center for Infectious Diseases - Shapiro Center, Boston, Massachusetts, United States|Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States|Englewood Hospital, Englewood, New Jersey, United States|Virtua Health - Virtua Voorhees Hospital - Pulmonology, Voorhees, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|The State University of New York - University at Buffalo - Department of Medicine, Buffalo, New York, United States|Mount Sinai School of Medicine - Medicine - Infectious Diseases, New York, New York, United States|Nuvance Health - Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Stony Brook Medicine - Stony Brook University Hospita, Stony Brook, New York, United States|East Carolina University Brody School of Medicine - Adult Specialty Care, Greenville, North Carolina, United States|Wake Forest Baptist Health - Infectious Diseases, Winston-Salem, North Carolina, United States|University of Toledo Medical Center - Ruppert Clinic, Toledo, Ohio, United States|St. Charles Health System - St. Charles Bend Hospital, Bend, Oregon, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|Kent County Memorial Hospital, Warwick, Rhode Island, United States|Monument Health - Clinical Research, Rapid City, South Dakota, United States|Hendrick Health - Hendrick Medical Center, Abilene, Texas, United States|Texas Tech University Health Science Center, Amarillo, Texas, United States|Baptist Hospitals of Southeast Texas Site, Beaumont, Texas, United States|Methodist Hospital - Houston, Houston, Texas, United States|University of Texas Health Science Center at Tyler, Tyler, Texas, United States|West Virginia University - Infectious Diseases Clinic, Morgantown, West Virginia, United Stateshttps://ClinicalTrials.gov/show/NCT04583969 United States
1282NCT04476888Convalescent Plasma Treatment in COVID-19COLLATECompletedNo Results AvailableCovid19Biological: Convalescent Plasma (CP)|Other: Drugs and supportive careDecrease length of stay|Overall mortality|Incidence of adverse events related to Convalescent Plasma transfusion|Ordinal scale|Improvement in Laboratory Parameters: Serum Ferritin|Improvement in Laboratory Parameters: Procalcitonin|Improvement in Laboratory Parameters: C-Reactive Protein|Improvement in Laboratory Parameters: D-Dimer|Improvement in Laboratory Parameters: Complete Blood count|Chest X-Ray findingsAga Khan UniversityAll18 Years and older Â  (Adult, Older Adult)Not Applicable110OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentCON000000000880April 26, 2020September 15, 2020October 10, 2020July 20, 2020January 20, 2021Aga Khan University Hospital, Karachi, Sind, Pakistanhttps://ClinicalTrials.gov/show/NCT04476888 Pakistan
1283NCT04422509Lanadelumab for Treatment of COVID-19 DiseaseCOVID_LANRecruitingNo Results AvailableCOVID-19Biological: lanadelumab|Other: regular careoxygen|adverse eventsRadboud University|TakedaAll16 Years and older Â  (Child, Adult, Older Adult)Phase 1|Phase 280Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentUMCN-AKF20.04October 3, 2020August 3, 2021August 3, 2021June 9, 2020September 14, 2020Jereoen Bosch hospital, 's-Hertogenbosch, Netherlands|Amsterdam UMC, Amsterdam, Netherlands|Rijnstate hospital, Arnhem, Netherlands|Tergooi ziekenhuizen, Blaricum, Netherlands|Amphia hospital, Breda, Netherlands|Haga hospital, Den Haag, Netherlands|Radboudumc, Nijmegen, Netherlands|Elisabeth-Tweesteden ziekenhuis, Tilburg, Netherlands|UMC Utrecht, Utrecht, Netherlands|Isala klinieken, Zwolle, Netherlandshttps://ClinicalTrials.gov/show/NCT04422509 Netherlands
1284NCT04626076International Registry of Healthcare Workers Exposed to COVID-19 PatientsUNITY GlobalRecruitingNo Results AvailableSARS-CoV Infection|Covid19Other: Comparative Observational Cohort StudyOccurrence of SARS-CoV-2 infection among HCWs caring for COVID-19 patients, in terms of time, geography, healthcare setting, type of HCW.|Occurrence of SARS-CoV-2 uninfected HCWs|Occurrence of SARS-CoV-2 infection with ambulatory status and no limitation of activities|Occurrence of SARS-CoV-2 infection with ambulatory status and limitation of activities|Occurrence of hospitalization due to COVID-19 illness with mild disease|Occurrence of hospitalization due to COVID-19 illness with severe disease|Occurrence of all-cause mortality|Type of prophylactic treatments by dose, frequency and duration, overall and by country/region/siteCertara|Bill and Melinda Gates Foundation|ParexelAll18 Years and older Â  (Adult, Older Adult)10000Industry|OtherObservationalObservational Model: Other|Time Perspective: ProspectiveCER-HCW-001August 13, 2020June 30, 2021October 31, 2021November 12, 2020November 12, 2020Aga Khan University, Karachi, Pakistanhttps://ClinicalTrials.gov/show/NCT04626076 Pakistan
1285NCT04328285Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare WorkersCOVIDAXISActive, not recruitingNo Results AvailableCOVID-19Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r TabletsOccurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)|Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.|corrected QT interval (ms)Centre Hospitalier Universitaire de Saint Etienne|Institut PasteurAll18 Years and older Â  (Adult, Older Adult)Phase 31200Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention20PH061|2020-001188-96April 14, 2020March 30, 2021March 30, 2021March 31, 2020December 28, 2020CHU d'Angers, Angers, France|CHU de Bordeaux, Bordeaux, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|AP-HP - HÃ´pital Bichat, Paris, France|CHU de Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-Ã‰tienne, Francehttps://ClinicalTrials.gov/show/NCT04328285 France
1286NCT04536298Vitamin D and COVID-19 TrialVIVIDRecruitingNo Results AvailableCOVID-19Dietary Supplement: vitamin D|Dietary Supplement: PlaceboRate of seeking healthcare visits (including hospitalizations, emergency room visits, or ambulatory or virtual clinician visits) for symptoms or concerns related to COVID-19 or deaths in participants newly diagnosed with COVID-19 (index cases)|Rate of hospitalization/death or emergency room visits related to COVID-19 infection among index cases|Rate of hospitalization/death or emergency room visits related to COVID-19 in index cases with high risk for disease progression (defined as age 50 or older, or age 18-49 with at least one co-morbidity or risk factor)|Self-reported disease severity in index cases|Time to seeking healthcare (including hospitalizations, emergency room visits, or ambulatory or other clinician visits) or death in index cases|ICU admission/ventilation support in index cases|SARS-CoV-2 infection in close household contacts|Time to symptom onset and self-reported disease severity in household contacts|Rate of healthcare visits (including hospitalizations, emergency room visits, or ambulatory or other clinician visits) for symptoms or concerns related to COVID-19 infection or deaths among household contacts who contract COVID-19Brigham and Women's Hospital|Harvard Medical School|Harvard School of Public Health|Fenway Health and Beth Israel Deaconess Medical Center|Tishcon Corporation|Takeda|Quest Diagnostics-Nichols Insitute|Karolinska Institutet|Philanthropic donationsAll18 Years and older Â  (Adult, Older Adult)Phase 32700Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment2020P002815December 28, 2020June 30, 2021June 30, 2021September 2, 2020April 6, 2021Brigham and Women's Hospital, Boston, Massachusetts, United Stateshttps://ClinicalTrials.gov/show/NCT04536298 United States
1287NCT04478539Extracorporeal Blood Purification as a Treatment Modality for COVID-19RecruitingNo Results AvailableCovid19Device: Extracorporeal blood purification using the oXirisÂ® (AN69ST) hemofilterChanges in cytokine levels of Interleukin (IL) 6, IL-8 and Tumor Necrosis Factor-Î± (pg/mL)|Changes in inflammatory markers; C-Reactive Protein (CRP) (mg/L)|Changes in thrombocyte counts (10^3 counts/microL)|Changes in the coagulation marker Fibrinogen (g/L)|ICU length of stay after admission (days)|Changes in Neutrophil-to-Lymphocyte Ratio|Changes in the coagulation marker D-Dimers (ng/mL)|Changes in the Activation Clotting Time (seconds).Zan Mitrev ClinicAll18 Years and older Â  (Adult, Older Adult)Not Applicable35OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentEBPZ.357June 1, 2020June 1, 2021July 1, 2021July 20, 2020July 20, 2020Zan Mitrev Clinic, Skopje, North Macedoniahttps://ClinicalTrials.gov/show/NCT04478539 North Macedonia
1288NCT04599959COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCRCompletedNo Results AvailableCovid-19Diagnostic Test: Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette CortisolSARS-CoV-2-RNA detectability in Swab and Salivette samplesBoehringer IngelheimAll18 Years and older Â  (Adult, Older Adult)Not Applicable144IndustryInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic0352-2150October 26, 2020January 20, 2021January 20, 2021October 23, 2020January 26, 2021Instituto Nacional de Enfermedades Respiratorias Ismael CosÃ­o Villegas, Mexico, Mexicohttps://ClinicalTrials.gov/show/NCT04599959 Mexico
1289NCT04578509Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on SalivaSALICOVRecruitingNo Results AvailableSARS-CoV-2 Infection|COVID-19Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Saliva sample|Diagnostic Test: axillary sweat sample|Other: Data collectionPositivity of RT-PCR on nasopharyngeal swab for the SARS-CoV-2 virus|Positivity of RT-PCR on saliva sample for the SARS-CoV-2 virus|Positivity of new detection approach on saliva sample for the SARS-CoV-2 virus|Positivity of antigenic test on nasopharyngeal swab for the SARS-CoV-2 virus|Practicability to samples|Practicability to premises|Practicability to interpretation|Practicability to render time|IgG Antibody detection in saliva|IgM Antibody detection in saliva|IgA Antibody detection in saliva|Positivity of canine olfactory detection of SARS-CoV-2|Patient tolerance of the salivary self-sampling|Operator tolerance of the salivary self-sampling|Cost of each approachAssistance Publique - HÃ´pitaux de ParisAllChild, Adult, Older Adult2750OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveAPHP200960|2020-A02431-38October 19, 20202021-04-01 00:00:002021-06-01 00:00:00October 8, 2020March 23, 2021SARS-CoV-2 screening device of Assistance Publique des HÃ´pitaux de Paris (AP-HP), Paris, Francehttps://ClinicalTrials.gov/show/NCT04578509 France
1290NCT04681040Risk Stratification of COVID-19 Using Urine BiomarkersRecruitingNo Results AvailableCovid19|Urine|Biomarker|Acute Respiratory Failure With HypoxiaRisk Stratification of COVID-19 Participants Using Urine Biomarkers|Prediction of COVID-19 Treatment by Urine L-FABP|Increase of O2 support, hospital days, worsening of chest X-ray and CT, and survival rate, at 14 and/or 30 days.|Comparison of Risk Stratification with Other BiomarkersNational Center for Global Health and Medicine, JapanAll20 Years and older Â  (Adult, Older Adult)1000OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveNCGM-G-003654-00December 19, 2020March 31, 2022August 31, 2023December 23, 2020March 15, 2021MD Mount Sinai, Baltimore, Maryland, United States|Hospital das Clinicas Ribeirao Preto, RibeirÃ£o Preto, San Paulo, Brazil|Danish National Biobank, KÃ¸benhavn, Denmark|Shonan General Hospital, Kamakura, Kanagawa, Japan|National Center Global Health and Medicine, Shinjuku, Tokyo, Japan|Yamanashi Prefectural Central Hospital, KÅfu, Yamanashi, Japan|Unilab Group, Manila, Philippineshttps://ClinicalTrials.gov/show/NCT04681040 Philippines
1291NCT04410263Microbiota in COVID-19 Patients for Future Therapeutic and Preventive ApproachesMICRO-COVRecruitingNo Results AvailableCorona Virus Infection|ARDS|CoinfectionDiagnostic Test: Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine)"Change of pro-inflammatory response over the ICU stay as a causative for primary endothelial dysfunction|Time-to-event ""pulmonary bacterial superinfection or death""|Positive bacteria and/ or SARS-CoV-2 cultures on handheld devices used in clinical routine and correlation to the adherence to disinfection protocols|Life Quality after COVID-19 Infection"University of ZurichAll18 Years and older Â  (Adult, Older Adult)300OtherObservationalObservational Model: Cohort|Time Perspective: Prospective2020-00646April 9, 2020December 30, 2023December 31, 2023June 1, 2020June 1, 2020University Hospital Zurich, ZÃ¼rich, Zurich, Switzerlandhttps://ClinicalTrials.gov/show/NCT04410263 Switzerland
1292NCT04703790Acceptability of a COVID-19 Vaccine Among US Adults Over Two Time PeriodsNot yet recruitingNo Results AvailableCovid19|Vaccine AcceptabilityIntention to get vaccinated for COVID-19|COVID-19 vaccination receivedColumbia University|Merck Sharp & Dohme Corp.All18 Years and older Â  (Adult, Older Adult)1200Other|IndustryObservationalObservational Model: Other|Time Perspective: ProspectiveAAAT51542021-02-01 00:00:002022-08-01 00:00:002022-08-01 00:00:00January 11, 2021January 19, 2021https://ClinicalTrials.gov/show/NCT04703790
1293NCT04393558Wearable Sensor to Monitor COVID-19 Like Signs and SymptomsRecruitingNo Results AvailableCOVID-19|Healthy ControlDevice: ADAM SensorBody temperature|Cough Frequency|Respiratory frequency|Heart Rate Instantaneous heart rate every 15 minutes.Shirley Ryan AbilityLabAll18 Years to 95 Years Â  (Adult, Older Adult)100OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveSTU00212522April 20, 2020December 31, 2022December 31, 2022May 19, 2020May 21, 2020Shirley Ryan AbilityLab, Chicago, Illinois, United Stateshttps://ClinicalTrials.gov/show/NCT04393558 United States
1294NCT04344015COVID-19 Plasma CollectionRecruitingNo Results AvailableCOVID-19Other: Plasma DonationNumber of patients who screen eligible for donation|Number of patients who consent to plasma donation|Number of plasma donations received|Safety of donation proceduresThomas Jefferson UniversityAll18 Years and older Â  (Adult, Older Adult)Not Applicable2000OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other20D.346April 13, 2020April 12, 2021April 12, 2021April 14, 2020May 11, 2020Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United Stateshttps://ClinicalTrials.gov/show/NCT04344015 United States
1295NCT04377763Developement and Evaluation of Serological Assays for COVID-19SEROCOVRecruitingNo Results AvailableCOVID-19Sensibility and specificity|Delay between the first symptoms and the positive serological resultAssistance Publique - HÃ´pitaux de ParisAll18 Years and older Â  (Adult, Older Adult)500OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective20MWI-SEROCOVJuly 15, 20202021-03-01 00:00:002021-03-01 00:00:00May 6, 2020February 25, 2021Laboratory of microbiology of hospital hygiene, Ambroise ParÃ© Hospital, APHP, Boulogne-Billancourt, Francehttps://ClinicalTrials.gov/show/NCT04377763 France
1296NCT04456036Rehabilitation Needs and Functional Recovery in Covid-19 Acute and Post-acute CareRECOVER-19RecruitingNo Results AvailableCOVID-19Change from pre-COVID-19 condition in ADL independence on the mod. Rankin scale score at the enrolment (T0) assessment, at 3, 6 and 12 months|Change from pre-COVID-19 condition in walking performance on the Walking Handicap scale (WHS) at 3, 6 and 12 months|Patient-reported health-related well-being perception on the 36-Item Short Form Survey - SF-36 at 3, 6 12 months follow-up|Change in global ADL disability on modified Barthel Index (mBI), from the enrolment (T0), at 3, 6 12 months follow-up|Change in walking capacity on Functional Ambulation Category (FAC), from the enrolment (T0) assessment, at 3, 6 12 months follow-up|Change in cognitive abilities on the Montreal Cognitive Assessment (MoCA) from the enrollment (T0) assessment, at 3, 6 12 months follow-up|Change in patient-reported pain on Numerical Rating Scale from the enrollment (T0) assessment, at 3, 6 12 months follow-up|Change in swallow abilities on Dysphagia Outcome Severity Scale (DOSS) from the first functional assessment in acute care, at 3, 6 12 months follow-up|Change in endurance on 6-Minutes Walking Test (6MWT) from the enrolment (T0) assessment, at 3, 6 12 months follow-up|Change in mood status on Beck Depression Inventory (BDI) from the enrolment (T0) assessment, at 3, 6 and 12 month follow-upUniversitÃ  Politecnica delle Marche|Maria Gabriella Ceravolo|Michela Coccia|Lauredana Ercolani|Elisa Andrenelli|Lucia Pepa|Rossella Cima|Michela AringoloAll18 Years and older Â  (Adult, Older Adult)100OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveNeuroRehabAN_Covid_2020July 1, 2020December 31, 2020June 30, 2021July 2, 2020December 1, 2020Neurorehabilitation Clinic, University Hospital Ospedali Riuniti di Ancona, Ancona, Italyhttps://ClinicalTrials.gov/show/NCT04456036 Italy
1297NCT04691609Assiut University Registry for ACS Patients During COVID-19 PandemicRecruitingNo Results AvailableACS-COVID-19-AssiutMain Number, distribution and oucome of all ACS patients coming to Assiut heart hospital|To register pathological events occurring to all acute coronary syndrome patients coming to Assiut university heart hospital through one year during COVID- 19 pandemicAssiut UniversityAllChild, Adult, Older Adult2500OtherObservationalObservational Model: Cohort|Time Perspective: Cross-SectionalACS in COVID-19 eraMarch 1, 20202023-03-01 00:00:002023-09-01 00:00:00December 31, 2020December 31, 2020Samah ObiedAllah Fouad, Assiut, Resident, Egypthttps://ClinicalTrials.gov/show/NCT04691609 Egypt
1298NCT04521296Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the PlaceboNot yet recruitingNo Results AvailableMild to Moderate COVID-19Drug: DWJ1248|Drug: PlaceboTime to SARS-CoV-2 eradication|Rate of SARS-CoV-2 eradication|Time to clinical improvement of subjective symptomsDaewoong Pharmaceutical Co. LTD.All19 Years and older Â  (Adult, Older Adult)Phase 290IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentDW_DWJ12482012020-08-01 00:00:002020-12-01 00:00:002020-12-01 00:00:00August 20, 2020August 20, 2020https://ClinicalTrials.gov/show/NCT04521296
1299NCT04513210Reliability of Standardized Protocol of Ultrasound of the Lungs in Prediction of Severity of Covid-19 InfectionEnrolling by invitationNo Results AvailableCovid19Relation of changes in ultrasound and progression to respiratory failure|Impact of ultrasonographic pneumonia signs on the day of admission on severity of COVID-19 infection|Sensitivity of ultrasonographic pneumonia signs in detecting respiratory failure|Sensitivity of ultrasound in detecting interstitial changes in the lungs|Impact change in severity of ultrasonographic pneumonia signs on severity of COVID-19 infectionJagiellonian UniversityAll18 Years and older Â  (Adult, Older Adult)300OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveJagiellonianU67October 10, 2020October 30, 2021February 28, 2022August 14, 2020October 19, 2020Jagiellonian University Medical College, Department of Neurology, KrakÃ³w, Polandhttps://ClinicalTrials.gov/show/NCT04513210 Poland
1300NCT04501796A Trial of NT-I7 in COVID-19 (SPESELPIS)RecruitingNo Results AvailableCOVID-19Drug: Double-Blind NT-I7|Drug: Double-Blind PlaceboEvaluate the safety of a single dose of NT-I7 in a dose escalation fashion|Evaluate the immunological effects of NT-I7 cumulatively for all doses on peripheral lymphocyte counts in COVID-19 patients.NeoImmuneTechAll19 Years to 75 Years Â  (Adult, Older Adult)Phase 130IndustryInterventionalAllocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentNIT-116 (SPESELPIS)November 27, 20202021-10-01 00:00:002021-12-01 00:00:00August 6, 2020March 18, 2021Nih/Niaid, Bethesda, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United Stateshttps://ClinicalTrials.gov/show/NCT04501796 United States
1301NCT04607941Study of Socio-demographic Factors, Behaviors and Practices Associated With Infection With SARS-CoV-2 Responsible for COVID-19ComCorRecruitingNo Results AvailableCovid19Other: Questionnaires|Other: Phone interviewsOdds-ratios of SARS-CoV-2 infection on socio-demographic factors, behaviors and practices and visited places reported by the participants in the online questionnaire|Proportion of cases infected in family environment by SARS-CoV-2 reported by participants in the phone interview|Proportion of cases infected in family environment by SARS-CoV-2 reported by participants in the online questionnaire|Proportion of cases infected in professional environment by SARS-CoV-2 reported by participants in the phone interview|Proportion of cases infected in professional environment by SARS-CoV-2 reported by participants in the online questionnaire|Level of adherence to mask-wearing reported in the phone interview|Level of adherence to mask-wearing reported in the online questionnaire|Level of adherence to hand-washing in the phone interview|Level of adherence to hand-washing in the online questionnaire|Odds-ratios of SARS-CoV-2 infection on socio-demographic factors, behaviors and practices and visited places reported by the participants in the phone interviewInstitut Pasteur|National Health Insurance Fund|IPSOSAll18 Years and older Â  (Adult, Older Adult)57720Industry|OtherObservationalObservational Model: Case-Control|Time Perspective: Prospective2020-047|2020-A02560-39October 27, 2020June 4, 2021June 30, 2021October 29, 2020November 2, 2020Caisse Nationale d'Assurance Maladie, Paris, France|IPSOS, Paris, Francehttps://ClinicalTrials.gov/show/NCT04607941 France
1302NCT04318015Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)PHYDRARecruitingNo Results AvailableCOVID-19|Severe Acute Respiratory SyndromeDrug: Hydroxychloroquine|Drug: Placebo oral tabletSymptomatic COVID-19 infection rate|Symptomatic non-COVID viral infection rate|Days of labor absenteeism|Rate of labor absenteeism|Rate of severe respiratory COVID-19 disease in healthcare personnelNational Institute of Respiratory Diseases, Mexico|SanofiAll18 Years and older Â  (Adult, Older Adult)Phase 3400Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionProfilaxisCOVIDApril 14, 2020December 31, 2020March 31, 2021March 23, 2020April 17, 2020"Instituto Nacional de Enfermedades Respiratorias, ""Ismael CosÃ­o Villegas"", Mexico, City, Mexico"https://ClinicalTrials.gov/show/NCT04318015 Mexico
1303NCT04392089Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDSNIRS-COVRecruitingNo Results AvailableCOVID-19|Respiratory FailureDevice: Masimo, LidCOChanges in cerebral oxygenation (ScO2) during cardiovascular and pulmonary optimization|Changes in peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization|Changes in systolic arterial pressure (SAP) during cardiovascular and pulmonary optimization|Changes in diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization|Changes in mean arterial pressure (MAP) during cardiovascular and pulmonary optimization|Changes in heart rate (HR) during cardiovascular and pulmonary optimization|Changes in stroke volume (SV) during cardiovascular and pulmonary optimization|Changes in cardiac output (CO) during cardiovascular and pulmonary optimization|Changes in systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization|Changes in peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization|Changes in pH during cardiovascular and pulmonary optimization|Changes in PaO2 during cardiovascular and pulmonary optimization|Changes in PaCO2 during cardiovascular and pulmonary optimization|Changes in arterial saturation (SaO2) during cardiovascular and pulmonary optimization|Changes in PvO2 during cardiovascular and pulmonary optimization|Changes in PvCO2 during cardiovascular and pulmonary optimization|Changes in mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization|Changes in lacatate during cardiovascular and pulmonary optimization|Changes in hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization|Changes in muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and systemic arterial pressure (SAP) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and mean arterial pressure (MAP) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and stroke volume (SV) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and heart rate (HR) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and cardiac output (CO) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and pH during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PaO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PaCO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and arterial saturation (SaO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PvO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and PvCO2 during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and lactate during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization|Association between cerebral oxygenation (ScO2) and muscular oxygenation (SmO2) during cardiovascular and pulmonary optimizationHvidovre University HospitalAll18 Years and older Â  (Adult, Older Adult)20OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveH-20027818May 1, 2020May 1, 2021May 1, 2021May 18, 2020May 18, 2020Hvidovre Hospital, Copenhagen, Denmarkhttps://ClinicalTrials.gov/show/NCT04392089 Denmark
1304NCT04502667Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19COVID-19RecruitingNo Results AvailableCovid19|Vitamin D|Children, OnlyDrug: CholecalciferolINTERLEUKINS (IL-2,6,7,10) (pg/ml)|FERRITIN (ng/ml)|DIMER-D|Vitamin D (ng/ml)CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico|Hospital Infantil de Mexico Federico Gomez|Hospital General de MÃ©xico Dr. Eduardo LiceagaAll1 Month to 17 Years Â  (Child)Phase 340OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentR-2020-3603-020July 15, 20202021-02-01 00:00:002021-04-01 00:00:00August 6, 2020August 6, 2020Hospital Centro Medico Nacional Siglo XXI, Mexico City, Distrito Federal, Mexicohttps://ClinicalTrials.gov/show/NCT04502667 Mexico
1305NCT04743349Steam Inhalations in COVID-19 PatientsSteam-COVIDRecruitingNo Results AvailableCovid19|Coronavirus Infection|CoronavirusProcedure: Steam inhalationsReduction in viral shedding|Clinical outcome|Negativization rateMeyer Children's HospitalAll18 Years to 100 Years Â  (Adult, Older Adult)Not Applicable200OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: TreatmentSteam-COVIDJanuary 26, 2021October 31, 2021October 31, 2021February 8, 2021February 8, 2021Meyer Children's Hospital, Florence, Italyhttps://ClinicalTrials.gov/show/NCT04743349 Italy
1306NCT04340544Hydroxychloroquine for the Treatment of Mild COVID-19 DiseaseCOMIHYTerminatedNo Results AvailableCOVID-19Drug: Hydroxychloroquine|Drug: PlaceboDifference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment|Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)|All-cause mortality within 28 daysUniversity Hospital Tuebingen|Robert Bosch Medical Center|UniversitÃ¤tsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical MedicineAll18 Years to 99 Years Â  (Adult, Older Adult)Phase 217OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentCOMIHYApril 22, 2020October 12, 2020October 12, 2020April 9, 2020November 2, 2020Institute for Tropical Medicine, TÃ¼bingen, Germanyhttps://ClinicalTrials.gov/show/NCT04340544 Germany
1307NCT04384380Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19CompletedNo Results AvailableCoronavirus InfectionDrug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]Time to negatively RT-PCR|Virologic assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Taoyuan General Hospital|Center for Drug Evaluation, Taiwan|Centers for Disease Control, Taiwan|Taiwan Food and Drug Administration|National Health Research Institutes, TaiwanAll20 Years to 79 Years Â  (Adult, Older Adult)Not Applicable33OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentTYGH109014April 1, 2020May 31, 2020May 31, 2020May 12, 2020August 4, 2020Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04384380/Prot_000.pdf"https://ClinicalTrials.gov/show/NCT04384380 Taiwan
1308NCT04487665Oral Manifestations of Coronavirus Disease 2019(COVID-19) :a Multicentre StudyNot yet recruitingNo Results AvailableCovid19oral ulcer|hyposalivationCairo UniversityAll18 Years to 40 Years Â  (Adult)50OtherObservationalObservational Model: Ecologic or Community|Time Perspective: Cross-Sectional8791September 15, 2020November 15, 2020December 15, 2020July 27, 2020July 27, 2020https://ClinicalTrials.gov/show/NCT04487665
1309NCT04422626Data Analysis of the Cytokine Adsorption Treatment on Coronavirus Disease-19 (COVID-19) Patients With Respiratory FailureCYTOAIDNot yet recruitingNo Results AvailableSARS-CoV-2|COVID-19Change in the partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio after CytoSorb therapy|Change in inflammatory biomarker levels during treatment|change in organ function|length of stay in ICU|length of hospital stay|Duration of mechanical ventilation|Duration of vasopressor therapy|Duration of renal replacement therapy|Occurrence of critical illness polyneuropathy and/or myopathy|need for extracorporeal membrane oxygenation (ECMO)|cost calculation|device-related adverse and serious adverse events|In-hospital mortalityUniversity of PecsAll18 Years and older Â  (Adult, Older Adult)42OtherObservationalObservational Model: Cohort|Time Perspective: Prospective20802-5/2020/EÃœIGJuly 1, 2020July 1, 2022December 1, 2022June 9, 2020June 11, 2020https://ClinicalTrials.gov/show/NCT04422626
1310NCT04389567Famotidine Outpatient COVID-19 Treatment StudyCompletedNo Results AvailableCOVID-19Drug: FamotidineSymptomatic improvement|Peripheral blood oxygen saturationNorthwell Health|Cold Spring Harbor LaboratoryAll18 Years and older Â  (Adult, Older Adult)10OtherObservationalObservational Model: Case-Only|Time Perspective: Retrospective1605914-1May 12, 2020May 25, 2020May 25, 2020May 15, 2020June 4, 2020Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United Stateshttps://ClinicalTrials.gov/show/NCT04389567 United States
1311NCT04659707Hyperpolarized 129Xe MRI of Survivors of COVID-19RecruitingNo Results AvailableCovid19Drug: Hyperpolarized Xe129Ventilation Defect PercentageUniversity of Kansas Medical CenterAll18 Years and older Â  (Adult, Older Adult)Phase 120OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic146646February 22, 2021December 31, 2021December 31, 2021December 9, 2020February 24, 2021University of Kansas Medical Center, Kansas City, Kansas, United Stateshttps://ClinicalTrials.gov/show/NCT04659707 United States
1312NCT04373200Human Ab Response & immunoMONItoring of COVID-19 PatientsHARMONICOVRecruitingNo Results AvailableSARS-CoV-2 Coronavirus|Acute Respiratory Distress SyndromeBiological: Blood samples collection|Other: Saliva collectionNumber of increased immune population|Number of decreased immune population|Number of statically different phenotypes compared to control patients|Gain or loss of functional phenotypic markers between D1 and D14|Gain or loss of functional phenotypic markers between between acute and mild infections|Gain or loss of functional phenotypic markers between D1 and month 4|Evaluation of V, D, J gene usage alterations in the immunoglobulin and T cell receptor (TCR) repertoires during ARDS linked to COVID-19|Identification of the Ig classes and of V, D, J sequences of anti-CoV-2 antibodies|Characterization of a new set of human antibodies from patients who have recovered of COVID-19Rennes University HospitalAll18 Years and older Â  (Adult, Older Adult)Not Applicable75OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other35RC20_9795_HARMONICOV|2020-A01100-39May 25, 2020May 25, 2021September 25, 2021May 4, 2020March 11, 2021CHU Rennes, Rennes, Francehttps://ClinicalTrials.gov/show/NCT04373200 France
1313NCT04595773COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)RecruitingNo Results AvailableCOVID-19Other: Aerobic Exercise Training|Other: Education6 minute walk test distance|Patient reported outcomes and quality of life|Free-living physical activity and sleep qualityNational Institutes of Health Clinical Center (CC)All18 Years to 80 Years Â  (Adult, Older Adult)Phase 1|Phase 290NIHInterventionalAllocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment10000102|000102-CCJanuary 22, 2021December 31, 2023December 31, 2023October 22, 2020March 25, 2021National Institutes of Health Clinical Center, Bethesda, Maryland, United Stateshttps://ClinicalTrials.gov/show/NCT04595773 United States
1314NCT04408391Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without AnosmiaANOSIRMWithdrawnNo Results AvailableCovid-19|AnosmiaOther: Brain MRI scanBrain regional homogeneity between COVID-19 patients with and without anosmia|Topography of supra- or sub-tentorial lesions between COVID-19 patients with and without anosmia|Fractional anisotropy between COVID-19 patients with and without anosmia|Mean diffusivity between COVID-19 patients with and without anosmia|Radial diffusivity between COVID-19 patients with and without anosmia|Self-assessed olfactory and gustatory test|Ability to detect odor|Ability to taste a pinch of sugar|Presence of thrombotic and hemorrhagic lesions|Presence of lesions with hyperintensity|Projection network analysis of all patients|Blinded independent component analysis of all patients|default mode network analysis of all patients|executive control network analysis of all patientsCentre Hospitalier Universitaire de NÄ«mesAll18 Years and older Â  (Adult, Older Adult)0OtherObservationalObservational Model: Case-Only|Time Perspective: ProspectiveNIMAO/2020-01/BL-001May 20, 2020July 6, 2020July 6, 2020May 29, 2020August 5, 2020CHU de Nimes, NÃ®mes, Francehttps://ClinicalTrials.gov/show/NCT04408391 France
1315NCT04348396Clinical and Biological Predictors of COVID-19 Disease in Older PatientsRecruitingNo Results AvailableCOVID-19Descriptive-epidemiological analysis of health conditions|Evaluation of frailty condition|Identification of biomarkers of inflammation|Assessment of functional capacity|Evaluation of drug consumption|Evaluation of inflamma-miRsIstituto Nazionale di Ricovero e Cura per AnzianiAll65 Years and older Â  (Older Adult)300OtherObservationalObservational Model: Case-Only|Time Perspective: ProspectiveINRCA_01_2020April 3, 20202020-12-01 00:00:002020-12-01 00:00:00April 16, 2020September 22, 2020IRCCS INRCA Hospital, Ancona, Italy|IRCCS INRCA Hospital, Casatenovo, Italy|IRCCS INRCA Hospital, Fermo, Italyhttps://ClinicalTrials.gov/show/NCT04348396 Italy
1316NCT04670328Role of Hematological Parameters in the Stratification of COVID-19 Disease SeverityCompletedNo Results AvailableCovid19Diagnostic Test: not requiredcomplete blood count- Hemoglobin. White blood count, platelet count, Neutrophil to lymphocyte ratio|PT, APTT and D-dimerFMH College of Medicine and DentistryAll17 Years to 75 Years Â  (Child, Adult, Older Adult)101OtherObservationalObservational Model: Case-Only|Time Perspective: RetrospectiveFMHCMDMay 1, 2020July 31, 2020July 31, 2020December 17, 2020December 17, 2020FMH college of medicine and dentistry, Lahore, Punjab, Pakistanhttps://ClinicalTrials.gov/show/NCT04670328 Pakistan
1317NCT04679272Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis PatientsProCOVRACompletedNo Results AvailableCovid19|Rheumatoid ArthritisHospitalization rates for COVID-19|Critical care transfer rate for COVID-19 and death due to COVID-19|Pulmonary comorbidities, corticosteroids or DMARDs use|Age|Number of Participants with co-morbidities|Type of clinical presentation|Type of associated treatmentsUniversity Hospital, MontpellierAll18 Years and older Â  (Adult, Older Adult)2000OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveRECHMPL20_0682December 1, 2020January 30, 2021February 1, 2021December 22, 2020March 1, 2021UH Montpellier, Montpellier, Francehttps://ClinicalTrials.gov/show/NCT04679272 France
1318NCT04481360Evaluation of Clinical Characteristics and Outcome of COVID19 Pneumonia in Assiut University HospitalNot yet recruitingNo Results AvailableCoronavirusDevice: CT of the chestClinical evaluationAssiut UniversityAll18 Years to 99 Years Â  (Adult, Older Adult)100OtherObservationalObservational Model: Cohort|Time Perspective: ProspectivePresentation of COVID19 in AUH2020-08-01 00:00:002021-08-01 00:00:002021-09-01 00:00:00July 22, 2020July 22, 2020https://ClinicalTrials.gov/show/NCT04481360
1319NCT04357457Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related PneumoniaAIRVM-COVIDRecruitingNo Results AvailableCovid 19|Hypoxemic Respiratory FailureDrug: Almitrine|Drug: PlaceboRate of endotracheal intubation|28-day mortality|In-hospital mortality|Number of ventilator-free days|Number of days in the ICU|Number of days in the hospital|Discontinuation rate of the treatmentAssistance Publique - HÃ´pitaux de ParisAll18 Years to 80 Years Â  (Adult, Older Adult)Phase 3212OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentAPHP200461|2020-001909-22September 3, 20202021-07-01 00:00:002021-07-01 00:00:00April 22, 2020March 22, 2021Hospital PitiÃ©-SalpÃªtriÃ¨re, Paris, Francehttps://ClinicalTrials.gov/show/NCT04357457 France
1320NCT04668235Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected)Not yet recruitingNo Results AvailableCOVID-19Drug: AZVUDINE|Drug: AZVUDINE placeboEvaluation of clinical improvement of AZVUDINE (FNC) in COVID-19 treatment|Clinical cure outcome rate|Recovery of body temperature|Clinical improvement of diarrhea, myalgia fatigue and other symptoms|Assessment of inflammatory biochemical markers (Reactive C Protein, erythrocyte sedimentation rate, and Procalcitonin)|Assessment of immunological function biochemical markers (IL-6, IgG, IgM, IgA, and complement factor C3 and C4)|Assessment of renal function biochemical markers (serum creatinine and calculated glomerular filtration rate)|Assessment of liver function biochemical markers (AST/TGO, ALT/TGP, ALP, GGT, BIL total, and direct BIL)|Evaluation of time to negative conversion of SARS-CoV-2 viral load by RT-PCR|Evaluation of the number of cycles for the detection of SARS-CoV-2 viral load by RT-PCR and application of the standard curve for calculating viral load|Analysis of the relationship between the calculated viral load and the clinical evolution of the participants in the experimental group (FNC) and the PLACEBO group|Time for improvement of pulmonary condition by imaging exams during treatment|Evaluation of pulmonary condition by imaging exams during treatment|Time for clinical improvement of respiratory signs and symptoms|Assessment of clinical improvement of respiratory signs and symptoms|Time for normalization of O2 saturation|Respiratory rate evaluation|Frequency of supplemental oxygenation or non-invasive ventilation|Frequency of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)|Proportion of moderate cases that progressed to severe cases|Assessment of hospitalization time|Evaluation of drug interaction events frequency|Evaluation of drug interaction events intensity|Assessment of adverse events frequency|Assessment of adverse events intensity|Assessment of unexpected adverse events frequency|Assessment of unexpected adverse events intensity|Assessment of serious adverse events frequency|Assessment of serious adverse events intensity|Overall mortality rate|Evaluation of the tolerability of azvudine in the 5 mg regimen orally QD up to 14 days|Assessment of adherence of azvudine in the 5 mg regimen orally QD up to 14 days|Time of use of azvudine in the 5 mg regimen orally QD up to 14 daysHRH Holdngs Limited|GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil|SANTA CASA DE MISERICORDIA DE CAMPOS HOSPITAL (SCMCH), Brazil|UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE (UENF), BrazilAll18 Years and older Â  (Adult, Older Adult)Phase 3342OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentFNC IGZ-12021-04-01 00:00:002021-07-01 00:00:002021-10-01 00:00:00December 16, 2020March 19, 2021Santa Casa de MisericÃ³rdia de Campos, Campos Dos Goytacazes, RJ, Brazilhttps://ClinicalTrials.gov/show/NCT04668235 Brazil
1321NCT04581083Validation of Laboratory Techniques, Strategies, and Types of Samples for Epidemiological Control in the Covid-19 PandemicCompletedNo Results AvailableCovid19Diagnostic Test: RT-PCR|Diagnostic Test: LAMP|Diagnostic Test: POOL RT-PCR|Diagnostic Test: POOL LAMPValidation|RT- PCR (Saliva)|LAMP|POOL PCR|POOL LAMPHunter College of City University of New York|Universidad Autonoma Juan Misael Saracho|Gobierno Autonomo Departamental De Tarija|SEDES - Tarija|CAINCO - BoliviaAll21 Years to 64 Years Â  (Adult)30OtherObservationalObservational Model: Other|Time Perspective: Cross-SectionalPROY - UAJMS001/2020October 8, 2020October 10, 2020October 30, 2020October 9, 2020January 22, 2021Universidad AutÃ³noma Juan Misael Saracho, Tarija, Boliviahttps://ClinicalTrials.gov/show/NCT04581083 Bolivia
1322NCT04367870COVID-19 Detection Test in OncologyEVIDENCERecruitingNo Results AvailableOncologyTo evaluate the ability of SARS-CoV-2 immunoassays, following a positive result, to identify patients with very low risk of recurrence of COVID-19 within 3 months.|To estimate the discordance rate between local immunoassay and a centralized ELISA in patients with a positive immunoassay, whatever the immunoassay.|To identify patients with very low risk of recurrence of COVID-19 within 6 months following a positive immunoassay result.|To characterize the evolution over time of the serologic response against SARS-CoV-2 (in a subgroup of patients).UNICANCERAll18 Years and older Â  (Adult, Older Adult)450OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveUC-TRA-2002|2020-A01002-37May 23, 2020May 31, 20212021-10-01 00:00:00April 29, 2020April 2, 2021Centre Hospitalier de Boulogne sur Mer, Boulogne-sur-Mer, France|Centre Jean Perrin, Clermont-Ferrand, France|Hopitaux Civils de Colmar, Colmar, France|HÃ´pital Universitaire PitiÃ© SalpÃªtriÃ¨re, Paris, France|Institut Curie, Paris, France|Centre EugÃ¨ne Marquis, Rennes, France|Institut Curie, Saint-Cloud, Francehttps://ClinicalTrials.gov/show/NCT04367870 France
1323NCT04365530Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital CityCOVIDGHPSJCiteRecruitingNo Results AvailableCOVIDClinical consequences of a Covid-19 infection in the care population|Risk factors at M6|Risk factors at year 1|Risk factors at year 2|Impact of hospital reorganization on medical care at M6|Impact of hospital reorganization on medical care at Year 1|Impact of hospital reorganization on medical care at Year 2Groupe Hospitalier Paris Saint JosephAllChild, Adult, Older Adult2000OtherObservationalObservational Model: Cohort|Time Perspective: OtherCohorte COVID GHPSJ CiteHApril 1, 2020April 1, 2022December 31, 2022April 28, 2020April 29, 2020HÃ´pital Marie Lannelongue, Le Plessis-Robinson, France|AURA Paris Plaisance, Paris, France|Fondation Sainte-Marie, Paris, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|HÃ´pital Bellan, Paris, Francehttps://ClinicalTrials.gov/show/NCT04365530 France
1324NCT04460703COVID-19 Vaccine Messaging, Part 1CompletedNo Results AvailableVaccination|COVID-19Other: Control message|Other: Baseline message|Other: Personal freedom message|Other: Economic freedom message|Other: Self-interest message|Other: Community interest message|Other: Economic benefit message|Other: Guilt message|Other: Embarrassment message|Other: Anger message|Other: Trust in science message|Other: Not bravery messageIntention to get COVID-19 vaccine|Vaccine confidence scale|Persuade others item|Fear of those who have not been vaccinated|Social judgment of those who do not vaccinateYale UniversityAll18 Years and older Â  (Adult, Older Adult)Not Applicable4000OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other2000027983July 3, 2020July 8, 2020July 8, 2020July 7, 2020July 21, 2020Yale University, New Haven, Connecticut, United Stateshttps://ClinicalTrials.gov/show/NCT04460703 United States
1325NCT04568031Study of AZD1222 for the Prevention of COVID-19 in JapanActive, not recruitingNo Results AvailableCOVID-19Drug: AZD1222|Drug: 0.9% (w/v) salineProportion of participants who have a post treatment seroresponse to the spike antigens of AZD1222|The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination|The incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs)|Biochemistry; change from baseline for blood chemistry measures|Haematology; change from baseline for hematology/hemostasis measures|Proportion of participants who have a post treatment|Genometric mean titres and genometric mean fold rise|Proportion of participants who have a post treatment seroresponse to AZD1222 as measured by SARS-CoV-2 nAbs|The incidence of serious adverse events (SAEs) and adverse events of specisl interest (AESIs) collected from Day1 through Day365AstraZeneca|Iqvia Pty LtdAll18 Years and older Â  (Adult, Older Adult)Phase 1|Phase 2256IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionD8111C00002August 23, 2020November 15, 2021November 15, 2021September 29, 2020March 17, 2021Research Site, Fukuoka-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Sumida-ku, Japan|Research Site, Toshima-ku, Japanhttps://ClinicalTrials.gov/show/NCT04568031 Japan
1326NCT04354597Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 PatientsMOPHYDANot yet recruitingNo Results AvailableCOVID-19Drug: HCQ & AZEffect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients|Safety of HCQ and AZ|Oxygen requirement|ICU admission|Mortality rateKing Hussein Cancer CenterAll25 Years to 70 Years Â  (Adult, Older Adult)Not Applicable200OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention20 KHCC 67May 1, 2020August 15, 2020October 15, 2020April 21, 2020May 5, 2020King Hussein Cancer Center, Amman, Jordanhttps://ClinicalTrials.gov/show/NCT04354597 Jordan
1327NCT04377711A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 PatientsCompletedNo Results AvailableCOVID-19Drug: Ciclesonide|Drug: PlaceboTime to alleviation of COVID-19-related symptoms by Day 30|Percentage of patients with hospital admission or death by day 30|All-cause mortality by day 30|COVID-19-related mortality by day 30|Percentage of patients with subsequent emergency department visit or hospital admission for reasons attributable to COVID-19 by day 30|Percentage of patients with alleviation of COVID-19-related symptoms defined as symptom-free for a continuous period of more than 24 hours (ie, later than 3 AM/PM assessments) by day 7, by day 14, and by day 30|Time to hospital admission or death|Change from baseline in oxygen saturation levels|Change from baseline in COVID-19 viral load in nasopharyngeal sample at day 30Covis Pharma S.Ã .r.l.All12 Years to 100 Years Â  (Child, Adult, Older Adult)Phase 3400IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentALV-020-001June 8, 2020January 5, 2021January 5, 2021May 6, 2020April 14, 2021University of Buffalo, Buffalo, New York, United Stateshttps://ClinicalTrials.gov/show/NCT04377711 United States
1328NCT04537299COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing HomesCOVID-FISNot yet recruitingNo Results AvailableCovid19|SARS-CoV InfectionDrug: Fisetin|Drug: PlaceboChange in COVID-19 SeverityMayo Clinic|National Institute on Aging (NIA)All65 Years and older Â  (Older Adult)Phase 2150Other|NIHInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment20-008867|1R01AG072301-012021-04-01 00:00:002023-12-01 00:00:002023-12-01 00:00:00September 3, 2020April 6, 2021Mayo Clinic, Rochester, Minnesota, United Stateshttps://ClinicalTrials.gov/show/NCT04537299 United States
1329NCT04401046COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress DisorderCOVID-TRAUMARecruitingNo Results AvailableCancerOther: Survey to assess Post traumatic stress and anxiety at inclusion and 6 months laterScore of the Impact of Event Scale Revisited scale|Factors associated with post-traumatic stress disorder|Measure of the patient's anxiety|proportion of patients perceiving poorer management of their cancer care since the start of the COVID-19 epidemic.|proportion of patients perceiving the implementation of all necessary measures to reduce the risk of exposure to COVID-19|proportion of patients stating that remote consultation is as useful as a face-to-face consultation|proportion of patients with access to a clinical psychology consultation (at the hospital or on the phone)|Score on the cancer recurrence scaleInstitut Paoli-CalmettesAll18 Years and older Â  (Adult, Older Adult)Not Applicable4000OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services ResearchCOVID-TRAUMA-IPC 2020-026May 20, 2020October 30, 2020October 30, 2020May 26, 2020July 28, 2020Institut Paoli-Calmettes, Marseille, Francehttps://ClinicalTrials.gov/show/NCT04401046 France
1330NCT04341922A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 PandemicActive, not recruitingNo Results AvailableDysfunctional WorryBehavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemicâ€¢ Covid-19-adapted version of the self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)|Montgomery Ã…sberg Depression Rating Scale - Self report (MADRS-S)|Adapted Covid-19 version of the Work and Social Adjustment Scale (WSAS)|Insomnia Severity Index (ISI)|Adapted Swedish version of the CoRonavIruS Health Impact Survey (CRISIS)|Intolerance of uncertainty Scale (IUS)|Patient Satisfaction Questionnaire (PSQ)|Adverse events (AE)Karolinska InstitutetAll16 Years and older Â  (Child, Adult, Older Adult)Not Applicable670OtherInterventionalAllocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment2020-01719May 9, 2020August 20, 2020September 10, 2021April 10, 2020October 19, 2020Karolinska Institutet, Stockholm, Swedenhttps://ClinicalTrials.gov/show/NCT04341922 Sweden
1331NCT04466462Cross-sectional Study of COVID-19 Infection in Hospital Health PersonnelCompletedNo Results AvailableSARS-CoV-2 InfectionNumber of participants with past SARS-CoV-2 infection|Number of infections in health personnel who have taken voluntary hydroxychloroquine as a prevention strategy for COVID-19 infection|Number of infections in health personnel based on the degree of exposure to patients infected with COVID-19.|Number of infected participants who are active smokers and/or have chronic lung disease and/ or have history of hypertension.Relationship of degree of exposure to participants infected with SARS-CoV-2 admitted to the hospital.Professional category.|Number of participants infected with SARS-CoV-2 that presented symptoms and their grade. Number of participants infected with SARS-CoV-2 who required hospitalization. Number of participants infected with SARS-CoV-2 who received treatment.|Number of family members infected from each participant with SARS-CoV-2 infectionFundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la CienciaAll18 Years and older Â  (Adult, Older Adult)1000OtherObservationalObservational Model: Case-Crossover|Time Perspective: OtherCOVID-HospMay 26, 2020June 30, 2020June 30, 2020July 10, 2020July 10, 2020Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain|Hospital Municipal de Badalona, Badalona, Barcelona, Spainhttps://ClinicalTrials.gov/show/NCT04466462 Spain
1332NCT04424134BromhexIne And Spironolactone For CoronÐ°VirUs Infection Requiring HospiTalizationBISCUITRecruitingNo Results AvailableCOVID 19Drug: Bromhexine and Spironolactone|Drug: Base therapyChange from baseline in clinical assessment score COVID 19 (CAS COVID 19)|- Combine endpoint -|C-reactive protein|D-dimer|EuroQol Group. EQ-5Dâ„¢|EuroQol Group. EQ VAS|HADS|Hospital length of stayLomonosov Moscow State University Medical Research and Educational CenterAll18 Years and older Â  (Adult, Older Adult)Phase 380OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: TreatmentMSU160520May 16, 2020July 18, 2020August 23, 2020June 9, 2020June 9, 2020Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Moscow Region, Russian Federationhttps://ClinicalTrials.gov/show/NCT04424134 Russian Federation
1333NCT04779021Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease DepartmentRecruitingNo Results AvailableCovid19|SARS-CoV InfectionOther: Hospitalisation for SARS-COV2 infectionClinical characteristics|Biological characteristics|Radiological characteristics|Number of patient hospitalised for Covid-19|Overall Inpatient Mortality|Requirement for mechanical ventilation|ICU Length of Stay (LOS)|Evolution of patient general state during hospitalisation|Biological testsCentre Hospitalier Universitaire de NiceAll18 Years and older Â  (Adult, Older Adult)1300OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective21infectiocovid01February 15, 2020December 31, 2021December 31, 2022March 3, 2021March 3, 2021CHU de NICE - Infectiologie, Nice, France|CHU de NICE - Urgences, Nice, Francehttps://ClinicalTrials.gov/show/NCT04779021 France
1334NCT04303507Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare SettingCOPCOVRecruitingNo Results AvailableCOVID19|Coronavirus|Acute Respiratory IllnessesDrug: Chloroquine or Hydroxychloroquine|Drug: PlaceboNumber of symptomatic COVID-19 infections|Symptoms severity of COVID-19|Number of asymptomatic cases of COVID-19|Number of symptomatic acute respiratory illnesses|Severity of symptomatic acute respiratory illnessesUniversity of OxfordAll16 Years and older Â  (Child, Adult, Older Adult)Not Applicable40000OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: PreventionVIR20001April 29, 20202021-04-01 00:00:002021-04-01 00:00:00March 11, 2020October 5, 2020RSUPN Cipto Mangunkusumo Hospital, Jakarta Pusat, Jakarta, Indonesia|Istituto Sacro Cuore Don Calabria, Negrar, Negrar Di Valpolicella VR, Italy|Mahosot hospital, Vientiane, Lao People's Democratic Republic|The Aga Khan University Hospital, Karachi, Pakistan|Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand|University Hospitals Of Morecambe Bay NHS Foundation Trust, Kendal, Cumbria, United Kingdom|Torbay and South Devon NHS Foundation Trust, Torquay, Devon, United Kingdom|The Princess Alexandra Hospital NHS Trust, Harlow, Essex, United Kingdom|West Hertfordshire Hospitals NHS Trust, Watford, Hertfordshire, United Kingdom|Lewisham and Greenwich NHS Trust, Woolwich, London, United Kingdom|Sherwood Forest Hospitals NHS Foundation Trust, Sutton In Ashfield, Nottinghamshire, United Kingdom|The Dudley Group NHS Foundation Trust, Dudley, West Midlands, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom|Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom|University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdomhttps://ClinicalTrials.gov/show/NCT04303507 United Kingdom
1335NCT04756479Mortality Due to COVID-19 in the COVID-AGEBRU StudyCOVID-AGEBRUCompletedNo Results AvailableCovid19|Old Age; Debility|Morbidity, MultipleAll-cause mortality during hospital admission (admission up to discharge time)|Prevalence of medical diseases and geriatric syndromesBrugmann University HospitalAll70 Years and older Â  (Older Adult)160OtherObservationalObservational Model: Case-Only|Time Perspective: RetrospectiveCOVID-19 AGE-BRUGMANN 2022/111March 1, 2020June 30, 2020June 30, 2020February 16, 2021February 16, 2021CHU Brugmann, Brussels, Belgiumhttps://ClinicalTrials.gov/show/NCT04756479 Belgium
1336NCT04570202Health cAre woRkers exposeD to COVID-19HARD-COVID19RecruitingNo Results AvailableDepression|Burnout, Professional|Post Traumatic Stress DisorderBehavioral: EMDREfficacy on symptoms of Post-Traumatic Stress Disorder|Efficacy on symptoms of Burnout|Efficacy on symptoms of Depression|Short-term efficacy on symptoms of PTSD|Short-term efficacy on symptoms of Burnout|Short-term efficacy on symptoms of Depression|Long-term efficacy on symptoms of PTSD|Long-term efficacy on symptoms of Burnout|Long-term efficacy on symptoms of Depression|Efficacy on symptoms of Anxiety|Long-term efficacy on symptoms of Anxiety|Efficacy on suicide attemptsUniversity Hospital, Tours|Institut National de la SantÃ© Et de la Recherche MÃ©dicale, FranceAll18 Years and older Â  (Adult, Older Adult)Not Applicable900OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentDR200160-HARD-COVID-19|2020-A01642-37|1-20-046 ID 48680November 20, 2020August 20, 2021August 20, 2022September 30, 2020March 23, 2021Centre Investigation Clinique 1415, Tours, Centre Val De Loire, France|Bretonneau Regional Universitary Hospital, Tours, Francehttps://ClinicalTrials.gov/show/NCT04570202 France
1337NCT04407143Study of the Immunity of Patients With Lung Cancer and COVID-19 InfectionSOLIDRecruitingNo Results AvailableLung Cancer|COVID|Corona Virus InfectionDiagnostic Test: IgG testDescription of the characteristics of patientsFundaciÃ³n GECPAll18 Years and older Â  (Adult, Older Adult)128OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveGECP 20/04_SOLIDApril 15, 2020September 30, 2021September 30, 2021May 29, 2020February 2, 2021Hospital General Universitario de Elche, Elche, Alicante, Spain|ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Insular de Gran canaria, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de TorrejÃ³n, TorrejÃ³n, Madrid, Spain|Hospital Universitario Son LlÃ tzer, Palma De Mallorca, Mallorca, Spain|Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain|Complejo Hospitalario de A CoruÃ±a, A CoruÃ±a, Spain|Hospital La Esperanza, A CoruÃ±a, Spain|Hospital Universitario de Ferrol, A CoruÃ±a, Spain|Hospital Virgen de los Lirios, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Dexeus, Barcelona, Spain|Hospital Universitario Cruces, Bilbao, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Universitario Puerto Real, Cadiz, Spain|Hospital General La Mancha Centro, Ciudad Real, Spain|Hospital Universitario San Pedro de AlcÃ¡ntara, CÃ¡ceres, Spain|Hospital Universitario Puerta del Mar, CÃ¡diz, Spain|Hospital Universitario Reina SofÃ­a, CÃ³rdoba, Spain|Hospital Universitario de VinalopÃ³, Elche, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Complejo Hospitalario de JaÃ©n, JaÃ©n, Spain|Complejo Asistencial Universitario de LeÃ³n, LeÃ³n, Spain|Hospital universitari Arnau de Vilanova, Lleida, Spain|Hospital San Pedro, LogroÃ±o, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|ClÃ­nica Universidad de Navarra, Madrid, Spain|Hospital de Sanchinarro, Madrid, Spain|Hospital General Universitario Gregorio MaraÃ±Ã³n, Madrid, Spain|Hospital Severo Ochoa, Madrid, Spain|Hospital Universitario de MÃ³stoles, Madrid, Spain|Hospital Universitario del Henares, Madrid, Spain|Hospital Universitario FundaciÃ³n AlcorcÃ³n, Madrid, Spain|Hospital Universitario Infanta Cristina, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Infanta SofÃ­a, Madrid, Spain|Hospital Universitario PrÃ­ncipe de Asturias, Madrid, Spain|Hospital General Universitario de MÃ¡laga, MÃ¡laga, Spain|Hospital Costa del Sol, MÃ¡laga, Spain|Complejo Hospitalario Universitario de Ourense Santa MarÃ­a Nai, Ourense, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|ClÃ­nica Universidad de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario Sant Joan de Reus, Reus, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Santa Cruz De Tenerife, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del RocÃ­o, Sevilla, Spain|Hospital Sant Pau i Santa Tecla, Tarragona, Spain|Hospital Universitario Nuestra SeÃ±ora de Candelaria, Tenerife, Spain|Hospital Universitari i PolitÃ©cnic La Fe, Valencia, Spain|Hospital ClÃ­nico Universitario de Valencia, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital de Manises, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital LluÃ­s AlcanyÃ­s, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital ClÃ­nico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario RÃ­o Ortega, Valladolid, Spain|Complejo Hospitalario Zamora, Zamora, Spainhttps://ClinicalTrials.gov/show/NCT04407143 Spain
1338NCT04423770COVID-19 Related Health and Infection Control Practices Among DentistsActive, not recruitingNo Results AvailableSevere Acute Respiratory Syndrome Coronavirus 2Other: No interventionCOVID-19 probable or confirmed case|Anxiety|Depression|Dental practice infection control efforts|Dentists' use of personal protective equipmentAmerican Dental AssociationAll18 Years and older Â  (Adult, Older Adult)4000OtherObservationalObservational Model: Ecologic or Community|Time Perspective: Prospective2023-08-20 00:00:00June 8, 2020June 8, 2021June 8, 2021June 9, 2020August 27, 2020American Dental Association, Chicago, Illinois, United Stateshttps://ClinicalTrials.gov/show/NCT04423770 United States
1339NCT04410562Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and PostpartumCOVID-PregRecruitingNo Results AvailablePregnancy Related|COVID|Covid-19Drug: Hydroxychloroquine|Drug: PlaceboNumber of PCR confirmed cases among pregnant women|Incidence of COVID-19 disease during pregnancy|Incidence of COVID-19-related admissions|Incidence of all-cause admissions|Incidence of all-cause outpatient attendances|Mean duration of symptoms-signs of COVID-19|Frequency and severity of adverse events|Incidence of preeclampsia|Incidence of gestational diabetes|Incidence of SARS-CoV-2 infections during pregnancy|Prevalence of intrauterine growth restriction|Maternal mortality rate|Proportion of neonates with SARS-CoV-2- intrauterine infection by PCR-confirmed SARS-CoV-2-infection in nasopharyngeal aspirate.|Proportion of neonates with clinical signs/symptoms of COVID-19|Prevalence of low birth weight (<10th centile according to local standards)|Prevalence of preterm birth (<37 weeks of gestational age)|Prevalence of embryo and foetal losses (miscarriages and stillbirths)|Frequency of congenital malformations|Proportion of adverse perinatal outcome|Neonatal morbidity|Neonatal mortality rateBarcelona Institute for Global Health|Hospital Clinic of Barcelona|FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|University Hospital of Torrejon|FundaciÃ³n de investigaciÃ³n HM|Hospital Sant Joan de Deu|Hospital del Mar|Hospital Universitario Infanta Leonor|Hospital Universitario FundaciÃ³n AlcorcÃ³n|Hospital General de Segovia|Institut CatalÃ  de la SalutFemaleChild, Adult, Older AdultPhase 3714OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment2020-001587-29May 13, 2020May 13, 2021August 1, 2021June 1, 2020January 22, 2021Hospital General de Segovia, Segovia, Cartilla Y LeÃ³n, Spain|Hospital del Mar, Barcelona, Catalunya, Spain|Hospital ClÃ­nic de Barcelona, Barcelona, Catalunya, Spain|Hospital de la Sant Creu i Sant Pau, Barcelona, Catalunya, Spain|Hospital Sant Joan de DÃ©u, Esplugues De Llobregat, Catalunya, Spain|Hospital Universitario FundaciÃ³n AlcorcÃ³n, AlcorcÃ³n, Madrid, Spain|HM Puerta del Sur, MÃ³stoles, Madrid, Spain|Hospital Universitario de TorrejÃ³n, TorrejÃ³n De Ardoz, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spainhttps://ClinicalTrials.gov/show/NCT04410562 Spain
1340NCT04727424Repurposed Approved Therapies for Outpatient Treatment of Patients With Early-Onset COVID-19 and Mild SymptomsRecruitingNo Results AvailableCovid19|SARS-Associated CoronavirusDrug: Fluvoxamine Maleate 100 MG [Luvox]|Drug: Metformin Extended Release Oral Tablet|Drug: Ivermectin oral tablets or sublingual waffles|Drug: PlaceboRate of fluvoxamine, ivermectin and metformin in changing the need for emergency care AND observation for more than 06 hours due to the worsening of COVID-19;|Rate of fluvoxamine, ivermectin and metformin in changing need for Hospitalization due to COVID-19 related complications, including lower respiratory tract infection (LRTI)|Change in viral load on day 03 and 07 after randomization (first 600 enrolled participants)|Time to clinical changes (up to 28 days of randomization), defined as greater than 50% symptoms changing in reference to baseline symptoms)|Time to clinical failure, defined as time to need for hospitalization due to the clinical progression of COVID-19|Number of days with respiratory symptoms since randomization|Rate of all-cause hospitalizations|Rate of COVID-19 related hospitalizations|All-Cause Death|Cardiovascular death|Respiratory death|Health and Functioning after COVID-19 disease|WHO ordinal scale for clinical improvement|Adverse Events|Adherence of Study drugCardresearchAll18 Years and older Â  (Adult, Older Adult)Phase 32724OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentTOGETHER_2January 19, 2021February 1, 2022March 1, 2022January 27, 2021March 24, 2021City of IbiritÃ©, IbiritÃ©, MG, Brazil|City of Sete Lagoas, Sete Lagoas, MG, Brazil|CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil|City of Brumadinho, Brumadinho, Minas Gerais, Brazil|Centro UniversitÃ¡rio FIPMOC, Montes Claros, Minas Gerais, Brazil|Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazilhttps://ClinicalTrials.gov/show/NCT04727424 Brazil
1341NCT04504240Role of Famotidine in the Clinical Improvement of COVID-19 Patients.Active, not recruitingNo Results AvailableCovid19Drug: Famotidine 20 MGTime to Clinical Improvement (TTCI)|Time to symptomatic recovery.|Mortality Rate|Duration of ICU Stay.|Total hospital stay.|Time to clinical failure or death.|Time to Viral clearance / COVID-19 recovery.Chattogram General Hospital|M Abdur Rahim Medical College and Hospital|First Affiliated Hospital Xi'an Jiaotong UniversityAll16 Years to 80 Years Â  (Child, Adult, Older Adult)Phase 3200OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment10000753/980August 1, 2020April 10, 2021April 10, 2021August 7, 2020March 11, 2021Chattogram General Hospital, Chittagong, Bangladesh|M. Abdur Rahim Medical College Hospital, DinÄjpur, Bangladeshhttps://ClinicalTrials.gov/show/NCT04504240 Bangladesh
1342NCT04389554D-dimer Levels in Pregnant With COVID-19CompletedNo Results AvailableCOVID-19|D-dimerOther: Blood D-dimer assayCompare D-dimer values of COVID-19 patients and healthy pregnant womenKanuni Sultan Suleyman Training and Research HospitalFemale18 Years to 45 Years Â  (Adult)300OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveMTalmacMay 14, 2020May 28, 2020May 29, 2020May 15, 2020June 1, 2020Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turgut Ozal, Turkeyhttps://ClinicalTrials.gov/show/NCT04389554 Turkey
1343NCT04371640Sirolimus in COVID-19 Phase 1SirCO-1WithdrawnNo Results AvailableSARS-CoV-2|Covid-19Drug: Sirolimus 1 MG/ML|Drug: PlaceboChange in SARS-CoV-2 viral burden from baseline to day 7 of treatment|Change in SARS-CoV-2 viral burden at days 1-6|Rate of treatment emergent adverse eventsWalter K. Kraft|Thomas Jefferson UniversityAll18 Years to 65 Years Â  (Adult, Older Adult)Phase 10OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment15680July 6, 20202021-07-01 00:00:002021-08-01 00:00:00May 1, 2020December 7, 2020Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United Stateshttps://ClinicalTrials.gov/show/NCT04371640 United States
1344NCT04384900Accelerated Prone Position Ventilation of Patients With COVID-19PROVENT-COVIDRecruitingNo Results AvailableCOVID-19Procedure: Prone position ventilationDays alive without respiratory life support (invasive mechanical ventilation) at day 28.|Days alive and out of hospital on day 28 after randomisation.|Days alive at day 28 without life support (vasopressor/inotropic support, invasive mechanical ventilation or renal replacement therapy).|Number of participants with one or more SARs as described in section 6.1 plus incidence of new persistent nerve injury or grade 3 or 4 (full-thickness skin loss or worse) pressure wounds.|28-days all-cause mortality.Nordsjaellands HospitalAll18 Years and older Â  (Adult, Older Adult)Not Applicable150OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: TreatmentH-20027361May 11, 20202020-11-01 00:00:002020-12-01 00:00:00May 12, 2020May 14, 2020NordsjÃ¦llands Hospital, HillerÃ¸d, Region Hovedstanden, Denmarkhttps://ClinicalTrials.gov/show/NCT04384900 Denmark
1345NCT04395664Arrhythmias in Patients With COVID-19ACOVIDCompletedNo Results AvailableCOVID-19Device: C3+ Holter MonitorIn-hospital mortality during hospitalization and a confirmed COVID-19 diagnosis|Incident intensive care unit admission during hospitalization and a confirmed COVID-19 diagnosis|Incident pulmonary embolism during hospitalization and a confirmed COVID-19 diagnosis|Incident cardiac arrest during hospitalization and a confirmed COVID-19 diagnosis|Incident hypoxic respiratory failure during hospitalization and a confirmed COVID-19 diagnosisHerlev and Gentofte HospitalAll18 Years and older Â  (Adult, Older Adult)1000OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveH-20021500April 16, 2020September 1, 2020September 1, 2020May 20, 2020September 9, 2020Department of Cardiology, Herlev & Gentofte Hospital, Copenhagen, Hellerup, Denmarkhttps://ClinicalTrials.gov/show/NCT04395664 Denmark
1346NCT04542954Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle EastOMC-KTRCompletedNo Results AvailableCovid19|Kidney Transplant Infection|Risk Factor, Cardiovascular|Immunosuppression|Outcome, Fatal|Graft FailureOther: Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle Eastpatient outcome|Kidney graft outcome|risk factors for getting COVID19 infectionHamid Al-Essa Organ Transplant Center|Ministry of Health, KuwaitChild, Adult, Older Adult104OtherObservationalObservational Model: Cohort|Time Perspective: Other2020/1481March 1, 2020August 31, 2020August 31, 2020September 9, 2020September 9, 2020OTC, MOH , Kuwait, Kuwait, Kuwaithttps://ClinicalTrials.gov/show/NCT04542954 Kuwait
1347NCT04762680Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and OlderVAT00002Active, not recruitingNo Results AvailableCOVID-19 (Healthy Volunteers)Biological: SARS-CoV-2 recombinant protein vaccine Formulation 1|Biological: SARS-CoV-2 recombinant protein vaccine Formulation 2|Biological: SARS-CoV-2 recombinant protein vaccine Formulation 3Presence of immediate adverse events|Presence of solicited injection site or systemic reactions|Presence of unsolicited adverse events|Presence of serious adverse events|Presence of adverse events of special interest|Presence of medically-attended adverse events|Neutralizing antibody titer at Day 1|Neutralizing antibody titer at Day 36|Neutralizing antibody titer fold-rise post-vaccination|2-fold rise and 4-fold-rise in neutralization antibody titer|Responders, as determined by neutralizing antibody titers at Day 36|Neutralizing antibody titer at all pre-defined time points|Neutralizing antibody titer fold-rise post-vaccination at all pre-defined time points|2-fold rise and 4-fold-rise in neutralization antibody titer at all pre-defined time points|Responders, as determined by neutralizing antibody titers at each pre-defined time point|Binding antibody concentrations|Binding antibody fold-rise|2-fold-rise and 4-fold rise in binding antibody concentration|Responders, as determined by binding antibody concentrations|Occurrences of laboratory-confirmed symptomatic COVID-19|Occurrences of symptomatic COVID-19 episodes associated with hospitalization|Occurrences of severe symptomatic COVID-19|Occurrences of death associated with symptomatic COVID-19|Occurrences of serologically-confirmed SARS-CoV-2 infectionSanofi Pasteur, a Sanofi Company|GlaxoSmithKline|SanofiAll18 Years and older Â  (Adult, Older Adult)Phase 2722IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionVAT00002|U1111-1251-4616February 24, 20212022-04-01 00:00:002022-04-01 00:00:00February 21, 2021April 5, 2021Investigational Site Number 8400251, Chandler, Arizona, United States|Investigational Site Number 8400220, Los Angeles, California, United States|Investigational Site Number 8400094, Rolling Hills Estates, California, United States|Investigational Site Number 8400173, San Diego, California, United States|Investigational Site Number 8400239, New Haven, Connecticut, United States|Investigational Site Number 8400212, Washington, District of Columbia, United States|Investigational Site Number 8400089, Hollywood, Florida, United States|Investigational Site Number 8400057, Melbourne, Florida, United States|Investigational Site Number 8400179, Orlando, Florida, United States|Investigational Site Number 8400201, Decatur, Georgia, United States|Investigational Site Number 8400187, Peoria, Illinois, United States|Investigational Site Number 8400048, Rockville, Maryland, United States|Investigational Site Number 8400199, Boston, Massachusetts, United States|Investigational Site Number 8400030, Omaha, Nebraska, United States|Investigational Site Number 8400230, New York, New York, United States|Investigational Site Number 8400203, New York, New York, United States|Investigational Site Number 8400207, Rochester, New York, United States|Investigational Site Number 8400233, Pittsburgh, Pennsylvania, United States|Investigational Site Number 8400097, North Charleston, South Carolina, United States|Investigational Site Number 8400191, Austin, Texas, United States|Investigational Site Number 3400002, Municipio Del Distrito Central, Honduras|Investigational Site Number 3400001, San Pedro Sula, Hondurashttps://ClinicalTrials.gov/show/NCT04762680 Honduras
1348NCT04395976Ayurveda as Prophylaxis for Suspected COVID-19 PatientsWithdrawnNo Results AvailableCovid-19Other: AyurvedaClinical confirmation of Covid-19British Ayurvedic Medical Council|All Party Parliamentary Group - Indian Traditional Sciences|University of WarwickAll18 Years and older Â  (Adult, Older Adult)Not Applicable0OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: PreventionBAMC01May 10, 2020June 10, 2020September 1, 2020May 20, 2020March 2, 2021British Ayurvedic Medical Council, London, United Kingdomhttps://ClinicalTrials.gov/show/NCT04395976 United Kingdom
1349NCT04641806Clinical and Immunological Evolution of Covid-19 Occurring in a Context of Non-Hodgkin LymphomaLYMPHO-Cov-2Not yet recruitingNo Results AvailableB-cell Lymphoma|Covid19Immunological response to SARS Cov2|Clinical evolution after Covid-19 diagnosisVersailles HospitalAll18 Years and older Â  (Adult, Older Adult)120OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveP20/21_LYMPHO-Cov-2December 15, 2020April 16, 2021September 16, 2021November 24, 2020November 24, 2020https://ClinicalTrials.gov/show/NCT04641806
1350NCT04583956ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19RecruitingNo Results AvailableCOVID-19Other: Placebo|Drug: Remdesivir|Biological: RisankizumabClinical efficacy in adults hospitalized with COVID-19 according to clinical status on an 8-point ordinal scale.|Change from baseline in C-reactive protein (CRP) concentration|Change from baseline in d-dimer concentration|Change from baseline in ferritin concentration|Change from baseline in fibrinogen concentration|Change from baseline in troponin concentration|Change in alanine aminotransferase (ALT) over time|Change in aspartate aminotransferase (AST) over time|Change in creatinine over time|Change in hemoglobin over time|Change in international normalized ratio (INR) over time|Change in platelets over time|Change in total bilirubin over time|Change in white blood cell (WBC) count with differential over time|Clinical efficacy, as assessed by time to recovery|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of study product administration|Duration of hospitalization|Duration of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Duration of new non-invasive ventilation or high flow oxygen use during the study|Duration of new oxygen use|Duration of non-invasive ventilation/high flow oxygen use|Incidence of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Mean change in the ordinal scale|Oxygenation use|Proportion of subjects alive and without respiratory failure|Subject 14-day mortality|Subject 29-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to death|Ventilator/ extracorporeal membrane oxygenation (ECMO) useNational Institute of Allergy and Infectious Diseases (NIAID)|Gritstone Oncology, Inc.All18 Years to 99 Years Â  (Adult, Older Adult)Phase 2200NIH|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment20-0013AOctober 14, 2020December 31, 2021December 31, 2021October 12, 2020April 12, 2021St Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Mayo Clinic, Phoenix - Infectious Diseases, Phoenix, Arizona, United States|The University of Arizona - Banner University Medical Center Tucson Campus - Tucson, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kern Medical Center, Bakersfield, California, United States|UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States|Hoag Hospital Newport Beach, Newport Beach, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States|Penrose Hospital - Emergency Medicine, Colorado Springs, Colorado, United States|St. Francis Medical Center, Colorado Springs, Colorado, United States|St. Anthony Hospital, Lakewood, Colorado, United States|St. Anthony Hospital North Health Campus, Westminster, Colorado, United States|Nuvance Health Danbury Hospital - Infectious Disease, Danbury, Connecticut, United States|Yale School of Medicine - The Anlyan Center for Medical Research & Education - Immunobiology, New Haven, Connecticut, United States|Nuvance Health - Norwalk Hospital - Asthma Pulmonary and Critical Care Medicine, Norwalk, Connecticut, United States|MedStar Washington Hospital Center - Infectious Diseases, Washington, District of Columbia, United States|Advent Health Orlando - Critical Care, Orlando, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Cook County Health and Hospitals System - Ruth M Rothstein CORE Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|Northwestern Medicine - Central DuPage Hospital - Infectious Disease, Winfield, Illinois, United States|University of Louisville - Division of Infectious Diseases, Louisville, Kentucky, United States|Pikeville Medical Center - Department of Infectious Disease, Pikeville, Kentucky, United States|Tulane University - Section of Pulmonary Diseases, Critical Care, and Environmental Medicine, New Orleans, Louisiana, United States|Louisiana State University Health Shreveport - Infectious Diseases, Shreveport, Louisiana, United States|TidalHealth - Peninsula Regional - Pulmonary and Critical Care, Salisbury, Maryland, United States|Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts, United States|Boston Medical Center - Center for Infectious Diseases - Shapiro Center, Boston, Massachusetts, United States|Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States|Englewood Hospital, Englewood, New Jersey, United States|Virtua Health - Virtua Voorhees Hospital - Pulmonology, Voorhees, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|The State University of New York - University at Buffalo - Department of Medicine, Buffalo, New York, United States|Mount Sinai School of Medicine - Medicine - Infectious Diseases, New York, New York, United States|Nuvance Health - Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Stony Brook Medicine - Stony Brook University Hospita, Stony Brook, New York, United States|East Carolina University Brody School of Medicine - Adult Specialty Care, Greenville, North Carolina, United States|Wake Forest Baptist Health - Infectious Diseases, Winston-Salem, North Carolina, United States|University of Toledo Medical Center - Ruppert Clinic, Toledo, Ohio, United States|St. Charles Health System - St. Charles Bend Hospital, Bend, Oregon, United States|Geisinger Medical Center-Department of Pulmonary and Critical Care Medicine, Danville, Pennsylvania, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|Kent County Memorial Hospital, Warwick, Rhode Island, United States|Monument Health - Clinical Research, Rapid City, South Dakota, United States|Hendrick Health - Hendrick Medical Center, Abilene, Texas, United States|Texas Tech University Health Science Center, Amarillo, Texas, United States|Baptist Hospitals of Southeast Texas Site, Beaumont, Texas, United States|Methodist Hospital - Houston, Houston, Texas, United States|University of Texas Health Science Center at Tyler, Tyler, Texas, United States|West Virginia University - Infectious Diseases Clinic, Morgantown, West Virginia, United Stateshttps://ClinicalTrials.gov/show/NCT04583956 United States
1351NCT04414904Determining the Reproductive Health of Men Post-COVID-19 InfectionWithdrawnNo Results AvailableInfertility, Male|Testosterone DeficiencyOther: Exposure: Covid-19 infectionSemen parameters|Sperm Parameters|Hormones measurement|Seminal Reactive oxygen species|Sperm DNA fragmentation rateImperial College LondonMale18 Years to 50 Years Â  (Adult)0OtherObservationalObservational Model: Case-Control|Time Perspective: Prospective20HH5998June 10, 2020June 10, 2020June 10, 2020June 4, 2020November 24, 2020Channa Jayasena, London, Outside U.S./Canada, United Kingdomhttps://ClinicalTrials.gov/show/NCT04414904 United Kingdom
1352NCT04638842Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19RecruitingNo Results AvailableGrief|Anxiety|Depression|Sleep Disturbance|Quality of LifeBehavioral: Online Intervention Grief COVID-19Decrease in the scores of the Center for Epidemiologic Studies Depression (CES-D) scale|Change in the score of Anxiety Symptoms in the Depression Anxiety Stress Scale (DASS-21)|Decrease in the score of The Pittsburgh Sleep Quality Index.|Decrease in the scores of the Post-Traumatic Stress Disorder Symptom Scale|Increase in Satisfaction with Life Scale|Decrease in the symptoms of General Anxiety Disorder|Decrease in the Plutchik Suicide Risk Scale|Decrease in Grief symptomsUniversidad Internacional de Valencia|Universidad Nacional Autonoma de Mexico|Universidad Autonoma de Ciudad Juarez|University of Buenos AiresAll18 Years to 60 Years Â  (Adult)Not Applicable42OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: TreatmentVIU-Grief-COVIDDecember 24, 2020June 1, 2021June 1, 2021November 20, 2020January 15, 2021Universidad AutÃ³noma de Ciudad JuÃ¡rez, JuÃ¡rez, Chihuahua, Mexico"""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04638842/ICF_000.pdf"https://ClinicalTrials.gov/show/NCT04638842 Mexico
1353NCT04726137European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) SARS-CoV-2 Antibody Study Protocol. Covid-19SARS-Cov2Not yet recruitingNo Results AvailableSars-Cov2 Antibodies in Children and Adolescents Living With HIVNumber of participants with presence of SARS-CoV-2 antibodies assessed by serology testsPENTA Foundation|Hospital st pierre, Belgium|University of Athens|University of Cape Town|Hospital General Universitario Gregorio MaraÃ±on|Hospital Sant Joan de Deu|Karolinska Institutet|Great Ormond Street Hospital for Children NHS Foundation Trust|Guy's and St Thomas' NHS Foundation Trust|North Manchester General Hospital (Northern Care Alliance NHS Group), Manchester|University Hospital Birmingham NHS Foundation Trust|Imperial College Healthcare NHS Trust|King's College Hospital NHS Trust|St George's University Hospitals NHS Foundation Trust|CHIPS+ cohort|Medical Research CouncilAllup to 24 Years Â  (Child, Adult)1150OtherObservationalObservational Model: Cohort|Time Perspective: Prospective17493/002March 30, 2021July 31, 2021April 30, 2022January 27, 2021January 27, 2021https://ClinicalTrials.gov/show/NCT04726137
1354NCT04382495The Impact of COVID-19 Pandemic on Cancer CareRecruitingNo Results AvailableCancerOther: surveypatients' and survivors' perspective of their cancer care during COVID-19 pandemicEl Zaitoun Specialized Hospital|Ain Shams UniversityAll18 Years and older Â  (Adult, Older Adult)400OtherObservationalObservational Model: Other|Time Perspective: Cross-SectionalCancer Care during Covid-19June 15, 2020June 1, 2021June 1, 2021May 11, 2020March 1, 2021EgyBrit Medical Centre, Cairo, Egypthttps://ClinicalTrials.gov/show/NCT04382495 Egypt
1355NCT04628143A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 PneumoniaNot yet recruitingNo Results AvailableCOVID-19Drug: Nafamostat MesilateTime to clinical improvement|Time to recovery|Proportion of patients with clinical improvement as defined by live discharge from hospital or a decline of 2 categories on the seven-category ordinal scale of clinical status|Proportion of patients with recovery as defined as the subject satisfies one of the following|Change of clinical status assessed by 7-category ordinal scale|Change in National Early Warning Score (NEWS)|Time to National Early Warning Score (NEWS) of â‰¤ 2 which is maintained|Duration of hospitalization|Duration of non-invasive ventilation or high flow oxygen use|Incidence of non-invasive ventilation or high flow oxygen use|Duration of supplement oxygen use|Incidence of supplement oxygen use|Duration of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use|Incidence of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use|28-Day mortalityChong Kun Dang PharmaceuticalAll18 Years and older Â  (Adult, Older Adult)Phase 2100IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentA108_01CVD2013November 20, 2020May 30, 2021June 30, 2021November 13, 2020November 13, 2020https://ClinicalTrials.gov/show/NCT04628143
1356NCT04331665Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 PneumoniaNot yet recruitingNo Results AvailableCOVID-19|PneumoniaDrug: RuxolitinibProportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more)|Number of adverse events|All cause mortality rate|Average duration of hospital stayUniversity Health Network, TorontoAll12 Years and older Â  (Child, Adult, Older Adult)Not Applicable64OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentU-DEPLOY: RUX-COVID|20-5315April 20, 2020October 30, 2020January 31, 2021April 2, 2020April 13, 2020Princess Margaret Cancer Centre, Toronto, Ontario, Canadahttps://ClinicalTrials.gov/show/NCT04331665 Canada
1357NCT04428801Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19Not yet recruitingNo Results AvailableCOVID-19Biological: autologous adipose-derived stem cellsTolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication|The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group|COVID-19 incidence rates in both the study and control groups|The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method.|The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.|Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM/IgG antibodies against SARS-Cov-2 between study group and control group.|Change of lymphocyte count in white blood cell counts from the baseline|Change of PaO2 arterial blood gases from the baseline|Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups|COVID-19 mortality rates for both study and control groups|Change of C-reactive protein (CRP) (mg/L) from the baseline|Change of D-dimer (mg/L) from the baseline|Change of Procalcitonin (ug)/L from the baseline|Change of pro-type B natriuretic peptide (pro-BNP) (pg/mL) from the baseline|Change of Bilirubin (mg/dL) from the baseline|Change of Creatinine (mg/dL) from the baseline|Change in blood test values for cytokine panels (IL-1Î², IL-6, IL-8, IL-10, TNFÎ±) from the baseline|The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. as compared to control group|Quantifying viral RNA in stool for baseline and final follow-up.Celltex Therapeutics CorporationAll18 Years and older Â  (Adult, Older Adult)Phase 2200IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: TreatmentCTX0020-003June 1, 2021June 1, 2022June 15, 2024June 11, 2020April 1, 2021https://ClinicalTrials.gov/show/NCT04428801
1358NCT04320732Risk Factors for Community- and Workplace Transmission of COVID-19RecruitingNo Results AvailableCoronavirusBehavioral: Observation of behavior and COVID-19 infection will be conducted.Rate of COVID-19 infectionOslo University Hospital|Age Labs ASAll18 Years and older Â  (Adult, Older Adult)250000OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveREK-124170March 27, 2020March 27, 2022March 20, 2030March 25, 2020June 25, 2020Oslo University Hospital, Oslo, Norwayhttps://ClinicalTrials.gov/show/NCT04320732 Norway
1359NCT04728919Nasal and Pulmonary Nitric Oxide Output in COVID-19 InfectionRecruitingNo Results AvailableCOVID-19|SARS-CoV-2 InfectionViral load of SARS-CoV-2 from different sample sites|Upper respiratory tract viruses|FeNO|FnNO|Change in FeNO|CHange in FnNO|Airway resistance at 20Hz, R20|Airway resistance at 5Hz, R5|Airway resistance at 20 Hz, R20|Change in R20|Change in R5|Reactance at 5Hz (X5)|Change in X5|Resonant frequency (Fres)|Change in Fres|Reactance area (AÐ¥)|Change in AX|FEV1|FVC|VC|FEV1/FVC|FEV1/VCTampere University HospitalAll18 Years to 70 Years Â  (Adult, Older Adult)80OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveR200090January 15, 2021January 15, 2022January 15, 2024January 28, 2021January 28, 2021Tampere University Hospital, Tampere, Finlandhttps://ClinicalTrials.gov/show/NCT04728919 Finland
1360NCT04408235High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and CoagulopathyCOVID-19 HDNot yet recruitingNo Results AvailableCOVID|Pneumonia, Viral|Coagulation DisorderDrug: EnoxaparinClinical worsening, defined as the occurrence of at least one of the following events, whichever comes first:|Any of the following events occurring within the hospital stay|Mortality at 30 daysAzienda Ospedaliero-Universitaria di ModenaAll18 Years to 80 Years Â  (Adult, Older Adult)Phase 3300OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: TreatmentEudraCT NÂ°: 2020-001972-132020-06-01 00:00:002021-06-01 00:00:002021-06-01 00:00:00May 29, 2020May 29, 2020Azienda Ospedaliero-Universitaria, Modena, Italyhttps://ClinicalTrials.gov/show/NCT04408235 Italy
1361NCT04521010Staff Absenteeism and Delivery of Healthcare Services During the COVID-19 PandemicCompletedNo Results AvailableCOVID-19 PandemicOther: COVID-19 pandemicNumber of days an individual person was absentPoznan University of Medical SciencesAllChild, Adult, Older Adult700OtherObservationalObservational Model: Other|Time Perspective: Retrospective3/2020/RehJanuary 1, 2020April 30, 2020April 30, 2020August 20, 2020August 20, 2020Department of Rehabilitation and Physiotherapy Rehabilitation,, PoznaÅ„, Polandhttps://ClinicalTrials.gov/show/NCT04521010 Poland
1362NCT04623047Using Smart Watches to Detect and Monitor COVID-19CovIdentifyNot yet recruitingNo Results AvailableCovid19Accuracy of predictive model using smart watch data to predict Covid-19 symptoms as measured by self-reports of symptom questionnaire.|Accuracy of predictive model using smart watch data to predict Covid-19 symptoms as measured by COVID-19 and influenza test result.|Accuracy of predictive model using smart watch data to predict Covid-19 symptoms as measured by hospital admission questionnaire.|Accuracy comparison of symptom-only model to sensor-only model to symptom + sensor model to predict Covid-19 symptoms.Duke UniversityAll18 Years and older Â  (Adult, Older Adult)100000OtherObservationalObservational Model: Other|Time Perspective: ProspectivePRO00106404July 1, 2021February 1, 2023February 1, 2023November 10, 2020March 9, 2021Duke University, Durham, North Carolina, United Stateshttps://ClinicalTrials.gov/show/NCT04623047 United States
1363NCT04312997The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 InfectionRecruitingNo Results AvailableCOVID-19Drug: PUL-042 Inhalation Solution|Drug: PlaceboSeverity of COVID-19|SARS-CoV-2 infection|Severity of COVID-19 over 14 days|Severity of COVID-19 symptoms|ICU admission|Mechanical Ventilation|MortalityPulmotect, Inc.|United States Department of DefenseAll18 Years and older Â  (Adult, Older Adult)Phase 2100Industry|U.S. FedInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentPUL-042-502June 16, 20202021-04-01 00:00:002021-05-01 00:00:00March 18, 2020March 17, 2021University of California Irvine, Orange, California, United States|Premeir Urgent Care of California, San Bernardino, California, United States|Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States|Invesclinic US LLC, Fort Lauderdale, Florida, United States|DBC Research Corp., Tamarac, Florida, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Ascension St. John, Bartlesville, Oklahoma, United States|Ascension St. John, Tulsa, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04312997 United States
1364NCT04655612Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic DiseasesCOVID-RIC1RecruitingNo Results AvailableCOVID-19|SARS-CoV Infection|Rheumatoid Arthritis|Spondyloarthritis|Ankylosing Spondylitis|Psoriatic ArthritisProportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis|Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.|Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease|Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristicsUniversity Hospital, MontpellierAll18 Years and older Â  (Adult, Older Adult)5000OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveRECHMPL20_0624December 1, 2020July 1, 2021July 30, 2021December 7, 2020December 29, 2020Centre hopsitalier universitaire de Montpellier, Montpellier, Occitanie, Francehttps://ClinicalTrials.gov/show/NCT04655612 France
1365NCT04346589Convalescent Antibodies Infusion in Critically Ill COVID 19 PatientsRecruitingNo Results AvailablePneumonia, Ventilator-Associated|Coronavirus InfectionBiological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patientsNumber of mechanical ventilation days.|Survival|Shift to Continuous Positive Airway Pressure (CPAP) ventilation|Referral to a sub-intensive care unit or discharge|Viral titer|Anti COVID 19 IgG antibodies|Anti COVID 19 IgM antibodies|C5a concentration|C3a concentration|Serum C5b-9 concentrationA.O. Ospedale Papa Giovanni XXIII|Aferetica - Italy (BO)All18 Years and older Â  (Adult, Older Adult)Not Applicable10OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentDFPP COVID 19April 15, 20202020-08-01 00:00:002020-08-01 00:00:00April 15, 2020June 9, 2020IRFMN - Clinical Research Center for Rare Diseases, Ranica, BG, Italy|ASST HPG23 - Unit of Nephrology, Bergamo, Italy|ASST Papa Giovanni XXIII - Microbiology and Virology Unit, Bergamo, Italy|Asst Pg23 - S.I.M.T, Bergamo, Italy|ASST-PG23 - Intensive Care Unit, Bergamo, Italyhttps://ClinicalTrials.gov/show/NCT04346589 Italy
1366NCT04497987A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and StaffBLAZE-2RecruitingNo Results AvailableCOVID-19|SARS-CoV2Drug: LY3819253|Drug: Placebo|Drug: LY3832479Percentage of Participants with COVID-19 within 21 Days of Detection|Percentage of Participants with Moderate or Worse Severity COVID-19 within 21 Days of Detection|Percentage of Participants with SARS-CoV-2|Percentage of Participants Who are Hospitalized or Have Died due to COVID-19|Percentage of Participants who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death|Percentage of Participants Who Die Due to COVID-19|Pharmacokinetics (PK): Mean Concentration of LY3819253 Administered Alone|PK: Mean Concentration of LY3819253 in the Presence of LY3832479|PK: Mean Concentration of LY3832479 in the Presence of LY3819253Eli Lilly and Company|National Institute of Allergy and Infectious Diseases (NIAID)|AbCellera Biologics Inc.|Shanghai Junshi Bioscience Co., Ltd.All18 Years and older Â  (Adult, Older Adult)Phase 35000Industry|NIH|OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention18063|J2X-MC-PYAD|CoVPN #3501August 2, 2020March 8, 2021June 29, 2021August 4, 2020February 23, 2021Unv of AL Sch of Med Div of Infectious Diseases, Birmingham, Alabama, United States|Care Access Research, Phoenix, Arizona, United States|Allergy and Asthma Clin of NW Ark, Bentonville, Arkansas, United States|Care Access Research LLC, Huntington Beach, California, United States|Alta Bates SMC, Oakland, California, United States|University of Colorado-Anschultz Medical Campus, Aurora, Colorado, United States|NIAID, Miami, Florida, United States|NIAID, Decatur, Georgia, United States|Belmont Village Lincoln Park, Lincoln Park, Illinois, United States|Family Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Care Access Rch Lake Charles, Lake Charles, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|NIAID - National Institute of Allergy & Infectious Diseases, Bethesda, Maryland, United States|Care Access, Boston, Massachusetts, United States|St. Paul IDA-CARe, Saint Paul, Minnesota, United States|Care Access, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Hospital & Medical Center, Omaha, Nebraska, United States|Care Access Research - Bronx, Bronx, New York, United States|NIAD, Chapel Hill, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Univ of Cin College of Med, Cincinnati, Ohio, United States|OSU Med Intl Med Houston Ctr, Tulsa, Oklahoma, United States|Donahoe Manor, Bedford, Pennsylvania, United States|Belmont Village, West Univ, Houston, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04497987 United States
1367NCT04481685A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)Active, not recruitingNo Results AvailableCovid19Drug: ATI-450|Drug: PlaceboRespiratory failure-free survival in participants with moderate-severe COVID-19 who are treated with ATI-450|Change in 7 point-ordinal scale|Change in oxygen saturation-normalization|Need for advanced respiratory care|All-cause mortality|Percentage of adverse events (AEs)|Percentage of serious adverse events (SAEs)|Proportion of participants with normalization of fever for 24 hours|Number of participants who develop new bacterial infection|Number of participants who develop new fungal infection|Incidence of Adult Respiratory distress Syndrome (ARDS2)|Change in serum cytokine Interleukin (IL)-6|Change in serum cytokine IL-8|Change in serum cytokines IL-1Î²|Change in serum cytokine Tumor Necrosis Factor (TNF-Î±)University of Kansas Medical CenterAll18 Years and older Â  (Adult, Older Adult)Phase 220OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: TreatmentIIT-2020-ATI-450-COVID-19July 20, 2020February 25, 20212022-07-01 00:00:00July 22, 2020April 5, 2021The University of Kansas Medical Center, Kansas City, Kansas, United Stateshttps://ClinicalTrials.gov/show/NCT04481685 United States
1368NCT04329832Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19HAHPSActive, not recruitingNo Results AvailableCOVID-19Drug: Hydroxychloroquine|Drug: AzithromycinCOVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery scoreIntermountain Health Care, Inc.|University of UtahAll18 Years and older Â  (Adult, Older Adult)Phase 285OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment1051355March 30, 2020December 18, 2020December 31, 2021April 1, 2020September 2, 2020Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United Stateshttps://ClinicalTrials.gov/show/NCT04329832 United States
1369NCT04757831Coronavirus-19 (COVID-19) and Related Outcomes in School Aged Children (ABC Health Outcomes in Children)Not yet recruitingNo Results AvailableCovid19; MIS-CDescribe the incidence of non-severe and severe COVID-19, including Multisystem Inflammatory Syndrome in Children (MIS-C).|Describe risk factors of non-severe and severe COVID-19.|Characterize outcomes associated with COVID-19 in children.|Describe characteristics of participants who attend in-person versus virtual classes.|Describe the duration of in-person school attendance.Duke UniversityAllup to 21 Years Â  (Child, Adult)1000000OtherObservationalObservational Model: Cohort|Time Perspective: ProspectivePro00107647May 15, 2021February 15, 2026February 15, 2026February 17, 2021March 23, 2021https://ClinicalTrials.gov/show/NCT04757831
1370NCT04703205Study in COvid-19 Patients With iveRmectin (CORVETTE-01)RecruitingNo Results AvailableCovid19Drug: Ivermectin 3 MG|Drug: PlaceboCOVID-19 PCR test (SARS-CoV-2 nucleic acid detection) Period until the COVID-19 PCR test (SARS-CoV-2 nucleic acid detection) becomes negativeKitasato UniversityAll20 Years and older Â  (Adult, Older Adult)Phase 2240OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentCORVETTE-01September 16, 2020September 30, 2021September 30, 2021January 11, 2021March 8, 2021Kitasato University, Sagamihara, Kanagawa, Japanhttps://ClinicalTrials.gov/show/NCT04703205 Japan
1371NCT04498065MYocardial DOmmages Related to COVID-19DOMY COVIDActive, not recruitingNo Results AvailableCovid19|Non Ischemic Myocardial Injury|Myocardial Infarction|Myocarditis|Troponin ElevationBiological: Biological data|Other: Clinical datacharacterize the myocardial damage associated with CoV-2 SARS infectionCentre Hospitalier Universitaire DijonAll18 Years and older Â  (Adult, Older Adult)200OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveCOTTIN AOIc 2020March 1, 2020July 1, 20202021-07-01 00:00:00August 4, 2020August 4, 2020Chu Dijon Bourgogne, Dijon, Francehttps://ClinicalTrials.gov/show/NCT04498065 France
1372NCT04545060VIR-7831 for the Early Treatment of COVID-19 in OutpatientsCOMET-ICEActive, not recruitingNo Results AvailableCovid19Biological: VIR-7831|Drug: PlaceboProportion of participants who have progression of COVID-19 through Day 29|Occurence of of adverse events (AEs)|Occurrence of serious adverse events (SAEs)|Occurrence of adverse events of special interest (AESI)|Incidence and titers (if applicable) of serum ADA to VIR-7831|Cmax|Clast|Tmax|Tlast|AUCinf|AUClast|%AUCextrap|t1/2|Vz|Vss|CL|Proportion of participants who have progression of COVID-19 through Day 29 as defined by visit to a hospital emergency room for management or illness, or hospitalization for acute management of illness or death|Mean change in FLU PRO Plus total score comparing Vir 7831 vs Placebo (AUC through Day 7) and time to symptom alleviation using the FLU-Pro Plus|Change from baseline in viral load in nasal secretions by qRT-PCR at Day 8|Proportion of participants who progress to develop severe and/or critical respiratory COVID-19 as manifest by requirement for and method of supplemental oxygen at Day 8, Day 15, Day 22 or Day 29|29-day, 60-day, and 90-day all-cause mortalityVir Biotechnology, Inc.|GlaxoSmithKlineAll18 Years and older Â  (Adult, Older Adult)Phase 2|Phase 31360IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentVIR-7831-5001|GSK Study 214367August 27, 20202021-03-01 00:00:002021-07-01 00:00:00September 10, 2020March 29, 2021Investigative Site, Anniston, Alabama, United States|Investigative Site, Cullman, Alabama, United States|Investigative Site, Mesa, Arizona, United States|Investigative Site, Tucson, Arizona, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Northridge, California, United States|Investigative Site, Oxnard, California, United States|Investigative Site, Rolling Hills Estates, California, United States|Investigative Site, Sacramento, California, United States|Investigative Site, Doral, Florida, United States|Investigative Site, Gainesville, Florida, United States|Investigative Site, Hialeah, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miramar, Florida, United States|Investigative Site, North Miami, Florida, United States|Investigative Site, Palmetto Bay, Florida, United States|Investigative Site, Pembroke Pines, Florida, United States|Investigative Site, Pompano Beach, Florida, United States|Investigative Site, Tampa, Florida, United States|Investigative Site, Tampa, Florida, United States|Investigative Site, Atlanta, Georgia, United States|Investigative Site, Atlanta, Georgia, United States|Investigative Site, Decatur, Georgia, United States|Investigative Site, Stockbridge, Georgia, United States|Investigative Site, Idaho Falls, Idaho, United States|Investigative Site, Mishawaka, Indiana, United States|Investigative Site, Lake Charles, Louisiana, United States|Investigative Site, Marrero, Louisiana, United States|Investigative Site, Baltimore, Maryland, United States|Investigative Site, Caro, Michigan, United States|Investigative Site, Hazelwood, Missouri, United States|Investigative Site, Las Vegas, Nevada, United States|Investigative Site, Las Vegas, Nevada, United States|Investigative Site, Santa Fe, New Mexico, United States|Investigative Site, Bronx, New York, United States|Investigative Site, Asheboro, North Carolina, United States|Investigative Site, Charlotte, North Carolina, United States|Investigative Site, Columbus, Ohio, United States|Investigative Site, Smithfield, Pennsylvania, United States|Investigative Site, Chattanooga, Tennessee, United States|Investigative Site, Austin, Texas, United States|Investigative Site, Baytown, Texas, United States|Investigative Site, Beaumont, Texas, United States|Investigative Site, Denton, Texas, United States|Investigative Site, El Paso, Texas, United States|Investigative Site, Forney, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Humble, Texas, United States|Investigative Site, Laredo, Texas, United States|Investigative Site, McAllen, Texas, United States|Investigative Site, Mesquite, Texas, United States|Investigative Site, Sugar Land, Texas, United States|Investigative Site, Kirkland, Washington, United States|Investigative Site, Seattle, Washington, United States|Investigative Site, Vienna, Austria|Investigative Site, Vienna, Austria|Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Investigative Site, MaringÃ¡, Parana, Brazil|Investigative Site, Natal, Rio Grande Do Norte, Brazil|Investigative Site, Passo Fundo, Rio Grande Do Sul, Brazil|Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Investigative Site, ChapecÃ³, Santa Catarina, Brazil|Investigative Site, Santo AndrÃ©, Sao Paulo, Brazil|Investigative Site, Vila Assuncao, Sao Paulo, Brazil|Investigative Site, Campinas, SÃ£o Paulo, Brazil|Investigative Site, Sarnia, Ontario, Canada|Investigative Site, Toronto, Ontario, Canada|Investigative Site, QuÃ©bec, Quebec, Canada|Investigative Site, Bellavista, Callao, Peru|Investigative Site, El Agustino, Lima, Peru|Investigative Site, Huaral, Lima, Peru|Investigative Site, San Isidro, Lima, Peru|Investigative Site, Bella Vista, Peru|Investigative Site, Lima, Peru|Investigative Site, Terrassa, Barcelona, Spain|Investigative Site, Albacete, Spain|Investigative Site, Centelles, Spain|Investigative Site, Girona, Spain|Investigative Site, Granada, Spain|Investigative Site, Granada, Spain|Investigative Site, Vigo, Spain|Investigative Site, Belfast, United Kingdomhttps://ClinicalTrials.gov/show/NCT04545060 United Kingdom
1373NCT04716088Rapid Antigen Testing for SARS-CoV-2 Among Healthcare Workers to Prevent Spread of COVID-19CompletedNo Results AvailableSARS-CoV-2 Rapid Antigen TestDiagnostic Test: Rapid antigen test for SARS CoV2SARS CoV2 infectionThe University Clinic of Pulmonary and Allergic Diseases Golnik|Insitute of Microbiology and Immunology, Faculty of Medicine, University of LjubljanaAll18 Years to 65 Years Â  (Adult, Older Adult)36OtherObservationalObservational Model: Case-Only|Time Perspective: ProspectiveRADT for COVID-19 GolnikNovember 18, 2020December 2, 2020December 22, 2020January 20, 2021January 22, 2021Universitiy Clinic for respiratory and allergic diseases, Golnik, Sloveniahttps://ClinicalTrials.gov/show/NCT04716088 Slovenia
1374NCT04371107Proactive Care of Ambulatory COVID19 PatientsAMBU-COVIDNot yet recruitingNo Results AvailableCovid19|Azithromycin|AmbulatoryOther: consultation|Drug: AzithromycinLength of symptom duration (in days) with azithromycin treatmentCentre Hospitalier Universitaire, AmiensAll18 Years and older Â  (Adult, Older Adult)Phase 364OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentPI2020_843_0039April 29, 20202020-06-01 00:00:002020-07-01 00:00:00May 1, 2020May 6, 2020CHU Amiens, Amiens, Francehttps://ClinicalTrials.gov/show/NCT04371107 France
1375NCT04651374COVID-19 And Geko Evaluation: The CAGE StudyCAGENot yet recruitingNo Results AvailableCovid19Device: geko T3Feasibility of recruitment|Safety of device: AE|Protocol Adherence|Mortality|MorbidityLawson Health Research InstituteAll18 Years and older Â  (Adult, Older Adult)Not Applicable40OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentISS-COV-0022020-12-01 00:00:002021-03-01 00:00:002021-04-01 00:00:00December 3, 2020December 24, 2020London Health Sciences Centre, London, Ontario, Canadahttps://ClinicalTrials.gov/show/NCT04651374 Canada
1376NCT04374487Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated ComplicationsActive, not recruitingNo Results AvailableCOVID 19Drug: Convalescent Plasma|Other: Standard Care TherapyThe primary outcome is a composite measure of the avoidance of - 1. Progression to severe ARDS (P/F ratio 100) and 2. All-cause Mortality at 28 days|Time to symptom resolution-Fever,Shortness of Breath,Fatigue|Hospital length of stay|Change in SOFA pre and post transfusion|Duration of respiratory support required a. Duration of Invasive Mechanical Ventilation b. Duration of Non-Invasive|Radiological improvement|Adverse events (AE) associated with transfusion|To measure the change in RNA levels (Ct values) of SARS-CoV-2 from RT-PCR [Time Frame: Days 0, 1, 3, and 7 after transfusion]|Levels of bio-markers pre and post transfusion|Need of Vasopressor useMax Healthcare Insititute LimitedAll18 Years to 85 Years Â  (Adult, Older Adult)Phase 2100OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentMHC-COVID-19-CPMay 9, 2020August 9, 2021August 9, 2021May 5, 2020July 22, 2020Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, Indiahttps://ClinicalTrials.gov/show/NCT04374487 India
1377NCT04647305Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 TransmissionCOVPROSHIELDActive, not recruitingNo Results AvailableSARS-CoV-2 InfectionOther: Closed face shield with Surgical face mask use|Other: Surgical face mask use onlyCOVID-19 incidence|Adherence to closed face shields use|Percentage of participants with a positive serological test at baseline|Percentage of seroconversion in the experimental group and active control groupUniversity of Los Andes, Columbia|United NationsAll18 Years and older Â  (Adult, Older Adult)Not Applicable233OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention1010166518January 16, 20212021-03-01 00:00:002021-03-01 00:00:00November 30, 2020March 3, 2021Universidad de los Andes, BogotÃ¡, Colombiahttps://ClinicalTrials.gov/show/NCT04647305 Colombia
1378NCT04770649Vaccine Observation to Include All Communities for Equitable ScienceVOICESRecruitingNo Results AvailableVaccine Response Impaired|Vaccine Adverse ReactionBiological: COVID-19 vaccineDetermine whether the microbiome composition can predict effectiveness of vaccine.|Identify correlations between microbiome composition and immune system response to the vaccine|Track coronavirus variants of any individuals infected|Build a library of samples and data for future researchPersephone BiosciencesAll18 Years and older Â  (Adult, Older Adult)10000IndustryObservationalObservational Model: Cohort|Time Perspective: ProspectivePB-2021-012021-04-01 00:00:002022-12-01 00:00:002023-12-01 00:00:00February 25, 2021February 25, 2021Persephone Biosciences, Inc., San Diego, California, United Stateshttps://ClinicalTrials.gov/show/NCT04770649 United States
1379NCT04350671Interferon Beta 1a in Hospitalized COVID-19 PatientsIB1aICEnrolling by invitationNo Results AvailableCOVID-19Drug: Interferon Beta-1A|Drug: Lopinavir / Ritonavir|Drug: Single Dose of HydroxychloroquineTime to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse eventsShahid Beheshti University of Medical SciencesAll50 Years and older Â  (Adult, Older Adult)Phase 440OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentInterferon Beta 1a in COVID-19April 15, 2020April 20, 2020April 24, 2020April 17, 2020April 20, 2020Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic ofhttps://ClinicalTrials.gov/show/NCT04350671 Islamic Republic of
1380NCT04567953COVID-19 Tests With Saliva SpecimensActive, not recruitingNo Results AvailableCovid19Other: Saliva collectionThe clinical evaluation of saliva as specimen for COVID-19 molecular testParadigm Laboratories LLCAll18 Years and older Â  (Adult, Older Adult)Not Applicable2000IndustryInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: ScreeningPLRD202001July 28, 2020January 30, 2021June 27, 2021September 29, 2020September 29, 2020Paradigm Laboratories, Tucson, Arizona, United Stateshttps://ClinicalTrials.gov/show/NCT04567953 United States
1381NCT04382391Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory SymptomsSAVIORIIRecruitingNo Results AvailableCOVID|Corona Virus Infection|Respiratory Failure|Respiratory Distress Syndrome, Adult|ARDS, Human|SARS (Severe Acute Respiratory Syndrome)Device: gammaCoreÂ® Sapphire (non-invasive vagus nerve stimulator)|Other: Standard of care therapiessummarize and compare the incidence of clinical events in patients randomized to use of gammaCore Sapphire plus standard of care vs standard of care alone in patients hospitalized for CoViD-19.|evaluate cytokine trends|evaluate supplemental oxygen requirements|decrease mortality of CoViD-19 patients|delay onset of ventilation|compare clinical improvement in patients randomized to use of gammaCore Sapphire plus standard of care vs standard of care alone in patients hospitalized for CoViD-19.Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)|ElectroCore INCAll18 Years and older Â  (Adult, Older Adult)Not Applicable60Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment2020-132-AGHMay 8, 2020September 1, 2021June 30, 2022May 11, 2020March 10, 2021AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|AHN West Penn Hospital, Pittsburgh, Pennsylvania, United Stateshttps://ClinicalTrials.gov/show/NCT04382391 United States
1382NCT04382651Study of Efficacy and Safety of MAS825 in Patients With COVID-19MAS-COVIDActive, not recruitingNo Results AvailableCOVID-19 Pneumonia, Impaired Respiratory FunctionDrug: MAS825|Drug: Matching placeboAPACHE II severity of disease score on Day 15 or on day of discharge (whichever is earlier)|Serum C-reactive protein (CRP levels)|Ferritin levels|Proportion of participants without the need for invasive mechanical ventilation|Proportion of participants with at least one level improvement in clinical status|Clinical status over timeNovartis Pharmaceuticals|NovartisAll18 Years and older Â  (Adult, Older Adult)Phase 2140IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentCMAS825F12201June 7, 2020January 6, 2021April 14, 2021May 11, 2020January 25, 2021Novartis Investigative Site, Chula Vista, California, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Irvine, California, United States|Novartis Investigative Site, La Mesa, California, United States|Novartis Investigative Site, Mission Hills, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Idaho Falls, Idaho, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Lafayette, Louisiana, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Bend, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Mesquite, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04382651 United States
1383NCT04566965Serology to Covid for Recording Exposures and Evaluating NeedsSCREENRecruitingNo Results AvailableCovid19|Coronavirus|SARS-CoV InfectionDiagnostic Test: SARS-CoV-2The 12-month cumulative incidence of acquired COVID infection in the study cohort.Children's Hospital Medical Center, CincinnatiAll18 Years and older Â  (Adult, Older Adult)230OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveSCREENAugust 18, 2020December 31, 2022December 31, 2023September 28, 2020September 28, 2020Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United Stateshttps://ClinicalTrials.gov/show/NCT04566965 United States
1384NCT04577105Risk Factors and Computed Tomography Findings in COVID-19.CompletedNo Results AvailableCovid19|ARDS|Pneumonia, Viral|Computed TomographyDiagnostic Test: Simple chest tomographyAssessment of the level of suspicion of SARS-CoV2 infection|Evaluate the severity degree of pulmonary affection by chest computed tomography|Percentage of patients requiring endotracheal intubation|Death from any cause|Modified Sequential Organ Failure Assessment (mSOFA)|Sepsis-induced coagulopathy (SIC)|National Early Warning Scale (NEWS 2)|COVID-GRAM severe illness risk score|Rapid Severity Index for COVID-19 (qCSI)|Neutrophil-Lymphocyte Ratio (NLR)|Alveolar-arterial gradient of oxygen|Berlin Criteria for Acute Respiratory Distress SyndromeInstituto Nacional de Cardiologia Ignacio ChavezAllChild, Adult, Older Adult233OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective20-1177April 1, 2020August 31, 2020October 1, 2020October 6, 2020October 8, 2020Instituto Nacional Ignacio Chavez, Ciudad de mexico, Mexicohttps://ClinicalTrials.gov/show/NCT04577105 Mexico
1385NCT04415086Treatment of Patients With COVID-19 With Convalescent PlasmaCOOPCOVID-19RecruitingNo Results AvailableCOVID-19Biological: convalescent plasmaTime elapsed until clinical improvement or hospital discharge|acute adverse events|Clinical Status|Duration of clinical events|SARS-CoV-2 in nasopharyngeal swab|IgG, IgM and IgA titers for SARS-CoV-2|Neutralizing antibodiesUniversity of Sao Paulo General Hospital|MinistÃ©rio da CiÃªncia, Tecnologia, InovaÃ§Ãµes e ComunicaÃ§Ãµes|Faculty of Medicine of RibeirÃ£o Preto (FMRP-USP)|Hospital de ClÃ­nicas, Faculdade de Medicina Universidade Estadual de Campinas|Hospital Sirio-Libanes|Hospital Israelita Albert Einstein|Grupo Hospitalar ConceiÃ§Ã£o|Hospital Ernesto DornellesAll18 Years and older Â  (Adult, Older Adult)Phase 2120OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentCOOP-COVID-19-MCTICJune 1, 2020April 20, 2022May 22, 2022June 4, 2020October 29, 2020University of Sao Paulo - General Hospital, SÃ£o Paulo, SP, Brazilhttps://ClinicalTrials.gov/show/NCT04415086 Brazil
1386NCT04631861Physical Activity and the Risk of COVID-19 Infection and MortalityCompletedNo Results AvailableCovid19SARS-CoV-2 positivity rate (%)|COVID-19 related mortality rate (%)Wonju Severance Christian HospitalAll18 Years and older Â  (Adult, Older Adult)132069OtherObservationalObservational Model: Case-Control|Time Perspective: Retrospective2020AN0292January 1, 2014July 31, 2020July 31, 2020November 17, 2020November 17, 2020https://ClinicalTrials.gov/show/NCT04631861
1387NCT04426279Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With ImmunosuppressantsCORhumRecruitingNo Results AvailableSars-CoV2|Rheumatoid Arthritis|Rheumatic DiseasesOther: questionnaire assesmentanalysis of Covid-19-related morbidity and mortality in patients with IRC under IS.|To evaluate the frequency of Covid-19 in patients with IRC under IS.|To compare the morbidity and mortality of patients with IRC under IS during the Covid-19 epidemic wave (March to August 2020) with the six months prior to this wave (September 2019 to February 2020).|Patients' conduct in relation to their treatment during the epidemic wave (maintenance, modification or discontinuation) and the impact on their disease (loss of remission, flare, corticosteroids requirement and need for switch of DMARD therapy)University Hospital, LilleAll18 Years and older Â  (Adult, Older Adult)1500OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective2020_49|2020-A01650-39August 18, 20202021-02-01 00:00:002021-02-01 00:00:00June 11, 2020January 7, 2021Lille University Hospital, Lille, Francehttps://ClinicalTrials.gov/show/NCT04426279 France
1388NCT04691908Immunogenicity, Efficacy and Safety of QazCovid-inÂ® COVID-19 VaccineActive, not recruitingNo Results AvailableCovid19|SARS-CoV Infection|Vaccine Adverse ReactionBiological: QazCovid-inÂ®-vaccine against COVID-19|Other: PlaceboTerms of seroconversion (the proportion of persons with a fourfold or higher change in antibody titers to SARS-CoV-2)|To evaluate the immunogenicity of the QazCovid-inÂ® vaccine inactivated against COVID-19 versus placebo|Frequency of confirmed cases of COVID-19|Changing of antigen-specific cellular immunity level|Frequency of adverse events up to seven days after immunization|Frequency of adverse events up to 21 days after immunization|Incidence of serious adverse events during the studyResearch Institute for Biological Safety Problems|City polyclinic No. 4 of the UZO of Almaty|Clinic of the International Institute of Postgraduate Education|City Multidisciplinary Hospital of the Health Department of the Akimat of Zhambyl RegionAll18 Years and older Â  (Adult, Older Adult)Phase 33000OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: PreventionQAZCOV-III-01/2020December 25, 2020March 31, 2021July 30, 2021December 31, 2020February 24, 2021Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeyskiy, Jambul, Kazakhstanhttps://ClinicalTrials.gov/show/NCT04691908 Kazakhstan
1389NCT04718220Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19STOPCOVID19RecruitingNo Results AvailableCovid19|Pregnancy Related|Maternal Complication of Pregnancy|Coronavirus|Neonatal Infection|Prenatal Stress|Preterm BirthDiagnostic Test: Antibody testing for SARS-CoV-2 IgG|Diagnostic Test: Testing for SARS-CoV-2 RNA|Diagnostic Test: Testing for SARS-CoV-2 IgM/IgGRate of preterm delivery|Rate of preeclampsia|Rate of gestational hypertension|Rate of cesarean section|Rate of stillbirth|Rate of fetal growth restriction|Rate of fetal hydrops|Rate of oligohydramnios|Perinatal death|Rate of premature preterm rupture of membranes|Rate of neonatal intensive care unit (NICU) admission|Rate of neonatal sepsis|Rate of oxygen therapy|Percentage of infants with low 5-minute Apgar|Percentage of infants with abnormal umbilical cord gas|Low birth weight|Confirmed congenital infection|Probable congenital infection|Possible congenital infectionWashington University School of Medicine|Mercy ResearchFemaleChild, Adult, Older AdultNot Applicable420OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic202012075March 1, 20212022-11-01 00:00:002022-11-01 00:00:00January 22, 2021April 8, 2021Washington University Medical Center, Saint Louis, Missouri, United Stateshttps://ClinicalTrials.gov/show/NCT04718220 United States
1390NCT04564287An Observational Study of Neurologic Function After COVID-19 InfectionEnrolling by invitationNo Results AvailableCOVID-19MRI brain abnormalities|Neurological Examination|Autonomic TestingNational Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)All18 Years and older Â  (Adult, Older Adult)100NIHObservationalObservational Model: Cohort|Time Perspective: Prospective10000094|000094-NOctober 28, 2020December 1, 2021December 1, 2022September 25, 2020December 17, 2020National Institutes of Health Clinical Center, Bethesda, Maryland, United Stateshttps://ClinicalTrials.gov/show/NCT04564287 United States
1391NCT04382586Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized ParticipantsActive, not recruitingNo Results AvailableCOVID-19 Pulmonary Complications|COVID-19Drug: Zanubrutinib|Drug: Supportive Care|Drug: PlaceboRespiratory failure-free survival rate at day 28|Median reduction in days spent on supplemental oxygen|All-cause mortality|Proportion of participants experiencing respiratory failure or death|Mechanical ventilation-free survival|Days on mechanical ventilation|Duration of hospitalization|Time to discharge|PaO2:FiO2 and/or oxygenation index|Change from Baseline to Day 14 in WHO - 8 Point Ordinal ScaleBeiGeneAll18 Years and older Â  (Adult, Older Adult)Phase 293IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentBGB-3111-219July 6, 2020February 2, 2021April 30, 2021May 11, 2020February 12, 2021Honor Health, Scottsdale, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|Olive View - UCLA Medical Center, Sylmar, California, United States|MedStar Heath Research Institute/ MedStar Washington Hospital Center, Washington, District of Columbia, United States|Augusta University, Augusta, Georgia, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham And Women's Hospital, Boston, Massachusetts, United States|Morristown Medical Center, Morristown, New Jersey, United States|Rutgers University Hospital, Newark, New Jersey, United States|Atlantic Health System, Inc. / Chilton Medical Center, Pompton Plains, New Jersey, United States|Overlook Medical Center, Summit, New Jersey, United States|Therapeutic Concepts, Houston, Texas, United States|Covenant Health System, Lubbock, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United Stateshttps://ClinicalTrials.gov/show/NCT04382586 United States
1392NCT04365439Convalescent Plasma for COVID-19Active, not recruitingNo Results AvailableBlood Plasma Therapy|COVIDBiological: Blood plasmaTiters of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors|Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma|Change in inflammatory cytokines concentration (e.g. IL-6, HMGB1)|Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs|Number of patients with improvement in the 7-points Ordinal Scale|Proportion of patients with adverse events, severity of adverse eventsEnos Bernasconi|Ente Ospedaliero Cantonale, BellinzonaAll18 Years to 75 Years Â  (Adult, Older Adult)Not Applicable11OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment2020-00895July 20, 2020December 20, 2020June 30, 2021April 28, 2020March 29, 2021Ospedale Regionale Locarno, Locarno, Ticino, Switzerlandhttps://ClinicalTrials.gov/show/NCT04365439 Switzerland
1393NCT04444310Antibody Responses in Contacts of COVID-19 PatientsActive, not recruitingNo Results AvailableCOVID-19Measure level of Abs in asymptomatic close contacts of COVID 19 patients.Assiut UniversityAll18 Years to 80 Years Â  (Adult, Older Adult)100OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveAssiut13June 15, 2020June 18, 2020September 30, 2020June 23, 2020June 23, 2020AssiutU, Assiut, Egypthttps://ClinicalTrials.gov/show/NCT04444310 Egypt
1394NCT04724395Disability Following Hospitalization in People of Working-age Surviving SARS-CoV-2 Infection - COVID-19DisCOVIDNot yet recruitingNo Results AvailableCOVID-19Other: HospitalizationPost-acute COVID-19 disability from the care provider's perspective, 9 months after hospitalization|Post-acute COVID-19 disability from the care provider's perspective, 18 months after hospitalization|Post-acute COVID-19 disability from the care provider's perspective, 24 months after hospitalization|Post-acute COVID-19 disability from the patient's perspectives, 9 months after hospitalization|Post-acute COVID-19 disability from the patient's perspectives, 18 months after hospitalization|Post-acute COVID-19 disability from the patient's perspectives, 24 months after hospitalization|Type of treatments|Acceptable symptom state (questionnaire self-administered on ComPARe IT dedicated platform)|Health-related quality of life (questionnaire self-administered on ComPARe IT dedicated platform)|Pain (questionnaire self-administered on ComPARe IT dedicated platform)|Impairments, activity limitations and participation restrictions, health-related quality of life Fatigue (questionnaire self-administered on ComPARe IT dedicated platform)|Impairments, activity limitations and participation restrictions, health-related quality of life (questionnaires self-administered on ComPARe IT dedicated platform)|Urinary symptoms, if applicable (questionnaire self-administered on ComPARe IT dedicated platform)|Female sexual dysfunction, if applicable (questionnaire self-administered on ComPARe IT dedicated platform)|Erectile dysfunction, if applicable (questionnaire self-administered on ComPARe IT dedicated platform)|Global activity limitations and participation restrictions (questionnaire self-administered on ComPARe IT dedicated platform)|Work Ability (questionnaire self-administered on ComPARe IT dedicated platform)|Work productivity (questionnaire self-administered on ComPARe IT dedicated platform)|Comorbidities (score completed by the investigator during a face-to-face visit)|Impairments, activity limitations and participation restrictions (checklist completed by the investigator during a face-to-face visit)|Mobility test to assess the consequences of neurological, cardiorespiratory, osteoarticular or respiratory impairments (clinical assessment by the investigator during a face-to-face visit)|Locomotor impairments (clinical assessment by the investigator during a face-to-face visit)|Upper extremities impairments (clinical assessment by the investigator during a face-to-face visit)|Respiratory impairment (clinical assessment by the investigator during a face-to-face visit)|Cognitive impairments (clinical assessment by the investigator during a face-to-face visit)|Muscular impairments (clinical assessment by the investigator during a face-to-face visit)|Respiratory impairments (clinical assessment by the investigator during a face-to-face visit)|Total costs|Costs drivers|Estimated Years lived with Disability|Burden of post-acute COVID-19 on participant's close relative|Resource utilization|Symptoms of anxiety and/or depression of participant's close relative|Symptoms of post-traumatic stressAssistance Publique - HÃ´pitaux de ParisAll18 Years to 70 Years Â  (Adult, Older Adult)800OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveP2006012021-01-01 00:00:002023-01-01 00:00:002023-01-01 00:00:00January 26, 2021January 26, 2021Cochin Hospital, Paris, Francehttps://ClinicalTrials.gov/show/NCT04724395 France
1395NCT04554264Complicated Grief in ICU in the Aftermath of COVID-19DEPARTSRecruitingNo Results AvailableComplicated Grief|Intensive Care|Covid19Other: questionnaireProportion of complicated grief 4 month after death in relative from patients who died in ICU after covid-19 infection evaluate with ICG score.|Proportion of complicated grief 6 month after death in relative from patients who died in ICU after covid-19 infection evaluate with ICG score.|Proportion of complicated grief 12 month after death in relative from patients who died in ICU after covid-19 infection evaluate with ICG score.Centre Hospitalier Universitaire, Amiens|University Hospital, Lille|University Hospital, RouenAll18 Years and older Â  (Adult, Older Adult)Not Applicable160OtherInterventionalAllocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive CarePI2020_843_0071September 1, 20202021-09-01 00:00:002022-09-01 00:00:00September 18, 2020September 18, 2020CHU Amiens, Amiens, Francehttps://ClinicalTrials.gov/show/NCT04554264 France
1396NCT04508985The McGill RAAS-COVID-19 TrialRAAS-COVIDNot yet recruitingNo Results AvailableCOVID-19|Cardiovascular DiseasesOther: Temporarily holding the RAAS inhibitor [intervention]|Other: RAAS inhibitor [continued standard of care]Global rank scoreMcGill University Health Centre/Research Institute of the McGill University Health Centre|Jewish General Hospital (Montreal, Quebec, Canada)|Montreal General Hospital (Montreal, Quebec, Canada)|UniversitÃ© de Lorraine, Centre d'Investigation Clinique- PlurithÃ©matique InsermAll18 Years and older Â  (Adult, Older Adult)Not Applicable40OtherInterventionalAllocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentMP-37-2021-6614September 1, 2020January 1, 2021September 1, 2021August 11, 2020August 19, 2020https://ClinicalTrials.gov/show/NCT04508985
1397NCT04629638Maternal Attachment and Depression Anxiety Score Evaluation in COVID-19 Positive Pregnant WomenCompletedNo Results AvailableCovid19|Depression, Anxiety|Pregnancy RelatedOther: Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scoresMaternal attachment in SARS- cov2 positive and negative pregnant women|Edinburgh depression scores in in SARS- cov2 positive and negative pregnant women|Postpartum anxiety scale scores in in SARS- cov2 positive and negative pregnant womenKanuni Sultan Suleyman Training and Research HospitalFemale18 Years to 45 Years Â  (Adult)500OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectivematernalattachmentcovidAugust 1, 2020November 15, 2020November 20, 2020November 16, 2020December 22, 2020Pinar Yalcin Bahat, Istanbul, Ä°Ì‡stanbul, Turkeyhttps://ClinicalTrials.gov/show/NCT04629638 Turkey
1398NCT04509999Bicalutamide to Block TMPRSS2 in Males With COVID-19 InfectionRecruitingNo Results AvailableCOVID-19Drug: Bicalutamide 150 Mg Oral Tablet|Drug: PlaceboProportion x 100 = percent of patients with improved COVID-19 symptomsUniversity of FloridaMale18 Years to 99 Years Â  (Adult, Older Adult)Phase 3100OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentIRB202001669-A|OCR38162October 26, 20202022-09-01 00:00:002022-09-01 00:00:00August 12, 2020January 27, 2021University of Florida Clinincal Research Vehicle, Gainesville, Florida, United Stateshttps://ClinicalTrials.gov/show/NCT04509999 United States
1399NCT04563689Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 PatientsCompletedNo Results AvailableCovid19Other: CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|Other: placebo rinseexploratory change in viral load|number of patients who have decrease in viral load of SARS-CoV-2 in spontaneous saliva measured by quantitative PCR|number of patients with adverse events during 5 days study durationDentaid SLAll18 Years to 90 Years Â  (Adult, Older Adult)Not Applicable23IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: OtherCOVID-POC1June 18, 2020October 22, 2020October 23, 2020September 24, 2020November 20, 2020Escuela odontologia. Facultad de Salud Hospital del Valle, Cali, Colombiahttps://ClinicalTrials.gov/show/NCT04563689 Colombia
1400NCT04840459Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized SettingRecruitingNo Results AvailableCovid19Biological: BAMLANIVIMAB|Biological: CASIRIVIMAB|Biological: IMDEVIMABMinimize and/or eliminate the number of patients with mild to moderate COVID-19 who are at high risk for progressing to severe COVID-19 and/or hospitalization.Sohail Rao|DHR Health Institute for Research and DevelopmentAll12 Years and older Â  (Child, Adult, Older Adult)Phase 21000OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment1686206November 20, 2020December 31, 2021January 31, 2022April 12, 2021April 12, 2021DHR Health Institute for Research and Development, Edinburg, Texas, United States|DHR Health, Edinburg, Texas, United States|Starr County Memorial Hospital, Rio Grande City, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04840459 United States
1401NCT04331171Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' TriageCOVID CALL 15CompletedNo Results AvailableCOVID-19Device: Web application usersTo assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess the evolution over time of the COVID 19 epidemic|To assess the evolution over space of the COVID 19 epidemic|To assess symptoms|To assess the users populationWeprom|Institut Pasteur|Assistance Publique - HÃ´pitaux de Paris|DOCAPOST|Direction GÃ©nÃ©rale de l'Offre de SoinsAll18 Years and older Â  (Adult, Older Adult)12000000Other|IndustryObservationalObservational Model: Cohort|Time Perspective: ProspectiveWP-2020-02March 17, 2020November 15, 2020November 15, 2020April 2, 2020April 8, 2021All French Emergency services, Le Mans, Francehttps://ClinicalTrials.gov/show/NCT04331171 France
1402NCT04559009COVID-19 Amyotrophic Lateral Sclerosis (ALS) RegistryRecruitingNo Results AvailableCovid19|Amyotrophic Lateral SclerosisCOVID-19 incidence and prevalence in the ALS populationAtrium HealthAll18 Years and older Â  (Adult, Older Adult)100OtherObservationalObservational Model: Case-Control|Time Perspective: ProspectiveAH-NSI-COVID19-ALSOctober 15, 2020December 31, 2023April 30, 2024September 22, 2020November 4, 2020Neurosciences Institute, Neurology - Charlotte, Charlotte, North Carolina, United Stateshttps://ClinicalTrials.gov/show/NCT04559009 United States
1403NCT04445233COVID-19 Household Transmission StudyCO-HOSTActive, not recruitingNo Results AvailableCOVID-19Number of Households with New SARS-CoV-2 Infection by Day 28|Risk Factors Associated with Secondary Household Transmission|Number of Self-Swab Tests vs. NP Swabs at Day 1 with Detectable Viral LoadUniversity of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences InstituteAll1 Year and older Â  (Child, Adult, Older Adult)315OtherObservationalObservational Model: Cohort|Time Perspective: Prospective20-0982|550KR242023April 29, 20202021-06-01 00:00:002021-06-01 00:00:00June 24, 2020December 7, 2020University of North Carolina Health Care, Chapel Hill, North Carolina, United Stateshttps://ClinicalTrials.gov/show/NCT04445233 United States
1404NCT04527614Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory InfectionPICOVEnrolling by invitationNo Results AvailableInfluenza, Human|SARS Virus|COVID-19|Espiratory Tract InfectionsDiagnostic Test: qRT-PCR and serologyTime to occurrence of ILI and ARI both in participants previously exposed to SARS-COV-2 and controls|Number of patients with ILI or ARI, diagnosed with COVID-19, influenza, RSV|Validation of (SimplySpiro) to replace nasopharyngeal swabs|Identify the antibody characteristics in participants with reinfection with SARS-CoV-2|Correlation of the pre-existing antibody characteristics for COVID-19 with disease severity.|Correlation of the level of neutralization antibodies against influenza subtypes with protection against influenza reinfectionSciensano|Mensura EDPB|Institute of Tropical Medicine, Belgium|UniversitÃ© Libre de BruxellesAll18 Years and older Â  (Adult, Older Adult)Not Applicable2000OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: DiagnosticPICOV2021September 24, 2020May 30, 2021May 30, 2021August 26, 2020October 19, 2020Sciensano, Brussels, Belgiumhttps://ClinicalTrials.gov/show/NCT04527614 Belgium
1405NCT04447144Nutritional Habits, and Coronavirus Disease 2019 (COVID-19) OutcomeRecruitingNo Results AvailableCovid19|Chronic Inflammation|Non-Communicable Chronic DiseasesWestern versus Mediterranean diet in COVID-19 outcome|Gut- Lung axis in COVID-19|Protective role of minerals and vitamins in COVID-19 patients|non-communicable diseases and COVID-19Cairo UniversityAll18 Years to 80 Years Â  (Adult, Older Adult)200OtherObservationalObservational Model: Cohort|Time Perspective: Prospective1003June 1, 2020August 1, 2020September 1, 2020June 25, 2020June 30, 2020Faculty of Medicine Cairo University, Cairo, Egypthttps://ClinicalTrials.gov/show/NCT04447144 Egypt
1406NCT04704388Study Project Comparing the Sequelae of COVID-19 Infection in Patients Who Have and Have Not Received Ventilatory Support in Critical CareCOMEBACCompletedNo Results AvailableCovid19post-intensive care syndrome (PICS)|Evaluate the 3-month mortality of patients released alive from intensive care|Describe the overall state of health and the main organ sequelae of these patients|functional respiratory sequelaeAssistance Publique - HÃ´pitaux de ParisAll18 Years and older Â  (Adult, Older Adult)478OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveCOMEBACJune 1, 2020October 1, 2020October 1, 2020January 11, 2021April 1, 2021BicÃªtre Hospital, Le Kremlin-BicÃªtre, Francehttps://ClinicalTrials.gov/show/NCT04704388 France
1407NCT04386083Neurologic Manifestations of COVID-19CORONARecruitingNo Results AvailableCoronavirus Disease 2019Mortality (binary outcome)|Respiratory failure (binary outcome)|Duration of ventilator dependence (continuous outcome)|Intensive care unit (ICU) admission (binary outcome)University of the Philippines|Asian Hospital and Medical Center, Muntinlupa City, Philippines|Baguio General Hospital and Medical Center, Baguio City, Philippines|Cagayan Valley Medical Center, Tuguegarao City, Philippines|Capitol Medical Center, Quezon City, Philippines|Cardinal Santos Medical Center, San Juan City, Philippines|Chong Hua Hospital, Cebu City, Philippines|De La Salle University Medical Center|East Avenue Medical Center, Philippines|Jose B. Lingad Memorial Regional Hospital, San Fernando, Pampanga, Philippines|Jose R. Reyes Memorial Medical Center|Lung Center of the Philippines|Manila Doctors Hospital, Philippines|Manila Medical Center, Philippines|Makati Medical Center|New Era General Hospital, Philippines|Quirino Memorial Medical Center, Philippines|Ospital ng Makati, Philippines|Dr. Pablo O. Torre Memorial Hospital, Bacolod City, Philippines|Philippine Heart Center|Research Institute for Tropical Medicine, Philippines|San Juan De Dios Educational Foundation Inc. - Hospital, Philippines|San Lazaro Hospital, Philippines|Southern Isabela Medical Center, Philippines|St. Luke's Medical Center, Philippines|St Lukes Medical Center, Bonifacio Global City, Philippines|Southern Philippines Medical Center|The Medical City, Philippines|University of the East Ramon Magsaysay Memorial Medical Center, Inc, Philippines|University of Santo Tomas Hospital, Philippines|Veterans Memorial Medical Center, Philippines|Jose N. Rodriguez Memorial Hospital, Caloocan City|Zamboanga City Medical Center, Zamboanga City|Western Visayas Medical Center, Iloilo City|Northern Mindanao Medical Center, Cagayan de Oro City|Vicente Sotto Memorial Medical Center, Cebu City|Perpetual Succor Hospital, Cebu CityAll19 Years and older Â  (Adult, Older Adult)1342OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveRGAO-2020-0348June 10, 20202020-12-01 00:00:002021-03-01 00:00:00May 13, 2020July 28, 2020Philippine General Hospital - University of the Philippines Manila, Manila, Philippineshttps://ClinicalTrials.gov/show/NCT04386083 Philippines
1408NCT04673162Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia PatientsNot yet recruitingNo Results AvailableCovid19Drug: Methylprednisolone, PlaceboLength of hospitalizationAzienda UnitÃ  Sanitaria Locale Reggio EmiliaAll18 Years and older Â  (Adult, Older Adult)Phase 3260OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentRCT-MP-COVID-192020-12-01 00:00:002021-04-01 00:00:002021-06-01 00:00:00December 17, 2020December 17, 2020SOC Pneumologia, SOC Malattie Infettive, SOC Reumatologia, Az USL-IRCCS di Reggio Emilia, Reggio Emilia, Italyhttps://ClinicalTrials.gov/show/NCT04673162 Italy
1409NCT04501783Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19Active, not recruitingNo Results AvailableCOVID-19Drug: Favipiravir|Drug: Standard of care (SOC)|Drug: standard concomitant therapyTime to clinical improvement|Time to viral clearance|Rate of clinical improvement at separate time points|Rate of viral clearance at separate time points|Time to body temperature normalization|Rate of resolution of lung changes on CT|Rate of adverse drug reactions (ADR) and serious ADR|Rate of severe ADR|Rate therapy termination due to ADRR-PharmAll18 Years to 60 Years Â  (Adult)Phase 3168IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentTL-FVP-t-01May 20, 2020July 29, 20202020-08-01 00:00:00August 6, 2020August 6, 2020"Medical center LLC ""Neuroprofi"", Korolev, Russian Federation|Federal budgetary institution of science ""Central Research Institute of Epidemiology"" of Russian Federal Supervision Service for Consumer Rights Protection and People's Welfare, Moscow, Russian Federation|Medical centers JSC ""Medsi Group of Companies"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow ""City Clinical Hospital â„–57 of the Moscow City Healthcare Department"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow ""City Clinical Hospital â„–67 n.a. LA Vorokhobova of the Moscow City Healthcare Department"", Moscow, Russian Federation|State budgetary institution of health care of the city of Moscow ""Infectious Diseases Clinical Hospital â„–1 of the Moscow City Healthcare Department"", Moscow, Russian Federation|Medical center LLC ""Medical Center Eco-safety"", Saint Petersburg, Russian Federation|St. Petersburg State Budgetary Healthcare Institution ""City Hospital No. 40 of the Kurortny District"", Saint Petersburg, Russian Federation|Budgetary healthcare institution of the Voronezh region ""Voronezh Regional Clinical Hospital No. 1"", Voronezh, Russian Federation|State Budgetary Healthcare Institution of the Moscow Region ""Zhukovskaya City Clinical Hospital""., Zhukovskiy, Russian Federation"https://ClinicalTrials.gov/show/NCT04501783 Russian Federation
1410NCT04482621Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART TrialDARTRecruitingNo Results AvailableCOVID-19Drug: Decitabine|Other: Placebo SalineChange in clinical state as assessed by a 6-point ordinal scale|Safety as assessed by adverse events|Change in oxygenation index|Change in fraction of inspired oxygen|Time (days) to clinical improvement|Overall survival|Length of stay in hospital|Ventilator free days|Time to Polymerase chain reaction (PCR) negativity|Percentage of patients with National Early Warning Score 2 of 3 or moreJohns Hopkins UniversityAll18 Years and older Â  (Adult, Older Adult)Phase 240OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentIRB00247544September 14, 20202021-05-01 00:00:002021-07-01 00:00:00July 22, 2020September 25, 2020Johns Hopkins University, Baltimore, Maryland, United Stateshttps://ClinicalTrials.gov/show/NCT04482621 United States
1411NCT04828135Dual MRI for Cardiopulmonary COVID-19 Long HaulersNot yet recruitingNo Results AvailableCovid19Drug: Hyperpolarized 129Xenon gasChange in percentage of high barrier uptake on 129Xe MRI predicts outcomes as measured by FVC|Change in percentage of low RBC transfer on 129Xe MRI predicts outcomes as measured by DLCOBastiaan Driehuys|Duke UniversityAll18 Years and older Â  (Adult, Older Adult)Phase 230OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: DiagnosticPro00107681May 29, 2021December 30, 2022December 30, 2022April 1, 2021April 1, 2021Duke Asthma, Allergy, and Airway Center, Durham, North Carolina, United Stateshttps://ClinicalTrials.gov/show/NCT04828135 United States
1412NCT04648709Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19COVIMMUNITYRecruitingNo Results AvailableCovid19Diagnostic Test: ELISPOT|Diagnostic Test: QUANTIFERONT cell immune response|B cell immune response|Platelet immune response|Immune response and chronic formsCentre Hospitalier Universitaire de Saint EtienneAll18 Years and older Â  (Adult, Older Adult)100OtherObservationalObservational Model: Cohort|Time Perspective: Prospective20CH207|2020-A02943-36March 9, 20212021-06-01 00:00:002022-12-01 00:00:00December 1, 2020April 8, 2021CHU Saint-Etienne, Saint-Ã‰tienne, Francehttps://ClinicalTrials.gov/show/NCT04648709 France
1413NCT04338672The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical PatientsRecruitingNo Results AvailableEmergency Service, Hospital|General SurgeryOther: COVID-19 PandemicRates of emergency visits needing surgical consult|The ratio of severe presentations to non-severe presentations|The impact of age on ED attendance rates|Differences in ED surgical visits (in terms of capacity and severity) of surgical patients depending on the presentation and the co morbiditySheba Medical CenterAll18 Years and older Â  (Adult, Older Adult)10000OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveSMC-20-7078-YZ-CTILApril 5, 2020April 1, 2021April 1, 2022April 8, 2020April 21, 2020Sheba Medical Center, Ramat Gan, Israelhttps://ClinicalTrials.gov/show/NCT04338672 Israel
1414NCT04836754The Effect of Covid-19 on Breast Milk Microbiome and Its Bioactive ComponentsNot yet recruitingNo Results AvailableCovid19|Human Milkdata analysis:maternal and infant health|Microbiological Analysis:human milkAysu YÄ±ldÄ±z Karaahmet|The Scientific and Technological Research Council of Turkey|Halic UniversityFemale18 Years to 35 Years Â  (Adult)30OtherObservationalObservational Model: Case-Control|Time Perspective: Cross-SectionalCovid-19May 1, 2021July 1, 2021September 1, 2021April 8, 2021April 8, 2021Haseki Training and Research Hospital, Sultangazi, Istanbul, Turkeyhttps://ClinicalTrials.gov/show/NCT04836754 Turkey
1415NCT04343248Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)Active, not recruitingNo Results AvailableCOVID-19|Viral Respiratory IllnessesDrug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-ComplexSymptomatic laboratory-confirmed COVID-19|Symptomatic laboratory-confirmed VRIRomark Laboratories L.C.All55 Years to 120 Years Â  (Adult, Older Adult)Phase 3800IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: PreventionRM08-3006May 12, 2020June 30, 2021June 30, 2021April 13, 2020April 1, 2021The Chappel Group Research, Kissimmee, Florida, United States|Clinical Trial Specialists, Inc., Acworth, Georgia, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Centex Studies, Inc., Houston, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04343248 United States
1416NCT04488562Home Monitoring and Evaluation After Admission for COVID-19 in the NetherlandsHOMECOMIN'RecruitingNo Results AvailableCOVID-19|Pulmonary FibrosisVAS|Temperature|Oxygen measurements|Forced Vital Capacity (FVC) home spirometry in %|Forced Vital Capacity (FVC) home spirometry in L|Forced Vital Capacity (FVC) hospital spirometry in %|Forced Vital Capacity (FVC) hospital spirometry in L|Adherence to weekly home spirometry|EQ5D|FAS|GRoC|ABC tool|Correlation between FVC, HRCT patterns, symptoms and quality of life|Predictors for the course of recovery of COVID-19 infection after hospital admission|Satisfaction of patients and caregivers with the use of a home monitoring systemErasmus Medical Center|Leiden University Medical Center|VU University Medical Center|Dutch Society of Physicians for Pulmonology and TuberculosisAll18 Years and older Â  (Adult, Older Adult)150OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveMEC-2020-0318May 8, 2020December 1, 2021December 31, 2021July 28, 2020July 28, 2020Amsterdam University Center - location VUmc, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus MC, Rotterdam, Netherlandshttps://ClinicalTrials.gov/show/NCT04488562 Netherlands
1417NCT04844242A Cross Sectional Study of the Systems Immunology and Viral Diversity of SARS-CoV2 Infection, COVID-19 Disease and Multisystem Inflammatory Syndrome in ChildrenMISC-COVIDRecruitingNo Results AvailableSARS-CoV2 Infection|Multisystem Inflammatory Syndrome in ChildrenCharacterization of immune responsesTuberculosis Research Centre, India|National Institutes of Health (NIH)All1 Year to 15 Years Â  (Child)180Other|NIHObservationalObservational Model: Case-Control|Time Perspective: Cross-Sectional2020 034December 23, 2020June 22, 2021June 22, 2021April 14, 2021April 14, 2021Tuberculosis Research Centre, Chennai, Tamilnadu, Indiahttps://ClinicalTrials.gov/show/NCT04844242 India
1418NCT04681001Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care WorkersRecruitingNo Results AvailableRespiratory Viral Infection|Common Cold|Severe Acute Respiratory Syndrome (SARS) Pneumonia|COVID-19|Corona Virus DiseaseDevice: nasal sprayPresence of COVID-19 symptoms including symptoms of respiratory viral infection documented in a diary|Nasal swabs for analysis of viruses by PCR|Serology of antibodies against SARS-CoV-2|Number of viral co-infections dedected by PCRMarinomed Biotech AGAll18 Years to 70 Years Â  (Adult, Older Adult)Not Applicable300IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionCOVID-19/CHC_20_04December 20, 2020May 30, 2021June 30, 2021December 23, 2020January 11, 2021Gesundheitsverbund, Klinik Favoriten, Vienna, Austria|Gesundheitsverbund Klinik Floridsdorf, Vienna, Austriahttps://ClinicalTrials.gov/show/NCT04681001 Austria
1419NCT04423692Knowledge About Covid-19 Infection in Pregnant WomenRecruitingNo Results AvailableViral InfectionOther: labsThe number of pregnant women who have knowledge about covid-19Aljazeera HospitalFemale18 Years to 42 Years Â  (Adult)30OtherObservationalObservational Model: Other|Time Perspective: ProspectiveKnowledge about covid 19June 1, 2020August 15, 2020August 20, 2020June 9, 2020July 21, 2020Aljazeera( Al Gazeera) hospital, Giza, Egypthttps://ClinicalTrials.gov/show/NCT04423692 Egypt
1420NCT04459312National Covid-19 Surveillance PhysiciansNAT-COV-SURVRecruitingNo Results AvailableAntibody COVID-19Diagnostic Test: Antibody test (SARS-CoV2)Presence of antibodies against SARS-COV2Heinrich-Heine University, Duesseldorf|Dr. WetzchewaldAll18 Years to 99 Years Â  (Adult, Older Adult)600OtherObservationalObservational Model: Cohort|Time Perspective: Prospective2020_2June 1, 2020July 10, 2020September 30, 2020July 7, 2020July 8, 2020University Hospital Duesseldorf, Dept. of Anesthesiology, Duesseldorf, Germanyhttps://ClinicalTrials.gov/show/NCT04459312 Germany
1421NCT04361500Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood FilterCOSARecruitingNo Results AvailableCOVID-19Device: Seraph 100Survival|Length of ICU stay|Length of Hospital stay|Length of ventilator therapy|Adverse eventsHannover Medical School|Medical Clinic V Nephrology, Academic Teaching Hospital BrunswickAll18 Years to 99 Years Â  (Adult, Older Adult)100OtherObservationalObservational Model: Case-Only|Time Perspective: ProspectiveCOSA-8998April 15, 2020October 1, 2020October 1, 2021April 24, 2020April 24, 2020Academic Teaching Hospital Brunswick, Brunswick, Lower Saxony, Germany|Hannover Medical School, Hannover, Germanyhttps://ClinicalTrials.gov/show/NCT04361500 Germany
1422NCT04326036Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 InfectionGARM-COVID19RecruitingNo Results AvailablePulmonary Alveolar Proteinosis|COPD|Idiopathic Pulmonary Fibrosis|Viral Pneumonia|Coronavirus Infection|Interstitial Lung DiseaseProcedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous UseIncidence of Treatment-Emergent Adverse Events|Pulmonary Function Analysis|Digital OximetryBlack Tie Medical, Inc.|Robert W. Alexander, MDAll18 Years to 90 Years Â  (Adult, Older Adult)Early Phase 110Industry|OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentGARM COVID19March 25, 2020November 1, 2021December 31, 2021March 30, 2020October 12, 2020Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United Stateshttps://ClinicalTrials.gov/show/NCT04326036 United States
1423NCT04332991Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic DiseaseORCHIDCompletedHas ResultsCoronavirus|Acute Respiratory Infection|SARS-CoV InfectionDrug: Hydroxychloroquine|Drug: PlaceboCOVID Outcomes Scale Score on Study Day 15 (14 Days After Randomization)|COVID Ordinal Outcomes Scale on Study Day 3 (2 Days After Randomization)|COVID Ordinal Outcomes Scale on Study Day 8 (7 Days After Randomization)|COVID Ordinal Outcomes Scale on Study Day 29 (28 Days After Randomization)|All-location, All-cause Mortality Assessed on Study Day 15 (14 Days After Randomization)|All-location, All-cause Mortality Assessed on Study Day 29 (28 Days After Randomization)|Number of Patients Dead or With Receipt of ECMO Between Enrollment and Day 28|Oxygen-free Days Through Day 28|Ventilator-free Days Through Day 28|Vasopressor-free Days Through Day 28|ICU-free Days to Day 28|Hospital-free Days to Day 28Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)All18 Years and older Â  (Adult, Older Adult)Phase 3479Other|NIHInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentPETAL 05 OrchidApril 2, 2020June 19, 2020July 23, 2020April 3, 2020March 17, 2021March 17, 2021University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT04332991/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT04332991/SAP_001.pdf"https://ClinicalTrials.gov/show/NCT04332991 United States
1424NCT04401475A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19RecruitingNo Results AvailableCOVID-19|ARDSBiological: SOC plus 15mg/kg EB05 IV|Other: SOC plus Placebo IVthe proportion of patients that are alive without any need for oxygen support defined as a score of 3 or less on the WHO COVID-19 nine-point scale|Time to therapeutic response (primary efficacy endpoint).|The proportion of patients with clinical improvement, defined as a decrease of two points or more on the WHO 9 - point ordinal scale at Day 28|The proportion of patients that are alive and discharged home without any need for oxygen support (WHO Scale of â‰¤ 2) at Day 28.|The proportion of patients that are alive and free of respiratory failure (WHO scale â‰¤ 4) at Day 28.|The proportion of patients with clinical improvement, defined as a decrease of two points or more on the WHO 9 - point ordinal scale at Day 60.|The proportion of patients with clinical improvement, defined as a decrease of one point or more on the WHO 9 - point ordinal scale at Day 28.|The proportion of patients with clinical improvement, defined as a decrease of one point or more on the WHO 9 - point ordinal scale at Day 60.|The proportion of patients that are alive and discharged home without any need for oxygen support (WHO Scale of â‰¤ 2) at Day 60.|The proportion of patients that are alive and free of respiratory failure (WHO scale â‰¤ 4) at Day 60.|Time to clinical improvement by 2 points on the WHO ordinal scale described above.|Time to clinical improvement by 1 point on the WHO ordinal scale described above.|Change in the NEWS-2 Scale at 28 days.|Time to News-2 = 0.|The proportion of patients that experience disease progression, defined as an increase of one point or more in the WHO 9-point ordinal scale, at Day 28.|Ventilator-free days.|Duration of ventilation.|Mortality rate at 28-days and 60-days post-treatment initiation.|Duration of hospitalization.|Time to independence from supplementary oxygen therapy.|Time to normalization of oxygen saturation, defined as SaO2/SpO2 > 94% sustained a minimum of 24 hours.|Change in Sequential Organ Failure Assessment (SOFA) score, while hospitalized.|Radiological response to treatment based on Thoracic Computerized Tomography Scan (CT-Scan) or Chest X-Ray.|Change in cytokines, including IL-6, and C-reactive protein (CRP) levels.|Time to resolution of fever for at least 48 hours without antipyretics.|The decision by the attending physician to initiate treatment with another targeted immunomodulator (i.e. dexamethasone).|Change in the Berlin ARDS severity scale.|Change in Acute Kidney Injury Network (AKIN) classification.|Change in troponin levels.Edesa Biotech Inc.|JSS Medical Research Inc.All18 Years and older Â  (Adult, Older Adult)Phase 2396IndustryInterventionalAllocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentEB05-04-2020November 25, 20202021-04-01 00:00:002021-04-01 00:00:00May 26, 2020January 12, 2021St. Jude Medical Center/ Providence, Fullerton, California, United States|St. Joseph Hospital, Orange - Providence, Orange, California, United States|University of Miami Hospital, Coral Gables, Florida, United States|Methodist Medical Center IL, Peoria, Illinois, United States|Providence Regional Medical Center - Everett, Everett, Washington, United States|UW Medicine Valley Medical Center, Renton, Washington, United States|West Virginia University Medicine Heart & Vascular Institute, Morgantown, West Virginia, United States|North York General Hospital, Toronto, Ontario, Canada|HÃ´pital Maisonneuve Rosemont, MontrÃ©al, Quebec, Canadahttps://ClinicalTrials.gov/show/NCT04401475 Canada
1425NCT04581928Patients Reactions Towards Their Diagnosis as Having COVID-19RecruitingNo Results AvailableCovid19Time to recoveryClinAmygateAll18 Years and older Â  (Adult, Older Adult)300OtherObservationalObservational Model: Cohort|Time Perspective: OtherPR0020October 10, 2020April 10, 2021April 15, 2021October 9, 2020February 16, 2021Asalam, Maadi, Cairo, Egypthttps://ClinicalTrials.gov/show/NCT04581928 Egypt
1426NCT04771351Study to Evaluate a Single Dose of STI-2020 (COVI-AMGâ„¢) in Hospitalized Adults With COVID-19RecruitingNo Results AvailableCovid19Biological: COVI-AMG|Drug: PlaceboProportion of subjects who are alive and free of respiratory failure at Day 29|Viral load reduction|Time to sustained clinical improvement|Proportion of subjects with clinical improvement|All-cause mortality at Day 29Sorrento Therapeutics, Inc.All18 Years and older Â  (Adult, Older Adult)Phase 2280IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentAMG-COV-2022021-04-01 00:00:002021-08-01 00:00:002021-10-01 00:00:00February 25, 2021April 12, 2021Teradan Clinical Trials, Brandon, Florida, United Stateshttps://ClinicalTrials.gov/show/NCT04771351 United States
1427NCT04405102COVID-19 Ozanimod Intervention StudyCOZIRecruitingNo Results AvailableCOVID-19Drug: Ozanimod|Other: Standard of careDaily Patient progression assessed with the World Health Organization-adapted 6-points ordinal scale|The mean oxygen flow required to maintain the oxygen saturation (SpO2) target at 92%|Rate of non invasive ventilation (NIV) / high flow nasal therapy (HFNT) use|Rate of intubation|Ventilator-free days at day 28|Rate of ICU admission/length of stay/mortality|Severity index measurementCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|Celgene|Bristol-Myers Squibb|Institut universitaire de cardiologie et de pneumologie de QuÃ©bec, University LavalAll18 Years to 85 Years Â  (Adult, Older Adult)Phase 248Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment2021-3474September 16, 2020January 1, 2023January 1, 2024May 28, 2020September 30, 2020Institut universitaire de cardiologie et de pneumologie de QuÃ©bec - UniversitÃ© Laval, QuÃ©bec, Canadahttps://ClinicalTrials.gov/show/NCT04405102 Canada
1428NCT04331509COVID-19 Symptom TrackerRecruitingNo Results AvailableCOVID-19Other: No InterventionPhysical health symptoms|Lack of physical health symptoms|FeverKing's College London|Zoe Global Limited|Massachusetts General Hospital|Harvard School of Public Health|Stanford UniversityAll18 Years and older Â  (Adult, Older Adult)10000000OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveCOVID-19 Symptom trackerMarch 23, 2020March 23, 2022March 23, 2022April 2, 2020April 7, 2020Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdomhttps://ClinicalTrials.gov/show/NCT04331509 United Kingdom
1429NCT04742569Wearable Diagnostic for Detection of COVID-19 InfectionRecruitingNo Results AvailableCOVID-19The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor.|The primary outcome of interest are performance of the BioSticker wearable for detecting early onset of active COVID-19 related symptoms.|The primary outcome of interest is the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19.|The secondary outcomes of interest include correlation of biometric data indicators to patient reported symptoms.ClinOne, Inc.|BioIntelliSense, Inc|Phillips North America, LLC|University of Colorado, Denver|United States Department of DefenseAll18 Years and older Â  (Adult, Older Adult)2352Industry|Other|U.S. FedObservationalObservational Model: Cohort|Time Perspective: Prospective1294415December 21, 20202021-06-01 00:00:002021-12-01 00:00:00February 8, 2021February 8, 2021ClinOne, Inc, Greenwood Village, Colorado, United Stateshttps://ClinicalTrials.gov/show/NCT04742569 United States
1430NCT04544605Special Chinese Medicine Out-patient Programme for Discharged COVID-19 PatientsRecruitingNo Results AvailablePost COVID-19Other: Individualized-Chinese herbal medicineChange in CM Diagnostic Pattern & Clinical Characteristics using CM Syndrome Differentiation Assessment|Change in Body Constitution Scores using Body Constitution Questionnaires Assessment|Lung Function Questionnaire in Lung Function Assessment|Blood Pressure in 6-minute Walk Test (6MWT)|Pulse in 6-minute Walk Test (6MWT)|SpO2 in 6-minute Walk Test (6MWT)|Distance Walked in 6-minute Walk Test (6MWT)|Number of Rests in 6-minute Walk Test (6MWT)|MRC Dyspnoea Scale in 6-minute Walk Test (6MWT)|Borg Scale of Perceived Exertion in 6-minute Walk Test (6MWT)|Peak Expiratory Flow (PEF) in Spirometry Assessment|Forced Expiratory Volume in 1 second (FEV1) in Spirometry Assessment|Force Vital Capacity (FVC) in Spirometry Assessment|FEV1/FVC ratio (%) in Spirometry Assessment|Quality of Life (WHO-QOL BREF HK)|Assessment on Western Medicine Visit FrequencyHong Kong Baptist University|The University of Hong Kong|Chinese University of Hong KongAllChild, Adult, Older Adult150OtherObservationalObservational Model: Case-Only|Time Perspective: OtherHA Covid-19September 7, 2020September 30, 2021December 31, 2021September 10, 2020September 16, 2020School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong, Chinahttps://ClinicalTrials.gov/show/NCT04544605 China
1431NCT04540484COVID-19 IgG Formation in Physicians at ALGH and Their Household MembersRecruitingNo Results AvailableCovid19|SARS-CoV Infection|Communicable DiseaseIdentifying positive COVID-19 IgG formation|Physician Prevalence of COVID-19 serum IgG|Household Member Prevalence of COVID-19 serum IgG|Physician Risk of Exposure|Physician and Household Member Transmission|Asymptomatic Infection|PPE Use and Positivity|Antibody PersistenceAdvocate Health Care|Terika Richardson- President's Fund|Medical Staff Fund- Dr. John Ruge|Advocate Foundation- Ally Regnier and Chrisy SantosAll18 Years and older Â  (Adult, Older Adult)900OtherObservationalObservational Model: Cohort|Time Perspective: Prospective1606472-1|M5500436August 26, 2020September 24, 2021September 24, 2021September 7, 2020September 9, 2020Advocate Lutheran General Hospital, Park Ridge, Illinois, United Stateshttps://ClinicalTrials.gov/show/NCT04540484 United States
1432NCT04534673Pegylated Interferon Lambda for Treatment of COVID-19 InfectionRecruitingNo Results AvailableCOVID-19Drug: Lambda 180 mcg S.CViral shedding in days since initial diagnosis|Rate of adverse events and severe adverse events|Time to clinical recovery|Rate of non-invasive or mechanical ventilation|Length of hospital stay|All-cause mortality|Undetectable COVID-19 virus levelsSoroka University Medical CenterAll18 Years and older Â  (Adult, Older Adult)Phase 240OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment0129-20-SOR|SCRC200006August 5, 2020December 31, 2021December 31, 2021September 1, 2020September 1, 2020Soroka UMC, Be'er Sheva, Israelhttps://ClinicalTrials.gov/show/NCT04534673 Israel
1433NCT04425317Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 PatientsCOVID_OFFRecruitingNo Results AvailableInfertility|COVID|IVFDiagnostic Test: Blood samplePresence or absence of SARS-CoV-2 in follicular fluid, cumulus cells, immature oocytes and endometrium|Presence of ACE2, TMPRSS and BSG receptors in cumulus cells, immature oocytes and endometriumCRG UZ BrusselFemaleup to 45 Years Â  (Child, Adult)Not Applicable20OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: DiagnosticCOVIDOFF001June 24, 2020June 15, 2021June 15, 2021June 11, 2020September 7, 2020Uz Brussels, Brussels, Belgiumhttps://ClinicalTrials.gov/show/NCT04425317 Belgium
1434NCT04614948A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in AdultsENSEMBLE 2RecruitingNo Results AvailableParticipants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19Biological: Ad26.COV2.S|Other: PlaceboNumber of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 and who were Seronegative at Baseline|Number of Participants with First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 Regardless of their Serostatus|Number of Participants with First Occurrence of COVID-19 Requiring Medical Intervention|SARS-CoV-2 Viral Load as Assessed by Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) in Participants with Molecularly Confirmed, Moderate to Severe/Critical COVID-19|Number of Participants with First Occurrence of Molecularly Confirmed Mild COVID-19|Number of Participants with First Occurrence of Molecularly confirmed COVID-19 Defined by the US FDA Harmonized Case Definition|Burden of Disease (BOD) Based on First Occurrence of Molecularly Confirmed Symptomatic COVID-19|Serologic Conversion Between Baseline and Other Blood Samples up to Unblinding Visit Using an Enzyme-linked Immunosorbent Assay (ELISA)|Number of Participants With Asymptomatic Infection Detected By Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)|Number of Participants with First Occurrence of SARS-CoV-2 Infection (Serologically and/or Molecularly Confirmed)|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Medically-attended Adverse Events (MAAEs)|Number of Participants with Medically-attended Adverse Events (MAAEs) Leading to Study Discontinuation|Number of Participants with Solicited Local Adverse Events (AEs) During 7 Days Following Each Vaccination|Number of Participants with Solicited Systemic AEs During 7 Days Following Each Vaccination|Number of Participants with Unsolicited Adverse Events (AEs) During 28 Days Post-vaccination|SARS-CoV-2 Binding Antibodies Assessed by ELISAJanssen Vaccines & Prevention B.V.All18 Years and older Â  (Adult, Older Adult)Phase 330000IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: PreventionCR108916|2020-003643-29|VAC31518COV3009November 16, 2020May 10, 2022May 23, 2023November 4, 2020April 14, 2021Achieve Clinical Research, LLC, Vestavia Hills, Alabama, United States|Hope Research Institute, Phoenix, Arizona, United States|Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States|Synexus Clinical Research US, Inc, Tucson, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Synexus Clinical Research US, Inc, Cerritos, California, United States|eStudySite, Chula Vista, California, United States|Ark Clinical Research, Long Beach, California, United States|Anthony Mills Medical, Inc, Los Angeles, California, United States|Catalina Research Institute, Montclair, California, United States|Benchmark Research, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Paradigm Clinical Research Centers, Inc., Wheat Ridge, Colorado, United States|JEM Research, LLC, Atlantis, Florida, United States|Prestige Clinical Research Center, Inc., Coral Gables, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Velocity Clinical Research, Hallandale Beach, Hallandale Beach, Florida, United States|Health Awareness inc., Jupiter, Florida, United States|Altus Research, Inc, Lake Worth, Florida, United States|Compass Research, Melbourne, Melbourne, Florida, United States|Suncoast Research Group, Miami, Florida, United States|Behavioral Clinical Research , Inc, North Miami, Florida, United States|Advent Health Orlando, Orlando, Florida, United States|Clinical NeuroScience Solutions, Inc, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Accel Research Sites, Eatonton, Georgia, United States|The University Of Chicago Medicine, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|The South Bend Clinic Center for Research, South Bend, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Heartland Research Associates, LLC, Newton, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Centennial Medical Group, Elkridge, Maryland, United States|Optimal Research, Rockville, Maryland, United States|Meridian Clinical Research, LLC, Rockville, Maryland, United States|Henry Ford Health Systems, Detroit, Michigan, United States|Cherry Street Services, Inc., Grand Rapids, Michigan, United States|Abbott Northwestern Hospital Clinic, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hassman Research Institute, LLC., Berlin, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Medpharmics, LLC, Albuquerque, New Mexico, United States|Meridian Clinical Research, LLC, Endwell, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Allergy Asthma Immunology of Rochester, PC (AAIR) - Research Center, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|American Health Network, LLC, Charlotte, North Carolina, United States|Wilmington Health Associates, Wilmington, North Carolina, United States|CTI Clinical Trial and Consulting Services, Cincinnati, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Clinical NeuroScience Solutions, Inc, Memphis, Tennessee, United States|Centennial Medical Center, Nashville, Tennessee, United States|Tekton Research Inc., Austin, Texas, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Centex Studies, Inc., McAllen, Texas, United States|Endeavor Clinical Trials, LLC, San Antonio, Texas, United States|JBR Clinical Research, Salt Lake City, Utah, United States|Alliance for Multispeciality Research, Norfolk, Virginia, United States|Anima, Alken, Belgium|Institute of Tropical Medicine Antwerp, Antwerpen, Belgium|AZ Sint-Jan, Brugge, Belgium|Hopital Erasme, Brussel, Belgium|Center for Vaccinology (CEVAC), Gent, Belgium|UZ Leuven, Leuven, Belgium|Az Sint-Maarten, Mechelen, Belgium|Private Practice RESPISOM Namur, Namur, Belgium|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Hospital federal dos servidores do estado, Rio de Janeiro, Brazil|Instituto Nacional de Infectologia Evandro Chagas (INI) - FIOCRUZ, Rio de Janeiro, Brazil|Centro de Referencia E Treinamento Dst/Aids, Sao Paulo, Brazil|Instituto de infectologia Emilio Ribas, SÃ£o Paulo, Brazil|Fundacion Cardiomet CEQUIN, Armenia, Colombia|IPS Centro Cientifico Asisitencial Jose Luis Accini S.A.S., Barranquilla, Colombia|Caja de Compensacion Familiar Cafam, Bogota, Colombia|Asistencia Cientifica de Alta Complejidad S.A.S, Bogota, Colombia|CAIMED Aguazul, Casanare, Colombia|Centro Medico Imbanaco de Cali S.A., Casanare, Colombia|Asociacion IPS Medicos Internistas de Caldas, Manizales, Colombia|Hospital General de Medellin Luz Castro de Gutierrez E.S.E, Medellin, Colombia|T Y C Inversiones S A S Grupsalud, Santa Marta, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Yopal - Casanare, Colombia|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU de Grenoble - HÃ´pital Albert Michallon, La Tronche, France|CHU de Montpellier, Hopital Saint-Eloi, Montpellier, France|Hopital Saint-Antoine, Paris Cedex 12, France|Hopital Cochin, Paris, France|Groupe Hospitalier Sud HÃ´pital Haut-Leveque Service d'hematologie, Pessac, France|CHU Saint-Etienne - HÃ´pital Nord, Saint-Etienne Cedex 2, France|Hopital Purpan, Toulouse Cedex 09, France|Hopital Rangueil, Toulouse, France|Centre Hospitalier Universitaire de Tours, Tours Cedex, France|HÃ´pital de Brabois Adultes, Vandoeuvre les Nancy, France|Uniklinik KÃ¶ln, KÃ¶ln, Germany|Klinikum rechts der Isar der TU Munchen, MÃ¼nchen, Germany|Riverside Medical Center, Bacolod, Philippines|West Visayas State University Medical Center, Iloilo City, Philippines|Tropical Disease Foundation, Makati, Philippines|Makati Medical Center, Manila, Philippines|Medical Center Manila, Manila, Philippines|TREAD Research Tygerberg Hospital, Cape Town, South Africa|Centre of Tuberculosis Research Innovation, Cape Town, South Africa|Worthwhile Clinical trials, Johannesburg, South Africa|Peermed Clinical Trial Centre, Kempton Park, South Africa|Dr AA Mahomed Medical Centre, Moloto, South Africa|VX Pharma, Pretoria, South Africa|Dr J.M. Engelbrecht Trial Site, Somerset West, South Africa|Be Part Yoluntu Centre, Western Cape, South Africa|Hosp. Univ. Germans Trias I Pujol, Badalona, Spain|Hospital Quiron Barcelona, Barcelona, Spain|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. Vall D Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Clinica Univ. de Navarra, Madrid, Spain|Hosp. Univ. de La Paz, Madrid, Spain|Hosp. Quiron Madrid Pozuelo, Madrid, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Powys Teaching Local Health Board - Bronllys Hospital, Brecon, United Kingdom|Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom|University Hospitals Bristol NHS Trust, Bristol, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Royal Free Hospital, Hampstead, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Guy's and St Thomas' Hospital, London,, United Kingdom|Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom|Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom|Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom|University of Oxford, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|Southampton General Hospital, Southampton, United Kingdomhttps://ClinicalTrials.gov/show/NCT04614948 United Kingdom
1435NCT04473118Assessment of Mental Health in Healthcare Workers Exposed to COVID-19 PatientsBADS-PTSDRecruitingNo Results AvailableCOVID-19Other: SurveyTo reflect the effect of COVID-19 on the burnout, anxiety, depression and stress levels of healthcare professionals during the COVID-19 crisis|To reflect the effect of COVID-19 on the post-trauma stress disorder levels of healthcare professionals following the COVID-19 crisisHamad Medical CorporationAll18 Years and older Â  (Adult, Older Adult)25000IndustryObservationalObservational Model: Cohort|Time Perspective: ProspectiveMRC-05-017July 11, 20202020-09-01 00:00:002021-06-01 00:00:00July 16, 2020July 16, 2020Hamad Medical Corporation, Doha, Qatarhttps://ClinicalTrials.gov/show/NCT04473118 Qatar
1436NCT04756466Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the ElderlyActive, not recruitingNo Results AvailableSARS CoV-2 Infection|ElderlyDietary Supplement: Placebo|Dietary Supplement: LactobacillusIncidence of SARS CoV-2 infection.|Incidence of hospital admissions caused by SARS-CoV-2 infection .|Incidence of ICU admissions caused by SARS-CoV-2 infection|Incidence of pneumonia caused by SARS-CoV-2 infection .|Incidence of need for oxygen support due to SARS-CoV-2 infection..|Incidence of gastrointestinal symptoms due to SARS-CoV-2 infection.|Days with body temperature> 37.5ÂºC.|Days of persistent cough.|Days of persistent feeling of fatigue.|Use of pharmacological treatments.|Serum levels of IgG antibody against SARS-CoV-2|Serum levels of IgA antibody against SARS-CoV-2Biosearch S.A.All60 Years and older Â  (Adult, Older Adult)Not Applicable201IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: OtherP055January 1, 2021April 30, 2021December 31, 2021February 16, 2021March 5, 2021Residencia San Marcos, Santiago De Compostela, A CoruÃ±a, Spain|Residencia Santa Olalla, Santiago De Compostela, A CoruÃ±a, Spain|Residencia San Simon de Ons, Santiago De Compostela, A CoruÃ±a, Spainhttps://ClinicalTrials.gov/show/NCT04756466 Spain
1437NCT04510038Colchicine vs Current Standard of Care in Hospitalized Patients With COVID-19 and Cardiac InjuryCOLHEART-19SuspendedNo Results AvailableCovid19|Myocardial InjuryDrug: Colchicine|Other: Covid-19 Standard of CareAll Cause Mortality|Mechanical Ventilation|Mechanical Circulatory Support|Time to Deterioration|Adverse Events|Troponin|Delta|BNP|Changes in C Reactive Protein|LOS|Re-Hospitalization|Changes in D DimerMiami Cardiac and Vascular Institute|University of California, Los AngelesAll18 Years to 100 Years Â  (Adult, Older Adult)Phase 2|Phase 375OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment152247January 1, 2020March 12, 2021January 1, 2022August 12, 2020March 16, 2021Baptist Health South Florida, Miami, Florida, United Stateshttps://ClinicalTrials.gov/show/NCT04510038 United States
1438NCT04432350Assessment of Mortality Rates in COVID-19 Infected Populations Treated With Repurposed MedicationsActive, not recruitingNo Results AvailableCOVID|Drug Effect|Drug Interaction|Risk ReductionThe rate of mortality in patients with a confirmed (positive test result) COVID-19 infection observed by PrescribeWellness pharmacies will be determined.|The relationship between high-risk cardio-pulmonary and vascular comorbidities (e.g., hypertension, dyslipidemia, diabetes, and chronic lung diseases) and mortality with use of repurposed medications for the treatment of COVID-19 will be investigated.|The MRSâ„¢ will be calculated using drug claim data from confirmed COVID-19 patients and explore the predictive value of MRSâ„¢ for ADE, LQTS and all-cause of death.|To compare the rates of death in COVID-19 confirmed patients treated with repurposed medications versus COVID-19 confirmed patients not treated with repurposed drugs.|The relationship between medications used to treat these underlying health conditions (e.g. ACE inhibitors, angiotensin type 1 receptor blockers, aliskiren, and mineralocorticoid antagonists) and mortality in patients with a confirmed COVID-19 infection.|To compare the MRSâ„¢ and its predictive value for ADE between confirmed COVID-19 patients treated with repurposed drugs and confirmed patients not treated with repurposed drugs.|To examine drug regimen patterns associated with higher risk of MRSâ„¢, ADEs, and higher rates of death in confirmed COVID-19 patients with and without repurposed medication.Tabula Rasa HealthCareAllChild, Adult, Older Adult50000IndustryObservationalObservational Model: Cohort|Time Perspective: RetrospectiveCOVID-19_TRHCPrescribeWellnessJune 15, 2020December 31, 2021May 31, 2022June 16, 2020March 16, 2021Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, Florida, United Stateshttps://ClinicalTrials.gov/show/NCT04432350 United States
1439NCT04699851Optimization of the Management of COVID-19 Through Tailored Recommendations to the CitizensVIGIE-COVIDRecruitingNo Results AvailableCOVID19|Tailored Recommendations|Citizen Self-reported SymptomsBehavioral: Tailored recommendations|Behavioral: General recommendationimprovement in mask wearing behavior|improvement in social distancing behavior|improvement in hand washing behavior|improvement in daily fruit consumption|improvement in the amount of daily sleep hours|improvement in the amount of weekly minutes of exercise|Platform participation|Platform sustainability short term|Platform sustainability long termLaval University|RÃ©seau-1 QuÃ©bec|RÃ©seau de recherche en santÃ© des populations du QuÃ©becAll18 Years and older Â  (Adult, Older Adult)Not Applicable1200OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Preventionvigie-covidNovember 18, 2020April 18, 2021May 18, 2021January 7, 2021January 8, 2021Laval University, Quebec, Canadahttps://ClinicalTrials.gov/show/NCT04699851 Canada
1440NCT04734860Study to Evaluate a Single Dose of STI-2020 (COVI-AMGâ„¢) in Adults With Mild COVID-19 SymptomsRecruitingNo Results AvailableCovid19Biological: COVI-AMG|Drug: PlaceboProportion of subjects who have remained out of the hospital or emergency room through Day 29|Viral load reduction from baseline to Day 8, 15, 29, 43, and 70|Proportion of subjects who have remained out of the hospital or emergency room through Day 43 and 70|Proportion of subjects who have 50%, 70%, and 90% reduction in PRO instrument score|Time to resolution of feverSorrento Therapeutics, Inc.All18 Years and older Â  (Adult, Older Adult)Phase 2500IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentAMG-COV-2012021-04-01 00:00:002021-09-01 00:00:002021-11-01 00:00:00February 2, 2021April 13, 2021Collaborative NeuroScience Research, LLC, Garden Grove, California, United States|Synergy Healthcare LLC, Bradenton, Florida, United States|Med-Care Research, Miami, Florida, United States|ETNA Medical Center, Tamarac, Florida, United Stateshttps://ClinicalTrials.gov/show/NCT04734860 United States
1441NCT04391309COVID-19 and Anti-CD14 Treatment TrialCaTTRecruitingNo Results AvailableCoronavirus Disease 2019 (COVID-19)|Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Biological: anti-CD14|Other: Placebo|Drug: remdesivirTime to Clinical Recovery|Days Alive and Free of Any Episodes of Acute Respiratory Failure through Day 28|Mean Change in the Ordinal Scale (Range 1 [Best] to 8 [Worst])|Ordinal Scale Value on Day 14 (Range 1 [Best] to 8 [Worst])|All-Cause Mortality through Days 28 and 60|Proportion of Participants Alive and Free of Any Episode of Acute Respiratory Failure through Day 28|Days Alive and Free of Invasive Mechanical Ventilation through Day 28|Proportion of Participants Alive and Free of Invasive Mechanical Ventilation through Day 28|Proportion of Participants Alive and Discharged from the Hospital through Day 28|Proportion of Participants who Begin Corticosteroid Therapy for Worsening COVID-19 Illness after Randomization|Serious Adverse Events (SAEs)|Adverse Events (AEs)|Safety of IC14 as Measured by Change from Baseline in ALT and AST Liver Function Tests|Safety of IC14 as Measured by Change from Baseline in Liver Function Measured by Total Bilirubin|Safety of IC14 as Measured by Change from Baseline in Serum Creatinine|Safety of IC14 as Measured by Change from Baseline in Hemoglobin|Safety of IC14 as Measured by Change from Baseline in White Blood Cell Count|Safety of IC14 as Measured by Change from Baseline in Differential White Blood Count|Safety of IC14 as Measured by Change from Baseline in Platelet Count|Safety of IC14 as Measured by Change from Baseline in Prothrombin TimeNational Institute of Allergy and Infectious Diseases (NIAID)|University of Washington|Implicit Bioscience|Vanderbilt University Medical Center|PPDAll18 Years and older Â  (Adult, Older Adult)Phase 2300NIH|Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentDAIT COVID-19-003|NIAID CRMS ID#: 38756|UM1AI109565April 12, 20212021-11-01 00:00:002022-02-01 00:00:00May 18, 2020April 14, 2021Harbor - UCLA Medical Center, Torrance, California, United States|University of Miami Medical Center, Miami Beach, Florida, United States|Sarasota Memorial Health Care System, Sarasota, Florida, United States|Emory University Medical Center, Atlanta, Georgia, United States|Ochsner Health, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United Stateshttps://ClinicalTrials.gov/show/NCT04391309 United States
1442NCT04552366A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy AdultsActive, not recruitingNo Results AvailableCOVID-19Biological: Ad5-nCoVIncidence of the AE in all groups|Seroconversion rate of the IgG antibody against SARS-CoV-2|Geomean titers of the IgG antibody against SARS-CoV-2|Seroconversion rate of the neutralizing antibody against SARS-CoV-2|Geomean titers of the neutralizing antibody against SARS-CoV-2|Incidence of Serious adverse events (SAE) in all groups|Cellular immune response by ELISpot|Geomean titers of neutralizing antibody response to Ad5-vector|Cellular immune response by ICS|Geomean titers of the IgA antibody against SARS-CoV-2Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China|Zhongnan HospitalAll18 Years and older Â  (Adult, Older Adult)Phase 1149OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: PreventionAMMS85-2004September 29, 2020December 31, 2020June 30, 2021September 17, 2020December 7, 2020Zhongnan Hospital, Wuhan, Hubei, Chinahttps://ClinicalTrials.gov/show/NCT04552366 China
1443NCT04816682Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver EnzymesSILCOVINT-21RecruitingNo Results AvailableCovid19|Liver DiseasesDrug: SilymarinImprovement in the COVID-19 stage of at least 1 point|Improvement in the activity of aminotranspherases|Improvement in the diabetes control|Improvement in the blood inflammatory markers|Improvement in the dyspnea|Improvement in the acute kidney injuryF.D. Roosevelt Teaching Hospital with Policlinic Banska BystricaAll19 Years and older Â  (Adult, Older Adult)Phase 430OtherInterventionalAllocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentSIL-COVINT-21March 17, 2021June 30, 2021December 30, 2021March 25, 2021March 25, 2021F.D.Roosevelt Teaching Hospital, Banska Bystrica, Slovakia|University Hospital Bratislava, Bratislava, Slovakiahttps://ClinicalTrials.gov/show/NCT04816682 Slovakia
1444NCT04361344Neurodegeneration Markers and Neurological Course in Severe Covid-19 InfectionMARNEVO-CovidTerminatedNo Results AvailableCOVID-19 Infection|EncephalitisBiological: blood samplesChange of neurodegeneration markers levelCentre Hospitalier de PAUAll18 Years and older Â  (Adult, Older Adult)Not Applicable2OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: DiagnosticCHPAU2020/02May 19, 2020October 25, 2020October 25, 2020April 24, 2020February 4, 2021CH de Pau, Pau, Francehttps://ClinicalTrials.gov/show/NCT04361344 France
1445NCT04747769COVID-19. CT-Scan Modeling in COVID19 SequelaeSILICOVILUNGNot yet recruitingNo Results AvailableCOVID-19Qualitative and quantitative parameters obtained by in silico modeling of intra-pulmonary vascular remodeling in 3D at 2-4 months.|Specific mechanical parameters of pulmonary parenchymal stiffness/localized compliances obtained by dynamic poromechanical modeling at 2-4 months.Assistance Publique - HÃ´pitaux de ParisAll18 Years and older Â  (Adult, Older Adult)50OtherObservationalObservational Model: Case-Only|Time Perspective: RetrospectiveAPHP2100062021-02-01 00:00:002021-04-01 00:00:002021-10-01 00:00:00February 10, 2021February 10, 2021HÃ´pital Avicenne APHP, Bobigny, Francehttps://ClinicalTrials.gov/show/NCT04747769 France
1446NCT04689711Prognostic Models for COVID-19 CareEnrolling by invitationNo Results AvailableCovid19Changes in model discrimination (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model discrimination (Model 2: mortality in patients receiving MV)|Changes in model discrimination (Model 3: length of stay in the ICU)|Changes in model calibration (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model calibration (Model 2: mortality in patients receiving MV)|Changes in model calibration (Model 3: length of stay in the ICU)|Changes in net benefit (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in net benefit (Model 2: mortality in patients receiving MV)|Changes in net benefit (Model 3: length of stay in the ICU)|Changes in model discrimination in external database after updating (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model discrimination in external database after updating (Model 2: mortality in patients receiving MV)|Changes in model discrimination in external database after updating (Model 3: length of stay in the ICU)|Changes in model calibration in external database after updating (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model calibration in external database after updating (Model 2: mortality in patients receiving MV)|Changes in model calibration in external database after updating (Model 3: length of stay in the ICU)|Changes in net benefit in external database after updating (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in net benefit in external database after updating (Model 2: mortality in patients receiving MV)|Changes in net benefit in external database after updating (Model 3: length of stay in the ICU)|Stakeholder perceptions, beliefs and opinions on COVID prediction modelsTufts Medical Center|Northwell Health|Erasmus Medical CenterAll18 Years and older Â  (Adult, Older Adult)16OtherObservationalObservational Model: Cohort|Time Perspective: ProspectivePCORI-ME-1606-35555December 7, 2020August 31, 2021August 31, 2021December 30, 2020December 30, 2020Tufts Medical Center, Boston, Massachusetts, United States|Northwell Health (The Feinstein Institutes for Medical Research), Manhasset, New York, United States"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04689711/Prot_SAP_000.pdf"https://ClinicalTrials.gov/show/NCT04689711 United States
1447NCT04743388Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune SystemRecruitingNo Results AvailableCOVID-19|Healthy Volunteers|Chronic Disease|Hematological Malignancies|Solid TumorBiological: BNT162b2|Biological: Other vaccine against SARS-Cov-2Neutralizing antibodies against SARS-CoV-2|Development of anti-S-RBD antibodies against SARS-CoV-2|Number of memory B-cells against SARS-CoV-2|Number of memory T-cells against SARS-CoV-2|Number of monocytes (CD14+, CD16+)|Interleukin 6 (IL-6), Interleukin 3 (IL-3), Interleukin 1b (IL-1b) levels|TNF-a levels|CRP levelsNational and Kapodistrian University of AthensAll18 Years and older Â  (Adult, Older Adult)600OtherObservationalObservational Model: Cohort|Time Perspective: Prospective900/24-12-2020January 4, 20212021-11-01 00:00:002022-04-01 00:00:00February 8, 2021February 11, 2021Department of Clinical Therapeutics, General Hospital of Athens ALEXANDRA, Athens, Greecehttps://ClinicalTrials.gov/show/NCT04743388 Greece
1448NCT04439045Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and SeverityCOBRAActive, not recruitingNo Results AvailableSARS-CoV-2 InfectionBiological: VPM1002|Other: PlaceboCOVID-19 infection|Incidence of hospitalization for COVID-19|Incidence of ICU admission for COVID-19|Incidence of ARDS|Mechanical ventilation for COVID-19|Secondary infection in COVID-19|COVID-19-related Mortality|Incidence of DVTUniversity Health Network, Toronto|Serum Institute of India Pvt. Ltd.|Max Planck Institute for Infection Biology|Verity PharmaceuticalsAll18 Years and older Â  (Adult, Older Adult)Phase 3122Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention20-5413June 24, 2020September 2, 2021December 1, 2021June 19, 2020March 22, 2021University Health Network, Toronto, Ontario, Canadahttps://ClinicalTrials.gov/show/NCT04439045 Canada
1449NCT04655638HFNT vs. COT in COVID-19COVID-HIGHRecruitingNo Results AvailableCovid19|Acute Respiratory FailureDevice: High Flow Nasal Therapy|Device: Conventional Oxygen TherapyProportion of patients needing escalation of treatment during hospital stay|Proportion of patients needing intubation during hospital stay|Proportion of patients who receive CPAP during hospital stay|Proportion of patients who receive NIV during hospital stay|Proportion of patients admitted to intensive care unit during hospital stay|Time to escalation of treatment to CPAP/NIV during hospital stay|Time to escalation of treatment to intubation/invasive ventilation during hospital stay|National Early Warning Score 2 (NEWS2) during hospital stay|Dyspnea score (BORG scale) during hospital stay|ROX index during hospital stay|Length of stay in hospital|Length of stay in ICU|Days free from CPAP/NIV during hospital stay|Ventilator-free days during hospital stay|Oxygen-free days during hospital stay|28-day mortality|60-day mortality|Hospital mortality|Treatment interruption due to intolerance during study treatmentAzienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo|Azienda Ospedaliera, Universitaria Policlinico Vittorio EmanueleAll18 Years and older Â  (Adult, Older Adult)Not Applicable364OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment1th Dec 2020February 10, 2021January 10, 2022March 1, 2022December 7, 2020March 19, 2021"Pulmonology and Respiratory Intensive Care Unit, S. Donato Hospital, Arezzo, Italy, Arezzo, Italy|Respiratory Medicine Unit, ""Policlinico-Vittorio Emanuele San Marco"" University Hospital, Catania, Italy, Catania, Italy|Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy G. Giglio Foundation, CefalÃ¹, Italy, CefalÃ¹, Italy|Department of Human Pathology of the Adult and Evolutive Age ""Gaetano Barresi"", Division of Anesthesia and Intensive Care, University of Messina, Policlinico ""G. Martino"", Messina, Italy, Messina, Italy|IRCCS MultiMedica, Value-Based Healthcare Unit, Sesto San Giovanni, Milan, Italy, Milan, Italy|University Hospital of Modena Policlinico, Respiratory Diseases Unit, Department of Medical and Surgical Sciences SMECHIMAI, University of Modena Reggio Emilia, Italy, Modena, Italy|AOU San Luigi Gonzaga, Orbassano, Italy|Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy Department of Anesthesia Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy, Palermo, Italy|Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy Department of Anesthesia Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy, Palermo, Italy|Department of Medicina e Chirurgia UniversitÃ  Insubria Varese-Como, Italy, Pavia, Italy|Emergency Department, ""S. Maria della Misericordia"" Hospital, Perugia, Italy., Perugia, Italy|Department of Pneumology, A.O.U. CittÃ  della Salute e della Scienza of Turin, Italy., Turin, Italy|U.O. Medicina Respiratoria del Policlinico G.B. Rossi, Verona, Italy"https://ClinicalTrials.gov/show/NCT04655638 Italy
1450NCT04414267Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19ACTIVATEIIRecruitingNo Results AvailableCOVID-19|Virus Diseases|Corona Virus Infection|Coronary Heart Disease|Chronic Obstructive Pulmonary DiseaseBiological: BCG vaccine|Biological: PlaceboPositive for the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 3.|Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 4|Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 5|Prevalence of IgG/IgM against SARS-CoV-2|Analysis of each of the components of the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19.|The impact of new cardiovascular events between the two study groups|Differences in repeated measurements of angiometric parameters (arterial hardness) between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters (central arterial pressures and reflected waves) between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters (endothelial function) between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters (thickness of the medial carotid sheath) between the two sub-study groups in Visit 3|Differences in repeated measurements of angiometric parameters (arterial hardness) between the two sub-study groups in Visit 5|Differences in repeated measurements of angiometric parameters (central arterial pressures and reflected waves) between the two sub-study groups in Visit 5|Differences in repeated measurements of angiometric parameters (thickness of the medial carotid sheath) between the two sub-study groups in Visit 5|Differences in repeated measurements of angiometric parameters (endothelial function) between the two sub-study groups in Visit 5|Differences in cardiac ultrasound at visit 5 between the two sub-study groups|Changes in the release of cytokines from blood mononuclear cells at visit 3 between the two sub-study groupsHellenic Institute for the Study of SepsisAll50 Years and older Â  (Adult, Older Adult)Phase 4900OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionActivate II|2020-002448-21May 26, 2020May 25, 2021May 25, 2021June 4, 2020July 14, 2020"General Hospital of Argolida - Nafplion Unit, NÃ¡fplio, Argos, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|Department of Therapeutics, Alexandra General Hospital, Athens, Greece|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|4th Department of Internal Medicine, ""Attikon"" University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece|Department of Pulmonary Medicine- General Hospital of Kerkyra, Corfu, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, IoÃ¡nnina, Greece|Department of Internal Medicine, General Hospital of Karditsa, KardÃ­tsa, Greece|General Hospital of Korinthos, KÃ³rinthos, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Greece|General Hospital of Ptolemaida MPODOSAKEIO, Ptolemaá¸¯da, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, ThessalonÃ­ki, Greece|General Hospital of Imathia - Veria Unit, VÃ©ria, Greece"https://ClinicalTrials.gov/show/NCT04414267 Greece
1451NCT04584710A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older AdultsActive, not recruitingNo Results AvailableCovid19Drug: RTB101|Drug: PlaceboTo determine the length of time from date of receipt of a positive SARS-CoV2 test result to date of first dose of study drug in asymptomatic adults age â‰¥ 65 years|To determine the feasibility of using an eDiary to assess study drug compliance in the study drug population|To determine the feasibility of using an eDiary to assess COVID-19 symptoms in the study population|To assess the incidence of treatment-emergent of AEs and SAEs in subjects assigned to RTB101 as compared to placebo|To determine the percentage of subjects treated with RTB101 as compared to placebo who develop symptomatic laboratory-confirmed COVID-19 from first dose through Day 14|To determine the percentage of subjects treated with RTB101 as compared to placebo who die from any cause from first dose of study drug through Day 14 and 21|To determine the percentage of subjects treated with RTB101 as compared to placebo who develop laboratory-confirmed COVID-19 from first dose through Day 14 and are subsequently hospitalized for any reason through Day 21|To determine the percent of subjects treated with RTB101 or placebo who have laboratory-confirmed SARS-CoV-2 infection regardless of symptoms from first dose of study drug through Days 7, 14, 21.Restorbio Inc.|National Institute on Aging (NIA)All65 Years and older Â  (Older Adult)Phase 260Industry|NIHInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionRTB101-211|3R01AG064802-02S1October 13, 20202021-02-01 00:00:002021-02-01 00:00:00October 14, 2020February 9, 2021University of Connecticut, UConn Center on Aging, Farmington, Connecticut, United States|Hebrew Senior Life, Marcus Institute for Aging Research, Roslindale, Massachusetts, United Stateshttps://ClinicalTrials.gov/show/NCT04584710 United States
1452NCT04709068Risk Stratification and Early Alerting Regarding COVID-19 HospitalizationRiskSEARCHRecruitingNo Results AvailableCovid19Device: Current HealthHospitalization|Recovery|ICU Admission|DeathCurrent Health|Biomedical Advanced Research and Development AuthorityAll21 Years and older Â  (Adult, Older Adult)2050Industry|U.S. FedObservationalObservational Model: Cohort|Time Perspective: ProspectivePro00047371February 8, 2021March 19, 2021July 1, 2021January 14, 2021February 11, 2021Current Health, New York, New York, United Stateshttps://ClinicalTrials.gov/show/NCT04709068 United States
1453NCT04314232Mechanisms for Covid-19 Disease ComplicationsCOVID MECHRecruitingNo Results AvailableCOVID|Coronavirus InfectionNumber of participants with ICU admission or death|Number of participants with ICU admission|Number of participants with death from all causes|Total duration of ICU stay|Total duration of hospital stayUniversity Hospital, AkershusAll18 Years and older Â  (Adult, Older Adult)200OtherObservationalObservational Model: Cohort|Time Perspective: Prospective117589March 18, 2020December 31, 2021December 31, 2021March 19, 2020June 26, 2020Akershus University Hospital, LÃ¸renskog, Norwayhttps://ClinicalTrials.gov/show/NCT04314232 Norway
1454NCT04718480Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected PatientsRecruitingNo Results AvailableCovid19Drug: Placebo|Drug: FluvoxamineTime to clinical recovery after treatmentSigmaDrugs Research Ltd.All18 Years to 70 Years Â  (Adult, Older Adult)Phase 2100IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentSD-COVID19-01|2020-002299-11November 27, 20202021-08-01 00:00:002021-12-01 00:00:00January 22, 2021January 22, 2021DÃ©l-pesti CentrumkÃ³rhÃ¡z, Budapest, Hungary|Semmelweis Egyetem PulmonolÃ³giai Klinika, Budapest, Hungary|OrszÃ¡gos KorÃ¡nyi PulmonolÃ³giai IntÃ©zet, Budapest, Hungary|Debreceni Egyetem KenÃ©zy Gyula KÃ³rhÃ¡z InfektolÃ³gia, Debrecen, Hungaryhttps://ClinicalTrials.gov/show/NCT04718480 Hungary
1455NCT04328129Household Transmission Investigation Study for COVID-19 in Tropical RegionsEPI-COVID-19RecruitingNo Results AvailableCoronavirus Infections|Severe Acute Respiratory Syndrome|SARS-CoV InfectionProcedure: Human biological samplesEvaluation of the extent of the virus transmission within households|Characterization of the secondary cases|In New-Caledonia, evaluation of the extent of the virus transmission within contact personsInstitut Pasteur|Institut Pasteur de la Guyane|Centre Hospitalier AndrÃ©e Rosemon de Cayenne|Institut Pasteur de la Guadeloupe|Centre Hospitalier de la Guadeloupe|Institut Pasteur de Nouvelle-CalÃ©donie|Centre Hospitalier Territorial de Nouvelle CalÃ©donieAllChild, Adult, Older AdultNot Applicable1300Industry|OtherInterventionalAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening2020-009March 23, 2020March 23, 2022March 23, 2022March 31, 2020September 23, 2020Centre Hospitalier AndrÃ©e Rosemon, Cayenne, French Guiana|Institut Pasteur de la Guyane, Cayenne, French Guiana|Institut Pasteur de Guadeloupe, Les Abymes, Guadeloupe|Institut Pasteur de Nouvelle-CalÃ©donie, NoumÃ©a, New Caledoniahttps://ClinicalTrials.gov/show/NCT04328129 New Caledonia
1456NCT04383587Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare WorkersCompletedNo Results AvailableSARS-CoV 2|COVID-19Other: Serologic testingPrevalence of COVID19 Antibody Positivity|Ability to predict immune status/antibody positivityMayo ClinicAll18 Years and older Â  (Adult, Older Adult)Not Applicable300OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research20-004054May 6, 2020July 1, 2020July 31, 2020May 12, 2020September 1, 2020Mayo Clinic in Florida, Jacksonville, Florida, United Stateshttps://ClinicalTrials.gov/show/NCT04383587 United States
1457NCT04788459Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult VolunteersRecruitingNo Results AvailableCOVID-19|Protection Against COVID-19 and Infections With SARS-CoV- 2|COVID-19 ImmunisationBiological: COVID-eVax|Device: CliniporatorÂ® and EPSGunIncidence of solicited local Adverse events (AEs) at the injection site (for Phase 1)|Incidence of solicited systemic AEs (for Phase 1)|Incidence of unsolicited AEs (for Phase 1)|White Blood Cell (WBC) levels (for Phase 1)|Red Blood Cell (RBC) levels (for Phase 1)|Platelets levels (for Phase 1)|Alanine Transaminase (ALT) levels (for Phase 1)|Aspartate Transaminase (AST) levels (for Phase 1)|Creatine Phosphokinase (CPK) levels (for Phase 1)|Quantitative antibody titers, binding to the specific SARS-CoV-2 antigen (for Phase 2)|SARS-CoV-2 neutralizing antibody titer (for Phase 2)|Change from baseline in antigen-specific cellular immune responses to SARS-CoV-2 (for Phase 2)|Percentage of subjects who seroconverted (for Phase 2)|Quantitative antibody titers, binding to the specific SARS-CoV-2 antigen (for Phase 1)|SARS-CoV-2 neutralizing antibody titer (for Phase 1)|Change from baseline in antigen-specific cellular immune responses to SARS-CoV-2 (for Phase 1)|Percentage of subjects who seroconverted (for Phase 1)|Incidence of solicited local AEs at the injection site (for Phase 2)|Incidence of solicited systemic AEs (for Phase 2)|Incidence of unsolicited AEs (for Phase 2)|White Blood Cell (WBC) levels (for Phase 2)|Red Blood Cell (RBC) levels (for Phase 2)|Platelets levels (for Phase 2)|Alanine Transaminase (ALT) levels (for Phase 2)|Aspartate Transaminase (AST) levels (for Phase 2)|Creatine Phosphokinase (CPK) levels (for Phase 2)Takis|Rottapharm BiotechAll18 Years to 65 Years Â  (Adult, Older Adult)Phase 1|Phase 2160IndustryInterventionalAllocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: PreventionCOV-1/2-01|2020-003734-20February 25, 20212021-09-01 00:00:002022-06-01 00:00:00March 9, 2021March 16, 2021San Gerardo Hospital, Monza, Italy|Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy|INMI Lazzaro Spallanzani, Rome, Italyhttps://ClinicalTrials.gov/show/NCT04788459 Italy
1458NCT04499300Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of AgeRecruitingNo Results AvailableCovid19Other: Data collection from medical filesDemographic data|Comorbidities|Cumulative Illness Rating Scale-Geriatric (CIRS-G)|Treatments|Signs and symptoms|Fever|Hypoxemia|Tachycardia|Hypotension|Gasometry|Infectious data|Blood count|Ionogram|Liver function|Coagulation|Renal function|Albumin|CRP|Fibrinogen|D-dimers at hospital admission or first recorded|NTproBNP|CK|Troponin|Ferritin|Procalcitonin|Biology - highest rate|Biology - lowest rate|Percentage of pulmonary involvement on chest CT scan|Number of pulmonary lobes affected|Type of lesions|Need for oxygenotherapy|Means of ventilation|Treatment received|Length of ICU Stay|Status at hospital exit|MortalityMurielle Surquin|Brugmann University HospitalAll90 Years and older Â  (Older Adult)50OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveCHUB-COVID-19-90+June 9, 20202020-12-01 00:00:002020-12-01 00:00:00August 5, 2020August 7, 2020CHU Brugmann, Brussels, Belgiumhttps://ClinicalTrials.gov/show/NCT04499300 Belgium
1459NCT04311697Intravenous Aviptadil for Critical COVID-19 With Respiratory FailureCOVID-AIVCompletedNo Results AvailableCritical COVID-19 With Respiratory Failure|Acute Respiratory Distress Syndrome (ARDS)|Corona Virus Infection|Acute Lung InjuryDrug: Aviptadil by intravenous infusion + standard of care|Drug: Normal Saline Infusion + standard of careResolution of Respiratory Failure (Composite Endpoint)|Improvement on NIAID Scale (key secondary measure)|Survival through day 28 and day 60|Time to ICU discharge|Time on ventilation|Time to extubation|Time to discharge alive|Multi-organ failure free daysNeuroRx, Inc.|Lavin Consulting, LLCAll18 Years to 100 Years Â  (Adult, Older Adult)Phase 2|Phase 3196Industry|OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentCOVID-AIVMay 15, 2020February 22, 2021February 22, 2021March 17, 2020February 26, 2021St. Jude Medical Center, Fullerton, California, United States|University of California - Irvine, Irvine, California, United States|Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Heartland/Mosaic Health, Saint Joseph, Missouri, United States|Hendrick Health, Abilene, Texas, United States|Texas Health Harris Methodist Hospital, Fort Worth, Texas, United States|Texas Health Hospital Frisco, Frisco, Texas, United States|Houston Methodist Hospital, Houston, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04311697 United States
1460NCT04510441Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using ElectrocardiogramsAI-COV-19RecruitingNo Results AvailableCoronavirusOther: Nil interventionAccuracy of machine learning to be able to predict outcome of coronavirus (COVID-19) infection|Accuracy of machine learning to be able to predict prognosis of coronavirus (COVID-19) infection|Accuracy of machine learning to be able to predict cardiac involvement of coronavirus (COVID-19) infection|Accuracy of machine learning vs human assessment to diagnose coronavirus (COVID-19) infectionImperial College London|Imperial College Healthcare NHS Trust|Chelsea and Westminster Hospital NHS Foundation Trust|LONDON NORTH WEST UNIVERSITY HEALTHCARE NHS TRUSTAll18 Years and older Â  (Adult, Older Adult)2000OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective20HH5967May 26, 2020May 1, 2022May 1, 2022August 12, 2020August 12, 2020London North West University Healthcare NHS Trust, London, United Kingdom|Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom|Imperial College London (Hammersmith campus), London, United Kingdom|St Mary's Hospital, London, United Kingdom"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04510441/Prot_SAP_000.pdf"https://ClinicalTrials.gov/show/NCT04510441 United Kingdom
1461NCT04406038Study of the Spread of COVID-19 in Saint Petersburg, RussiaActive, not recruitingNo Results AvailableCOVID19Prevalence of the SARS-COV-2 infection in Saint Petersburg, Russia|Prevalence odds ratios|Immune response dynamicsEuropean University at St. PetersburgAll18 Years and older Â  (Adult, Older Adult)1038OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveCDRU-001May 27, 2020October 28, 2021October 28, 2021May 28, 2020February 3, 2021"Clinic ""Scandinavia"", Saint Petersburg, Russian Federation""""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04406038/Prot_ICF_000.pdf"https://ClinicalTrials.gov/show/NCT04406038 Russian Federation
1462NCT04824651Covid-19 Vaccine Cohort in Specific PopulationsCOV-POPARTNot yet recruitingNo Results AvailableImmune DeficiencyBiological: COVID-19 vaccineHumoral immunity to Covid-19 vaccination using 2 serological criteria:|Percentage of participants seroconverting for Anti Nucleoprotein ABANRS, Emerging Infectious Diseases|Institut National de la SantÃ© Et de la Recherche MÃ©dicale, FranceAll18 Years and older Â  (Adult, Older Adult)10500OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveANRS0001SMarch 25, 2021September 25, 2024September 25, 2024April 1, 2021April 1, 2021https://ClinicalTrials.gov/show/NCT04824651
1463NCT04448145Determinants of SARS-COV2 (COVID-19) Persistence After ConvalescenceRecruitingNo Results AvailableCOVID-19|Corona Virus Infection|SARS-CoV 2Duration of SARS-CoV-2 viral persistence in naso/oropharyngeal samples|Duration of SARS-CoV-2 viral persistence in stool or rectal swab samples|Duration of SARS-CoV-2 viral persistence in semen samples|Duration of SARS-CoV-2 viral persistence in breast milk samples|Prevalence of cell immune responses|Duration of COVID-19 Symptoms|Prevalence of post-viral sequelae|Prevalence of SARS-CoV-2 persistence and bacterial/viral community structuresColumbia UniversityAll7 Years and older Â  (Child, Adult, Older Adult)325OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveAAAS9722March 26, 2020May 1, 2022May 1, 2022June 25, 2020April 12, 2021Columbia University Medical Center, New York, New York, United Stateshttps://ClinicalTrials.gov/show/NCT04448145 United States
1464NCT04403243COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized TrialCOLORITRecruitingNo Results AvailableCOVID 19Drug: Colchicine|Drug: Ruxolitinib 5 MG|Drug: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Other: standard therapychange from baseline in clinical assessment score COVID 19 (CAS COVID 19) Frame: baseline|Combine endpoint: Time to death or mechanical ventilation|C-reactive protein|D-dimer|EuroQol Group. EQ-5Dâ„¢|exposure area on lung CTLomonosov Moscow State University Medical Research and Educational CenterAll18 Years and older Â  (Adult, Older Adult)Phase 270OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentMSU080520May 8, 2020July 22, 2020August 23, 2020May 27, 2020May 27, 2020Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Moscow Region, Russian Federationhttps://ClinicalTrials.gov/show/NCT04403243 Russian Federation
1465NCT04360707Solid Organ Transplant Recipients With SARS-CoV-2 French RegistryTX-COVIDRecruitingNo Results AvailableSARS-CoV-2Clinical Presentation and Incidence of Covid-19 Infection in Different Cohorts of Solid Organ Transplant PatientsUniversity Hospital, Strasbourg, FranceAll1 Year and older Â  (Child, Adult, Older Adult)300OtherObservationalObservational Model: Case-Only|Time Perspective: Prospective7766April 8, 2020April 8, 2021April 8, 2021April 24, 2020May 5, 2020Service de NÃ©phrologie et Transplantation, Strasbourg, Francehttps://ClinicalTrials.gov/show/NCT04360707 France
1466NCT04828161A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19EMPATHYNot yet recruitingNo Results AvailableCOVID-19Drug: ensovibep|Drug: PlaceboPart A - SARS-CoV-2 viral load|Part B - Occurrence of hospitalizations, emergency room visits or death|Part A - Occurrence of hospitalizations, emergency room visits or death|Part A - Time to sustained clinical recovery|Part A - Serious adverse events (SAEs) and AEs of Special Interest (AESIs)|Part A - Vital Signs: Heart Rate (bpm)|Part A - Vital Signs: Blood Pressure Systolic and Diastolic (mmHg)|Part A - Vital Signs: Body Temperature (Â°C)|Part A - Vital Signs: Respiratory Rate (breaths per minute)|Part A - Vital Signs: Oxygen Saturation (SpO2)|Part A - Number of Participants with Laboratory Abnormalities|Part A - Free and total ensovibep concentration in serum (mass per volume units)|Part A - Observed maximum concentration (Cmax)|Part A - Time to Cmax (Tmax)|Part A - The area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)|Part A - The area under the concentration-time curve from time zero extrapolated to infinity time (AUCinf)|Part A - Terminal Elimination Half-Life (TÂ½)|Part A - Terminal Elimination rate constant (Î»z)|Part A - The apparent volume of distribution during terminal phase associated with Î»z (Vz)|Part A - Apparent total body clearance of the drug from plasma (CL)|Part B - SARS-CoV-2 viral load|Part B - Time to sustained clinical recovery|Part B - Proportion of patients with treatment-emergent ADAs (TE-ADA)|Part B - SAEs and AESIs|Part B - Vital Signs: Heart Rate (bpm)|Part B - Vital Signs: Blood Pressure Systolic and Diastolic (mmHg)|Part B - Vital Signs: Body Temperature (Â°C)|Part B - Vital Signs: Respiratory Rate (breaths per minute)|Part B - Vital Signs: Oxygen Saturation (SpO2)|Part B - Number of Participants with Laboratory AbnormalitiesMolecular Partners AG|Novartis Pharmaceuticals|Iqvia Pty Ltd|Datamap|SYNLAB Analytics & Services Switzerland AG|Q2 SolutionsAll18 Years and older Â  (Adult, Older Adult)Phase 2|Phase 32100Industry|OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentMP0420-CP302|2021-000890-10April 15, 20212022-05-01 00:00:002022-06-01 00:00:00April 1, 2021April 1, 2021https://ClinicalTrials.gov/show/NCT04828161
1467NCT04621149An Outpatient Study Investigating Non-prescription Treatments for COVID-19PROFACT-01RecruitingNo Results AvailableCOVID-19Other: chlorine dioxide|Dietary Supplement: zinc acetate|Drug: Famotidine|Other: placebo|Dietary Supplement: lactoferrin, green tea extractReduction in Participant Symptoms of COVID-19|Incidence of Treatment-Emergent Adverse Events|Rate of Hospitalization|Change in Oxygen Saturation|Change in Body TemperatureProfact, Inc.All20 Years to 70 Years Â  (Adult, Older Adult)Phase 2120OtherInterventionalAllocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentProfact-01November 15, 2020March 31, 2021March 31, 2021November 9, 2020December 29, 2020AZ Good Health Center, Tempe, Arizona, United Stateshttps://ClinicalTrials.gov/show/NCT04621149 United States
1468NCT04394208Silymarin in COVID-19 PneumoniaSCOPERecruitingNo Results AvailableCOVID-19|Viral Pneumonia Human CoronavirusDrug: Silymarin|Drug: PlaceboTime to clinical improvement|Clinical outcome|Duration of Mechanical Ventilation|Hospitalization|Virologic Response|Adverse eventsCairo UniversityAll18 Years and older Â  (Adult, Older Adult)Phase 350OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: TreatmentCairoU COVID-19 Study GroupAugust 16, 2020January 30, 2021February 28, 2021May 19, 2020August 18, 2020Cairo University, Giza, Cairo, Egypthttps://ClinicalTrials.gov/show/NCT04394208 Egypt
1469NCT04470609Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged â©¾60 YearsEnrolling by invitationNo Results AvailableCOVID-19Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Placebo on a 0- and 28-day scheduleAdverse reactions/events rate|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIb|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIb|Serious adverse events|Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ib|Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ib|Level of Neutralizing antibodies against SARS-CoV-2 Phase Ib|Level of IgG antibodies against SARS-CoV-2 Phase Ib|Level of Neutralizing antibodies against SARS-CoV-2 Phase IIb|Level of IgG antibodies against SARS-CoV-2 Phase IIbChinese Academy of Medical Sciences|West China Second University Hospital|Yunnan Center for Disease Control and PreventionAll60 Years and older Â  (Adult, Older Adult)Phase 1|Phase 2471OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention20200402July 10, 20202020-11-01 00:00:002021-11-01 00:00:00July 14, 2020July 14, 2020West China Second University Hospital, Sichuan University / West China women's and children's Hospital, Chengdu, Sichuan, Chinahttps://ClinicalTrials.gov/show/NCT04470609 China
1470NCT04478019SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral SheddingSHIELDRecruitingNo Results AvailableCOVID-19|SARS-CoV 2Drug: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinseNumber of Participants with COVID-19 diagnosis|SARS-Cov-2 Viral Load|Fidelity of the treatment regimen|Feasibility of the treatment regimenUniversity of Wisconsin, MadisonAll18 Years and older Â  (Adult, Older Adult)Early Phase 1250OtherInterventionalAllocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention2020-0540|A534265|SMPH/MEDICINE/INFECT DIS|Protocol Version 6/1/2020July 7, 2020April 30, 2022April 30, 2022July 20, 2020April 8, 2021University of Wisconsin-Madison, Madison, Wisconsin, United Stateshttps://ClinicalTrials.gov/show/NCT04478019 United States
1471NCT04313322Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem CellsRecruitingNo Results AvailableUse of Stem Cells for COVID-19 TreatmentBiological: WJ-MSCsClinical outcome|CT Scan|RT-PCR resultsStem Cells ArabiaAll18 Years and older Â  (Adult, Older Adult)Phase 15OtherInterventionalAllocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentCOVID-19March 16, 2020June 30, 2020September 30, 2020March 18, 2020March 18, 2020Stem Cells Arabia, Amman, Jordanhttps://ClinicalTrials.gov/show/NCT04313322 Jordan
1472NCT04411680Study of Sargramostim in Patients With COVID-19iLeukPulmActive, not recruitingNo Results AvailableCOVID-19|Sars-CoV2Drug: Sargramostim|Drug: Standard of careChange in oxygenation parameter of P(A-a)O2 gradient by Day 6|Percent of patients who have been intubated by Day 14|Change in ordinal scale|All cause 28-day mortality|Number of patients with treatment-emergent serious adverse events or clinically significant adverse drug reactions (ADRs)Partner Therapeutics, Inc.|United States Department of DefenseAll18 Years and older Â  (Adult, Older Adult)Phase 2122Industry|U.S. FedInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentPTX-001-002August 18, 20202021-03-01 00:00:002021-05-01 00:00:00June 2, 2020March 2, 2021St. Jude Medical Center, Fullerton, California, United States|St. Joseph Hospital of Orange, Orange, California, United States|California Pacific Medical Center - Van Ness Campus, San Francisco, California, United States|TidalHealth Peninsula Regional, Inc, Salisbury, Maryland, United States|University of Missouri Health Care, Columbia, Missouri, United States|Great Plains Health, North Platte, Nebraska, United States|Richmond University Medical Center, Staten Island, New York, United States|Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Memorial Hermann Hospital Affiliated with the University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States|University of Utah Health, Salt Lake City, Utah, United Stateshttps://ClinicalTrials.gov/show/NCT04411680 United States
1473NCT04348435A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19Active, not recruitingNo Results AvailableCOVID-19Drug: HB-adMSCs|Drug: PlacebosIncidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9Hope Biosciences|Hope Biosciences Stem Cell Research FoundationAllChild, Adult, Older AdultPhase 2100Industry|OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: PreventionHBCOV02May 14, 2020May 30, 2021July 30, 2021April 16, 2020March 25, 2021Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04348435 United States
1474NCT04378777Immunophenotyping Assessment in a COVID-19 CohortIMPACCActive, not recruitingNo Results AvailableCoronavirus Disease 2019 (COVID-19)|SARS-CoV-2Procedure: Biological sample collection|Procedure: Data Collection: Clinical Care AssessmentsMortality Rate Among COVID-19 Patients|Proportion of Patients with COVID-19 who Require Intensive Care Unit (ICU)-Level Care, Mechanical Ventilatory Support (MV), and/or Extracorporeal Membrane Oxygenation (ECMO) Over Time to Day 28|Proportion of Patients with COVID-19 who Develop Shock, Secondary Organ Failure, or Secondary Infection Over Time to Day 28|Mechanistic: Longitudinal Assessment of Viral Load by Semi-Quantitative Polymerase Chain Reaction (PCR) Over Time to Day 28|Mechanistic: Antibody Isotype/Subclass Classification and Functionality Over Time through Day 28 and at follow-up through month 12|Mechanistic: Longitudinal Assessment of Inflammatory Mediators as Collected Over Time to Day 28|Mechanistic: Longitudinal Assessment of Markers of Myocardial Injury Over Time to Day 28|Duration of Mechanical Ventilation in Patients with COVID-19 Over Time to Day 28|Proportion of Patients with COVID-19 with Requirement for New (Or Increased from Baseline if on Home Oxygen) Supplemental Oxygen Over Time to Day 28|Requirement for Extracorporeal Membrane Oxygenation (ECMO) in COVID-19 Patients with COVID-19 Over Time to Day 28|Mechanistic: Immune Cell Frequencies and Activation Status (CyTOF) in Blood and Endotracheal Aspirate over time Through Day 28 and In blood at Select Study Visits Through Month 12|Mechanistic: Gene Expression (Transcriptomics) in Blood|Mechanistic: Gene Expression (Transcriptomics) in Respiratory Epithelium|Mechanistic: Gene Expression (Transcriptomics) in Plasma Protein|Mechanistic: Gene expression (Transcriptomics) in Metabolic Profiling|Mechanistic: Circulating Immune Mediators Assessed by OLINK MethodologyNational Institute of Allergy and Infectious Diseases (NIAID)|Benaroya Research Institute|Boston Children's HospitalAll18 Years and older Â  (Adult, Older Adult)1227NIH|OtherObservationalObservational Model: Cohort|Time Perspective: ProspectiveDAIT-COVID-19-002|NIAID CRMS ID#: 38733May 1, 2020March 19, 20212022-03-01 00:00:00May 7, 2020April 2, 2021University of Arizona (UA) College of Medicine - Tucson: UA Health Sciences Asthma and Airway Disease Research Center, Tucson, Arizona, United States|University of California, Los Angeles: Department of Medicine, Los Angeles, California, United States|University of California San Francisco School of Medicine, San Francisco, California, United States|Stanford Medicine: Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, United States|Yale School of Medicine, New Haven, Connecticut, United States|University of Florida Health Gainesville, Gainesville, Florida, United States|University of Florida Health Jacksonville, Jacksonville, Florida, United States|University of South Florida Health Tampa, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|University of Oklahoma ,Oklahoma Health Sciences Center: Pulmonary/Critical Care, Department of Medicine, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Texas at Austin: UT Health Austin, Austin, Texas, United States|Baylor College of Medicine: Department of Medicine, Houston, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04378777 United States
1475NCT04351646Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak)Not yet recruitingNo Results AvailableCOVID-19Antibody titres to SARS-CoV-2St George's, University of LondonAll18 Years and older Â  (Adult, Older Adult)500OtherObservationalObservational Model: Cohort|Time Perspective: Prospective2020.0075April 15, 2020April 15, 2022April 15, 2022April 17, 2020April 17, 2020St. Georges Hospital Foundation Trust, London, United Kingdomhttps://ClinicalTrials.gov/show/NCT04351646 United Kingdom
1476NCT04538469Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and StaffVINCINot yet recruitingNo Results AvailableCardiovascular Diseases|Delirium|Critical Illness|Intensive Care Unit Delirium|Thoracic Diseases|Respiratory Failure|Cardiac Disease|Cardiac FailureOther: COVID visitation restrictionsDuration of delirium|Incidence of delirium|Length of critical care stay|Length of hospital stay|Doses of specified drugs during ICU admission|Length of time ventilated|MortalityUniversity of Glasgow|Golden Jubilee National HospitalAll18 Years to 100 Years Â  (Adult, Older Adult)1000OtherObservationalObservational Model: Cohort|Time Perspective: Retrospective20/ANAES/022020-09-01 00:00:002021-12-01 00:00:002021-12-01 00:00:00September 4, 2020September 4, 2020https://ClinicalTrials.gov/show/NCT04538469
1477NCT04632043Early Versus Delayed Intubation of Patients With COVID-19EUDOCORecruitingNo Results AvailableCOVID-19|Acute Hypoxemic Respiratory FailureOther: Endotracheal intubationTime from onset of severe acute hypoxemic respiratory failure to intubation|Organ failure-free days|Need for continuous renal replacement therapy|Ventilator-free days|ICU-free days|Mortality|Number of severe post-intubation adverse eventsEvangelismos HospitalAll18 Years and older Â  (Adult, Older Adult)Not Applicable80OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment32635, 13-10-2020November 18, 2020May 1, 2021June 1, 2021November 17, 2020March 3, 2021Evangelismos Hospital, Athens, Attiki, Greecehttps://ClinicalTrials.gov/show/NCT04632043 Greece
1478NCT04370015Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.Not yet recruitingNo Results AvailableSARS-CoV-2|Healthcare WorkersDrug: Hydroxychloroquine|Drug: Placebo oral tabletPrevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 week study period|Safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment|Confirmed SARS-CoV-2 infection based on symptoms and confirmed by RT-PCR|Clinical disease severity in confirmed SARS-CoV-2 participants|Incidence of any acute respiratory infectionServices Institute of Medical Sciences, PakistanAll18 Years to 60 Years Â  (Adult)Not Applicable374OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention16082019May 15, 2020June 30, 2020October 15, 2020April 30, 2020May 6, 2020https://ClinicalTrials.gov/show/NCT04370015
1479NCT04703777Relationship Between Social Status and Use of Healthcare Services During the Confinement Period Linked to the COVID-19 EpidemicRecruitingNo Results AvailableCovid-19Retrospective study on the relationship between social status and use of healthcare services during the confinement period linked to the COVID-19 epidemic in Bas-Rhin, FranceUniversity Hospital, Strasbourg, FranceAll18 Years and older Â  (Adult, Older Adult)500OtherObservationalObservational Model: Case-Only|Time Perspective: Retrospective7814April 4, 2020April 4, 2021April 4, 2021January 11, 2021January 11, 2021Adult Emergency Department - Strasbourg University Hospitals, Strasbourg, Francehttps://ClinicalTrials.gov/show/NCT04703777 France
1480NCT04345315Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.CORSARecruitingNo Results AvailableCOVID-19|SARS-CoV-2Other: serological test|Other: Rapid molecular test|Genetic: Next generation Sequencing (NGS) analysis|Other: serum chemistry analysisepidemiology|Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies evaluation|methods comparison|correlation between biochemical and coagulative factors with SARS-CoV-2 positivity.|phylogenetic map|interactions between the virus and host cellsIstituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|AUSL RomagnaAll18 Years and older Â  (Adult, Older Adult)500OtherObservationalObservational Model: Cohort|Time Perspective: OtherIRSTB113March 27, 20202021-03-01 00:00:002022-03-01 00:00:00April 14, 2020April 15, 2020UO Microbiologia,Centro Servizi Pievesestina, AUSL Romagna, Cesena, FC, Italy|Irst Irccs, Meldola, FC, Italyhttps://ClinicalTrials.gov/show/NCT04345315 Italy
1481NCT04452669VentaProst in Subjects With COVID-19 Requiring Mechanical VentilationVPCOVIDRecruitingNo Results AvailableCOVID-19Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)Reduction in Respiratory Failure|Reduction in Cardiac/Circulatory Failure|Improvement in Oxygenation|Improved Clinical OutcomesAerogen Pharma Limited|Ohio State UniversityAll18 Years and older Â  (Adult, Older Adult)Phase 220Industry|OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentAPC-VPCOV-CLN-001September 15, 2020May 1, 2021September 1, 2021June 30, 2020February 1, 2021Ohio State University, Columbus, Ohio, United Stateshttps://ClinicalTrials.gov/show/NCT04452669 United States
1482NCT04357834WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical TrajectoriesWAVERecruitingNo Results AvailableCOVID|COVID 19|SARS-CoV 2Other: Equipment with smartwatch throughout hospital stay on the general wardDiagnostic accuracy of smartwatch data in predicting ICU requirement in COVID-19 contracted inpatients quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.85).|Diagnostic accuracy of routine physiological data in predicting ICU requirement in COVID-19 contracted in-patients quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.85).|Diagnostic accuracy of predicting hospital discharge without ICU admission in COVID-19 contracted in-patients quantified as area under the receiver operator characteristics curve|Change of heart rate from baseline (hospitalization) to ICU admission|Change of heart rate variability from baseline (hospitalization) to ICU admission|Change of skin temperature from baseline (hospitalization) to ICU admission|Change of blood oxygen saturation from baseline (hospitalization) to ICU admission|Change of respiration rate from baseline (hospitalization) to ICU admission|Change of physical activity from baseline (hospitalization) to ICU admission|Change of stress level from baseline (hospitalization) to ICU admission|Change of sleep pattern from baseline (hospitalization) to ICU admission|Change of steps per day from baseline (hospitalization) to ICU admission|Change of systolic blood pressure from baseline (hospitalization) to ICU admission|Change of diastolic blood pressure from baseline (hospitalization) to ICU admission|Change of body temperature from baseline (hospitalization) to ICU admission|Change of oxygen partial pressure (pO2) from baseline (hospitalization) to ICU admission|Change of CO2 partial pressure (pCO2) from baseline (hospitalization) to ICU admission|Change of blood pH from baseline (hospitalization) to ICU admission|Change of bicarbonate from baseline (hospitalization) to ICU admission|Change of base excess from baseline (hospitalization) to ICU admission|Change of oxygen flow rate from baseline (hospitalization) to ICU admissionUniversity Hospital Inselspital, Berne|ETH ZurichAll18 Years to 120 Years Â  (Adult, Older Adult)100OtherObservationalObservational Model: Other|Time Perspective: ProspectiveWAVEMay 1, 2020December 31, 2021December 31, 2021April 22, 2020November 5, 2020Emergency Department, University Hospital Bern, Inselspital, Bern, Switzerlandhttps://ClinicalTrials.gov/show/NCT04357834 Switzerland
1483NCT04410510P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19RecruitingNo Results AvailableCOVID|Coronavirus Infection|SARS-CoV 2|COVID19Drug: P2Et (Caesalpinia spinosa extract)|Other: PlaceboEvaluate the efficacy of P2Et in reducing the length of hospital stay of patients with clinical suspicion or confirmed case of COVID-19|Efficacy of P2Et in reducing the time to clinically significant improvement in patients with clinical suspicion or confirmed case of COVID-19|Proportion of patients with clinical suspicion or confirmed case of COVID-19, who achieve clinical improvement after 14 days of treatment|Proportion of patients with clinical suspicion or confirmed case of COVID-19, who achieve clinical improvement after 28 days of treatment|Efficacy of P2Et in reducing the proportion of hospitalized patients with clinical suspicion or confirmed case of COVID-19 who require admission to the ICU due to worsening clinical symptoms.|Efficacy of P2Et in reducing the proportion of patients with clinical suspicion or confirmed case of COVID-19 who die from the disease.|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) of the P2Et in patients with COVID-19Hospital Universitario San Ignacio|Pontificia Universidad JaverianaAll18 Years and older Â  (Adult, Older Adult)Phase 2|Phase 3100OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive CareCS002-COVID19September 30, 20202020-12-01 00:00:002021-06-01 00:00:00June 1, 2020October 5, 2020Hospital Universitario San Ignacio, BogotÃ¡, Colombiahttps://ClinicalTrials.gov/show/NCT04410510 Colombia
1484NCT04551378The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and SurvivorsRecruitingNo Results AvailableCOVID-19 Infection|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid NeoplasmOther: Quality-of-Life Assessment|Other: Survey AdministrationCoronavirus disease 2019 (COVID-19) specific psychological stress|Survey responses|Patient reported outcomes|Changes of survey responses|Changes in discrete responses|Incidence of survey question non-responseM.D. Anderson Cancer Center|National Cancer Institute (NCI)All18 Years to 39 Years Â  (Adult)600Other|NIHObservationalObservational Model: Cohort|Time Perspective: Prospective2020-0504|NCI-2020-06609July 13, 2020December 31, 2021December 31, 2021September 16, 2020April 1, 2021M D Anderson Cancer Center, Houston, Texas, United Stateshttps://ClinicalTrials.gov/show/NCT04551378 United States
1485NCT04421612COVID-19 - No Health Without Mental HealthCo-COVID-19RecruitingNo Results AvailableCovid19|AnxietyBehavioral: Co-mestring (co-coping)The Patient Health Questionnaire|The Generalized Anxiety Disorder Scale|Positive and negative affect|Perceived Stress Scale|Client Satisfaction ScaleHaukeland University HospitalAll18 Years and older Â  (Adult, Older Adult)Not Applicable400OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care126376April 2, 2020March 1, 2021December 31, 2021June 9, 2020February 26, 2021Haukeland University Hospital, Bergen, Norwayhttps://ClinicalTrials.gov/show/NCT04421612 Norway
1486NCT04366024A Novel Nomogram to Predict Severity of COVID-19RecruitingNo Results AvailableCOVID-19 Disease|Nomogram ModelOther: otherthe consistency of predicted severe rate and observed severe rate of COVID-19 patients|Duration of severe illnessXinqiao Hospital of ChongqingAll18 Years and older Â  (Adult, Older Adult)1000OtherObservationalObservational Model: Case-Only|Time Perspective: RetrospectiveXQonc-016January 17, 2020August 30, 2020December 31, 2021April 28, 2020July 14, 2020Xinqiao Hospital of Chongqing, Chongqing, Chongqing, Chinahttps://ClinicalTrials.gov/show/NCT04366024 China
1487NCT04534608COVID-19 Child Health Investigation of Latent Disease in HamburgC19CHILDActive, not recruitingNo Results AvailableSARS-CoV-2|Covid19Acute infection by SARS-CoV-2|Seroconversion for SARS-CoV-2|Immune phenotyping|HLA Typing|MatabolomicsUniversitÃ¤tsklinikum Hamburg-Eppendorf|Altona Children's Hospital|Wilhelmstift ChildrenÂ´s Hospital|Helios Mariahilf Klinik Hamburg|Asklepios Klinik Nord - HeidbergAllup to 18 Years Â  (Child, Adult)6000OtherObservationalObservational Model: Family-Based|Time Perspective: ProspectivePV7336May 11, 2020June 30, 2020March 31, 2021September 1, 2020September 1, 2020UniversitÃ¤tsklinikum Hamburg-Eppendorf, Hamburg, Germanyhttps://ClinicalTrials.gov/show/NCT04534608 Germany
1488NCT04806529An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and OlderWithdrawnNo Results AvailableInfluenzaDrug: Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|Drug: ComparatorPrimary endpoint - preventing first occurrence of virologically-confirmed (RT-PCR) symptomatic COVID-19 cases as defined by ECDC guidance|Co-primary endpoint - If successful, the co-primary measure of efficacy is preventing first-occurrence of symptomatic COVID-19 as defined by the US FDA guidance|Secondary endpoint #1 - preventing first occurrence of RT-PCR confirmed severe COVID-19|Secondary endpoint #2 - number of subjects hospitalized with RT-PCR-confirmed COVID-19 versus placebo|Secondary endpoint #3- number of subjects admitted to ICU with RT-PCR-confirmed COVID-19 versus placeboSeqirusAll18 Years and older Â  (Adult, Older Adult)Phase 2|Phase 30IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: PreventionV451_07December 15, 2020December 15, 2020April 9, 2022March 19, 2021March 23, 2021https://ClinicalTrials.gov/show/NCT04806529
1489NCT04371835COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited SettingsRecruitingNo Results AvailableHIV-infection/Aids|Coronavirus InfectionClinical features of symptomatic COVID-19 in people living with HIV (PLWH)|Clinical outcomes of symptomatic COVID-19 in PLWH|Seroprevalence of COVID-19 in all parent study participantsKirby Institute|University of Witwatersrand, South Africa|University of Liverpool|UniversitÃ© Montpellier|UNITAID|ViiV HealthcareAll18 Years and older Â  (Adult, Older Adult)1500Other|IndustryObservationalObservational Model: Cohort|Time Perspective: Prospective2020-04-COHIVEAugust 12, 2020December 31, 2021December 31, 2021May 1, 2020April 8, 2021Hospital G de Agudos JM Ramos Mejia, Buenos Aires, Ciudad De Buenos Aires, Argentina|LaboratÃ³rio de Pesquisa Clinica Em Hiv/Aids - Instituto Nacional de Infectologia - Fiocruz, Rio de Janeiro, Brazil|Central Hospital of YaoundÃ©, YaoundÃ©, Cameroon|CitÃ© Verte Hospital, YaoundÃ©, Cameroon|HÃ´pital Militaire de RÃ©gion NÂ°1, YaoundÃ©, Cameroon|CART CRS, VHS Hospital, Chennai, Tamil Nadu, India|Univerity of Malaya Medical Centre, Kuala Lumpur, Malaysia|Institute of Human Virology, Nigeria (IHVN), Abuja, Nigeria|Desmond Tutu HIV Foundation, Cape Town, South Africa|Perinatal HIV Research Unit (PHRU), Johannesburg, South Africa|Clinical HIV Research Unit (CHRU), Wits Health Consotium (Pty) Ltd, Johannesburg, South Africa|Ezintsha, Parktown, South Africa|HIV-NAT (The HIV Netherlands Australia Thailand Research Collaboration), Thai Red Cross AIDS Research Centre, Bangkok, Thailand|Infectious Diseases Institute, Kampala, Uganda|University of Zimbabwe Clinical Research Centre, Harare, Zimbabwehttps://ClinicalTrials.gov/show/NCT04371835 Zimbabwe
1490NCT04401033Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study)DECORECompletedNo Results AvailableSARS-CoV 2|COVIDBehavioral: Telephonic medical visit|Procedure: Gastrointestinal endoscopy|Procedure: Abdominal ultrasoundSARS-CoV-2 infection in patients|SARS-CoV-2 infection in HCWHospital del RÃ­o HortegaAll18 Years and older Â  (Adult, Older Adult)450OtherObservationalObservational Model: Cohort|Time Perspective: Prospective3May 11, 2020June 30, 2020June 30, 2020May 26, 2020July 28, 2020Hospital Rio Hortega, Valladolid, Spain"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT04401033/Prot_SAP_000.pdf"https://ClinicalTrials.gov/show/NCT04401033 Spain
1491NCT04708327Phase 2 Trial to Evaluate Safety and Efficacy of CYTO-205 in Mild COVID-19Not yet recruitingNo Results AvailableCovid19Drug: Naltrexone HydrochlorideProportion of patients who demonstrate progression of COVID-19 diseaseCytocom, Inc.All18 Years and older Â  (Adult, Older Adult)Phase 275IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentCYTO-0012021-04-01 00:00:002022-04-01 00:00:002022-04-01 00:00:00January 13, 2021January 13, 2021https://ClinicalTrials.gov/show/NCT04708327
1492NCT04644341Tele-monitoring of COVID-19 Survivors for Long-Term ImpactsRecruitingNo Results AvailableCOVID-19Combination Product: cardiovascular and respiratory systems monitoringBlood pressure|Breathing sounds average power|Risk of aspiration|SaO2 level|Montreal Cognitive Assessment (MoCA)University of Manitoba|Function Four Ltd.All18 Years to 90 Years Â  (Adult, Older Adult)20OtherObservationalObservational Model: Case-Only|Time Perspective: RetrospectiveB2020:114 (HS24395)January 15, 2021August 31, 2021November 1, 2021November 25, 2020February 26, 2021University of Manitoba, Winnipeg, Manitoba, Canadahttps://ClinicalTrials.gov/show/NCT04644341 Canada
1493NCT04344600Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) InfectionPROTECTRecruitingNo Results AvailableSars-CoV2Drug: Peginterferon lambda alfa-1a subcutaneous injection|Other: SalineProportion of participants with no evidence of SARS-CoV-2 infection|Time (days) to no detection of SARS-CoV-2 in two upper respiratory samplesJohns Hopkins University|Eiger BioPharmaceuticalsAll18 Years to 80 Years Â  (Adult, Older Adult)Phase 2164Other|IndustryInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: PreventionIRB00248163May 29, 20202021-06-01 00:00:002021-12-01 00:00:00April 14, 2020August 20, 2020Johns Hopkins Hospital, Baltimore, Maryland, United Stateshttps://ClinicalTrials.gov/show/NCT04344600 United States
1494NCT04500626Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 PatientsNot yet recruitingNo Results AvailableCovid19Drug: Oxygen7-level COVID Ordinal Outcome Scale|Length of hospital stay|Days with oxygen supplementation|Daily oxygen flow values required to obtain saturation values â‰¥90%,|ICU admission|ICU length of stay|Days on invasive mechanical ventilation or high flow oxygenation|Major arterial and venous thrombotic events|Sleep quality|Fatigue|Mortality|Incidence of any adverse events related to HBOTOttawa Hospital Research Institute|Climate FoundationAll18 Years and older Â  (Adult, Older Adult)Phase 2|Phase 3234OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: TreatmentOHRI-HBOT-0012021-04-01 00:00:002022-08-01 00:00:002022-08-01 00:00:00August 5, 2020February 23, 2021The Ottawa Hospital, Ottawa, Ontario, Canadahttps://ClinicalTrials.gov/show/NCT04500626 Canada
1495NCT04484545Prognostic Factors in Patients Admitted to an Urban Teaching Hospital With COVID-19 InfectionActive, not recruitingNo Results AvailableCOVID-19Diagnostic Test: Prognostic scoremortalityGlasgow Royal InfirmaryAll18 Years to 100 Years Â  (Adult, Older Adult)250OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveIRAS 282807April 1, 2020June 1, 2021June 1, 2021July 23, 2020July 23, 2020Glasgow Royal Infirmary, Glasgow, United Kingdomhttps://ClinicalTrials.gov/show/NCT04484545 United Kingdom
1496NCT04659889Clinical and Haematological Phenotypes in Long COVIDRecruitingNo Results AvailableLong Covid|Covid19Diagnostic Test: Blood sampling (venesection)Observation of frequency of abnormal haematological parameters and association with long-Covid clinical phenotypes versus controls.HCA International LimitedAll18 Years and older Â  (Adult, Older Adult)100OtherObservationalObservational Model: Case-Control|Time Perspective: Cross-SectionalLCV2020-12-01 00:00:002021-06-01 00:00:002021-06-01 00:00:00December 9, 2020December 9, 2020The Physicians' Clinic, London, United Kingdomhttps://ClinicalTrials.gov/show/NCT04659889 United Kingdom
1497NCT04632537BCG Vaccination to Prevent COVID-19NUEVAWithdrawnNo Results AvailableCOVID-19Drug: TiceÂ® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Drug: Preservative-free salineIncidence of symptomatic rt-PCR-confirmed SARS-CoV-2 infection|incidence of Serology-confirmed infection with SARS-CoV-2|severity of COVID-19 disease|symptomatic respiratory infection|effect of prior adult immunization with other vaccines associated with trained immunityHenry M. Jackson Foundation for the Advancement of Military Medicine|Harvard Medical School|Uniformed Services University of the Health Sciences|United States Department of Defense|Immunization HealthCare Division, Defense Health AgencyAll18 Years to 64 Years Â  (Adult)Phase 30Other|U.S. FedInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: PreventionUSUHS.2020-062December 7, 2020March 23, 2021March 23, 2021November 17, 2020March 26, 2021https://ClinicalTrials.gov/show/NCT04632537
1498NCT04388410Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19EPCOvid-1RecruitingNo Results AvailableCOVID-19Biological: convalescent plasmaSeverity and death|Adverse events that require study treatment interruption|Time to clinical improvement|Antibodies against SARS-CoV-2|Disease progression 1|Disease progression 2|Time on mechanical ventilation|Number of days with fever|Adverse events attributed to the study interventionInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Hospital San Jose Tec de Monterrey|Instituto Nacional de Enfermedades Respiratorias|Instituto Nacional de Cardiologia Ignacio Chavez|Hospital General Dr. Manuel Gea GonzÃ¡lez|Hospital Regional de Alta Especialidad del Bajio|Instituto Nacional de Cancerologia de MexicoAll18 Years and older Â  (Adult, Older Adult)Phase 2|Phase 3410OtherInterventionalAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment3380August 25, 2020November 30, 2020December 31, 2020May 14, 2020August 26, 2020Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Tlalpan, Mexicohttps://ClinicalTrials.gov/show/NCT04388410 Mexico
1499NCT04598347Evaluation of the Possible Vertical Transmission of SARS-CoV-2 Through Study of Amniotic Fluid and Chorionic Villi of Affected Pregnant Women for the COVID-19RecruitingNo Results AvailableCovid19|Pregnancy RelatedPerinatal SARS-CoV-2 infectionFundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant PauFemale18 Years to 90 Years Â  (Adult, Older Adult)225OtherObservationalObservational Model: Case-Only|Time Perspective: ProspectiveIIBSP-COV-2020-59August 8, 2020January 8, 2022January 23, 2022October 22, 2020October 26, 2020Hospital de la Santa Creu i Sant Pau, Barcelona, Spainhttps://ClinicalTrials.gov/show/NCT04598347 Spain
1500NCT04668170Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic ManagementIMMUNOMARKCOVRecruitingNo Results AvailableCOVID-19Biological: Blood collection on admission and longitudinally|Biological: Blood collection on their first consultation and 10 to 14 days laterImmune signature on admission : phenotypic profile of blood T-cells|Immune signature on admission : inflammatory cytokines|Dynamics of cellular immunity: CD4 and CD8 T cells|Dynamics of cellular immunity: gd T cells|Dynamics of cellular immunity: T cell transcriptomic analysis|Dynamics of cellular immunity: humoral immunityUniversity Hospital, ToulouseAll18 Years to 110 Years Â  (Adult, Older Adult)340OtherObservationalObservational Model: Cohort|Time Perspective: RetrospectiveRC31/20/0187May 5, 2020December 31, 2021December 31, 2021December 16, 2020December 16, 2020University Hospital Bordeaux, Bordeau, France|University Hospital Toulouse, Toulouse, Francehttps://ClinicalTrials.gov/show/NCT04668170 France
